<SEC-DOCUMENT>0001493152-23-040577.txt : 20231113
<SEC-HEADER>0001493152-23-040577.hdr.sgml : 20231113
<ACCEPTANCE-DATETIME>20231113164426
ACCESSION NUMBER:		0001493152-23-040577
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		63
CONFORMED PERIOD OF REPORT:	20230930
FILED AS OF DATE:		20231113
DATE AS OF CHANGE:		20231113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NanoVibronix, Inc.
		CENTRAL INDEX KEY:			0001326706
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36445
		FILM NUMBER:		231399595

	BUSINESS ADDRESS:	
		STREET 1:		525 EXECUTIVE BLVD
		CITY:			ELMSFORD
		STATE:			NY
		ZIP:			10523
		BUSINESS PHONE:		(914) 233-3004

	MAIL ADDRESS:	
		STREET 1:		525 EXECUTIVE BLVD
		CITY:			ELMSFORD
		STATE:			NY
		ZIP:			10523

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Nano Vibronix, Inc.
		DATE OF NAME CHANGE:	20111206

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Nano Vibronix Inc
		DATE OF NAME CHANGE:	20050510
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10-q.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:NAOV="http://nanovibronix.com/20230930">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_NAOV_nanovibronix.com_20230930 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20230101_20230930 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DDocumentFiscalPeriodFocus_Q3 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityCentralIndexKey_0001326706 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:DocumentFiscalPeriodFocus">Q3</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityCentralIndexKey">0001326706</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:DeferredRevenue" contextRef="AsOf2023-09-30" id="xdx2ixbrl0095" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-09-30" id="xdx2ixbrl0116" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2022-12-31" id="xdx2ixbrl0117" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-09-30_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0122" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0123" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-09-30_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0141" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0142" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-09-30_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0160" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0161" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-09-30_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0179" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0180" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-09-30_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0198" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0199" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0281" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0283" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0360" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0367" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0369" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0371" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0373" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0378" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0380" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-07-012022-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0390" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0391" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants" contextRef="From2022-07-012022-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0394" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0398" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0399" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0400" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0401" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0402" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0404" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0407" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0408" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0409" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0410" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0411" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0418" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0419" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0427" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0429" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0431" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0433" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0437" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0438" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0439" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0440" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0447" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0449" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0451" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0453" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0457" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0458" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0459" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0460" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0461" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0463" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0464" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0467" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0468" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0469" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0470" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0473" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0474" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants" contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0477" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants" contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0478" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants" contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0479" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants" contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0480" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants" contextRef="From2022-01-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0481" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants" contextRef="From2022-01-012022-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0483" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants" contextRef="From2022-01-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0484" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0487" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0488" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0489" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0490" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2022-01-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0491" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2022-01-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0492" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2022-01-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0494" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0497" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0498" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0499" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0500" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0501" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0502" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0503" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0507" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0508" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0509" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0510" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0517" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0519" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0521" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0523" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0527" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0528" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0529" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0530" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0537" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0539" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0541" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0543" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0547" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0548" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0549" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0550" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0551" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0553" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0554" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0557" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0558" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0559" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0560" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0561" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0563" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0564" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0569" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0570" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0571" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0572" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0573" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0574" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0576" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0579" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0580" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0581" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0582" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0583" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0584" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0585" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0589" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0590" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0591" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0592" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0599" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0601" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0603" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0605" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0609" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0610" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0611" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0612" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0619" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0621" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0623" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0625" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0629" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0630" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0631" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0632" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0639" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0641" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0643" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0645" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0649" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0650" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0651" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0652" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0653" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0655" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0656" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0659" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0660" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0661" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0662" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0663" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0665" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0666" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0671" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0672" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0673" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0674" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0675" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0676" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0678" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0681" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0682" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0683" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0684" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0685" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0687" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0688" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0693" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0694" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0695" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0696" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0697" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0698" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0699" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0700" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-01to2023-09-30" id="xdx2ixbrl0701" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0705" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0706" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0707" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0708" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0709" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0710" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0711" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0715" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0716" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0717" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0718" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0725" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0727" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0729" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0731" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0735" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0736" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0737" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0738" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember" id="xdx2ixbrl0745" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember" id="xdx2ixbrl0747" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember" id="xdx2ixbrl0749" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember" id="xdx2ixbrl0751" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:NoncashInterestExpense" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0771" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0816" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0819" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-07-012023-09-30_custom_EmployeeOptionsMember" id="xdx2ixbrl0913" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-09-30_custom_EmployeeOptionsMember" id="xdx2ixbrl0915" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-07-012022-09-30_custom_EmployeeOptionsMember" id="xdx2ixbrl0917" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-04-012022-06-30_custom_EmployeeOptionsMember" id="xdx2ixbrl0961" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-04-012022-06-30_custom_EmployeeOptionsMember" id="xdx2ixbrl0963" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-07-012022-09-30_custom_EmployeeOptionsMember" id="xdx2ixbrl0975" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-07-012022-09-30_custom_EmployeeOptionsMember" id="xdx2ixbrl0977" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-03-31_custom_EmployeeOptionsMember" id="xdx2ixbrl0995" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-03-31_custom_EmployeeOptionsMember" id="xdx2ixbrl0997" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-04-012023-06-30_custom_EmployeeOptionsMember" id="xdx2ixbrl1017" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-04-012023-06-30_custom_EmployeeOptionsMember" id="xdx2ixbrl1019" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodSharesStockOptionsExpired" contextRef="From2023-04-012023-06-30_custom_EmployeeOptionsMember" id="xdx2ixbrl1021" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2023-04-012023-06-30_custom_EmployeeOptionsMember" id="xdx2ixbrl1023" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-07-012023-09-30_custom_EmployeeOptionsMember" id="xdx2ixbrl1035" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-07-012023-09-30_custom_EmployeeOptionsMember" id="xdx2ixbrl1037" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="NAOV:StockIssuedDuringPeriodSharesStockOptionsExpired" contextRef="From2023-07-012023-09-30_custom_EmployeeOptionsMember" id="xdx2ixbrl1039" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2023-07-012023-09-30_custom_EmployeeOptionsMember" id="xdx2ixbrl1041" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_custom_PrivateInvestorsMember" id="xdx2ixbrl1111" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember_custom_PrivateInvestorsMember" id="xdx2ixbrl1121" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember_custom_PrivateInvestorsMember" id="xdx2ixbrl1123" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-07-012023-09-30_srt_EuropeMember" id="xdx2ixbrl1157" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-07-012023-09-30_srt_AsiaMember" id="xdx2ixbrl1162" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-07-012022-09-30_srt_AsiaMember" id="xdx2ixbrl1163" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-07-012022-09-30_custom_OtherCountryMember" id="xdx2ixbrl1168" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-09-30_custom_OtherCountryMember" id="xdx2ixbrl1170" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-09-30_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1304" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-09-30_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1305" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1309" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1310" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="naov-20230930.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-01-01to2023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_SeriesDPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_SeriesDPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_SeriesEPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_SeriesEPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_SeriesFPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_SeriesFPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-012023-08-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-01</xbrli:startDate>
        <xbrli:endDate>2023-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-222023-05-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-22</xbrli:startDate>
        <xbrli:endDate>2023-05-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-31_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-082023-02-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-08</xbrli:startDate>
        <xbrli:endDate>2023-02-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-152023-02-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-15</xbrli:startDate>
        <xbrli:endDate>2023-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-302023-08-30_custom_PurchaseAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-30</xbrli:startDate>
        <xbrli:endDate>2023-08-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-30_custom_PurchaseAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-30_custom_PurchaseAgreementMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A1WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A1WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-302023-08-30_custom_PurchaseAgreementMember_custom_A1WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A1WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-30</xbrli:startDate>
        <xbrli:endDate>2023-08-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A2WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-302023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A2WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-30</xbrli:startDate>
        <xbrli:endDate>2023-08-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-302023-08-30_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-30</xbrli:startDate>
        <xbrli:endDate>2023-08-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-05_custom_WainwrightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:WainwrightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-052023-07-05_custom_WainwrightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:WainwrightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-05</xbrli:startDate>
        <xbrli:endDate>2023-07-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_EmployeeOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_EmployeeOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_EmployeeOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_EmployeeOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-30_custom_A1WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A1WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-302023-08-30_custom_A1WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A1WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-30</xbrli:startDate>
        <xbrli:endDate>2023-08-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-30_custom_A2WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A2WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-302023-08-30_custom_A2WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A2WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-30</xbrli:startDate>
        <xbrli:endDate>2023-08-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-30_custom_WainwrightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:WainwrightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-302023-08-30_custom_WainwrightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:WainwrightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-30</xbrli:startDate>
        <xbrli:endDate>2023-08-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_EmployeeOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_EmployeeOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_EmployeeOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_custom_EmployeeOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_EmployeeOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_EmployeeOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_EmployeeOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_EmployeeOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_EmployeeOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_EmployeeOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_EmployeeOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_EmployeeOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_SellingAndMarketingExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_SellingAndMarketingExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_SellingAndMarketingExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_SellingAndMarketingExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember_custom_PrivateInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_WarrantMember_custom_PrivateInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_WarrantMember_custom_PrivateInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_WarrantMember_custom_PrivateInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_WarrantMember_custom_PrivateInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_WarrantMember_custom_PrivateInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_StockOptionsEmployeeAndNonEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NAOV:StockOptionsEmployeeAndNonEmployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_StockOptionsEmployeeAndNonEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NAOV:StockOptionsEmployeeAndNonEmployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_WarrantMember33335218">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_WarrantMember33335218">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_country_AU">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_country_AU">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_country_AU">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_country_AU">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_srt_AsiaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_srt_AsiaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_srt_AsiaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_srt_AsiaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_OtherCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NAOV:OtherCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_OtherCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NAOV:OtherCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_OtherCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NAOV:OtherCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_OtherCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NAOV:OtherCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:TwoCustomersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:TwoCustomersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:CustomersOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:CustomersOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:CustomersTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:CustomersTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:TwoCustomersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:TwoCustomersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:CustomersOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:CustomersOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:CustomersTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:CustomersTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-09_custom_LicensingAgreementMember_custom_SanuwaveHealthIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:LicensingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_PriceAtValuationMember_custom_SanuwaveHealthIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">NAOV:PriceAtValuationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_PriceAtValuationMember_custom_SanuwaveHealthIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">NAOV:PriceAtValuationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_MeasurementInputExercisePriceMember_custom_SanuwaveHealthIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_SanuwaveHealthIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_SanuwaveHealthIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_SanuwaveHealthIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_SanuwaveHealthIncMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SanuwaveHealthIncMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_MeasurementInputPriceVolatilityMember_custom_SanuwaveHealthIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_SanuwaveHealthIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_DerivativeAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_custom_DerivativeAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_DerivativeAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_custom_DerivativeAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_DerivativeAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_DerivativeAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_DerivativeAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_DerivativeAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_DerivativeAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_DerivativeAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_DerivativeAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_DerivativeAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_DerivativeAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_DerivativeAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-252021-02-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-25</xbrli:startDate>
        <xbrli:endDate>2021-02-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-142023-03-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-14</xbrli:startDate>
        <xbrli:endDate>2023-03-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ArbitratorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:ArbitratorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ArbitratorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:ArbitratorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-06_us-gaap_SubsequentEventMember_custom_PrefundedWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PrefundedWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-06_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326706</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90F_edei--DocumentType_c20230101__20230930_zD2hg5PeC04e"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--DocumentQuarterlyReport_c20230101__20230930_zFNy2XGTB23e"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span>
<b>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the quarterly period ended <span id="xdx_903_edei--DocumentPeriodEndDate_c20230101__20230930_zHOvnPYPTuh8"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">September 30, <span id="xdx_90F_edei--DocumentFiscalYearFocus_c20230101__20230930_zncXfpYY8qb2"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--DocumentTransitionReport_c20230101__20230930_zVPn0ebZGENl"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>
<b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the transition period from ________ to ________</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
File Number: <span id="xdx_906_edei--EntityFileNumber_c20230101__20230930_zER1G41UqeN8"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityFileNumber">001-36445</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-q_001.jpg" alt="" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_907_edei--EntityRegistrantName_c20230101__20230930_zhgk15HRYJJj"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityRegistrantName">NanoVibronix,
Inc</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityIncorporationStateCountryCode_c20230101__20230930_zU3jEvOUhjRb"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20230101__20230930_zn6U4a44ufx2"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityTaxIdentificationNumber">01-0801232</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    incorporation or organization)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
                                            Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    Number)</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityAddressAddressLine1_c20230101__20230930_zcLHvTRhE3i7" title="Entity address, address line one"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityAddressAddressLine1">525
    Executive Blvd</ix:nonNumeric></span>. <span id="xdx_90E_edei--EntityAddressCityOrTown_c20230101__20230930_zloa7YVSOto5" title="Entity ddress, city or town"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityAddressCityOrTown">Elmsford</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressStateOrProvince_c20230101__20230930_z3ulgvu5kJR7" title="Entity address, state or province"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">New York</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityAddressPostalZipCode_c20230101__20230930_zF69OK9gM95k"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityAddressPostalZipCode">10523</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive office)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#8217;s
telephone number, including area code: <b><span id="xdx_902_edei--CityAreaCode_c20230101__20230930_z4oVgJ4fgd57"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:CityAreaCode">(914)</ix:nonNumeric></span> <span id="xdx_901_edei--LocalPhoneNumber_c20230101__20230930_zjoNgtkqyTGf"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:LocalPhoneNumber">233-3004</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Former
name, former address and</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>former
fiscal year, if changed since last report)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--Security12bTitle_c20230101__20230930_zVPWWrqQAhbg"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:Security12bTitle">Common
    stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--TradingSymbol_c20230101__20230930_zk87HgHQvgU2"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:TradingSymbol">NAOV</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--SecurityExchangeName_c20230101__20230930_zy6kSFCTnxVe"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span>
Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_908_edei--EntityCurrentReportingStatus_c20230101__20230930_ztu0EiE0RrEh"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically and every Interactive Data File required to be submitted pursuant to
Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant has been required to submit
and post such files). <span id="xdx_90B_edei--EntityInteractiveDataCurrent_c20230101__20230930_z9iO1HkmIXYc"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--EntityFilerCategory_c20230101__20230930_zOtccuqI0xG8"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--EntitySmallBusiness_c20230101__20230930_zXgxZfk4kw35"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--EntityEmergingGrowthCompany_c20230101__20230930_z3CWzG2aGHz1"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9744; <span id="xdx_906_edei--EntityShellCompany_c20230101__20230930_zJ9S5ybBCrDe"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares outstanding of the registrant&#8217;s Common Stock as of November 13, 2023 was <span id="xdx_903_edei--EntityCommonStockSharesOutstanding_iI_c20231113_zpi8Lm42EGC9"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2023-11-13" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,046,308</ix:nonFraction></span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NanoVibronix,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Quarter
Ended September 30, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">TABLE
OF CONTENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">PART I. FINANCIAL INFORMATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">Financial Statements (Unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">Condensed Consolidated Balance Sheets as of September 30, 2023 (Unaudited) and December 31, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">Unaudited Condensed Consolidated Statements of Stockholders&#8217; Equity for the Three and Nine Months Ended September 30, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">Notes to Unaudited Condensed Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009">Quantitative and Qualitative Disclosures about Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">Controls and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">PART II. OTHER INFORMATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">Legal Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013">Risk Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_014">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_015">Defaults Upon Senior Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_016">Mine Safety Disclosures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_017">Other Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_018">Exhibits</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_019">Signatures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>PART
I - FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_002"></span>ITEM
1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_003"></span>NanoVibronix,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed
Consolidated Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Amounts
in thousands except share and per share data)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_111_pn3n3_zRC7989QFnl" summary="xdx: Statement -  Condensed Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_492_20230930_zOHRhnXjcAjf" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_495_20221231_zwzwWEeToeKg" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(unaudited)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">ASSETS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--Cash_i02I_pn3n3_maACzydB_zNgRt6CknC94" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; padding-left: 10pt">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,787</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,713</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccountsReceivableNetCurrent_i02I_pn3n3_maACzydB_z2GofdmJbnee" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Trade receivables, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_pn3n3_maACzydB_zQrGVV7BNMnh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Prepaid expenses and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">170</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">712</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--InventoryNet_i02I_pn3n3_maACzydB_zT1ju1JKQ4fk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Inventory, net</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,179</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,175</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsCurrent_i02TI_pn3n3_mtACzydB_maAziaA_zGYNC6V7Zgv8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,168</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,609</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsNoncurrentAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Noncurrent assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_i02I_pn3n3_maANzfDV_zg70NyAJtYV" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Fixed assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherAssetsNoncurrent_i02I_pn3n3_maANzfDV_zne4PGD1R1H1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--SeveranceAssetsNoncurent_i02I_pn3n3_maANzfDV_zkbqnkyxaqv4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Severance pay fund</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NAOV:SeveranceAssetsNoncurent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">165</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NAOV:SeveranceAssetsNoncurent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">179</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_pn3n3_maANzfDV_zfMougalUfHg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Operating lease right-of-use assets, net</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">81</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsNoncurrent_i02TI_pn3n3_mtANzfDV_maAziaA_zPCnIzrVfbof" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Total non-current assets</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">193</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">270</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--Assets_i01TI_pn3n3_mtAziaA_z4Uzf2pwGcHf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Total assets</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,361</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,879</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccountsPayableCurrent_i02I_pn3n3_maLCzAIs_zrNn7yedVd1l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Trade payables</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">62</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">66</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherAccountsPayableAndAccruedLiabilities_i02I_pn3n3_maLCzAIs_zyVLLm6LH3O7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accrued expenses and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,311</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,148</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredRevenue_i02I_pn3n3_maLCzAIs_ztO6wPFLZbAa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0095">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredRevenue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_pn3n3_maLCzAIs_z15nK3yDISve" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Operating lease liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">81</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesCurrent_i02TI_pn3n3_mtLCzAIs_maLzZGv_z9k4COm1uk95" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Total current liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,392</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,316</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesNoncurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherAccruedLiabilitiesNoncurrent_i02I_pn3n3_maLzZGv_zPEMt0BD2Oid" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accrued severance pay</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesNoncurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">206</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">223</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredIncomeNoncurrent_i02I_pn3n3_maLzZGv_zBUJMMwpwkgc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Deferred licensing income</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeNoncurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">73</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">107</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Liabilities_i01TI_pn3n3_mtLzZGv_maLASEzaX6_zxprN2M5Sly3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Total liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,671</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,646</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CommitmentsAndContingencies_i01I_pn3n3_maLASEzaX6_z6ZfBKDPYwah" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Commitments and contingencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0116">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0117">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stockholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PreferredStockValue_i02I_pn3n3_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z9ofLJXpSm32" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Series C Preferred stock of <span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zIIj3PdeQTo4" title="Preferred stock, par value">$<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zdU6PBRZXm6" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value - Authorized: <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zRkJV8xD8ELl" title="Preferred stock, shares authorized"><span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zFkTWme5PKq3" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-09-30_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000,000</ix:nonFraction></ix:nonFraction></span></span> shares at September 30, 2023 and December 31, 2022, respectively; Issued and outstanding: <span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zZnJv1OqT4E" title="Preferred stock, shares issued"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zeDwm2KzcxG6" title="Preferred stock, shares outstanding"><span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zoOvy97CxlM2" title="Preferred stock, shares issued"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z6jdG1fR7St6" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-09-30_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares at both September 30, 2023 and December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0122">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0123">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PreferredStockValue_i02I_pn3n3_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zteilTCfc303" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Series D Preferred stock of $<span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zkSReGpXE3t7" title="Preferred stock, par value"><span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zOx2M11Ge7nj" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30_us-gaap_SeriesDPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_us-gaap_SeriesDPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value - Authorized: <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zg02T34V3QW1" title="Preferred stock, shares authorized"><span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_znsKXmMDCUUi" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-09-30_us-gaap_SeriesDPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31_us-gaap_SeriesDPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">506</ix:nonFraction></ix:nonFraction></span></span> shares at September 30, 2023 and December 31, 2022, respectively; Issued and outstanding: <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zR3I0ndtZwOc" title="Preferred stock, shares issued"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zOXtOuGwkZra" title="Preferred stock, shares outstanding"><span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zh3T7JzHeHy4" title="Preferred stock, shares issued"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zLk6UzGvHGz2" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-09-30_us-gaap_SeriesDPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_SeriesDPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_us-gaap_SeriesDPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_SeriesDPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares at both September 30, 2023 and December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0141">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0142">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PreferredStockValue_i02I_pn3n3_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zxDRcu3Eejdj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Series E Preferred stock of $<span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zPpcjJSzuj1l" title="Preferred stock, par value"><span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zFHLfpFeRBRj" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30_us-gaap_SeriesEPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_us-gaap_SeriesEPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value - Authorized: <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_ztkoieP9x5sl" title="Preferred stock, shares authorized"><span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zygwJR1T6hYa" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-09-30_us-gaap_SeriesEPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31_us-gaap_SeriesEPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,999,494</ix:nonFraction></ix:nonFraction></span></span> shares at September 30, 2023 and December 31, 2022, respectively; Issued and outstanding: <span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_z5kZQau3iHpl" title="Preferred stock, shares issued"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zu1vKMT8Zs1j" title="Preferred stock, shares outstanding"><span id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zCrmhH3rz1S4" title="Preferred stock, shares issued"><span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zSQRxiEXdplf" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-09-30_us-gaap_SeriesEPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_SeriesEPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_us-gaap_SeriesEPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_SeriesEPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares at both September 30, 2023 and December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0160">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0161">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PreferredStockValue_i02I_pn3n3_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_maSEzgHc_zXRE9ecFH7D8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Series F Preferred stock of $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zv7ZImTw17Ok" title="Preferred stock, par value"><span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zkVjpaIzBVOl" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30_us-gaap_SeriesFPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_us-gaap_SeriesFPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span> </span>par value - Authorized: <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zpFAX7RiM7fc" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-09-30_us-gaap_SeriesFPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000</ix:nonFraction></span> and <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zcHmAWHJdyBb" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31_us-gaap_SeriesFPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span> shares at September 30, 2023 and December 31, 2022, respectively; Issued and outstanding: <span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zBNP58QCOueg" title="Preferred stock, shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zkcJ7jUR3Yl7" title="Preferred stock, shares outstanding"><span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zjPdteinGEvd" title="Preferred stock, shares issued"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zIlh0Xjp9a5i" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-09-30_us-gaap_SeriesFPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_SeriesFPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_us-gaap_SeriesFPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_SeriesFPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares at both September 30, 2023 and December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0179">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0180">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PreferredStockValue_i02I_pn3n3_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_maSEzgHc_zjQq1yOaoTne" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Preferred stock, value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0198">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0199">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CommonStockValue_i02I_maSEzgHc_zhSN2ZASW1Hc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 7.1pt">Common stock of $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230930_zeu7UdFv4oJ2" title="Common stock, par value"><span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231_ziP9KWbqVHTg" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value - Authorized: <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20230930_zPFBGEZJqakc" title="Common stock, shares authorized"><span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231_zzJutBtw3Rw2" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000,000</ix:nonFraction></ix:nonFraction></span></span> shares at September 30, 2023 and December 31, 2022, respectively; Issued and outstanding: <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_pid_c20230930_zdM159ySu6o6" title="Common stock, shares issued"><span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230930_zG41PNgiQp9g" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,842,331</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231_zEdP3xpo526e" title="Common stock, shares issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zOVW71Ko9z72" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,641,146</ix:nonFraction></ix:nonFraction></span></span> shares at September 30, 2023 and December 31, 2022, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AdditionalPaidInCapital_i02I_pn3n3_maSEzgHc_z2CkuwUktS0i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additional paid in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70,025</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">65,634</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_pn3n3_maSEzgHc_z2iqEjfrqimj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accumulated other comprehensive income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">54</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pn3n3_maSEzgHc_zBTJtA6WtO3d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">65,283</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">62,385</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--StockholdersEquity_i02TI_pn3n3_maLASEzaX6_mtSEzgHc_zJZZrqfP4UPk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Total stockholders&#8217; equity</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,690</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,233</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pn3n3_mtLASEzaX6_z7Ij6G5MYWlf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Total liabilities and stockholders&#8217; equity</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,361</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,879</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>NanoVibronix,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed
Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Amounts
in thousands except share and per share data)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_113_pn3n3_zr5NyzR9GXPi" summary="xdx: Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20230701__20230930_z7qEWClSnGs4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20220701__20220930_zG4vcuB3Ghd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20230930_zcDN16884Rn2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20220930_zaW4JH7Raw93" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maGPzYzH_zadBTuys0qze" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">458</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">97</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,106</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">854</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CostOfRevenue_msGPzYzH_z9yuGK0A0C45" style="vertical-align: bottom; background-color: White">
    <td>Cost of revenues</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">109</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">306</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">387</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--GrossProfit_iT_pn3n3_mtGPzYzH_maOILzBdq_zmNvUQoeUsdk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">349</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">80</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">467</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingExpensesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_i01_pn3n3_maOEzIkW_zArN7tdAIMx" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">33</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">49</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">123</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">176</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--SellingAndMarketingExpense_i01_pn3n3_maOEzIkW_zwAjjJZFKfVl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Selling and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">190</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">217</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">631</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">760</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_i01_pn3n3_maOEzIkW_zl7ik6wmrQQ" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">General and administrative</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">796</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">738</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,780</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,835</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingExpenses_i01T_pn3n3_mtOEzIkW_msOILzBdq_z3GxT8dGMgEj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total operating expenses</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,019</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,004</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,534</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,771</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingIncomeLoss_iT_pn3n3_mtOILzBdq_maILFCOzh10_zKgg7qxI84Fh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">670</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">924</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,734</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,304</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InterestExpense_iN_pn3n3_di_msILFCOzh10_zZESgqJE7gbc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0281">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">102</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0283">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--FinancialExpensesNet_maILFCOzh10_z2Erc3EZJ6Ic" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financial expense, net</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="NAOV:FinancialExpensesNet" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">19</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="NAOV:FinancialExpensesNet" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">16</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="NAOV:FinancialExpensesNet" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">44</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="NAOV:FinancialExpensesNet" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">47</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pn3n3_mtILFCOzh10_maNILzoOo_zjYMZQDXdiX6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss before taxes on income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">724</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">940</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,880</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,351</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_iN_pn3n3_di_msNILzoOo_zPkAbioDz8Kc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income tax expense</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_iT_pn3n3_mtNILzoOo_zQlklQSIaYfg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">727</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">955</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,898</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,389</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Basic and diluted net loss available for holders of common stock</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--EarningsPerShareBasic_pid_c20230701__20230930_zlKFi3I3jO1k" title="Basic net loss available for holders of common stock" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_pid_c20230701__20230930_zh0avbwaNkoc" title="Diluted net loss available for holders of common stock" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.42</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--EarningsPerShareBasic_pid_c20220701__20220930_zAwy6Bs5Pgo" title="Basic net loss available for holders of common stock" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pid_c20220701__20220930_z5YvBJTAlthk" title="Diluted net loss available for holders of common stock" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.68</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_pid_c20230101__20230930_zmTGDMZyiLe6" title="Basic net loss available for holders of common stock" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20230930_zTnLstYnHs7a" title="Diluted net loss available for holders of common stock" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.73</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--EarningsPerShareBasic_pid_c20220101__20220930_ztc4Ghq2mzza" title="Basic net loss available for holders of common stock" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20220930_zPlDlShgxS57" title="Diluted net loss available for holders of common stock" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.42</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average common shares outstanding:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Basic and diluted</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930_zOQq2Kl9ciq2" title="Weighted average common shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930_zCfhpjirqRHl" title="Weighted average common shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,721,026</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220701__20220930_zK9z3m3iQET7" title="Weighted average common shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220701__20220930_zR4l7hblcMGk" title="Weighted average common shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,399,890</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930_zYZVAZShq0Vl" title="Weighted average common shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930_zhNdvS1U6713" title="Weighted average common shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,678,684</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220101__20220930_zpK4ijIOmCAh" title="Weighted average common shares outstanding, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220101__20220930_zy16tDJ09E4j" title="Weighted average common shares outstanding, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcyAoVW5hdWRpdGVkKQA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,399,890</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLossAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Comprehensive loss:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_i01_pn3n3_maCINOTziN0_zMYYQ8siMOAa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Net loss available to common stockholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">727</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">955</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,898</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,389</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_i01N_pn3n3_di_msCINOTziN0_ziwiOVAxDfK3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Change in foreign currency translation adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">57</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--ComprehensiveIncomeNetOfTax_i01T_pn3n3_mtCINOTziN0_zGvqolDFgOY4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Comprehensive loss available to common stockholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">726</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">961</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,934</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,446</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_005"></span>NanoVibronix,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed
Consolidated Statement of Stockholders&#8217; Equity (Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Amounts
in thousands except share and per share data)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_114_pn3n3_zkLbXsBnT478" summary="xdx: Statement - Condensed Consolidated Statement of Stockholders&apos; Equity (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesCPreferredStockMember_z3uAP9yS4VOf" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesDPreferredStockMember_zXO9wL8meno4" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesEPreferredStockMember_zteOdqgprSC3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesFPreferredStockMember_zNUpvtlgeljl" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zM5A1jG0ISSk" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zOxeqFHmCRKg" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zmmWNt6wa568" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zsvcitLVCmga" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B8_zxejyzVnQTr" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    C Preferred Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
    D Preferred Stock</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
    E Preferred Stock</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series
    F Preferred Stock</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    Paid - in</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    Other Comprehensive</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Stockholders&#8217;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_436_c20220701__20220930_eus-gaap--StockholdersEquity_iS_zONnPX9ntMS3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    June 30, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20220701__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zxzsQIXTSnHd" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0367">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0357">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_pid_c20220701__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zm4mjJmUacN8" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0369">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0358">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20220701__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zymrf5Y6POMh" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0371">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0359">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20220701__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z36RNL4oHg8b" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0373">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0360">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk7HV1ar9wrd" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,399,890</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">63,468</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">59,371</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,134</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_z3QmcuS9qofc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0377">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0378">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0379">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0380">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0381">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">116</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0383">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0384">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">116</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants_zKN30dSxQtrl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reversal
    of warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0387">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0388">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0389">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0390">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0391">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">135</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0393">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0394">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">135</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_zchikKd3JKib" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currency
    translation adjustment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0397">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0398">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0399">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0400">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0401">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0402">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2022-07-012022-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0404">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_pn3n3_zLsEdpyc64bk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0407">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0408">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0409">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0410">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0411">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0412">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0413">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">955</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">955</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_438_c20220701__20220930_eus-gaap--StockholdersEquity_iE_zck7XJyVjUJf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    September 30, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_pid_c20220701__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zqSuMUiCD3ne" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0427">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0417">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_pid_c20220701__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z0L148j81gJj" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0429">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0418">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_pid_c20220701__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zd4crwITlhx5" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0431">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0419">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_pid_c20220701__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zol1LBSmu9Qa" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0433">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0420">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5cidmF3Cg77" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,399,890</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">63,449</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">60,326</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,154</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    C Preferred Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    D Preferred Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    E Preferred Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    F Preferred Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    Paid - in</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    Other Comprehensive</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Stockholders&#8217;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_43E_c20220101__20220930_eus-gaap--StockholdersEquity_iS_zkl8WBAvN4Lb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20220101__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zSHEjFpqsEdf" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0447">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0437">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_pid_c20220101__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z79cFPyOSdU4" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0449">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0438">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20220101__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zUjz9aCc9Ywb" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0451">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0439">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20220101__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zPDNv4Z4hHei" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0453">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0440">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqMkRTNSxEFd" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,399,890</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">63,162</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">60</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">56,937</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,313</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zRfLDNA80oy4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0457">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0458">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0459">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0460">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0461">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">287</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0463">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0464">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">287</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zDhb7Ee0ZOvj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    of warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0467">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0468">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0469">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0470">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0471">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">135</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0473">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0474">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">135</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants_zPuDA4ZxCOy3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reversal
    of warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0477">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0478">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0479">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0480">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0481">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants" contextRef="From2022-01-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">135</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0483">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0484">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">135</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_zvND7ELiLQR5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currency
    translation adjustment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0487">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0488">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0489">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0490">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0491">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0492">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2022-01-012022-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">57</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0494">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">57</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_pn3n3_z2ukJ8KCG1Qa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0497">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0498">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0499">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0500">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0501">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0502">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0503">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,389</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,389</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_43F_c20220101__20220930_eus-gaap--StockholdersEquity_iE_z6WN4DHGyitd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    September 30, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--SharesOutstanding_iE_pid_c20220101__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zmLKWwlS6ud6" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0517">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0507">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_pid_c20220101__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zXNESGVWVyO5" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0519">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0508">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--SharesOutstanding_iE_pid_c20220101__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zLMbq4bn6aU4" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0521">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0509">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20220101__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zQk48djjB4Ad" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0523">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0510">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIYcorB74Gcf" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,399,890</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">63,449</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">60,326</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,154</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    C Preferred Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    D Preferred Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    E Preferred Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    F Preferred Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    Paid - in</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    Other Comprehensive</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Stockholders&#8217;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_438_c20230701__20230930_eus-gaap--StockholdersEquity_iS_zt3LVwGc19ak" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    June 30, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20230701__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zTToyroKamT6" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0537">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0527">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20230701__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zn3qYIRJy1Zc" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0539">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0528">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20230701__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zQZeSxLpRnz2" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0541">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0529">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20230701__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_znqT6iiTwGrc" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0543">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0530">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zubXDuROLdh4" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,662,330</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">65,774</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">55</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">64,556</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,165</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_z4z6XzLSj29b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0547">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0548">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0549">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0550">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0551">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0553">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0554">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--StockIssuedDuringPeriodValueOther_zAXPJEtoNPjg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0557">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0558">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0559">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0560">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhleornUmzy8" title="Issuance of common stock, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">180,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0561">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,215</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0563">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0564">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,215</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_zReHCN09dAFj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currency
    translation adjustment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0569">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0570">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0571">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0572">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0573">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0574">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0576">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_pn3n3_zdhVW9SUAqkb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0579">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0580">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0581">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0582">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0583">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0584">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0585">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">727</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">727</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_435_c20230701__20230930_eus-gaap--StockholdersEquity_iE_zZ48jv1MWscj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    September 30, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pid_c20230701__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zyN5my0fCNy" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0599">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0589">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_pid_c20230701__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zCdUWEmcXm7l" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0601">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0590">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_pid_c20230701__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zSIFFG2Be8x" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0603">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0591">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20230701__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zvYA9BDPXmN4" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0605">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0592">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zi33i6VNE0fh" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,842,330</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70,025</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">54</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">65,283</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,690</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    C Preferred Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    D Preferred Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    E Preferred Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    F Preferred Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    Paid - in</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    Other Comprehensive</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Stockholders&#8217;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_438_c20230101__20230930_eus-gaap--StockholdersEquity_iS_zVDDtSRtB0E6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zEn0du3ttrig" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0619">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0609">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zR17wwTegLnf" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0621">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0610">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z12BsPMZ4V8k" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0623">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0611">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zl4tzQNInl88" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0625">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0612">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcbFdNMvueKf" title="Beginning balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,641,146</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">65,634</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">62,385</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,233</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_433_c20230101__20230930_eus-gaap--StockholdersEquity_iS_zm8SdzjYy1I2" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zSIxzMO7kpEl" title="Balance, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0639">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0629">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zRq3Be8S4OC6" title="Balance, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0641">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0630">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zEKPiWCk0tm3" title="Balance, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0643">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0631">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_znYThfyNnhP3" title="Balance, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0645">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0632">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpXHc0as7bN4" title="Balance, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,641,146</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">65,634</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">62,385</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,233</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zS7N3Ce8mVxj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0649">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0650">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0651">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0652">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0653">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">169</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0655">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0656">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">169</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueOther_zT0N51Ggnbf4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0659">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0660">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0661">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0662">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjdDGXkodfyh" title="Issuance of common stock, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">180,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0663">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,215</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0665">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0666">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,215</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_zvfRV06coqu4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currency
    translation adjustment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0671">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0672">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0673">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0674">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0675">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0676">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2023-01-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">36</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0678">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">36</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zbmPlWKDIY76" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    of options</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0681">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0682">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0683">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0684">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zargKkkIJG3b" title="Exercise of options, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,458</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0685">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0687">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0688">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zvwsk1UYtfsc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rounding
    up of fractional shares due to stock split</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0693">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0694">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0695">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0696">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGTib4Upqnp" title="Rounding up of fractional shares due to stock split, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,726</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0697">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0698">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0699">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0700">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0701">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_pn3n3_zPtvMyBScmq2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0705">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0706">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0707">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0708">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0709">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0710">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0711">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,898</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,898</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_439_c20230101__20230930_eus-gaap--StockholdersEquity_iE_zvobvn8zFvq" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    September30, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_pid_c20230101__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zevkrFIK41c4" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0725">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0715">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_pid_c20230101__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zHB7I7dM9Df8" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0727">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0716">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20230101__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zHhcHPzJdVe9" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0729">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0717">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_pid_c20230101__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z7icTmzvuEL8" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0731">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0718">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIBGS0SwcL5d" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,842,330</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70,025</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">54</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">65,283</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,690</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_43E_c20230101__20230930_eus-gaap--StockholdersEquity_iE_zhuBqBmgmN3b" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20230101__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zhnRPLnpA054" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0745">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0735">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_pid_c20230101__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zhIETJmeWz64" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0747">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0736">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_pid_c20230101__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zBU6JTFTyztg" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0749">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0737">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_pid_c20230101__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zSmb4o2tvf6j" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0751">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0738">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxCosBY8KIqj" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,842,330</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70,025</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">54</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">65,283</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,690</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_006"></span>NanoVibronix,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed
Consolidated Statements of Cash Flows (Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Amounts
in thousands except share and per share data)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_112_pn3n3_zyBnDACSDJ3e" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20230930_z6olgaw3CwC7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20220101__20220930_znG68m33g8jf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_i01_pn3n3_maNCPBUz3YD_zcRtPaZbB7a8" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,898</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,389</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DepreciationDepletionAndAmortization_i02_pn3n3_maNCPBUz3YD_zHHCpYNSSYcf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ShareBasedCompensation_i02_pn3n3_maNCPBUz3YD_zD7xXx0hstLi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">169</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">287</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--NoncashInterestExpense_i02_pn3n3_maNCPBUz3YD_zpRamhPOicE5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Noncash interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NAOV:NoncashInterestExpense" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">102</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0771">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--EquitySecuritiesFvNiGainLoss_i02N_pn3n3_di_msNCPBUz3YD_zSsHDUyCpdZi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Change in fair value of equity investment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInAccountsReceivable_i02N_pn3n3_di_msNCPBUz3YD_zTY8YkbxojF6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Trade receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i02N_pn3n3_di_msNCPBUz3YD_zdr5ZCLh3X4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Prepaid expenses and other accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">542</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,008</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInInventories_i02N_pn3n3_di_msNCPBUz3YD_z0f3Uzbh5Rf8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,004</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,378</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInAccountsPayableTrade_i02_pn3n3_maNCPBUz3YD_zCQTBpYpWHP1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Trade payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">46</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_i02_pn3n3_maNCPBUz3YD_zGX58rWSW1Rb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Other accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">61</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">77</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInDeferredRevenue_i02_pn3n3_maNCPBUz3YD_zZTGUFvSca49" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">55</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">78</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--IncreaseDecreaseInAccruedSeverancePayNet_i02_pn3n3_maNCPBUz3YD_zfoNnFf4uw46" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Accrued severance pay, net</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="NAOV:IncreaseDecreaseInAccruedSeverancePayNet" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="NAOV:IncreaseDecreaseInAccruedSeverancePayNet" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_pn3n3_mtNCPBUz3YD_maCCERCzxOh_z4taKem61TJ9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 30pt">Net cash used in operating activities</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,111</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,704</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_pn3n3_di_msNCPBUzaX9_zW80RFQLU0jh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Purchases of equipment</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_pn3n3_mtNCPBUzaX9_maCCERCzxOh_zsp7MMTa6Xt" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Net cash used in investing activities</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maNCPBUzYp0_z2BLVZ929Jkb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Proceeds from issuance of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,215</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0816">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromStockOptionsExercised_i01_pn3n3_maNCPBUzYp0_z0Bs6F2cG7v3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Proceeds from exercise of options</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0819">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_pn3n3_mtNCPBUzYp0_maCCERCzxOh_zsWKl18LGH01" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,222</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_maCCERCzxOh_zmmShdoYuLc2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Effects of currency translation on cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">36</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">57</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_pn3n3_mtCCERCzxOh_zvdLoZ4VlZV4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Net increase (decrease) in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,074</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,765</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_pn3n3_zwtALC0M2tXl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Cash at beginning of period</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,713</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,737</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_pn3n3_zTRg89m7WKK7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Cash at end of period</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,787</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,972</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_007"></span>NanoVibronix,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
to Condensed Consolidated Financial Statements (Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Amounts
in thousands except share and per share data)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:NatureOfOperations"><p id="xdx_805_eus-gaap--NatureOfOperations_zvtoRsJwU95f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 &#8211; <span id="xdx_827_zgAAM6YqGzga">DESCRIPTION OF BUSINESS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NanoVibronix,
Inc. (the &#8220;Company&#8221;), a Delaware corporation, commenced operations on October 20, 2003 and is a medical device company focusing
on noninvasive biological response-activating devices that target wound healing and pain therapy and can be administered at home, without
the assistance of medical professionals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s principal research and development activities are conducted in Israel through its wholly owned subsidiary, NanoVibronix
(Israel 2003) Ltd., a company registered in Israel, which commenced operations in October 2003.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="NAOV:GoingConcernAndLiquidityTextBlock"><p id="xdx_801_ecustom--GoingConcernAndLiquidityTextBlock_zMmT5rxIC1cc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 &#8211; <span id="xdx_820_zk2DvL6R2hZ7">GOING CONCERN, LIQUIDITY AND OTHER UNCERTAINTIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity
and Going Concern</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue to operate is dependent mainly on its ability to successfully market and sell its products and the
receipt of additional financing until profitability is achieved. In August 2023, the Company received net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20230801__20230831_zhqmgj7jqGVd" title="Proceeds from issuance sale of equity"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2023-08-012023-08-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,215,000</ix:nonFraction></span> from
the sale of our equity securities. During the three and nine months ended September 30, 2023, the Company has incurred losses as well
as negative cash outflows from operating activities and expects to incur losses and negative cash outflows from operating activities
through at least fiscal year 2024. Because the Company does not have sufficient resources to fund its operations for the next twelve
months from the date of this filing and there could be a significant arbitration payment due (see Note 9), substantial doubt exists as
to the Company&#8217;s ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will need to raise additional capital to finance its losses and negative cash flows from operations and may continue to be dependent
on additional capital raising as long as our products do not reach commercial profitability. If the Company is unable to obtain additional
financing, the development of its product candidates and the Company&#8217;s commercial strategy may be impacted and there could be a
material adverse effect on the Company&#8217;s business and financial condition. These financial statements do not include any adjustments
that may result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Uncertainties</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 23, 2023, we received a letter from the Listing Qualifications Department of Nasdaq indicating that we no longer comply with the
minimum stockholders&#8217; equity requirement under Nasdaq Listing Rule 5550(b)(1) (the &#8220;Rule&#8221;) for continued listing on
Nasdaq because our stockholders&#8217; equity of approximately $<span id="xdx_90C_eus-gaap--StockholdersEquity_iI_pn5n6_c20230331_zYwx4zz4VUVe" title="Stockholder&apos;s equity"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.2</ix:nonFraction></span> million as reported in our Quarterly Report on Form 10-Q for the
period ended March 31, 2023, is below the required minimum of $<span id="xdx_902_eus-gaap--StockholdersEquity_iI_pn5n6_c20230331__srt--RangeAxis__srt--MinimumMember_zUklhW6vLmca" title="Stockholder&apos;s equity"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.5</ix:nonFraction></span> million, and as of May 22, 2023, we did not meet the alternative compliance
standards relating to the market value of listed securities of $<span id="xdx_901_ecustom--ValueOfListedSecurites_iI_pn6n6_c20230522_zdfmiMlumnsk" title="Value of listed securities"><ix:nonFraction name="NAOV:ValueOfListedSecurites" contextRef="AsOf2023-05-22" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">35</ix:nonFraction></span> million or net income from continuing operations of $<span id="xdx_900_eus-gaap--NetIncomeLoss_pn3d_c20230522__20230522_zV3rMQU4XvHb" title="Net income from continuing operations"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-05-222023-05-22" format="ixt:numdotdecimal" decimals="-3" unitRef="USD">500,000</ix:nonFraction></span> in the
most recently completed fiscal year or in two of the last three most recently completed fiscal years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Nasdaq Listing Rules, we had 45 calendar days, or until July 7, 2023, to submit a plan to regain compliance. On July
7, 2023, we submitted our plan to regain compliance with the Nasdaq minimum stockholders&#8217; equity standard. On July 19, 2023, the
Staff granted the Company&#8217;s plan and granted our request for continued listing pursuant to an extension through November 20, 2023
to evidence compliance with the Rule. We believe that upon filing of this Form 10-Q, we should have provided sufficient evidence of compliance
with Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian
and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s
border with the Gaza Strip and in other areas within the State of Israel. Following the attack, Israel&#8217;s security cabinet declared
war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror
attacks. Moreover, the clash between Israel and Hezbollah in Lebanon, may escalate in the future into a greater regional conflict</span>,
especially in the northern part of Israel where our Israel office is located which stores approximately $<span id="xdx_906_eus-gaap--InventoryNet_iI_pn5n6_c20231031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zg5GePQ0Qte7"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2023-10-31_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.1</ix:nonFraction></span> million worth of our inventory.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This conflict could cause a<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n
inability to receive supplies and materials, shortages of materials or difficulties in procuring our materials, among others, or
conversely, our ability to ship products to our US facilities or overseas customers, may adversely impact our ability to
commercialize and manufacture our product candidates and products in a timely manner. This could also cause delays the review of our product candidates by regulatory agencies, which in turn would have a material adverse impact on our ability to
commercialize those  product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_802_eus-gaap--SignificantAccountingPoliciesTextBlock_zbQvJSucPhWc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 &#8211; <span id="xdx_827_zTpsvuW9FIKf">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zBY09KwdrUt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zuuL4Fa8DtHb">Basis
of presentation and principles of consolidation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts
and transactions have been eliminated in consolidation. The Company&#8217;s condensed consolidated financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for the interim
financial information and with instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the accompanying
unaudited interim consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary
to state fairly the financial position and results of operations of the Company. These condensed consolidated financial statements and
notes thereto are unaudited and should be read in conjunction with the Company&#8217;s audited financial statements for the year ended
December 31, 2022, as found in the Company&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the
&#8220;SEC&#8221;) on April 17, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
balance sheet for December 31, 2022 was derived from the Company&#8217;s audited financial statements for the year ended December 31,
2022. The results of operations for the periods presented are not necessarily indicative of results that could be expected for the entire
fiscal year due to seasonality and other factors. Certain information and footnote disclosures normally included in the consolidated
financial statements in accordance with U.S. GAAP have been omitted in accordance with the rules and regulations of the SEC for interim
reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_843_eus-gaap--UseOfEstimates_z5P9bh2OVXV3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zqp2oKoziQlc">Use
of estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and
assumptions. The Company believes that the estimates, judgments and assumptions used are reasonable based upon information available
at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during
the reporting period. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_84F_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zzV043tV41G9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zyFn95UYln8">Foreign
currency translation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-U.S.
dollar denominated transactions and balances have been re-measured to U.S. dollars. All gains and losses from re-measurement of monetary
balance sheet items denominated in non-U.S. dollar currencies are reflected in the statements of operations as other comprehensive income,
as appropriate. The cumulative translation gains for the periods ended September 30, 2023 and 2022 were $<span id="xdx_901_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_pn3n3_c20230101__20230930_zbWCWbb4IAS8" title="Gains and losses from foreign currency translation"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_pn3n3_c20220101__20220930_zchb15iSrutd" title="Gains and losses from foreign currency translation"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">57</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_847_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zBAmZ7iek945" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_z6mPWqtr7zX9">Revenue
recognition</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
from product sales are recognized in accordance with ASC 606 &#8220;Revenue Recognition.&#8221; Five basic steps must be followed before
revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying
the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction
price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised
goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires
the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of
each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance
obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the
satisfied performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from product sales is recorded at the net sales price, or &#8220;transaction price,&#8221; which includes estimates of variable consideration
that result from coupons, discounts and distributor fees, processing fees, as well as allowances for returns and government rebates.
The Company constrains revenue by considering factors that could otherwise lead to a probable reversal of revenue. Collectability of
revenue is reasonably assured based on historical evidence of collectability between the Company and its customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
from sales to distributors are recognized at the time the products are delivered to the distributors (&#8220;sell-in&#8221;). The Company
does not grant rights of return, credits, rebates, price protection, or other privileges on its products to distributors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zDSs0khjhCVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zueI98NmfDe1">Recently
adopted accounting standards</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13,
Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;)
and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, and ASU 2019-05 (collectively, &#8220;Topic
326&#8221;). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. This ASU is effective
for interim and annual reporting periods beginning after December 15, 2022, including interim periods within those fiscal years. The
Company adopted ASU 2016-13 as of January 1, 2023, and there was no material impact on its condensed consolidated financial statements
upon adoption.</span></p>

</ix:nonNumeric><p id="xdx_85A_zKL4xcse8Vd5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zUC6nYDaty42" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 &#8211;<span id="xdx_822_zM2k2FhcpeY6"> STOCKHOLDERS&#8217; EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common
stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
common stock confers upon the holders the right to receive notice to participate and vote in general meetings of the Company, and the
right to receive dividends, if declared, and to participate in the distribution of the surplus assets and funds of the Company in the
event of liquidation, dissolution or winding up of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reverse
stock split</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2023, the Company effected a reverse stock split of its common stock at a ratio of 1 post-split share for every 20 pre-split
shares. The Company&#8217;s common stock begin trading on a split-adjusted basis when the market opened on February 9, 2023 (the &#8220;Reverse
Stock Split&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the effective time of the Reverse Stock Split, every 20 shares of the Company&#8217;s issued and outstanding common stock were converted
automatically into one issued and outstanding share of common stock without any change in the par value per share. Stockholders holding
shares through a brokerage account had their shares automatically adjusted to reflect the <span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20230208__20230208_zLC1i1LhWeOj" title="Reverse stock split"><ix:nonNumeric contextRef="From2023-02-082023-02-08" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-20 Reverse Stock Split</ix:nonNumeric></span>. The Reverse Stock
Split affected all stockholders uniformly and did not alter any stockholder&#8217;s percentage interest in the Company&#8217;s equity,
except to the extent that the Reverse Stock Split resulted in a stockholder owning a fractional share. Any fractional share of a stockholder
resulting from the Reverse Stock Split was rounded up to the nearest whole number of shares. Proportional adjustments were made to the
number of shares of the Company&#8217;s common stock issuable upon exercise or conversion of the Company&#8217;s equity awards, warrants
and other convertible securities, as well as the applicable exercise or conversion price thereof. On February 16, 2023, the Company rounded
up fractional shares to its nearest whole number of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20230215__20230216_z2wwKcccHXd6" title="Fractional shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="From2023-02-152023-02-16" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,726</ix:nonFraction></span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references in this Report to number of shares, price per share and weighted average number of shares of common stock outstanding prior
to the Reverse Stock Split have been adjusted to reflect the Reverse Stock Split on a retroactive basis, unless otherwise noted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Issuance
of common stock for cash through private placement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 30, 2023, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with an institutional
investor for the issuance and sale in a private placement (the &#8220;Private Placement&#8221;) of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlFv0NaUbej4" title="Number of new share issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-08-302023-08-30_custom_PurchaseAgreementMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">180,000</ix:nonFraction></span> shares (the &#8220;Common
Shares&#8221;) of common stock, par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXkviiOOVyCi" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share (the &#8220;Common Stock&#8221;), pre-funded warrants (&#8220;Pre-Funded Warrants&#8221;)
to purchase up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGBfViebVFS4" title="Number of securities called by warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,726,977</ix:nonFraction></span> shares of common stock, with an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrXBo42AE23k" title="Class of warrant or right, exercise price of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share, A-1 Warrants (the &#8220;A-1 Warrants&#8221;)
to purchase up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zw3vbYxYjMF6" title="Number of securities called by warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A1WarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,906,977</ix:nonFraction></span> shares of Common Stock, with an exercise price of $<span id="xdx_908_eus-gaap--WarrantExercisePriceIncrease_pid_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zHPPujQoM1H" title="Warrant exercise price"><ix:nonFraction name="us-gaap:WarrantExercisePriceIncrease" contextRef="From2023-08-302023-08-30_custom_PurchaseAgreementMember_custom_A1WarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.47</ix:nonFraction></span> per share, and A-2 Warrants (the &#8220;A-2 Warrants&#8221;
and together with the A-1 Warrants, the &#8220;Warrants<b><i>&#8221;</i></b> ) to purchase up to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_z1OTkJGj2wRk" title="Number of securities called by warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,906,977</ix:nonFraction></span> shares of Common Stock with
an exercise price of $<span id="xdx_90D_eus-gaap--WarrantExercisePriceIncrease_pid_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zPDC2CFwamLj" title="Warrant exercise price"><ix:nonFraction name="us-gaap:WarrantExercisePriceIncrease" contextRef="From2023-08-302023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.47</ix:nonFraction></span> per share. The A-1 Warrants are exercisable immediately upon issuance and expire <span id="xdx_909_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zLVai5Gpwz62" title="Class of warrant or right expire date"><ix:nonNumeric contextRef="From2023-08-302023-08-30_custom_PurchaseAgreementMember_custom_A1WarrantsMember" format="ixt:datemonthdayyearen" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">March 1, 2029</ix:nonNumeric></span>. The A-2 Warrants
are exercisable immediately upon issuance and expire <span id="xdx_906_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zPS1XQ2gnNSd" title="Class of warrant or right expire date"><ix:nonNumeric contextRef="From2023-08-302023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember" format="ixt:datemonthdayyearen" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">October 1, 2024</ix:nonNumeric></span>. The combined purchase price for one Common Share and the accompanying
Warrants was $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zlm50Hz5cl7e" title="Class of warrant or right exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.72</ix:nonFraction></span>, and the combined purchase price for one Pre-Funded Warrant and the accompanying Warrants was $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zILTh77GSs2l" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.7199</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net proceeds to the Company from the Private Placement are approximately $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20230830__20230830__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zswqXNxNBuil" title="Proceeds from issuance of private placement"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2023-08-302023-08-30_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,215,000</ix:nonFraction></span>, after deducting placement agent fees and expenses
and estimated offering expenses payable by the Company. The Company intends to use the net proceeds received from the Private Placement
for general corporate purposes, including funding of our development programs, commercial planning and sales and marketing expenses,
potential strategic acquisitions, general and administrative expenses and working capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;) served as the Company&#8217;s exclusive placement agent in connection with the Private
Placement, pursuant to that certain engagement letter, dated as of July 5, 2023, as amended, between us and Wainwright (the &#8220;Engagement
Letter&#8221;). As part of Wainwright&#8217;s compensation, we issued to Wainwright or its designees warrants (the &#8220;Placement Agent
Warrants&#8221;) to purchase up to an aggregate of <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230705__srt--TitleOfIndividualAxis__custom--WainwrightMember_zzMwmkvEsIik" title="Number of securities called by warrants or rights"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-07-05_custom_WainwrightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">218,023</ix:nonFraction> </span>shares of Common Stock at an exercise price equal to $<span id="xdx_908_eus-gaap--SharePrice_iI_pid_c20230705__srt--TitleOfIndividualAxis__custom--WainwrightMember_zAzEnEDVXIwk" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-07-05_custom_WainwrightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.15</ix:nonFraction> </span>per share. The
Placement Agent Warrants are exercisable immediately upon issuance and expire <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20230705__20230705__srt--TitleOfIndividualAxis__custom--WainwrightMember_zdOA1L7DcnRk" title="Class of warrant or right expire date"><ix:nonNumeric contextRef="From2023-07-052023-07-05_custom_WainwrightMember" format="ixt:datemonthdayyearen" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">March 1, 2029</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-based
compensation and Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and nine-month period ended September 30, 2023, <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zwU73p1gvLgb" title="Number of options, exercised"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-07-012023-09-30_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span> and<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zq8u4ttHowbi" title="Number of options, exercised"> <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-012023-09-30_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,459</ix:nonFraction></span> employee options were exercised respectively. During the three
and nine-month period ended September 30, 2022, <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_ztRgjbj3PONa" title="Number of options, exercised"><span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z9Vw6YBYG04l" title="Number of options, exercised"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-07-012022-09-30_custom_EmployeeOptionsMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-09-30_custom_EmployeeOptionsMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> employee options were exercised. During the three and nine-month period ended September
30, 2023, <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_dxL_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zLWXgG66SCm9" title="Number of employee options granted::XDX::-"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_dxL_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zQR2mJdHWk8" title="Number of employee options granted::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0913"><span style="-sec-ix-hidden: xdx2ixbrl0915">no</span></span></span></span> employee options were granted. During the three and nine-month period ended September 30, 2022, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_dxL_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zEob1MEI8nm1" title="Number of employee options granted::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0917">0</span></span> and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zateONgWrs7c" title="Number of employee options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-09-30_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,000</ix:nonFraction></span> employee options
were granted, respectively. During the three and nine-month period ended September 30, 2023, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zPxxhvlvH9g6" title="Number of employee options expired"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2023-07-012023-09-30_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span> and <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zgX9q3tgJCG4" title="Number of employee options expired"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2023-01-012023-09-30_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000</ix:nonFraction></span> employee options expired. During
the three and nine-month period ended September 30, 2022, <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zcqLjKaA47nc" title="Number of employee options expired"><span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zDu5BGUxuKu6" title="Number of employee options expired"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-07-012022-09-30_custom_EmployeeOptionsMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-09-30_custom_EmployeeOptionsMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> employee options expired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The options granted to employees and board members
were recorded at a fair value and vested over three years. During the three and nine-month period ended September 30, 2023, stock-based
compensation expense of $<span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_znkmRBm3AN02" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-07-012023-09-30_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zRLWYT3exfm8" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-09-30_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">169</ix:nonFraction></span> was recorded for options that vested, respectively. During the three and nine-month period ended
September 30, 2022, stock-based compensation expense of $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z1tdMI9wGC77" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-07-012022-09-30_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">116</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zfBERijeiVAb" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-09-30_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">285</ix:nonFraction></span> was recorded for options that vested, respectively.</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zEFWXkHaWf5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zhm3L1Jach92" style="display: none">SCHEDULE
OF OPTIONS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Shares Under</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Options</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise Price</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>per Share</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Remaining</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Life (Years)</b></p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%">Outstanding &#8211; December 31, 2021</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zNYffLFvX0Uc" title="Shares Under Options Outstanding, Balance" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,000</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zgSkhIkOChO" title="Weighted Average Exercise Price per Share, Outstanding Balance" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">31.86</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 14%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zDt92FjsGQp3" title="Weighted Average Remaining Life (Years), Outstanding"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_EmployeeOptionsMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.77</ix:nonNumeric></span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zlnZXpA0aVik" title="Shares Under Options, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-03-31_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z8RyMpLwyUr9" title="Weighted Average Exercise Price per Share, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-03-31_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">15.56</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_dtY_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zuZ0btfr18r3" title="Weighted Average Remaining Life (Years), Granted"><ix:nonNumeric contextRef="From2022-01-012022-03-31_custom_EmployeeOptionsMember" format="ixt-sec:duryear" name="NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm">9.89</ix:nonNumeric></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z1knTaIsHKY1" title="Shares Under Options, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-03-31_custom_EmployeeOptionsMember" format="ixt:zerodash" decimals="INF" sign="-" unitRef="Shares">-</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zUTR0v6d3qyl" title="Weighted Average Exercise Price per Share, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-03-31_custom_EmployeeOptionsMember" format="ixt:zerodash" decimals="INF" sign="-" unitRef="USDPShares">-</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding &#8211; March 31, 2022</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zMVdeEOodzCf" title="Shares Under Options Outstanding, Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-03-31_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">133,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zQl75Nkjlwkg" title="Weighted Average Exercise Price per Share, Outstanding Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-03-31_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">26.00</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zr5TxapXQV4a" title="Weighted Average Remaining Life (Years), Outstanding"><ix:nonNumeric contextRef="From2022-04-012022-06-30_custom_EmployeeOptionsMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.63</ix:nonNumeric></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Granted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zCUkBXnTWWyc" title="Shares Under Options, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0961">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z7XmzNglk7ze" title="Weighted Average Exercise Price per Share, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0963">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zBpqS1kVzeWc" title="Shares Under Options, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-04-012022-06-30_custom_EmployeeOptionsMember" format="ixt:zerodash" decimals="INF" sign="-" unitRef="Shares">-</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zLJTMOxelFuh" title="Weighted Average Exercise Price per Share, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-04-012022-06-30_custom_EmployeeOptionsMember" format="ixt:zerodash" decimals="INF" sign="-" unitRef="USDPShares">-</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding &#8211; June 30, 2022</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zqJCIWFX3hnd" title="Shares Under Options Outstanding, Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-06-30_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">133,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zo5qK40TN7U1" title="Weighted Average Exercise Price per Share, Outstanding Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-06-30_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">26.00</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zrboyDLisHW2" title="Weighted Average Remaining Life (Years), Outstanding"><ix:nonNumeric contextRef="From2022-07-012022-09-30_custom_EmployeeOptionsMember" format="ixt-sec:duryear" name="NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm">7.63</ix:nonNumeric></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9.9pt">Granted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zuAB7KtmwOgc" title="Shares Under Options, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0975">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zzpgR4r4mgj5" title="Weighted Average Exercise Price per Share, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9.9pt">Exercised</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z2jdDHBBrw8h" title="Shares Under Options, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-07-012022-09-30_custom_EmployeeOptionsMember" format="ixt:zerodash" decimals="INF" sign="-" unitRef="Shares">-</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zDQELXuJ2IQa" title="Weighted Average Exercise Price per Share, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-07-012022-09-30_custom_EmployeeOptionsMember" format="ixt:zerodash" decimals="INF" sign="-" unitRef="USDPShares">-</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding &#8211; September 30, 2022</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zsOdobhd7Pg8" title="Shares Under Options Outstanding, Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-09-30_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">133,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2d_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z0CCFpvoNyBl" title="Weighted Average Exercise Price per Share, Outstanding Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">26.00</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z3pE2Gl58YG6" title="Weighted Average Remaining Life (Years), Outstanding"><ix:nonNumeric contextRef="From2022-07-012022-09-30_custom_EmployeeOptionsMember" format="ixt-sec:duryear" name="NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm">7.63</ix:nonNumeric></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding &#8211; December 31, 2022</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zhoB7bKlR414" title="Shares Under Options Outstanding, Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">147,619</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zZTMNuwfXMNd" title="Weighted Average Exercise Price per Share, Outstanding Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">24.42</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zVuDGsTgBHac" title="Weighted Average Remaining Life (Years), Outstanding"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_EmployeeOptionsMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.24</ix:nonNumeric></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Granted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zwxCNY9xMY36" title="Shares Under Options, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0995">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zc8I37J80Oh8" title="Weighted Average Exercise Price per Share, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0997">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesStockOptionsExpired_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zu0ljdrBE1Yj" title="Shares Under Options, Expired" style="text-align: right">(<ix:nonFraction name="NAOV:StockIssuedDuringPeriodSharesStockOptionsExpired" contextRef="From2023-01-012023-03-31_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">3,000</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pp2d_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zdsxMDbbetIc" title="Weighted Average Exercise Price per Share, Expired" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-03-31_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">39.20</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm_dtY_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zZYIkwfFvCKg" title="Weighted Average Remaining Life (Years), Expired"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_EmployeeOptionsMember" format="ixt-sec:duryear" name="NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm">0.51</ix:nonNumeric></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zKKlmfoL5fgh" title="Shares Under Options, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-012023-03-31_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">5,459</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zHwArBRA0DI1" title="Weighted Average Exercise Price per Share, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-03-31_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.40</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_dtY_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zGoCC7x1TOGd" title="Weighted Average Remaining Life (Years), Exercised"><ix:nonNumeric contextRef="From2023-01-012023-03-31_custom_EmployeeOptionsMember" format="ixt-sec:duryear" name="NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm">0.51</ix:nonNumeric></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding &#8211; March 31, 2023</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zzICRKZrDv99" title="Shares Under Options Outstanding, Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-03-31_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">139,160</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zxY9fQSGAIP8" title="Weighted Average Exercise Price per Share, Outstanding Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-03-31_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">25.01</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_znvzozuZiFNh" title="Weighted Average Remaining Life (Years), Outstanding"><ix:nonNumeric contextRef="From2023-04-012023-06-30_custom_EmployeeOptionsMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.91</ix:nonNumeric></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 7.1pt">Granted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zQPtlU2u1WR3" title="Shares Under Options, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1017">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zqgXorGAlGqi" title="Weighted Average Exercise Price per Share, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1019">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 7.1pt">Expired</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--StockIssuedDuringPeriodSharesStockOptionsExpired_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zZ5ViEPywVh7" title="Shares Under Options, Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1021">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pp2d_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zyNPEuuCmYKd" title="Weighted Average Exercise Price per Share, Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1023">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 7.1pt">Exercised</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zWIMiZpYYdgk" title="Shares Under Options, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-04-012023-06-30_custom_EmployeeOptionsMember" format="ixt:zerodash" decimals="INF" sign="-" unitRef="Shares">-</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zy5ROLzGpry6" title="Weighted Average Exercise Price per Share, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-04-012023-06-30_custom_EmployeeOptionsMember" format="ixt:zerodash" decimals="INF" sign="-" unitRef="USDPShares">-</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding &#8211; June 30, 2023</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zlXYWrrCA7l" title="Shares Under Options Outstanding, Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-06-30_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">139,160</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zbXorH9UYMq6" title="Weighted Average Exercise Price per Share, Outstanding Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">25.01</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zPFowipxeFCh" title="Weighted Average Remaining Life (Years), Outstanding"><ix:nonNumeric contextRef="From2023-07-012023-09-30_custom_EmployeeOptionsMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.91</ix:nonNumeric></span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 7.1pt">Granted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zaUnOBFzx8ei" title="Shares Under Options, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1035">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z7pFjnUsTmXi" title="Weighted Average Exercise Price per Share, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1037">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 7.1pt">Expired</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--StockIssuedDuringPeriodSharesStockOptionsExpired_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zETeSBLjgvJb" title="Shares Under Options, Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1039">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pp2d_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zIkf0SEaFru3" title="Weighted Average Exercise Price per Share, Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1041">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 7.1pt">Exercised</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zg3uTmKbCKyh" title="Shares Under Options, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-07-012023-09-30_custom_EmployeeOptionsMember" format="ixt:zerodash" decimals="INF" sign="-" unitRef="Shares">-</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zrbsjjr17xX7" title="Weighted Average Exercise Price per Share, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-07-012023-09-30_custom_EmployeeOptionsMember" format="ixt:zerodash" decimals="INF" sign="-" unitRef="USDPShares">-</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding &#8211; September 30, 2023</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zHePMHa2Oby7" title="Shares Under Options Outstanding, Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-09-30_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">139,160</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2d_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zE9Ci5cTdJlf" title="Weighted Average Exercise Price per Share, Outstanding Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-09-30_custom_EmployeeOptionsMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">25.01</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z9vxGd4z7K27" title="Weighted Average Remaining Life (Years), Outstanding"><ix:nonNumeric contextRef="From2023-07-012023-09-30_custom_EmployeeOptionsMember" format="ixt-sec:duryear" name="NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm">6.91</ix:nonNumeric></span></td>
    <td style="text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AC_zaOEmmrGypkh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:exclude><!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zExjcrz8ZHZb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total stock-based expense recognized in the financial statements for services received from employees and non-employees is shown in the
following table.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zC3XcNGR5IIa" style="display: none">SCHEDULE
OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20230701__20230930_zJPm9rJ3YLul" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20220701__20220930_z8Ayol1U9W37" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20230101__20230930_z4eXWo6J0sv8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20220930_zkau9nLXEj64" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zpm9UNQIDlji" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-07-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-07-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zxAO96Pf7cfe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Selling and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-07-012023-09-30_us-gaap_SellingAndMarketingExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-07-012022-09-30_us-gaap_SellingAndMarketingExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-09-30_us-gaap_SellingAndMarketingExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-09-30_us-gaap_SellingAndMarketingExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zJLrHJnV5C3g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-07-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-07-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">108</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">146</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">264</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zQ1JG9Blffpd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">116</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">169</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">287</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zhCI0bKjvrfd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Stock based compensation expense</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">116</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">169</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">287</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A7_zsDGAXzQJCxk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2023, the total unrecognized estimated compensation cost related to non-vested stock options granted prior to that date
was $<span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20230930_zKVv5POdawNb" title="Non-vested stock options granted, unrecognized estimated compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">159</ix:nonFraction></span>, which is expected to be recognized over a weighted average period of approximately <span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20230930_zzNUxds7L2pa" title="Non-vested stock options granted, weighted average period"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.19</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 30, 2023, the Company granted (a) Pre-Funded Warrants to purchase up to <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgLlKrYWqyi1"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-08-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,906,977</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of Common Stock with an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8sDOiEjMW87"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-08-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share, (b) A-1 Warrants to purchase up to <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zYyu2zjnwsX7"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-08-30_custom_A1WarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,906,977</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of Common Stock with an exercise price of $<span id="xdx_906_eus-gaap--WarrantExercisePriceIncrease_pid_c20230830__20230830__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zAAhcBrwMzPh" title="Warrant exercise price"><ix:nonFraction name="us-gaap:WarrantExercisePriceIncrease" contextRef="From2023-08-302023-08-30_custom_A1WarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.47</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share and (c) A-2 Warrants to purchase up to <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zGGqxRjfGPrj"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-08-30_custom_A2WarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,906,977</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of Common Stock with an exercise price of $<span id="xdx_907_eus-gaap--WarrantExercisePriceIncrease_pid_c20230830__20230830__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zMkGtiS8shcg"><ix:nonFraction name="us-gaap:WarrantExercisePriceIncrease" contextRef="From2023-08-302023-08-30_custom_A2WarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.47</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share, or a total of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230830__20230830__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zoAtEc7xw6Y1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-08-302023-08-30_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,540,931</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants,
in conjunction with the Private Placement disclosed above. The A-1 Warrants and A-2 Warrants are exercisable immediately upon
issuance and expire on <span id="xdx_909_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zHLF7G5BJiG9"><ix:nonNumeric contextRef="From2023-08-302023-08-30_custom_PurchaseAgreementMember_custom_A1WarrantsMember" format="ixt:datemonthdayyearen" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">March
1, 2029</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_906_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zcKEkV8QAEa3"><ix:nonNumeric contextRef="From2023-08-302023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember" format="ixt:datemonthdayyearen" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">October
1, 2024</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the same Private
Placement, the Company granted Placement Agent Warrants to Wainwright, or its designees, to purchase up to an aggregate of <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__srt--TitleOfIndividualAxis__custom--WainwrightMember_ziJKg2u1UTi3"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-08-30_custom_WainwrightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">218,023</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of Common Stock at an exercise price equal to $<span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20230830__srt--TitleOfIndividualAxis__custom--WainwrightMember_z6j9oBc7RhZ3"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-08-30_custom_WainwrightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.15</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share. The Placement Agent Warrants are exercisable immediately upon issuance and expire <span id="xdx_904_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20230830__20230830__srt--TitleOfIndividualAxis__custom--WainwrightMember_z4hE5HGKB5Yl"><ix:nonNumeric contextRef="From2023-08-302023-08-30_custom_WainwrightMember" format="ixt:datemonthdayyearen" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">March
1, 2029</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2023 and 2022, there were <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgkwpILmJbUg" title="Warrants, granted" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNUT0NLSE9MREVSU5IgRVFVSVRZIChEZXRhaWxzIE5hcnJhdGl2ZSkA"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,758,954</ix:nonFraction></span> and <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwSCyeSMHzKc" title="Warrants, granted" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNUT0NLSE9MREVSU5IgRVFVSVRZIChEZXRhaWxzIE5hcnJhdGl2ZSkA"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,500</ix:nonFraction></span> warrants granted, respectively. For the nine months
ended September 30, 2023 and 2022, there were <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_do_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoqf0PEG2xNi" title="Warrants, exercised" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNUT0NLSE9MREVSU5IgRVFVSVRZIChEZXRhaWxzIE5hcnJhdGl2ZSkA"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span> and <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_do_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zn3A0mi9JvT5" title="Warrants, exercised" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNUT0NLSE9MREVSU5IgRVFVSVRZIChEZXRhaWxzIE5hcnJhdGl2ZSkA"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,500</ix:nonFraction></span> warrants exercised and/ or cancelled.</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z8XvFRFCbLxj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zDfgzzEvrEod" style="display: none">SCHEDULE
OF WARRANTS ACTIVITY</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Outstanding &#8211; December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zddE0YuW9FJ9" title="Warrants, Outstanding, Balance" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_WarrantMember_custom_PrivateInvestorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">115,467</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_ziHWn2I0kot6" title="Warrants, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_custom_PrivateInvestorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zDDixifz4nae" title="Warrants, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1111">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Cancelled</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zXwywzl08eMb" title="Warrants, Canceled" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_custom_PrivateInvestorsMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">12,500</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding &#8211; September 30, 2022</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zSmCVZnG2QMh" title="Warrants, Outstanding, Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-09-30_us-gaap_WarrantMember_custom_PrivateInvestorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">115,467</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding &#8211; December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zYiwyjNql9n7" title="Warrants, Outstanding, Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_WarrantMember_custom_PrivateInvestorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">78,252</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zfiMd1yDDYh" title="Warrants, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember_custom_PrivateInvestorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,758,954</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_z5MSJuCusr78" title="Warrants, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1121">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Cancelled</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zzRrVoAVykbj" title="Warrants, Canceled" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1123">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding &#8211; September 30, 2023</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_z9fjFUmp2Q8d" title="Warrants, Outstanding, Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-09-30_us-gaap_WarrantMember_custom_PrivateInvestorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,837,206</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zpzRfliPdog7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_802_eus-gaap--EarningsPerShareTextBlock_zqoQOBemvow3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 &#8211; <span id="xdx_820_zupmYl9Pvvxb">LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDER</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of shares
of common stock outstanding during the period. All outstanding stock options and warrants for the nine months ended September 30, 2023
and 2022 have been excluded from the calculation of the diluted net loss per share because all such securities are anti-dilutive for
all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z69lLnUAhqbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the Company&#8217;s
securities, in common stock equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would
be anti-dilutive:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zkvBOAvkpBB" style="display: none">SUMMARY
OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20230930_zC12P28pi2oi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,<br />
2023</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20220930_zIQsFF93BkCa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,<br />
2022</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsEmployeeAndNonEmployeeMember_zn8H6Gp4XC4j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: justify">Stock Options &#8211; employee and non-employee</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-09-30_custom_StockOptionsEmployeeAndNonEmployeeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">139,160</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-09-30_custom_StockOptionsEmployeeAndNonEmployeeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">133,000</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_ziANJ0ezVMC3" style="vertical-align: bottom; background-color: White">
    <td>Warrants</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember33335218" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,758,954</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember33335218" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">115,467</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_z2j1vvNZGx24" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,898,114</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">248,467</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_z504HyESbaM7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Dilutive loss per share</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,898,114</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">248,467</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
</table>
</ix:nonNumeric><p id="xdx_8AA_zuDvMg26a6hb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_80A_eus-gaap--SegmentReportingDisclosureTextBlock_zgAWaOPuLZHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6 &#8211; <span id="xdx_82E_z9zV6bnxXrA4">GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company manages its business on the basis of one reportable segment and derives revenues from selling its products directly to patients
as well as through distributor agreements. The following is a summary of revenues within geographic areas:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock"><p id="xdx_89D_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_z3DOMyvmdXR3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zJfCAPWGswq" style="display: none">SUMMARY
OF REVENUE WITHIN GEOGRAPHIC AREAS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20230701__20230930_z02zv56I2Oeh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20220701__20220930_zc4W7I99Nx02" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20230930_z7dl2fup9kt3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20220930_z14epOvXBal9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--US_zeeLV1M7X788" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-07-012023-09-30_country_US" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">445</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-07-012022-09-30_country_US" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">90</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-09-30_country_US" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,037</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-09-30_country_US" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">828</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--AU_zQ5o3QuASst2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Australia/New Zealand</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-07-012023-09-30_country_AU" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-07-012022-09-30_country_AU" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-09-30_country_AU" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-09-30_country_AU" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__srt--EuropeMember_zgKVvqvUx6Se" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Europe</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1157">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-07-012022-09-30_srt_EuropeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-09-30_srt_EuropeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-09-30_srt_EuropeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__srt--AsiaMember_zUPESZMg6uOk" style="vertical-align: bottom; background-color: White">
    <td>Asia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1162">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1163">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-09-30_srt_AsiaMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-09-30_srt_AsiaMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__custom--OtherCountryMember_z5DkMGZVzMbg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Other</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-07-012023-09-30_custom_OtherCountryMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1168">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-09-30_custom_OtherCountryMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">34</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1170">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zDD5KOjit4q1" style="vertical-align: bottom; background-color: White">
    <td>Total</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">458</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">97</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,106</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">854</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zeKUERsx4vca" style="display: none; vertical-align: bottom; background-color: White">
    <td>Revenues geographic areas</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">458</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">97</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,106</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">854</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AB_zjLEUTX1HQv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
both the three and nine months ended September 30, 2023, our two largest customers comprised approximately <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zqDGPKtskgz6" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-07-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">96</ix:nonFraction></span>% and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zIboCg8ok9o2" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">93</ix:nonFraction></span>% of total revenues,
respectively. Customer one comprised <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersOneMember_zCbf7zbUyi8j" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-07-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">49</ix:nonFraction></span>% and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersOneMember_zIkYM4B4l9F6" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">58</ix:nonFraction></span>% while customer two comprised <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersTwoMember_zdwuFN4T0lu8" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-07-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersTwoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">46</ix:nonFraction></span>% and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersTwoMember_zAH4mCwxs8jf" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersTwoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">35</ix:nonFraction></span>%, respectively. During the three and nine months
ended September 30, 2022, our two largest customers comprised approximately <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zxo5GYHm9ZNe" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-07-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">76</ix:nonFraction></span>% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zqguEbFWrnq9" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">92</ix:nonFraction></span>% of total revenues, respectively. Customer one
comprised <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersOneMember_zgx6JE4b0Yrg" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-07-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">76</ix:nonFraction></span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersOneMember_zvi1NAzf53Be" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">35</ix:nonFraction></span>% while customer two comprised <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersTwoMember_zC1YU8Q1A9Y3" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-07-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersTwoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersTwoMember_zFitgrlE5DQ3" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersTwoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">57</ix:nonFraction></span>%, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_80C_eus-gaap--LesseeOperatingLeasesTextBlock_zhCvuBgKUHz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7 &#8211; <span id="xdx_829_z6Y42CuujNgj">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has operating lease agreements with terms up to <span id="xdx_900_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20230930__srt--RangeAxis__srt--MinimumMember_zjwnJ90Ks2d5" title="Lease term"><ix:nonNumeric contextRef="AsOf2023-09-30_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">2</ix:nonNumeric></span>-<span id="xdx_907_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20230930__srt--RangeAxis__srt--MaximumMember_zx38Ce9sGZ5a" title="Lease term"><ix:nonNumeric contextRef="AsOf2023-09-30_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">3</ix:nonNumeric></span> years, including car and office space leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s weighted-average remaining lease term relating to its operating leases is <span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230930_zO7QWleLsBbb" title="Weighted-average remaining lease term"><ix:nonNumeric contextRef="AsOf2023-09-30" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">0.56</ix:nonNumeric></span> years, with a weighted-average discount
rate of <span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20230930_zPCMvoyJLg01" title="Weighted-average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company incurred $<span id="xdx_90B_eus-gaap--OperatingLeaseExpense_pn3n3_c20230101__20230930_zZ5R5BISVhNa" title="Operating lease, expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--OperatingLeaseExpense_pn3n3_c20220101__20220930_zlh1HbBKPgTd" title="Operating lease, expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></span> of lease expense for its operating leases for the nine months ended September 30, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_892_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zLxqwPJ6zV63" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the amount and timing of liabilities arising from the Company&#8217;s operating leases as
of September 30, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zfexwvnadMd5" style="display: none">SCHEDULE
OF LIABILITIES ARISING FROM OPERATING LEASES</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20230930_zdSdZyzWgiV6" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzL7T_zraQzhGcZhwk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzL7T_zj93CSK5ksjd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzL7T_zQ90fMenEHQd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total undiscounted operating lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_z2KyuYjpTUU8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: Imputed interest</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zXGsFqHDIzfe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Present value of operating lease liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zo0XuwuHb8v1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:OtherAssetsDisclosureTextBlock"><p id="xdx_800_eus-gaap--OtherAssetsDisclosureTextBlock_zzvdBBB6okJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8 &#8211; <span id="xdx_828_zVDSaOwCJKcj">OTHER ASSETS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2020, pursuant to a licensing agreement entered into in March 2020, the Company received <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20200409__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zLQHvBfS1ZMa" title="Warrants and rights outstanding term"><ix:nonNumeric contextRef="AsOf2020-04-09_custom_LicensingAgreementMember_custom_SanuwaveHealthIncMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">10</ix:nonNumeric></span>-year warrants to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20200409__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zunQsrt2zHn9" title="Warrants issued to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2020-04-09_custom_LicensingAgreementMember_custom_SanuwaveHealthIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,000</ix:nonFraction></span>
shares of Sanuwave Health, Inc. at a price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200409__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zO7kLut3k8ql" title="Exercise price of warrants per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-04-09_custom_LicensingAgreementMember_custom_SanuwaveHealthIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.19</ix:nonFraction></span> per share. The fair value for warrants received was estimated at the date of grant
and at each reporting period using a Black-Scholes-Merton pricing model with the following underlying assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="NAOV:ScheduleOfWarrantsAssumptionsTableTextBlock"><p id="xdx_899_ecustom--ScheduleOfWarrantsAssumptionsTableTextBlock_zFCDePnuDPP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zNrs91gyCtqa" style="display: none">SCHEDULE
OF WARRANTS ASSUMPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, <br /> 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br />2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Price at valuation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20230930__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zbLmK52CByL1" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-09-30_custom_PriceAtValuationMember_custom_SanuwaveHealthIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.02</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20221231__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zRNhRtck9nX3" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_custom_PriceAtValuationMember_custom_SanuwaveHealthIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.02</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zFEjQwQNjodc" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-09-30_us-gaap_MeasurementInputExercisePriceMember_custom_SanuwaveHealthIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.19</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_znqqZEmcGNg9" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_SanuwaveHealthIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.19</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zxaqRMIL5P1k" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_SanuwaveHealthIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.61</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zkNFvV1yFqpg" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_SanuwaveHealthIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.96</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230930__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zGLILhGZdGPd" title="Expected term (in years)"><ix:nonNumeric contextRef="AsOf2023-09-30_custom_SanuwaveHealthIncMember_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">7</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zVnNidrWcmA" title="Expected term (in years)"><ix:nonNumeric contextRef="AsOf2022-12-31_custom_SanuwaveHealthIncMember_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">8</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zeiIrl805H45" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-09-30_us-gaap_MeasurementInputPriceVolatilityMember_custom_SanuwaveHealthIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">147.8</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zN2OgJdmeXhi" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_SanuwaveHealthIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">155.6</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zP9heDp8HHDk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers this to be Level 3 inputs and is valued at each reporting period. For the three and nine months ended September 30,
2023, changes in the fair value of these warrants amounted to $(<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230701__20230930_zWWnjdbmOxHk" title="Fair value of warrants"><span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20230930_zB1DUsEnYvVd" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></ix:nonFraction></span></span>) for both periods, leaving a balance of $<span id="xdx_904_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_c20230930_zYemgK95da5a" title="Warrants leaving balance"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span> as of September 30, 2023.
For the three and nine months ended September 30, 2022, changes in the fair value of these warrants amounted to $(<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220701__20220930_zI12FiNSGqM5" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span>) and $(<span id="xdx_903_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20220930_zEVXpQljD4Ue" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12</ix:nonFraction></span>), respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financial
Instruments Measured at Fair Value on a Recurring Basis</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability
in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants
would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 inputs: Inputs, other than quoted prices included in Level 1, that are observable either directly or indirectly; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own
    assumptions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers between Level 3 during the three and nine months ended September 30, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"><p id="xdx_893_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zpo1qsKTo0kj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents changes in Level 3 asset and liability measured at fair value for the quarters ended September 30, 2023 and
2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_z0NEQTYj6Gn2" style="display: none">SCHEDULE
OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Asset</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Balance &#8211; December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zUxKh6Ddht2g" title="Balance beginning" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="AsOf2021-12-31_custom_DerivativeAssetMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Fair value adjustments &#8211; Sanuwave warrants</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zdCZPYVEy2Sk" title="Fair value adjustments - Sanuwave warrants" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-03-31_custom_DerivativeAssetMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance &#8211; March 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zMclxCGl37vi" title="Balance beginning" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="AsOf2022-03-31_custom_DerivativeAssetMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Fair value adjustments &#8211; Sanuwave warrants</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zNkfGvDw4OKg" title="Fair value adjustments - Sanuwave warrants" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-04-012022-06-30_custom_DerivativeAssetMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance &#8211; June 30, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zpY4Ffqob7T5" title="Balance beginning" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="AsOf2022-06-30_custom_DerivativeAssetMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 7.1pt">Fair value adjustments &#8211; Sanuwave warrants</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zmI0PKlZa9gb" title="Fair value adjustments - Sanuwave warrants" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-07-012022-09-30_custom_DerivativeAssetMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance &#8211; September 30, 2022</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_pn3n3_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zpnfSRk84IZ6" title="Balance ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="AsOf2022-09-30_custom_DerivativeAssetMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance &#8211; December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20230101__20230331__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_z6jsim1FAC46" title="Balance beginning" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="AsOf2022-12-31_custom_DerivativeAssetMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Fair value adjustments &#8211; Sanuwave warrants</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20230331__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zDESfAW8F5Gi" title="Fair value adjustments - Sanuwave warrants" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-03-31_custom_DerivativeAssetMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance &#8211; March 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20230401__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zN2AtoAvA57b" title="Balance beginning" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="AsOf2023-03-31_custom_DerivativeAssetMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Fair value adjustments &#8211; Sanuwave warrants</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230401__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_z31cVTHyhSq5" title="Fair value adjustments - Sanuwave warrants" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-04-012023-06-30_custom_DerivativeAssetMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance &#8211; June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20230701__20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zctTQIEQJghh" title="Balance beginning" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="AsOf2023-06-30_custom_DerivativeAssetMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Fair value adjustments &#8211; Sanuwave warrants</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230701__20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_z3UfqnDNCVE9" title="Fair value adjustments - Sanuwave warrants" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-07-012023-09-30_custom_DerivativeAssetMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance &#8211; September 30, 2023</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_pn3n3_c20230701__20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zJetDClqh2pj" title="Balance ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="AsOf2023-09-30_custom_DerivativeAssetMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zURpUu5fA6Jc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z9La9bA9cEh2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the Company&#8217;s assets and liabilities which are measured at fair value on a recurring basis by level
within the fair value hierarchy:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zfe70fG0cZua" style="display: none">SCHEDULE
OF ASSETS AND LIABILITY MEASURED AT FAIR VALUE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z1aYneIPZOB8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level I</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9nEX2WzvbPc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level II</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ztsGne2KXYCe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level III</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20230930_zF5sobBJeuff" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of September 30, 2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level I</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level II</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level III</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Asset:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherAssetsNoncurrent_iI_pn3n3_zpoGgf4YjdN5" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">Other assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1304">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1305">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-09-30_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zPLK0zFyOA6a" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level I</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zj1jCnxhtmJl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level II</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zLa4v91soDf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level III</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20221231_z8eM9y6jLsZk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of December 31, 2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level I</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level II</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level III</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Asset:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherAssetsNoncurrent_iI_pn3n3_zvA3TpYOPNy2" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">Other assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1309">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1310">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zl13PQJ7QnCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 &#8211; <span id="xdx_82B_zB7bL6g6XZKe">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pending
litigation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2021, Protrade Systems, Inc. (&#8220;Protrade&#8221;) filed a Request for Arbitration (the &#8220;Request&#8221;) with the
International Court of Arbitration (the &#8220;ICA&#8221;) of the International Chamber of Commerce alleging the Company is in breach
of an Exclusive Distribution Agreement dated March 7, 2019 (the &#8220;Exclusive Distribution Agreement&#8221;) between Protrade and
the Company. Protrade alleges, in part, that the Company has breached the Exclusive Distribution Agreement by discontinuing the manufacture
of the DV0057 Painshield MD device in favor of an updated 10-100-001 Painshield MD device. Protrade claims damages estimated at $<span id="xdx_90C_eus-gaap--LossContingencyDamagesSoughtValue_pn6n6_c20210225__20210226_zb3LWKzJb3b1" title="Litigation damages sought value"><ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="From2021-02-252021-02-26" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">3</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2022, the arbitrator issued a final award, which, determined that (i) the Company had the right to terminate the Exclusive
Distribution Agreement; (ii) the Company did not breach the duty of good faith and fair dealing with regard to the Exclusive Distribution
Agreement; and (iii) the Company did not breach any confidentiality obligations to Protrade. Nevertheless, the arbitrator determined
that the Company did not comply with the obligation to supply Protrade with a year&#8217;s supply of patches, and awarded Protrade $<span id="xdx_901_eus-gaap--LossContingencyDamagesSoughtValue_c20230314__20230315_z8CbTyi4HHsf" title="Loss contingency damages sought value"><ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="From2023-03-142023-03-15" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500,250</ix:nonFraction></span>,
which consists of $<span id="xdx_90C_eus-gaap--LossContingencyDamagesAwardedValue_c20230314__20230315_zduAhMSb5p14" title="Loss contingency damages sought value"><ix:nonFraction name="us-gaap:LossContingencyDamagesAwardedValue" contextRef="From2023-03-142023-03-15" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,432,000</ix:nonFraction></span> for &#8220;lost profits&#8221; and $<span id="xdx_900_eus-gaap--LossContingencyDamagesPaidValue_c20230314__20230315_zZXat2vCa801" title="Loss contingency damages paid value"><ix:nonFraction name="us-gaap:LossContingencyDamagesPaidValue" contextRef="From2023-03-142023-03-15" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,250</ix:nonFraction></span> as reimbursement of arbitration costs, on the grounds that the
Company allegedly failed to supply Protrade with certain patches utilized by users of DV0057 Painshield MD device. The arbitrator based
the decision on the testimony of Protrade&#8217;s president who asserted that a user would use in excess of 33 patches per each device.
The Company believes that the number of patches per device alleged by Protrade is grossly inflated, and that these claims were not properly
raised before the arbitrator. Accordingly, on April 13, 2022, the Company submitted an application for the correction of the award which
the arbitrator denied on June 22, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 5, 2022, Protrade filed a Petition with the Supreme Court of New York Nassau County seeking to confirm the Award. On April 13,
2022, the Company submitted an application to the ICA seeking to correct an error in the award based on the evidence that the Company
only sold 2-3 reusable patches per device contrary to the 33 reusable patches claimed by Protrade. The same arbitrator who issued the
award, denied the application.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2022, the Company filed a cross-motion seeking to vacate arbitration award on the grounds that the arbitrator exceeded her authority,
that the award was procured by fraud, and that the arbitrator failed to follow procedures established by New York law. In particular,
the Company averred in its motion that Protrade&#8217;s witness made false statements in arbitration, and that the arbitrator resolved
a claim that was never raised by Protrade and that has no factual basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2022, the court issued a decision granting Protrade its petition to confirm the award and denying the cross-motion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 9, 2022, the Company filed a motion to re-argue and renew its cross-motion to vacate the arbitration decision based on newer
information that was not available during the initial hearing. On the same day, the Company also filed a notice of appeal with the Appellate
Division, Second Department. On March 21, 2023, the court denied the motion to re-argue and renew.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 10, 2023, the Company filed its appeal with the Appellate Division, Second Department. The Company intends to continue to vigorously
pursue its opposition to the award in all appropriate fora.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2023 and December 31, 2022, the Company accrued the amount of the arbitration award to Protrade of
approximately $<span id="xdx_906_eus-gaap--LossContingencyDamagesAwardedValue_pn5n6_c20230101__20230930__srt--TitleOfIndividualAxis__custom--ArbitratorMember_zvbJTCy0uhFj" title="Damages awarded value"><span id="xdx_902_eus-gaap--LossContingencyDamagesAwardedValue_pn5n6_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ArbitratorMember_ztRJewDVAizj" title="Damages awarded value"><ix:nonFraction name="us-gaap:LossContingencyDamagesAwardedValue" contextRef="From2023-01-012023-09-30_custom_ArbitratorMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:LossContingencyDamagesAwardedValue" contextRef="From2022-01-012022-12-31_custom_ArbitratorMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.9</ix:nonFraction></ix:nonFraction></span></span>
million, including interest which is classified in &#8220;Other accounts payable and accrued expenses&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_80A_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z1kmIKpinJW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10 &#8211; <span id="xdx_826_z2HYDhJVn8J8">RELATED PARTY TRANSACTION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
firm of FisherBroyles LLP is handling the Company&#8217;s Protrade litigation and appeals. For the three and nine months ended September
30, 2023, the Company have been billed and paid legal fees from FisherBroyles amounting to $<span id="xdx_90F_eus-gaap--LegalFees_pn3n3_c20230701__20230930_zwWshmzeO7hd" title="Legal fees paid"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">176</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--LegalFees_pn3n3_c20230101__20230930_zfl67S9IbOb1" title="Legal fees paid"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">264</ix:nonFraction></span>, respectively, which have been
recorded as part of &#8220;General and administrative expenses&#8221; in the condensed consolidated statements of operations. As has
been previously disclosed, one of the Company&#8217;s board members, Aurora Cassirer, is a partner at FisherBroyles. Ms. Cassirer does
not provide any legal services or legal advice to the Company<b>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_zqHZWXrJQ6x" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11 &#8211; <span id="xdx_829_zakteqd6uyKe">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 6, 2023, an investor exercised <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zhezIuGQ2XNh" title="Exercised warrant"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-11-06_us-gaap_SubsequentEventMember_custom_PrefundedWarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">203,977</ix:nonFraction></span> pre-funded warrants at $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zndWSw7PhBpj" title="Warrant price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-11-06_us-gaap_SubsequentEventMember_custom_PrefundedWarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfZual2q9C2j" title="Purchase warrant"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-11-06_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">203,977</ix:nonFraction></span> shares of common
stock from the Securities Purchase Agreement entered into by the Company on August 30, 2023.</span></p>

</ix:nonNumeric><p id="xdx_810_z5lWawZZBngb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_008"></span>ITEM
2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following discussion and analysis of the results of operations and financial condition of NanoVibronix, Inc. (the &#8220;Company&#8221;)
as of September 30, 2023 and for the nine months ended September 30, 2023 and 2022 should be read in conjunction with our financial statements
and the notes to those financial statements that are included elsewhere in this Quarterly Report on Form 10-Q. This discussion and analysis
should be read in conjunction with the Company&#8217;s audited financial statements and related disclosures as of December 31, 2022 and
for the year then ended December 31, 2022, which are included in the Form 10-K filed with the Securities and Exchange Commission (&#8220;SEC&#8221;)
on April 17, 2023. References in this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations to
&#8220;us&#8221;, &#8220;we&#8221;, &#8220;our&#8221; and similar terms refer to the Company.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cautionary
Note Regarding Forward-Looking Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Quarterly Report on Form 10-Q contains &#8220;forward-looking statements,&#8221; which include information relating to future events,
future financial performance, financial projections, strategies, expectations, competitive environment and regulation. Words such as
&#8220;may,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221;
&#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;future,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221;
&#8220;estimates,&#8221; and similar expressions, as well as statements in future tense, identify forward-looking statements. Forward-looking
statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance
or results will be achieved. Forward-looking statements are based on information we have when those statements are made or management&#8217;s
good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance
or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could
cause such differences include, but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    history of losses and expectation of continued losses;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
                                            economic and political instability and conflicts, such as the conflict between Russia and
                                            Ukraine, could adversely affect our business, financial condition or results of operations;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    conduct our operations in Israel. Conditions in Israel, including the recent attack by Hamas and other terrorist organizations from
    the Gaza Strip and Israel&#8217;s war against them, may affect our operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increasing
    inflation could adversely affect our business, financial condition, results of operations or cash flows;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    geographic, social and economic impact of COVID-19 on the Company&#8217;s business operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    ability to raise funding for, and the timing of, clinical studies and eventual U.S. Food and Drug Administration approval of our
    product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
    actions that could adversely affect the price of or demand for our approved products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
    acceptance of existing and new products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Favorable
    or unfavorable decisions about our products from government regulators, insurance companies or other third-party payers (including
    the U.S. Centers for Medicare and Medicaid Services);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
    of product liability claims and the availability of insurance;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    ability to successfully develop and commercialize our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    ability to generate internal growth;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
    related to computer system failures and cyber-attacks;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    ability to obtain regulatory approval in foreign jurisdictions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uncertainty
    regarding the success of our clinical trials for our products in development;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
    related to our operations in Israel, including political, economic and military instability;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    price of our securities is volatile with limited trading volume;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    ability to regain compliance with the continued listing requirements of the NASDAQ capital market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    ability to maintain effective internal control over financial reporting and to remedy identified material weaknesses;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are a &#8220;smaller reporting company&#8221; and have reduced disclosure obligations that may make our stock less attractive to
    investors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    intellectual property portfolio and our ability to protect our intellectual property rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    ability to recruit and retain qualified regulatory and research and development personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unforeseen
    changes in healthcare reimbursement for any of our approved products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    adoption of health policy changes and health care reform;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lack
    of financial resources to adequately support our operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Difficulties
    in maintaining commercial scale manufacturing capacity and capability;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    ability to generate internal growth;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in our relationship with key collaborators;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in the market valuation or earnings of our competitors or companies viewed as similar to us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    failure to comply with regulatory guidelines;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uncertainty
    in industry demand and patient wellness behavior;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    economic conditions and market conditions in the medical device industry;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
    sales of large blocks of our common stock, which may adversely impact our stock price; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depth
    of the trading market in our common stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or
risk factors that we are faced with that may cause our actual results to differ from those anticipated in our forward-looking statements.
For a discussion of these and other risks that relate to our business and financial performance, you should carefully review the risks
and uncertainties described under the heading &#8220;Item 1A. Risk Factors&#8221; and elsewhere in this Quarterly Report on Form 10-Q
and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, and those described from time to time in our future
reports filed with the Securities and Exchange Commission. Moreover, new risks regularly emerge, and it is not possible for us to predict
or articulate all risks we face, nor can we assess the impact of all risks on our business or the extent to which any risk, or combination
of risks, may cause actual results to differ from those contained in any forward-looking statements. All forward-looking statements included
in this Form 10-Q are based on information available to us on the date of this Quarterly Report on Form 10-Q. Except to the extent required
by applicable laws or rules, we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result
of new information, future events or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a medical device company focusing on noninvasive biological response-activating devices that target wound healing and pain therapy
and can be administered at home, without the assistance of medical professionals. Our WoundShield, PainShield and UroShield products
are backed by novel technology which relates to ultrasound delivery through surface acoustic waves. The global wound care device market
totaled approximately $20.8 billion in 2022 and it is expected to grow to $27.2 billion by 2027 at a CAGR of 5.4% during 2022-2027 (as
reported by Markets and Markets in June 2022).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Protrade
Proceeding</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2021, Protrade Systems, Inc. (&#8220;Protrade&#8221;) filed a Request for Arbitration (the &#8220;Request&#8221;) with the
International Court of Arbitration (the &#8220;ICA&#8221;) of the International Chamber of Commerce alleging that we were in breach of
the Exclusive Distribution Agreement. Protrade alleges, in part, that we breached the Exclusive Distribution Agreement by discontinuing
the manufacture of the DV0057 Painshield MD device in favor of an updated 10-100-001 Painshield MD device. Protrade claims damages estimated
at $3 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2022, the arbitrator issued a final award, which, determined that (i) we had the right to terminate the Exclusive Distribution
Agreement; (ii) we did not breach the duty of good faith and fair dealing with regard to the Exclusive Distribution Agreement; and (iii)
we did not breach any confidentiality obligations to Protrade. Nevertheless, the arbitrator determined that we did not comply with the
obligation to supply Protrade with a year&#8217;s supply of patches, and awarded Protrade $1,500,250, which consists of $1,432,000 for
&#8220;lost profits&#8221; and $68,250 as reimbursement of arbitration costs, on the grounds that we allegedly failed to supply Protrade
with certain patches utilized by users of DV0057 Painshield MD device. The arbitrator based the decision on the testimony of Protrade&#8217;s
president who asserted that a user would use in excess of 33 patches per each device. We believe that the number of patches per device
alleged by Protrade is grossly inflated, and that these claims were not properly raised before the arbitrator. Accordingly, on April
13, 2022, we submitted an application for the correction of the award which the arbitrator denied on June 22, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 5, 2022, Protrade filed a Petition with the Supreme Court of New York Nassau County seeking to confirm the award. On April 13,
2022, we submitted an application to the ICA seeking to correct an error in the award based on the evidence that we only sold 2-3 reusable
patches per device contrary to the 33 reusable patches claimed by Protrade. The same arbitrator who issued the award, denied the application.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2022, we filed a cross-motion seeking to vacate arbitration award on the grounds that the arbitrator exceeded her authority,
that the award was procured by fraud, and that the arbitrator failed to follow procedures established by New York law. In particular,
we averred in our motion that Protrade&#8217;s witness made false statements in arbitration, and that the arbitrator resolved a claim
that was never raised by Protrade and that has no factual basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2022, the court issued a decision granting Protrade its petition to confirm the award and denying the cross-motion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 9, 2022, we filed a motion to re-argue and renew its cross-motion to vacate the arbitration decision based on newer information
that was not available during the initial hearing. On the same day, we also filed a notice of appeal with the Appellate Division, Second
Department. On March 21, 2023, the court denied the motion to re-argue and renew.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 10, 2023, we filed our appeal with the Appellate Division, Second Department. We intend to continue to vigorously pursue our opposition
to the award in all appropriate fora.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nasdaq
Minimum Stockholders&#8217; Equity Requirement </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 23, 2023, we received a letter from the Listing Qualifications Department of the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) indicating
that we no longer comply with the minimum stockholders&#8217; equity requirement under Nasdaq Listing Rule 5550(b)(1) (the &#8220;Rule&#8221;)
for continued listing on Nasdaq because our stockholders&#8217; equity of approximately $2.2 million as reported in our Quarterly Report
on Form 10-Q for the period ended March 31, 2023, is below the required minimum of $2.5 million, and as of May 22, 2023, we did not meet
the alternative compliance standards relating to the market value of listed securities of $35 million or net income from continuing operations
of $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Nasdaq Listing Rules, we had 45 calendar days, or until July 7, 2023, to submit a plan to regain compliance. On July
7, 2023, we submitted our plan to regain compliance with the Nasdaq minimum stockholders&#8217; equity standard. On July 19, 2023, the
Staff granted the Company&#8217;s plan and granted our request for continued listing pursuant to an extension through November 20, 2023
to evidence compliance with the Rule. We believe that upon filing of this Form 10-Q, we should have provided sufficient evidence of compliance
with Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
there can be no assurance that we will be able to regain and maintain compliance. If we do not regain compliance by the end of the extension
granted by Nasdaq, or we fail to satisfy another Nasdaq requirement for continued listing, Nasdaq staff could provide notice that our
common stock will become subject to delisting. In such event, Nasdaq rules permit us to appeal the decision to reject its proposed compliance
plan or any delisting determination to a Nasdaq Hearings Panel. Accordingly, there can be no guarantee that we will be able to maintain
our Nasdaq listing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
critical accounting policy is one that is both important to the portrayal of our financial condition and results of operation and requires
management&#8217;s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect
of matters that are inherently uncertain. Our critical accounting policies are more fully described in both (i) &#8220;Item 7. Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations&#8221; and (ii) Note 3 of the Notes to the Consolidated Financial
Statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022. There have not been any material changes
to such critical accounting policies since December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
currency of the primary economic environment in which our operations are conducted is the U.S. dollar (&#8220;$&#8221; or &#8220;dollar&#8221;).
Accordingly, our functional currency is the dollar.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Three
Months Ended September 30, 2023 Compared to Three Months Ended September 30, 2022</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenues</i>.
For the three months ended September 30, 2023 and 2022, our revenues were approximately $458,000 and $97,000, respectively, an increase
of approximately 372%, or $362,000 between the periods. The increase in revenues was mainly due to the increase in volume of sales to
veteran administration facilities (&#8220;VA&#8221;) and to workers&#8217; compensation customers, as well as increased orders from Ultra
Pain Products, LLC (&#8220;UPPI&#8221;), one of our two largest customers. There were no price increases attributable to the increase
in revenues for the three months ended September 30, 2023 as compared to the three months ended September 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended September 30, 2023, the percentage of revenues attributable to our products was: PainShield Plus &#8211; 53%,
PainShield MD &#8211; 44% and UroShield &#8211; 3%. For the three months ended September 30, 2022, the percentage of revenues attributable
to our products was: PainShield Plus - 0%, PainShield MD &#8211; 92% and UroShield - 8%. For the three months ended September 30, 2023
and 2022, the percentage of revenues that was derived from distributors was 96% and 83%, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Gross
Profit</i>. For the three months ended September 30, 2023 and 2022, gross profit was approximately $349,000 and $80,000, respectively,
an increase of approximately 336% or $269,000, between the periods, mainly due to increased sales to VA customers, workers&#8217; compensation
customers and UPPI.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
profit as a percentage of revenues was approximately 76% and 82% for the three months ended September 30, 2023 and 2022, respectively.
The decrease in gross profit is primarily attributable to the increased sales to UPPI which are sold at lower gross margins than our
sales to VA customers and workers&#8217; compensation customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses</i>. For the three months ended September 30, 2023 and 2022, research and development expenses were approximately
$33,000 and $49,000, respectively, a decrease of approximately 7% or $16,000, between the periods. The decrease was mainly due to a decrease
in expenses incurred for product re-development in 2023 and decreased payments to subcontractors and consultants for our research and
development activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses as a percentage of total revenues were approximately 7% and 51% for the three months ended September 30, 2023
and 2022, respectively. This decrease was due to higher expenses incurred in 2022 for product re-development to obtain FDA approval of
Painshield Plus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development expenses consist mainly of payroll expenses to employees involved in research and development activities, stock-based
compensation expenses, expenses related to subcontracting, patents application and registration, clinical trial and facilities expenses
associated with and allocated to research and development activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Selling
and Marketing Expenses</i>. For the three months ended September 30, 2023 and 2022, selling and marketing expenses were approximately
$190,000 and $217,000, respectively, a decrease of approximately 12%, or $27,000, between the periods. The decrease was mainly due to
a decrease in payments to subcontractors and sales consultants due to budgetary constraints before the equity financing in the third
quarter of 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling
and marketing expenses as a percentage of total revenues were approximately 41% and 224% for the three months ended September 30, 2023
and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling
and marketing expenses consist mainly of payroll expenses to direct sales and marketing employees, stock-based compensation expenses,
travel expenses, conventions, advertising and marketing expenses, rent and facilities expenses associated with and allocated to selling
and marketing activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses</i>. For the three months ended September 30, 2023 and 2022, general and administrative expenses were approximately
$796,000 and $738,000, respectively, an increase of approximately 8%, or $58,000, between the periods. The increase was primarily due
to increased legal fees related to our ongoing litigation matters in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses as a percentage of total revenues were approximately 174% and 761% for the three months ended September 30,
2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
general and administrative expenses consist mainly of payroll expenses for management and administrative employees, stock-based compensation
expenses, accounting, legal and facilities expenses associated with general and administrative activities and costs associated with being
a publicly traded company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
expense</i>. For the three months ended September 30, 2023 and 2022, interest expense were $35,000 and $0, respectively. This pertains
to the interest on the Company&#8217;s judgment liability for the 3rd quarter of 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
tax expense.</i> For the three months ended September 30, 2023 and 2022, tax expenses were $3,000 and $15,000, respectively. The tax
expense is computed by multiplying income before taxes at our Israeli subsidiary by the appropriate tax rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
loss.</i> Our net loss decreased by approximately $228,000, or 24%, to approximately $727,000 for the three months ended September 30,
2023 from approximately $955,000 in the same period of 2022. The decrease in net loss resulted primarily from the factors described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nine
Months Ended September 30, 2023 Compared to Nine Months Ended September 30, 2022</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenues</i>.
For the nine months ended September 30, 2023 and 2022, our revenues were approximately $1,106,000 and $854,000 respectively, an increase
of approximately 30%, or $252,000 between the periods. The increase was due to increased orders from UPPI which did not occur in the
second and third quarter of 2022 combined with higher sales to VA facilities and workers&#8217; compensation customers. There were no
price increases attributable to the increase in revenues for the nine months ended September 30, 2023 as compared to the nine months
ended September 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
revenues may fluctuate as we add new consumers or when existing distributors or consumers make large purchases of our products during
one period and no purchases during another period. Therefore, any growth or decrease in revenues by quarter may not be linear or consistent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2023, the percentage of revenues attributable to our products was: PainShield Plus - 39%, PainShield
MD - 55% and UroShield &#8211; 6%. For the nine months ended September 30, 2022, the percentage of revenues attributable to our products
was: PainShield Plus - 38%, PainShield MD &#8211; 60% and UroShield &#8211; 2%. For the nine months ended September 30, 2023 and 2022,
the portion of our revenues that was derived from distributors was 94% for both the respective periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Gross
Profit</i>. For the nine months ended September 30, 2023 and 2022, gross profit was approximately $800,000 and $467,000, respectively,
an increase of approximately 71% or $333,000, between the periods, mainly due to increased sales to VA customers and workers&#8217; compensation
customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
profit as a percentage of revenues was approximately 72% and 55% for the nine months ended September 30, 2023 and 2022, respectively.
The increase in gross profit as a percentage resulted primarily because of the increased sales to VA and workers&#8217; compensation
customers which are sold at higher gross margins than our sales to UPPI.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses</i>. For the nine months ended September 30, 2023 and 2022, research and development expenses were approximately
$123,000 and $176,000, respectively, a decrease of approximately 30%, or $53,000, between the periods. The decrease was mainly due to
a decrease in expenses incurred for product re-development in 2023 and decreased payments to subcontractors and consultants for our research
and development activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development expenses consist mainly of payroll expenses to employees involved in research and development activities, stock-based
compensation expenses, expenses related to subcontracting, patents application and registration, clinical trial and facilities expenses
associated with and allocated to research and development activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses as a percentage of total revenues were approximately 11% and 21% for the nine months ended September 30, 2023
and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Selling
and Marketing Expenses</i>. For the nine months ended September 30, 2023 and 2022, selling and marketing expenses were approximately
$631,000 and $760,000, respectively, a decrease of approximately 17%, or $129,000, between the periods. The decrease was due to lesser
payments made to sales consultants and building website sales portals in 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling
and marketing expenses consist mainly of payroll expenses to direct sales and marketing employees, stock-based compensation expenses,
travel expenses, conventions, advertising and marketing expenses, rent and facilities expenses associated with and allocated to selling
and marketing activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling
and marketing expenses as a percentage of total revenues were approximately 57% and 89% for the nine months ended September 30, 2023
and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses</i>. For the nine months ended September 30, 2023 and 2022, general and administrative expenses were approximately
$2,780,000 and $2,835,000, respectively, a decrease of approximately 2%, or $55,000, between the periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
general and administrative expenses consist mainly of payroll expenses for management and administrative employees, stock-based compensation
expenses, accounting, legal and facilities expenses associated with general and administrative activities and costs associated with being
a publicly traded company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses as a percentage of total revenues were approximately 251% and 332% for the nine months ended September 30,
2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financial
expense, net. </i>For the nine months ended September 30, 2023 and 2022, financial expenses, net was approximately $44,000 compared to
$47,000, respectively, a decrease of approximately $3,000 between the periods mainly due to the change in fair value of the investment
in Sanuwave.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
expense</i>. For the nine months ended September 30, 2023 and 2022, interest expense was $102,000 and $0, respectively. This pertains
to the interest on the Company&#8217;s judgment liability for the first nine months of 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
tax expenses.</i> For the nine months ended September 30, 2023 and 2022, tax expenses were $18,000 and $38,000, respectively. The tax
expense is computed by multiplying income before taxes at our Israeli subsidiary by the appropriate tax rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
loss.</i> Our net loss decreased by approximately $491,000, or 14%, to approximately $2,898,000 for the nine months ended September 30,
2023 from approximately $3,389,000 in the same period of 2022. The decrease in net loss resulted primarily from the factors described
above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred losses in the amount of approximately $2,898,000 during the nine months ended September 30, 2023, as we continue to maintain
significant net operating losses from operations. In August 2023, we received net proceeds of $4,215,000 from the sale of our equity
securities. We also had negative cash flow from operating activities of $3,111,000 for the nine months ended September 30, 2023. We had
a cash balance of just over $3,787,000 as of September 30, 2023 and we expect to continue to incur losses and negative cash flows from
operating activities. Due to the continued expected negative cash flow from operations and the potential arbitration payment, if we are
unsuccessful in our appeals, the Company does not have sufficient resources to fund operations for at least the next twelve months from
the date of this filing. As such, there is substantial doubt of our ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will need to continue to raise additional capital to finance our losses and negative cash flows from operations and may continue to be
dependent on additional capital raising as long as our products do not reach commercial profitability. If we are unable to raise additional
capital, we will need to adjust our business plan and reduce workforce which could have a material adverse effect on the Company and
its financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine-month period ended September 30, 2023, we met our short-term liquidity requirements from our existing cash reserves and from
the sale of our securities. Our future capital requirements and the adequacy of our available funds will depend on many factors, including
our ability to successfully commercialize our products and our development of future products and competing technological and market
developments. We expect to continue to incur losses and negative flows from operations. We intend to use the proceeds generated from
equity financings, or strategic alliances with third parties, either alone or in combination with equity financing to meet our short-term
liquidity requirements as well as to advance our long-term plans. There are no assurances that we are able to raise additional capital,
as required, on terms favorable to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any material commitments to capital expenditures as of September 30, 2023, other than the $1.9 million owed to Protrade under
the court decision, which we continue to appeal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2023, we have no off-balance sheet transactions, arrangements, obligations (including contingent obligations), or other
relationships with unconsolidated entities or other persons that have, or may have, a material effect on our financial condition, changes
in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2023, we had cash of approximately $3,787,000, compared to approximately $2,713,000 as of December 31, 2022. We have
historically met our cash needs through a combination of issuance of equity, borrowing activities and sales. Our cash requirements are
generally for product development, research and development cost, marketing and sales activities, finance and administrative cost, capital
expenditures and general working capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
used in our operating activities was approximately $3,111,000 for the nine months ended September 30, 2023, compared to $5,704,000 for
the nine months ended September 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
used in our investing activities was approximately $1,000 for the nine months ended September 30, 2023, compared to $4,000 for the nine
months ended September 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
provided by financing activities was approximately $4,222,000 for the nine months ended September 30, 2023, which primarily results from
the sale of our securities in the Private Placement (as defined below), compared to $0 for the nine months ended September 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_009"></span>Item
3. Quantitative and Qualitative Disclosures about Market Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_010"></span>Item
4. Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company&#8217;s
disclosure controls and procedures as of September 30, 2023, the end of the period covered by this Quarterly Report on Form 10-Q. The
term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls
and other procedures of a company that are designed to provide reasonable assurance that information required to be disclosed by the
company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods
specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures are also designed to provide reasonable assurance that
such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer,
to allow timely decisions regarding required disclosure. Based on their evaluation, as of the end of the period covered by this Form
10-Q, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures (as defined
in Rules 13a-15(e) and 15d-15(e) under the Exchange Act were not effective because of the material weaknesses in our internal control
over financial reporting as described in Item 9A in our Annual Report on Form 10-K for the fiscal ended December 31, 2022, filed with
the SEC on April 17, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Remediation
Efforts to Address Material Weakness</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
the oversight of senior management and our audit committee, we have taken the steps below and we plan to take additional measures to
remediate the underlying causes of the material weakness in our internal control over financial reporting as described in Item 9A in
our Annual Report on Form 10-K for the fiscal ended December 31, 2022, filed with the SEC on April 17, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    took steps to remediate the stock issuance material weakness through creating a template documentation that needs to be filled out
    before any new equity issuances to ensure that there are no further over-issuances.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
    assistance from a current finance and accounting third-party service provider, we are formalizing our risk assessment process, policies
    and procedures, implementing revised control activities, controls documentation, and ongoing monitoring activities related to the
    internal controls over financial reporting including testing documentation to provide evidence that our system of internal controls
    over financial reporting meets the requirements of the COSO 2013 framework, and provide a foundation to communicate internal control
    deficiencies in a timely manner to those parties responsible for taking corrective action.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have expanded consultations with third party specialists on complex accounting matters, financial reporting and regulatory filings.
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have enhanced documentation of internal control activities</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have enhanced monitoring of the internal control activities process</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have added an additional level of review to ensure accurate inventory costing and recording </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the direction of the audit committee of the Board of Directors, management will continue to review and make necessary
changes to the overall design of the Company&#8217;s internal control environment, as well as to refine policies and procedures to improve
the overall effectiveness of internal control over financial reporting of the Company. After all the remediation efforts, not all material
weaknesses may be remediated, and others may arise in future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than described above in Item 4, there has been no change in our internal control over financial reporting that occurred during the last
fiscal quarter to which this report relates that has materially affected, or are reasonably likely to materially affect, our internal
control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_011"></span>Part
II - OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_012"></span>Item
1. Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may be involved in certain claims and litigation arising out of the ordinary course and conduct of business. Management
assesses such claims and, if it considers that it is probable that an asset had been impaired or a liability had been incurred and the
amount of loss can be reasonably estimated, provisions for loss are made based on management&#8217;s assessment of the most likely outcome.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2021, Protrade Systems, Inc. (&#8220;Protrade&#8221;) filed a Request for Arbitration (the &#8220;Request&#8221;) with the
International Court of Arbitration (the &#8220;ICA&#8221;) of the International Chamber of Commerce alleging we were in breach of an
Exclusive Distribution Agreement. Protrade alleges, in part, that we breached the Exclusive Distribution Agreement by discontinuing the
manufacture of the DV0057 Painshield MD device in favor of an updated 10-100-001 Painshield MD device. Protrade claims damages estimated
at $3 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2022, the arbitrator issued a final award, which, determined that (i) the Company had the right to terminate the Exclusive
Distribution Agreement; (ii) we did not breach the duty of good faith and fair dealing with regard to the Exclusive Distribution Agreement;
and (iii) we did not breach any confidentiality obligations to Protrade. Nevertheless, the arbitrator determined that we did not comply
with the obligation to supply Protrade with a year&#8217;s supply of patches, and awarded Protrade $1,500,250, which consists of $1,432,000
for &#8220;lost profits&#8221; and $68,250 as reimbursement of arbitration costs, on the grounds that we allegedly failed to supply Protrade
with certain patches utilized by users of DV0057 Painshield MD device. The arbitrator based the decision on the testimony of Protrade&#8217;s
president who asserted that a user would use in excess of 33 patches per each device. We believe that the number of patches per device
alleged by Protrade is grossly inflated, and that these claims were not properly raised before the arbitrator. Accordingly, on April
13, 2022, we submitted an application for the correction of the award which the arbitrator denied on June 22, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 5, 2022, Protrade filed a Petition with the Supreme Court of New York Nassau County seeking to confirm the award. On April 13,
2022, we submitted an application to the ICA seeking to correct an error in the award based on the evidence that we only sold 2-3 reusable
patches per device contrary to the 33 reusable patches claimed by Protrade. The same arbitrator who issued the award, denied the application.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2022, we filed a cross-motion seeking to vacate arbitration award on the grounds that the arbitrator exceeded her authority,
that the award was procured by fraud, and that the arbitrator failed to follow procedures established by New York law. In particular,
we averred in our motion that Protrade&#8217;s witness made false statements in arbitration, and that the arbitrator resolved a claim
that was never raised by Protrade and that has no factual basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2022, the court issued a decision granting Protrade its petition to confirm the award and denying the cross-motion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 9, 2022, we filed a motion to re-argue and renew our cross-motion to vacate the arbitration decision based on newer information
that was not available during the initial hearing. On the same day, we also filed a notice of appeal with the Appellate Division, Second
Department. On March 21, 2023, the Court denied the motion to re-argue and renew.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 10, 2023, we filed our appeal with the Appellate Division, Second Department. The appeal was fully submitted on October 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no other material proceedings in which any of our directors, officers or affiliates or any registered or beneficial stockholder of
more than 5% of our common stock, or any associate of any of the foregoing is an adverse party or has a material interest adverse to
our interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_013"></span>Item
1A. Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description of risk factors includes any material changes to, and supersedes the description of, the risk factors addressed
below associated with our business, financial condition and results of operations previously disclosed in &#8220;Item 1A. Risk Factors&#8221;
of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the SEC on April 17, 2023. Our business,
financial condition and operating results can be affected by a number of factors, whether currently known or unknown, including but not
limited to those described below, any one or more of which could, directly or indirectly, cause our actual financial condition and operating
results to vary materially from past, or from anticipated future, financial condition and operating results. Any of these factors, in
whole or in part, could materially and adversely affect our business, financial condition, operating results and stock price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion of risk factor contains forward-looking statements. This risk factor may be important to understanding other statements
in this Form 10-Q. The following information should be read in conjunction with the condensed consolidated financial statements and related
notes in Part I, Item 1, &#8220;Financial Statements&#8221; and Part I, Item 2, &#8220;Management&#8217;s Discussion and Analysis of
Financial Condition and Results of Operations&#8221; of this Form 10-Q.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
conduct our operations in Israel. Conditions in Israel, including the recent attack by Hamas and other terrorist organizations from the
Gaza Strip and Israel&#8217;s war against them, may affect our operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we are incorporated under the laws of the state of Israel and our operations are conducted in Israel, our business and operations are
directly affected by economic, political, geopolitical, and military conditions in Israel. Since the establishment of the State of Israel
in 1948, a number of armed conflicts have occurred between Israel and its neighboring countries and terrorist organizations active in
the region. These conflicts have involved missile strikes, hostile infiltrations and terrorism against civilian targets in various parts
of Israel, which have negatively affected business conditions in Israel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian
and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s
border with the Gaza Strip and in other areas within the State of Israel. Following the attack, Israel&#8217;s security cabinet declared
war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror
attacks. Moreover, the clash between Israel and Hezbollah in Lebanon, may escalate in the future into a greater regional conflict, especially in the northern part of Israel where our Israel office is located which stores approximately $2.1 million
worth of our inventory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
hostilities involving Israel, or the interruption or curtailment of trade within Israel or between Israel and its trading partners, or
the ability to ship our products overseas, could adversely affect our operations and results of operations and could make it more difficult
for us to raise capital. Parties with whom we may do business have sometimes declined to travel to Israel during periods of heightened
unrest or tension, forcing us to make alternative arrangements when necessary. The conflict situation in Israel could cause situations
where medical product certifying or auditing bodies could not be able to visit manufacturing facilities of our subcontractors in Israel
in order to review our certifications or clearances, thus possibly leading to temporary suspensions or even cancellations of our product
clearances or certifications. The conflict situation in Israel could also result in parties with whom we have agreements involving performance
in Israel claiming that they are not obligated to perform their commitments under those agreements pursuant to force majeure provisions
in such agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been travel advisories imposed as related to travel to Israel, and restriction on travel, or delays and disruptions as related to
imports and exports may be imposed in the future. An inability to receive supplies and materials, shortages of materials or difficulties
in procuring our materials, among others, or conversely, our ability to ship products to our US facilities or overseas customers, may
adversely impact our ability to commercialize and manufacture our product candidates and products in a timely manner. This could cause
a number of delays and/or issues for our operations, including delay of the review of our product candidates by regulatory agencies,
which in turn would have a material adverse impact on our ability to commercialize our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
members of our management and employees are located and reside in Israel. Shelter-in-place and work-from-home measures, government-imposed
restrictions on movement and travel and other precautions taken to address the ongoing conflict may temporarily disrupt our management
and employees&#8217; ability to effectively perform their daily tasks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Israel Defense Force (the &#8220;IDF&#8221;), the national military of Israel, is a conscripted military service, subject to certain
exceptions. Several of our employees are subject to military service in the IDF and have been and may be called to serve. It is possible
that there will be further military reserve duty call-ups in the future, which may affect our business due to a shortage of skilled labor
and loss of institutional knowledge, and necessary mitigation measures we may take to respond to a decrease in labor availability, such
as overtime and third-party outsourcing, for example, which may have unintended negative effects and adversely impact our results of
operations, liquidity or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is currently not possible to predict the duration or severity of the ongoing conflict or its effects on our business, operations and
financial conditions. The ongoing conflict is rapidly evolving and developing, and could disrupt our business and operations, interrupt
our sources and availability of supply and hamper our ability to raise additional funds or sell our securities, among others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Company&#8217;s financial statements have been prepared on a going concern basis, and do not include adjustments that might be necessary
if the Company is unable to continue as a going concern. Management has substantial doubt about the Company&#8217;s ability to continue
as a going concern.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates
the realization of assets and the satisfaction of liabilities in the normal course of business. During the nine months ended September
30, 2023, the Company&#8217;s cash used in operations was $3,111 leaving a cash balance of $3,787 as of September 30, 2023. Because the
Company does not have sufficient resources to fund our operations for the next twelve months from the date of this filing, management
has substantial doubt about the Company&#8217;s ability to continue as a going concern. The consolidated financial statements do not
include any adjustments relating to the recoverability and classification of asset amounts or the classification of liabilities that
might be necessary should the Company be unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will need to raise additional capital to finance its losses and negative cash flows from operations and may continue to be dependent
on additional capital raising as long as our products do not reach commercial profitability. There are no assurances that the Company
would be able to raise additional capital on terms favorable to it. If the Company is unsuccessful in commercializing its products and
raising capital, it will need to reduce activities, curtail, or cease operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with the continued listing requirements of Nasdaq, our common stock may be delisted and the price of our common stock
and our ability to access the capital markets could be negatively impacted.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is currently listed for trading on Nasdaq. We must satisfy Nasdaq&#8217;s continued listing requirements, including, among
other things, a minimum stockholders&#8217; equity of&#8201;$2.5 million and a minimum closing bid price of $1.00 per share or risk
delisting, which would have a material adverse effect on our business. A delisting of our common stock from Nasdaq could materially reduce
the liquidity of our common stock and result in a corresponding material reduction in the price of our common stock. In addition, delisting
could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in
the potential loss of confidence by investors, suppliers, customers and employees and fewer business development opportunities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 23, 2023, we received a letter from the Listing Qualifications Department of Nasdaq indicating that we no longer comply with the
minimum stockholders&#8217; equity requirement under Nasdaq Listing Rule 5550(b)(1) for continued listing on Nasdaq because our stockholders&#8217;
equity of approximately $2.2 million as reported in our Quarterly Report on Form 10-Q for the period ended March 31, 2023, is below the
required minimum of $2.5 million, and as of May 22, 2023, we did not meet the alternative compliance standards relating to the market
value of listed securities of $35 million or net income from continuing operations of $500,000 in the most recently completed fiscal
year or in two of the last three most recently completed fiscal years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Nasdaq Listing Rules, we had 45 calendar days, or until July 7, 2023, to submit a plan to regain compliance. On July
7, 2023, we submitted our plan to regain compliance with the Nasdaq minimum stockholders&#8217; equity standard. On July 19, 2023, the
Staff granted the Company&#8217;s plan and granted our request for continued listing pursuant to an extension through November 20, 2023
to evidence compliance with the Rule. We believe that upon filing of this Form 10-Q, we should have provided sufficient evidence of compliance
with Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
there can be no assurance that we will be able to regain and maintain compliance. If we do not regain compliance by the end of the extension
granted by Nasdaq, or we fail to satisfy another Nasdaq requirement for continued listing, Nasdaq staff could provide notice that our
common stock will become subject to delisting. In such event, Nasdaq rules permit us to appeal the decision to reject its proposed compliance
plan or any delisting determination to a Nasdaq Hearings Panel. Accordingly, there can be no guarantee that we will be able to maintain
our Nasdaq listing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_014"></span>Item
2. Unregistered Sales of Equity Securities and Use of Proceeds</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>August
2023 Private Placement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 30, 2023, we entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with an institutional investor
for the issuance and sale in a private placement (the &#8220;Private Placement&#8221;) of 180,000 shares (the &#8220;Common Shares&#8221;)
of common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), pre-funded warrants (&#8220;Pre-Funded Warrants&#8221;)
to purchase up to 2,726,977 shares of common stock, with an exercise price of $0.0001 per share, A-1 Warrants (the &#8220;A-1 Warrants&#8221;)
to purchase up to 2,906,977 shares of Common Stock, with an exercise price of $1.47 per share, and A-2 Warrants (the &#8220;A-2 Warrants&#8221;
and together with the A-1 Warrants, the &#8220;Warrants<b><i>&#8221;</i></b> ) to purchase up to 2,906,977 shares of Common Stock with
an exercise price of $1.47 per share. The A-1 Warrants are exercisable immediately upon issuance and expire March 1, 2029. The A-2 Warrants
are exercisable immediately upon issuance and expire October 1, 2024. The combined purchase price for one Common Share and the accompanying
Warrants was $1.72, and the combined purchase price for one Pre-Funded Warrant and the accompanying Warrants was $1.7199.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net proceeds to the Company from the Private Placement are approximately $4,215,000, after deducting placement agent fees and expenses
and estimated offering expenses payable by the Company. The Company intends to use the net proceeds received from the Private Placement
for general corporate purposes, including funding of our development programs, commercial planning and sales and marketing expenses,
potential strategic acquisitions, general and administrative expenses and working capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;) served as our exclusive placement agent in connection with the Private Placement,
pursuant to that certain engagement letter, dated as of July 5, 2023, as amended, between us and Wainwright (the &#8220;Engagement Letter&#8221;).
As part of Wainwright&#8217;s compensation, we issued to Wainwright or its designees warrants (the &#8220;Placement Agent Warrants&#8221;)
to purchase up to an aggregate of 218,023 shares of Common Stock at an exercise price equal to $2.15 per share. The Placement Agent Warrants
are exercisable immediately upon issuance and expire March 1, 2029.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_015"></span>Item
3. Defaults Upon Senior Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_016"></span>Item
4. Mine Safety Disclosures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_017"></span>Item
5. Other Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Second
Amendment to the Amended and Restated Distribution Agreement </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 22, 2023, we entered into a second amendment (the &#8220;Amendment&#8221;) to the Amended and Restated Distribution Agreement
for private labeled products, dated December 10, 2020 (as amended by the Amendment, the &#8220;Agreement&#8221;), between us and UPPI,
effective as of August 11, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Agreement, UPPI will continue to be the exclusive distributor of PainShield and PainShield Plus devices to the Durable Medical
Equipment distribution sector of the healthcare market in the United States. The Agreement also provides for an immediate re-stocking
order and minimum purchase guarantees through the end of 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term of the Amendment began on the effective date of the Amendment, August 11, 2023, and will continue for twelve (12) months or until
the Centers for Medicare and Medicaid Services assigns a reimbursement value to the PainShield product, whichever comes first. At the
end of such term, the parties agreed to enter into good faith negotiations to enter into a new distribution agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_018"></span>Item
6. Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
INDEX</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit    <br />
No.</b></span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1<b>*</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-1.htm">Second Amendment to the Amended and Restated Distribution Agreement for &#8220;Private-Labled&#8221; Products dated December 10, 2020 by and between NanoVibronix, Inc. and Ultra Pain Products Inc.</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*
    </span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2**</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-2.htm">Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101
    INS*</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101
    SCH*</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101
    CAL*</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Calculation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101
    DEF*</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101
    LAB*</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Labels Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101
    PRE*</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Presentation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104*</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished
    herewith.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_019"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NANOVIBRONIX,
    INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    November 13, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Brian Murphy</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    Murphy, Ph.D.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    November 13, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Stephen Brown</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen
    Brown</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJzVV9tu20gM/YL+A+GX7AJuajmbl7wpTpoa68RGYjQbFH0YS7Q9W2nGOzPy5ZP2L5cc3VxbcnaLFsUGASSLhzzkkMPhdDrdzp1+LxM08Mf14wimmK4S4RAecY4GVYSEGAx/vwJ6PuJCWmeEcv5nqTjQpIOkc3ne781I4KFraTG+giB4F1y8619Ar391cQGT+84blg+0mssYlZMiAaFimBi9MhKdMLvcwlRstdLpzlN9RGOlVmTuvJeL/4Z+L+jDg16LjTZfLIxGg86brv9707kzOlsR6nbrULEm3CaYEp3Ntet/702UWafTqydcI0UXYWgtOvugVZTRGjhC9IKgH/R6v9FrhQLhYV1QHsjI82bD76UiBQr1drsif9A+IBsN+v3SaIUALCCgsM0cOybscqgcpci6wigbDCqDhAEGgSxQpeEWm0MVGRQWbzB/DlUYRSbDuAp3InaF2zVLqQVxoUZ0IHJFsNVCrcTuRDh3WqoFFUSERoUqHsm/MhlLt5vi1l0nOvrC699jzsGlLzuCQ4EHUoBKAz5VOp//E/LQpY8iyXA8H1G58wpQdqVD6/2o6sBjQM8h8SgKt4C1hHlLu0TvEMcrRwVp7zGdoalCC7muSwgUGPiUoz6/IjukmmQmWlI2woVBX/ZNZCUIKtS+ydPSQ8IweBaGG0NjWGEApXjfSPi2+fuR8f5J4/0W483fD40/C6k2Ri6WjWtUS/dtHH1t6iWOSmtoLW2EGyoLtZigkTp+WgrajF5Y5JF2rzQYV7w9rnEPAOnVIfb6sPIGwHoLYD1CF7WAuZGWyvOkM0pmzK2amoBgrZAXZ+FTe72rIbTN+VO4ESYuXLzjVXxGDhjjkDf1Ah8xpVXINy4dCZHLRDJFk3J/8HEE17xShRKIXAtMqQZRrQfUoVKYa1PEA4LJLSyYF+MuN5WziXpR9+pmqj7Q4+mM4alwXa+GW8FHUJdQwcvlfXBxc0ZMK1onbvnglky80oY9mRMn71qtEHYoDFmQa4SU3FlSL+ezyC0lQVFBLHZ+N1dhFMFDFT11lDnCLy9kyP7ahbvc4x+Qg3HmrCPniPMnZELX7P+jbOytGbwFzF9mIhH5WPO9U3S7RRPx1PPvE9T7XgnCkvvnp+eHrKxvb9+0rs0eTYxc05g7VGsajbRpPFkKDFSgr87HU8JDtulGD/wbNjORHCrAvqFWwSHDSEY86KrF8ZEf1DwVqvlUf0V8lFWhsg1V6wcUiaNpNGqiLEGQo7q0YNH5vtVXAUe00RLjLKHxrDzfaVzP0rxSpmKWYMvgWCrCeF6PBnu6NBOyNrA6VKPht2k11BtdKxzPjL72W+qNLxUOKtRBwZ2QHvJVRTNW2MRVFxUB9g21CloZqEZPM3ARNzIcCA4ZbtDvMWo4/j7WRFJDwGP2zZ2SHY2YZiaphdA+bhwxK+lXE2bj1yPL8Z/04q+eUx3GdPegzIlkImQ8VAOxkk4kj3xRsiKpK5r568thKedOvCkQLZ12TO3bDHRGDXHXFIqXQwHY97tVcFzJOM9UTN0496Rp07ecAvkFSaJtv580G/kHmz172Q== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex10-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 10.1</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-1_002.jpg" ALT="">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-1_003.jpg" ALT="">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B><U>Exhibit 31.1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATIONS UNDER SECTION 302</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Brian Murphy, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this Quarterly Report on Form 10-Q of NanoVibronix, Inc. (the &ldquo;registrant&rdquo;);</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November 13, 2023</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Brian Murphy</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian Murphy</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Chief Executive Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Principal Executive Officer)</P></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp; </B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B><U>Exhibit 31.2</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATIONS UNDER SECTION 302</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Stephen Brown, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this Quarterly Report on Form 10-Q of NanoVibronix, Inc. (the &ldquo;registrant&rdquo;);</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November 13, 2023</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Stephen Brown</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen Brown</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp; </B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B><U>Exhibit 32.1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION FURNISHED PURSUANT TO 18 U.S.C. SECTION
1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This certification is furnished solely pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350) and accompanies the Quarterly Report on Form 10-Q (the &ldquo;Form 10-Q&rdquo;)
for the quarter ended September 30, 2023, of NanoVibronix, Inc. (the &ldquo;Company&rdquo;). I, Brian Murphy, the Chief Executive Officer
of the Company, certify that, based on my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) The Form 10-Q fully complies with the requirements
of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(2) The information contained in the Form 10-Q fairly
presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods covered
in this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November 13, 2023</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 46%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Brian Murphy</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian Murphy</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp; </B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B><U>Exhibit 32.2</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION FURNISHED PURSUANT TO 18 U.S.C. SECTION
1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This certification is furnished solely pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350) and accompanies the Quarterly Report on Form 10-Q (the &ldquo;Form 10-Q&rdquo;)
for the quarter ended September 30, 2023, of NanoVibronix, Inc. (the &ldquo;Company&rdquo;). I, Stephen Brown, the Chief Financial Officer
of the Company, certify that, based on my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1) The Form 10-Q fully complies with the requirements
of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(2) The information contained in the Form 10-Q fairly
presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods covered
in this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November 13, 2023</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 46%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Stephen Brown</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen Brown</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>form10-q_001.jpg
<TEXT>
begin 644 form10-q_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "" ;$# 2(  A$! Q$!_\0
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M*]+[6_J5/"HVS:MR6Q<X'_?(IOC/Q$-!T:1T :Y93Y>:?X50!]67/2[Z_P#
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MZ"\;(=6M0V,8,@YKRZ/4+;1?&POH)EN(6<DE#QS7K0\(Z#RQTBTW'UC%>?\
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..1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex10-1_001.jpg
<TEXT>
begin 644 ex10-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" -C IX# 2(  A$! Q$!_\0
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M>>&_$UAX(U?1[ZP\1V5B/'-[\7_AS\ IO!.E>)[K18?"?B3Q?H7QB^,7P?\
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M#4+SX1+\*=(GBOO <WQ-;XD6%UX0B_0V@ HHHH **** "BBB@ HHHH ****
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MOPW_ &6_!GA^'X?2^(/ ,Z1:[\,=(^&WQ;BTCQ_\1]+7XF^5XDA?3=+X<?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/B6#QA$FM6W_  EUY>7D]UJVL)>VTT5OIMX ?0W[:W_!0S]J/_@GS^S[\&/
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MPI\%_"6#2O$'P/N_VG?V9O'_ ,1_A_HW@'XBV?QE\66VE^-/!7Q7\.>%M/\
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M=4_9@\0>)EU7P[;7W_"96'@/4?@EK>CZAKFEVGA/4?$ITF^N?$EN 4OV2_\
M@J&/VB?^"DG[9W[#.O\ @=_!>A_"?P%X'^+O[*GC"^LM3M;_ /:$^$ND^(=6
M^#OQ]^(=FTQET>?P?X5^/VD'PS\/=;TRX:+QQX9N9?$EDDFGVXFKY*_;G_;3
M_P""CW[)'[47_!/CX,S_ !'_ &=GT3]OW]N7XR_!".SA^!NO:Q??"?X"Z;\3
MM$LO@SJFF>()/B[IT?B?XG7_ ,*O$FBZEXYO-6T.U\.P>+KN>RTO04L-(>;6
MG?'C_@CK\5?AW^TY_P $V?VM_P#@F]:^ ? 7Q$_8TL9OAG\3O!O[27[8W[5_
MQ \&>,OV7M4\+V_A/4/V=O VI^._A_\ M$ZOH^D^&]&O?%=O\-?$5I9>#='\
M,:KK[>+-6^'GB36=/\/Q>'OH#_@J!^P-^T_^U]^UC_P2X^.?P1/P%@\&_L*_
MM#7?QT^(EE\5/BA\0O!?B?Q;#>ZIX#\SPSX+TWPC\"OB=I4LL&F>%+N\35]<
MU_1EGOY[;2VTZ"WDEU>W /G+]O']NG_@H%^Q#\0/^"6_PE\9?%;]G"'7OVQ?
MVM/BS^SY\;_B!=_".^A\&Z)\+=-^,<"?"/XL^"M+O?BK8-X'\8W/P0\2^'9O
MB+H/BOQ3XZ\+6WBZ)WTB2PL],OAXA]L^.G[7G[7OPD_X)T?MD_MO^#?C1\$O
MC)X/\#?!S1?VAOV._B=H_P 'I/#_ (>\?>%+6UUU/$?A?XF^$(_BEXCE\1Z-
MK"Z;I7B7PGX\\%^(O JZEX=\7^';R"R:XT?7M)O]O_@J?^P)^U#^V+^TY_P3
M#^,WP,B_9_\ ^$2_8:_:,_X7]\0--^+_ ,4_B%X'UWQF@U7P1)_PB'A.P\'_
M  $^+&F$/IWAB[G?7=:U?30+R:#3QHKP22:I!E_M#_L4_ML_&3]B+]L/]B'P
M#\//V-O@A\'_ !Q^SGX0_9^_9)^'/A[X]_%C7?#G@=]5UOXE7'Q2\7_$'Q'_
M ,,B>';[PUX=\.^&;_X2>%O@[\)O!GA7Q98VECX4\6?VOXXTJ/7-'AT8 \)T
M[_@K1^T=\!-/_P"",'Q4_:3L_AC\2/V??^"M'@?X&^&?%6I^"O!&I_#SQY^S
M-^TC\=?AE\*O&'@^>TUJ_P#B)K_A3XB? K6_$/C77-)N=!U3POX4\>?#S0-%
MO/%5Y\1_B5/%;>%)_J#_ (+T_MS_ !^_X)P_L">(/VL_V<KKP/-X\\&?$;X>
M>%I_#?Q+\)W/B[P7XAT3QYKB:!>_;+;2=?\ "?B#3]6TF5[>_P!)O]/\0I9%
M5OK+4](U'[99WFD_.F@?\$B_VB_C/I__  1S^&7[6'B/X'>#_@7_ ,$E?!WP
M6\1S^'/@OXW\<?%?Q%^T]\??@A\-O 7@?P%?:S+X\^#/P>TOX3?#/POKG@<^
M*KZRB'Q2U;Q_H_B#5O ]]8^$3]E\6P?3'_!=C]@?]H3_ (*7?L(:Y^R5^SKJ
M'P:\/^*?%WQ$\ >*-6\5_&KQSXV\'>']!TCP-K4>OXTZV\#?"?XIZCXAU'5+
MB!-.^Q7,?ANUL89FU'^T[QX!IMP 9NL_M^_&;]GW_@JI\'_^":O[0LOA7QKX
M!_;+^"OC;Q_^RM^T/X$\)CP!XY\%_$'X=0>-]7\;_"OXP:#K?BKQGX(\;2-X
M6\-P:YX+^(_A+0? =O!K-_X=\$:S\*_$[ZKJ'C&P_/3X2?\ !9[]KJ+_ ()M
M?\%)?VVOB9H'A3Q]XF_8U_;[\7?L?:+8?##X/WUSX?\ #GPB\$>+?@=H_BK]
MH7Q=\/9/BAI_B3QOXA\*^&OBGXD\6:KX3TKXH^!?"NH#PSI&FW>L>"=%G\0^
M-]+_ $;O_P#@GO\ &SX[_P#!3KX1?\%(?VEKWX2>&[;]D+X(>-_AK^RO^SO\
M+_&_B[XAZ7JWQ'^)-KXAL/%OQD^*WQ4\6?"7X97&B(/#GB2]\(Z/\._#OPS\
M6I8WMCX?^(<?CB'4-'G\):M\V_\ !/\ _P"">7_!1O\ 8>^!'[37A#2=0_9"
MU#XC?&W_ (*8^,/VV++2(OC!\7-;^&WB/X+_ !8L_!.@_%3X"^/=6U']F30]
M8TC7+GPCX3U'3O"_CK2O!OB_3;/Q1K.B^*K[P@]OX5DT'7P#Z6_9\_:G^-7[
M9_P\^)'C/]@O]L3]EK]I'X/WUM^S5;_!WXV:Q\/KH?%#X<ZYJ_QANA^U?X:_
M:8^%6C^+_A\TOC'0/@&FE>+?@5H?_"N_V>[^ZU?6TTCQKH.J6UE:>+M>^7/V
M'OVU/^"C_P"UG^U1_P %"/@K:_$?]G8:'^P#^V]\#_@K+9S_  -UW1M1^+/P
M'UGXFZW:?&K5-2\0)\7M0A\+_$O3?A7X:UK4_ EYI6AW>@7'BNT@L-4T)[/6
M(Y]%^G/V(/\ @EGX5_92_;K_ &BOVR?AS\+?A5^RCX)^-?P*^'_PAN?V7OV?
M?%NMZ_\ "[Q)X]\-^,-7\5^)OCWX@T:Z\"?#GPEX#UQ[*30OA_X%\#_#OPR-
M M?#MEXI\?ZS/8^,_B?XC\.:)C_\$Q/V!OVG_P!D/]KO_@J/\=_C8?@-<>!_
MV[/V@=.^-WP]M/A9\4/B#XR\6>$+?2M2\?+#X<\9Z5XM^!?PRT=)KO2_%MI>
MRZGHGB35TM-0@N-*6QN[9(]9G /S^U;_ (*T?MA^&_ W_!;OQIK?QX_97\$W
M?_!+7XNZ_P""_@3I_P 5OA-=)H7QVL=*T?Q;KOAWP!\11I/QH\#:S?\ Q1^(
MUSI&B_#SP?JGPXU+P?ITWCC5(-0B\"ZG:WB>%K7WS]K'_@I]^UOX$F_X(6Z[
MX*\+Z#\$5_X*B?$7X,?#S]H7X2_$WP3+XN\8_!E?B1I_PMU[6X_ &LR:EX1N
M=&\;>'XO'/B+P\TGQ!\,>(K%Y;'PUJ.I_#_P]J6E^)?#FO?,_BC_ (-_?CC\
M<[[_ (*A>*?C#J7P(^&'Q@_:*_:ETK]M/_@G_P#M#? [XS_%K4?B[^S!\=_
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MXS?M%V/P5N?V6/\ @J7\#/AA\![G0?AK\8OB#?\ QD\&^%?A[\!A\!M9EO\
M2]=^ 'A?PK'J/C;2+O4==M=0TKQQ<2>!;U+2V@@\6L3?V_G&D?\ !,G]O'0/
M^"2]]_P1XT[QU^SW<>&+G3]7^ \'[:-[XI\?+KL7[+/B;XB7WB/6M?F_9B@^
M'(AE^--GX!U2\^%^E?#"/]H&/X?W-J+?Q[>?&^WNX9/A]= ')?MO_P#!7_\
M:G^$7PI_8;_X* ?LC?"W1OCI^Q3\7/V?Q^U5^UM\$];\*O=?M"_"_P" -AJG
MP2T?Q1XL^&VO>&_%ECH-WK'@*;XV10_$G3M7MO$FE^$K_P +OXKDU23X90>-
M=;\'_J[^R'^TW_PU-\3OB#\1OAE\;/"WQ<_9.\6_ W]GGXQ?L]7'A[P,F@ZG
M':?%Z_\ BUIWBR/Q5XHNM5?4]8O= U?X6?V-;^%[_P '^ ?$OP\UB7Q=X-^(
M5EKWBK1Q-HV1\)/V.-5^!7Q _9@^%WP_\$_#C4?V./V<?V(O&_[)]M>^-?B-
MJVK?%_Q*?$FH_ P62^(OAA;?!"W^'?B'3;O1_@LW_"9>))_B=I<_B+5_&.I7
M">!K2VL3#J?F7_!,;_@EWX7_ ."8GC']LGPW\(]>:[_9R^.GQ8\+_%'X&^!=
M2U75-5\0?!?2IM#U8^,?A*L]]9);S^!M \9:GJ>K?#B\34K_ %E_#^OMIWBY
M]1\4:5JGC'QB ?K11110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !7G?Q>^*O@?X%_"GXE_&KXF:S'X=^'7PD\!>+
MOB5XZUZ2*2X72/"/@C0;_P 2>(=0%M"#-=26NE:;=2Q6D :XNI52WMT>:5%/
MHE?G;^V3=?%#XG_%G]G7]F?X96NJ^%;>\\2V_P"T=XW^+GC/]FWXN_&GX VE
MU\!_$OA_Q#\&?A-XJUSX?^,/A#::#XV\2_%\:%\:="O8_B_HUEI>F?L\:AX5
M^(.FW6D?%GPIHGBT ]#_ &?_ -N_X _'O]A/P/\ \%"K/Q58>$_@!XC^!=[\
M=O%VMZI>)JB?#+1/"FAZCJ7Q5T#Q1<:)%>+<ZY\)M8T#Q7X3\80:1!=LOB#P
MMJUI817+K$C_ "WX0_X*5_&+XF_L:>(?^"@GPL_8C\6^+_V;8_A[XQ^+7PZ\
M'7'Q7L-$_:V^)_PS\*Z?JEQ:>,-#^!3_  _U#X?VMOXI&ER^)?#/A_\ X7_?
M>-=>^',EOKF@>&-8\=ZEH7POUG\6OV8_V!OVD[/X#?\ !9/_ ((<ZSX1^('A
M3X"?$75/&OQ%_8!_:=D^"OQK^'_[--MJ'Q'TO1O&7C/X'V.J>*KWXBZIX,^%
MWP[^*=MX>TO0H)O$'C?4?'&F7OQ>\0:-XG\;7)TBXUSW_5_B[_P4S^!W_!'G
M]EW]GK]DOX%_M _#C_@IC^S1X+^ W[,VJ?!Z^_9TE\>?!OQ?:_#2QT/X6ZUX
MIN?CYK_@;Q'^S?J7@[5/A_H5O\3M$\8^%_CMH&GZ?J>HIX>\3WB:[::CX-MP
M#]3OC[_P42\<?"/_ (*#_ 7_ ()[>%/@!X8\<>-_VD_A1\0/BM\-/B%XA^-^
MI^!/"-II_P ,-)U?4O%ND>.;#3?@KX_UO0;YY-'EM_#\V@V_B^VU-+FWN-0;
M16$]O#X7'_P6M\&ZI^Q+^VS^UEH?P \56_C?_@G;\8?B%\$/VKOV>O&'C[PY
MHVO>'?&OPHU.PTGQROP]^(/A72_'OA/Q_I:7=_L\+:E-!X8MO$1T[6%N9-#^
MRV1U/X__ ."@'[+GQE^-W_!9?]A"Y\-C]K70/A_X'_8T_:/^!WC/]LOX5> ?
MB/HMW\)OBU\6/ _BS3?AAXW;Q_\ #?PEX:^'LFM1Z_=:9K>LP6-J/A;IU\XT
M;QUI6C:#//IL7Q[X'^#/[5OP]_X(@_\ !3'_ ()H?%#]B'XM:3^U]X:O_B9H
MEC\7_A+\*_B=\3_!'_!1OQ)\2_%NE2:;^TYIWQ1M-$UO5O$OQ/\ %EE8:?9_
M$BX^)&HVFLZ=X>TKPEJ]_-X>B37_ (>_"X _?W]G/]O'X\?'B#]DCQ3/^R?X
M5TCX7?M@_!C0/C/X6\9^#/VCF^(6M_!O2?B#\&M9^,_P@TW]HCP#>?!+P-KG
M@:#XEZ9X:\3^$M.\8^$+CXC>!=-\<>&=6\-3>(KK4[OPO;>)?F3X3_\ !7_X
MY_'/X4?M8_%CX4_L0^%O%J?L@?M)?'#]E7QA\+H/VK6LOC/\6/BM^SYX<L_&
M?Q!L_P!GSPE>_L[P^'?B-;2>#IM1\1^%]+U7QMX.\:^(;+PWXBCM_"$-U9V<
M.H<%_P $M-+NOV2/A1^R=\-=%^#W[9FJ_%7X[_L^_LB>%?VE;'XM_!+]I_\
MX5[^R[XH_9I_94O=*^+$[?$OXH>&DT2V\,ZY=>"M-^&/PJ^#GPMU#6M!MOBI
MKD&J>$++_A!_$TB:;\'_ /!.'X3:M^S3XC_;!_:=^./P'_X*&:?\0O O_!67
M]O?]K[X!_!CP'^SC^UWXLTK]HSX,_'?X&W_PP\"2:+\-&T;3_@+X:^(_B;4=
M;U!_#?Q#^(L/@[XA^#['3KKPAXN\4>#_ (>>,M5E(!^S7QY_X*O:!^S-_P %
M(_V=_P!@+XR?!G4= \+_ +4%EX;@^&G[3VF>.[;4_ &G>./'<GQ,T?X;?"WQ
M]X9N_"FCZKX9\>_$CQE\+=9\*^#;"QU?Q!INMW&KZ)=V&J7)M?%UGX4F^,7_
M  55T;X=_P#!37]G3_@F;X0^"NI^/?%_Q\L_'$=U\9+[QW:>$OAWX \7?#+X
M43?'OQ[\.=3T^#PKXK\3:QXST7X+:A\/_'%O#::?9Z#?'XL> M*?7K-I?$M[
MX<_/[_@J!^R1\7?^"@W@3]L;PWX?^&_Q)\#_ +4_PX_8]_8"^/W[.7B?2? _
MQ&TWPEI/[:/[,'Q!_;'^)_B7X??!SXQ:YH_A/P-XF\8'P[\:]+^&.D:]8^(W
MM;"7XH_VR@DU#P=XLM?#?&^.OV:_C[X$_P""M?\ P1$^)_BCX:?%3XB2?!GP
MG^W!XU_;A^-_P^^$'Q4\4_"CPW^T)^V'\(?$Z2QZ5XIL/"VJI+\/?^%H^))/
M /P]L?[6\1S?"7X1Z!X&T#QQK>G:'X:CU:@#[A^&G_!6/XU_&WXY_M^?L_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW@7P]IOAG0=#MM0OX-<O=3\3ZG]$?\$X/&]KX4_X+=_\% 8/^"D7B#1?#/\
MP4QU[X5>'O#/[-'BC0[>?X7_ ++WQG_X)U:9)HOB6QU?]FWPCK^J^)]4G\6O
MXN\"OXQ^,%IXT^+?Q4\0:3<:1K>@^"-1M[#X5?&BYB /U:L_^"U'_!.34/V2
M=9_;PLOC1XXN_P!D+P]X^L_AGK?QTM_V:/VI)O#6E^+KZZBTR"*_T:+X,/XT
MM?#PU^ZTWPG+XYG\,1^!8?&NLZ)X+D\2+XIU?3](N/LOQC^U%\)/ 2_L_GQ)
M<^.$D_:?\;Z5\./@M;Z%\*_B9XQN?$GC+6?"7B#X@6>F:O!X.\)Z_)X&L(O
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M?''A$W'C>VUO2-1\)WVL:UI6C>(-(OX]8TK4[K3(+R[MO>[#XZ>!=2^,^H_
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M#HGC?P=);0>)O#^K>#OB=X8\'^,-,O=(NKN*VN!J&@VL<DH<VSSQ*)&_&?\
MX+#_ ++_ ,#?VH?C9^Q-X'\/_M:^(OV!/V^K6#]H_P",_P"Q'^U%X-U[3]$L
M-2\0>'H?V:OAO\:?A9XET1O%'@^3XEZE\6? 'C'X?:78:-INL#Q++X.\!Z]
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M0M8+*_T32+VRMHE@MK2[TVSN;6W@151(8+>:%XHHD1518XT5%554   #7HH
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MM[%2\+$6<#32M#;#$,32R%$4NV4@\.^'[6:VN;70M&MKBS,ILYX-,LH9K0W
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MK:SXA\*^%/'/Q9^&VMS+X-\9Z?K5OXW^!WQ!\4?"SXG>'X?"6J:!9>+;V_\
M#GC[P7XF\.)%9Z'.=:N=,-SH']J6%Y875U^!WA3Q)\3]-^'7@3XPZ5X8_P""
MH^M? 'Q;\??V5[7]M;X'>./@9^T=H_Q<^'/A+0/@O\<=,\4Q?#7X9:O<^)_V
MFOBO%/\ M!W7[(^H?MH>*/V<KGXE_"/XW^ ]+\=ZIX<N?B4VN_M22:S^C?\
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M97S:5H5IJFO^'?#=KJ6IBTM=7\8>)O"_@S1I-0\5^)="T;4/S9\#7/QQL?\
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M*>,OC5\1O!C^8?M??#;_ (*-_M(?M3_M5W7PPUO]MKX4?#/XO_\ !0#]A/\
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M#&O_ !#\>ZSXF /Z/**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK0?AUXE\!7GA3P;H^F#V72_V$_CMX=_:$^+?AGPE\%/%?@G5? _B;XH>)O\
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MXKT+X0^&K;Q-X^U+3[[XD^-/ASX$MSIJZMX7\/V%CJOC+3K[5_$WC+PW9VL
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MENO$5KJ%Q=? S3/&'@JT^(UHFG'4K+5_%FG6.BV&N'3/$\F@>1?"/_@I_P"
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M!J5I<Z;K5GINLZ/K.B^(=+U3P[KV@ZSIVGZSH>OZ9J&C:K8VFHV=Q;Q]A/\
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MX+7X>:;X5LO _@VSU:VZ+X_?\$__ (B_%/\ :\_:O\;P_LYP3?$#XE_M3?\
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M$FI+;/H.G1ZO<_S+_ +_ ()A_M\>!?V$?V/?A7^TI^S3K'QQOOA;_P $Y?\
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M\/>!M.^(7PW\13:1\6OAQ\+/A?XN\=ZIHWAKX8?#JWT72@#^@NBBB@ HHHH
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M_I4NNZ]\.]8\6Q^*&T#3?'6B:)!-K.K^$;W4(-?TW2H9=1O-/AM(WF'X'_\
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M-1TOQ7=ZAX;@TO6="TZT\;ZQG?MAVNH>*_\ @J#\#/AYX;^''PO^->O>*_\
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M>G>!4T']DOXP^'H-!\*^/M?^)OPU\::W'XN_:!^$'PXUK1[/PS8:]<>,?AJ
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M'Q!/9Z+'>RGP;QK^R'XS^)OPG^,/[->G?L[? S]FOX%?''QK\--7U/6O@?\
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MT3_@ES^WG'\%] \)ZGX7_9RL?$WPG_8-_P""0/[,_A2QT[X]>-;N+XA>/O\
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M*?!/[)5]H]KX&\'^+M6\#^"O$GQ6L9_CCI2^(/!6K>"?"?@K0F\=@'[%^/\
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MQ++]@OXZGXZ6GQ,U30/AW<^'[?\ X++ZU_P4,:PE\3+>:C-\&[G_ ()XZO\
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M;+PU\9/AAX^^%7B*\TYE34+30OB'X4U;PCJ]S8.WRK>P:?J]Q+:LWRK.B$\
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M;/A=X,^&ME\4'CTR_P! \-I?>%HOA[HFJ7GAR-+.U\03:UJT-O?^'HM,LEU
M ]#TG_@M-^P=I/[.W[/W[0GQR^)&N_L[67[0_P"S3)^U'X2\$?$SX8?&"#Q5
M)\/]$T;PUJWCO^P+:Q^',LGQ F\&+XIT^Y\_P+;:Y%XO\*,OQ&\$)X@^'D\'
MB9_JSPY^W=^R3XN^/5A^S-X<^-7A_5?C/K&J_%_P[H'AJ#2_%$>C>)_%O[/T
MVAP?'3P+X2^(%QH,/PY\6_$/X/R>(]*_X65\//#?BS5/&W@N-[V;Q!H-A#I&
MKO8_!_[-7_!,KXO_  F^(_\ P2V^(/Q#^*GPL\1R?\$[/V+?'/[(-]I_A/P?
MXHT]O'EIXB\$_#3P)H'C'1[S7-;U!M&U+2M)^$VCS:T)8!'K4OBS7K:RMM%M
MM&M1KGE_@/\ X)'_ +0^E?\ !1KX*_MU_$+]I7X5^+=-^#/[4/[?7Q:TKP'H
M7P?\2^$M0G^$W[8/PE\.?#SP=X&M9;'XAR^ =%\1?#6X\,VUQKVK^'_A_HTW
MQ*U?5_%7Q2^(NL>-?BGXK\1:YJ0!VG[9W_!4CXL?LS?MN?$;]EC0/!GP-F\*
M_#S_ ()J>/?^"C$OCWXI>+O$_@Z#4[3X9_$77? >M?!C4-2T^'4['PTWB*+1
M%UC3/BB--\0KH#WDFG7/PT\0BQ6_O_=_V=_^"N_[)GQG^'?[-&L>./$TOP5^
M,/[0_A?]FNZOO@=KNF^*_%FJ?";X@_M7:#K.L? _X<?$GQOX;\(MX4\$:C\7
M6\-Z[)\%;OXE3?#N_P#BSHG_  CVLZ!X?MIO%>BZ5,GC+_@GMK'C;_@K+X(_
MX*.:]K?PVUWP9X)_8Y/[*&G_  F\0^%+G5]?M]5/Q@U+XR6WQCTKQ-?)<Z5I
M.MZ1J%Y#X7TWP];:*;M;)+_7T\:6LNH+X?M/F/\ ;#_X),_M#_M0_M@:E^T9
M!^TQ\*M,\ Z!\>?^">OQP^$/PMUWX,>)/MOA"?\ 8^\;ZIXF^(&B>)-?\'_$
MOPQH_C[7?'TNMZQJ?ACXF^-?"GB;QSX/T'4K[X,>#+_X>^"-8\6Z]XJ /K/P
MU_P4V^!/AZX^++_'?XG?#/PY9Z/_ ,% O$W[ WPDMOAAH7[0'CS6M?\ BUIO
MP_\ "GB_PU\(_&NG7_P6\/W5O\?O%$E]XBN=.\+> ;7QGX!UJQD\+Z-X&^(/
MC7Q+>7UI']"Z#^UG\-/C5^Q]K7[7O[+_ (Q\/_$_X?7OPP^(7C_X>>([O2O$
MNF:/KEW\/X?$=KJFBZ[H.L6OAGQAX?O]-\3^%]7\*>)=$UC3]'\1>&]:T_4M
M/U33(-2TZXL:_+_4_P#@C]\3+WQ<?$,/QJ\#1VT?_!=#3/\ @L3#$_A;Q +A
M_#NG?#&'X5M\ )534C''K%UI5M%KA^)"S26-O?2RZ6?!%U;(NH/]6_L5?L%^
M.OV2/^"9X_83N_B!X3\=>,;+0/VE](LOB+!I.L>'_#5W<_M!_%#XK?$R&\N_
M#\D^KZK90>%)_BE)HTMG#J=_)K<6@)J"7FE/K#6>D@'PG^Q[_P %T=;^,>M?
ML91_&OX0>#-'\*?MB_L=?M!_MAZIK?P7\2>+/&_B3]D[PA^SCJ_B&T\0W'Q]
M\!-X<O\ 5+OX7>/[#09M+^&_Q>T"_P!-O];^*\-W\);?X6WMRMOXKG_2#P%_
MP5=_8#^*VE2:O\+?CZGQ,A.I?!S1--L/A[\,/C+XV\1>)]=^/7P[\2_%GX::
M!X'\*>&?AWJGB?Q]K][\.O!7CCQ9XLT/P5I&O:M\,M-\"^.1\3K/P?<^#/$]
MOI7FO['/_!.75/V5/^"7?_# ,?B?X>ZOXZB^!OQ3^#MW\8O#W@ZX\-:;XPO?
M&MGXTL_#WC#Q3X?2>YU@W>D6_BR"UU"QD\0:U--'ITTMEJD"WRVEEQWA;_@F
M9XN^&_PN_P""2<OA'QOX-U[XW_\ !*'PW<^#O#T.M0^(?"_PM^.OA?Q5^S5K
MW[,OQ&MM7FTF'Q!KOPV\1:YI>I:/\2?#OBE-!^)$?AW7M%U+PE>^'M?T_P 4
MW'B;20#N/VI_^"L?[,?P@_9<\6_'#X,?%/P1\:O&U[^QY\8/VS?@EX+\*Z;X
MW\=:;\1/A;\(-*MKB]\0^*M0^'FB:Q+\*/ ^N>+-0T?X8KX^^(;>&]&T3QSJ
MTVDSQ:EK/AS7?#T/0G_@J[^Q_P" /A3H'C3]HOXJ:3\'/&%I^QW\#_VT_BEX
M/?PO\2O$L/@;X0?&S6_#O@/1?%=AJ6A>";]?%/A^/XIZ^G@82Z$E]J]K=PR7
MFL:5IEE#=7$'Y<Z/_P &_'Q$^#GPFN/AI\ _VI_"=W<_$3_@F#^T7_P3>^->
MM?%WX4:G>:??1?'KXW?&']I._P#C+\-]#\&^-=)OO#VI6WQ'^.?Q&\(Z?X,\
M0^)O$6FZ#X)U/PQK5WJOC/7/!M[I7C?>_;(_X(/?%S]I71#H'A7]J3X;>$[?
MQ/\ \$H/@3_P34\?W_B'X)^*=6F_M']G_P#:"\(?'?2?BOX-L=-^+M@EA9>.
MY]/\0>'=0\*ZY?:O<>"8X=$U&WUKQN;S4+.R /VB\:_MV_LH_#WXU6W[//BK
MXM6MI\7;K6M,\))X8TWPGX]\1V4'Q UWX?:Y\6/#/PIU#Q;X:\*ZOX+TOXS>
M+_AIX>U#QUX*^#&I>(;3XJ^-/#$^B:OX5\'ZO:>)?#DFJ_,7[.?_  6)_8[_
M &A/V?? O[1<.K?$7P/X/^)VM?M&R^ -.UOX-?&G5M>\1?"[]F[X@Q>$?%WQ
MSAT_P]\.-0FA^#]KH&O_  ]\4^+OB0$F^'GPUU/QS%\//&7C*R\<>&_$NE:>
MWX.?L)?&[X*?MV?M(?M#>'?BO\(_$'[/'[4_CSX>_'OQ?\)OB%\+]?\ &'Q2
M^$GQZ\&?">T^#&N:A\$_B=%XTT#2=/T3QUX.@%OJ.N>(O"5[JGA_3(5\*^'O
M#]MI=_JEY=_G'X6_X((_$_1/V'OV1?V.]4^.WPR;QK^Q=XJ^,6K?LZ_MC?#7
MPU\4/@]^TC\!=8^(/QNM_B+I/Q3^'>K:3X^\3Z+K4NJ^"[GQ5X-^,/P \56H
M\#?$&YU3X?ZSI7Q&\):K\(;;5?'(!^GG_!2#]N/Q]^Q-J_["5EX-\&>#_&=K
M^V)^WE\!OV)=6?Q//K5I<>!/^%Y3ZZL/Q+T[^RKN*/7_ /A%H?#MWYO@^Y&E
M?V[+>VY3Q1HR6THN/4K/_@I)^Q==_&Q?V=1\9UB^+J_&^]_9JN]#N_AW\5].
MT#3?CU:>";KXBV7PMUCX@ZCX%MOAWH?BOQ=X+T[5M?\ AM8ZSXLL5^*5KHFO
M0_#B;Q5>:#K%O9>:?\%&?V&?&O[;>K_L,7WA;QSX6\#6O['/[=GP)_;;OXM?
MTW5M4N/B!/\  V?7&M?AC9OISPQ>&(?%4/B&\%QXUF37WT*6SMC'X2UE)Y1%
M\I:U_P $C_B;JWQXU'XLK\9? L&CWO\ P6 ^&O\ P5"31V\+^(9-0CT/X?\
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M(_VU?A'\7_@IXD\3?%WPFHF\3_%W_@HEX7_:\\">./#W[/O[4W[1^E_ _5?
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MX^'\GB >&+ZW^(WC"X]S\5?\%>?V1O!'P>\(?%_Q;=^-?#2^(- ^.WBCQ/\
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M/Q/L/B)I'F_#WXL_&'2OAU8V'@;5_&^N_!KX-ZEIFE^)?B_I.JV'C^;X4O\
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M@\+_ !O^%WCJU\(6J>.O#-SX6UW58W^(%OXI\+:YX8MO$_&_[=FG_ ?]I?\
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M^"_PB\$>#9-%A^-/P-^%/[07AY/B=XW\.?#OXI:C\-/C!\(?%'Q:T+QQ\/\
MX6:I%<V?QG\"^$)]!TOX6_%G6OA1X_\ %/B+X:?%'Q-IMGK_ (,'@:*7QZW<
M_M&?MPZ?^SI\8_ /PSUSX=2ZOH?B[Q+^S5X7N_$B>-=(L_$UU>_M2?M%:9^R
M_P"%-0\ ?#BSTW6]5\3^&_A;\2?$_@"Z^/?BWQOJWPJ\*^#O#GQ,^'UKX#UK
MXJ?$3Q%'\/(*?P[_ ."=OPG^']I^S/H4OQ&^-7CWP3^R4/AIJ?P9\!?$/7_
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M[:/XF^)?[)_X* _$/_@IDFD^,O&T6OZ/?_M6>/M'\5:);>+=8MY=$@N=4M?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBO2/ O@+PGI\MW)&MWK_ (O\8:_HWAS0-,@WW6I:MJ5K:6\;R2 4 =?1110
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M]Q'H?B5]!U6.RN)(U>*6U$5Y';27%JLP![]17S?XN_; _9?^'WC77OAWX_\
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MCD1@Z.C%74AE)!!H DHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#I5Y;^/O@-\3?$_PB^(EG#!Y]PMQI]CXV\(:Y9:?J44A@U2TMXK^VS;W$3,
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MQ%M_B19^++VV\'_$3P8/"7Q$\<_#J6V^(_@W4_!=YK]QX%UZYT&?QAX3MM4
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MX5_"?PMH?B'7_C(T?BCP]XD\">*M)\+:+KECHFK:9J^E^,GT>VL=1DM_TO\
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M24U[Q/\ #/X.^/+3Q9^S[^T3X^A^-O@_QO\ #_XC?$&QLM%/['_\%I1X@O\
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M#P/X)\<:7X6^(&@Z?XC\3ZS\._BU-X)M_B/X5UB'PYHFN7/A[4Y_(/%/B_\
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M?UK5O!/P!3PG?:$GQPT_Q)XQLK1_"7P;72?B);^-/'W[1,'C2_\ #U[^U/\
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MW.D^"/VL?@EX\\6:A'IFCVE[>R6VA>$/"^O:[?2^4?\ 1M.DBB\Z\FMK>?\
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M";Q5+K'PZ\77&F:=/XB\-:E+8VK1 '\Y_P"SM_P3IUSXO>/?^"??P6U'XO\
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M]E7]DGX6>$M$\:>(/BU\$#8^'?!X^*6H3>-/&/BK]HG2DU'5?BI\0/%?A?\
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M5>$K;PQ>^)_VNOV9M!L_&OA7X?\ CKP==:I\=/AC9VWBKP-\6-8G\/\ PO\
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MJZOH]QXGBT7Q3>>'[WQ-JOB>UM- :T\)>)M1O=-T'QUKFGZ'J=KX*UF%-?\
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MJ:1X0\%>-Y?AIXO\2WW_ !5),.B^&/B/"_@#7=18?9M+\:F/PM>20ZY+%8N
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /YQ?C1_P03T7XL>+?\ @L*9/&7A^+X5?\%!/A_#
MXG_9\^%-S>:ZG@OX+?M>>+M"TG6/C#\??&'AM-(N(+W7_%?QH^$OP,^(6G^*
M-!U.[UV'36^)GAHZ;8V6L0C4.\_;1_X)1_''XY?\$]/V(?V/O .M_!?X@>.?
M@?\ M+? ']HG]I7Q=\>O%OC72?#OQO\ $_A35/%OQ _:/\3O_9OPL^+%YXB\
M2_'[XM^-O%OBG5-.\2Z)I.A@>+-8GO9!%#%HEQ^_U% 'X6> /^"7WCOX+?\
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M-<TC1CXX_9I\3MX6\8:#X1\8-+X;\<VNO7O@;0]7M=1\,WO[2T4 ?A5\?/\
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M_@A_PD>I?ML?LO\ [6/PB^'_ (@^+/QC\%:/\3/"WPY_8FE_8P^-?PK^*WQ
M^'?P[MO%?P:UJ]T#Q=XY\9_"#Q]X)L/C)9P>+=#^'U]XR\&QZ6-<T!/W)HH
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M/V6/A%JB_!+_ (*/^'_BI\._"7QD^+'Q$,OQD_;"TC]EW0_!'C6Y^,?B_P"
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M:^#O'EQK%W8ZAX#^+?Q<\(ZS::5:Z_X+EO='\'>![GQ'JVH07&JWFA6?=?\
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MWX.V7BK2-2\8_#W0?$JP:1!3_:)_;RUC3?CO^R-X0^#,OB+3_A3K7[>WB?\
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M#17P#K'_  4C_9\\-P?$;QAXFT;XQZ'\ OA=H7[3FL^)_P!J?_A5FO\ B#X
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M\:_#?P:^!]E\0[+XD?#/X+_%R;Q!\"_BU^T-JGBK2_BQ\3?@QX*\50Z5\-/
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M?^&'CB]^&O\ PC>H_$[XNG7?B=\,(-)^",VG^+_A_-\2O&S:K\,='\9\%_\
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M_P""47PX\'P2>'OAYX^N_ _P^L?VK_V-OVH/"'@;3?"HO[3P=!^Q-\%_@?\
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M (V3^)]%\8>.?%7@_P#X)]?MT?%+PEK'PV'@G&G2I-IOPB\2_#;PI\*=6O\
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M+_Q3^&_B'PO%K-RMU^RWXI\%3Z>FH^.-!E(!ZJO_  3%@76/ FO:=^TE\4/
M^M^$M1_X*60WWB'X7Z3H7@_Q5=>%/^"GGQEC_:)^+%CX2\2ZB_BC4_A]XV^&
MGQCTOPWJ7PD^(NB27&I:'X/TBXT#4M+U7Q/?P>/=-\U\$?\ !(6+PCX;U_0[
MG]I77=9?Q)I'_!."TN[6U^#7PQ\'>$-)U/\ X)L_&F/XV?#B[\,>$O!$/A\:
M-I/Q U_2/#]KXRT*36-06T6]^(%SHNH6R^)?"-I\-_I;]K'_ (*">"?V8(IK
MFU\&:I\3]/T?]D3]H[]NSQ!K.A:W::5X>O/V<_V6#\*9/B<WPZ\0R6&JZ/\
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M;1IK*:3W*B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?XA^.O!WP@^/_@[Q)HTMMX&TS4=0^/\ 9^(I_AUI,NAS@'TU<_\ !-KX#_\
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M;'IWCW4/!6K:O\3],\.V>A>%_"FN^*1J>@:D/ ]IKOC3V/6?VS/VZ/#7Q#^
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MZ:+M-,;[3H]K:V$/O]% 'Y_>%O\ @G#\%/#/AG]FKX>S>,?BUXK^$_[*-K\
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MBLGCOPAICZ)<_HA10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/%/C[6O%WC_7G^%OV?X;:'J_Q"UOQ3J'A'P%INB>$/"-QH?A_0=%T^P^RJ*
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M^O=2O71KF^N[FZDEF??HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3;CT_P#8X_X*[?M\:[I/BCQ1XS\=Z!^T7K^I_P#!NYJ7_!3KPI\-KOX8>"-
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MPI;77PZ_9[^%GP?\;^ _B2GQ+U6\\3:K<_&GP];R^&?!OOO_  <&0SWOB/\
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MY#]@F@^:?#?_  5^_;\\!_ 'XZ_%Z3QCI_[2'C63_@A'^R3_ ,%'/"_@B_\
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MT*XD\7VTNGV[P>*)+CPMI^D^&)WU^)DU5YO#FE:9H,K79DTC3[+3VM[:+?H
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MK@20C93M1_X)>?$'6&1]8_X*M?\ !3+6'CBE@B?5[_\ 8'U1XH)BC30Q/?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?[)/Q+^,'A_X >#/'GC;4_C-XH_9M3]KK1OAW=? /]H70O$4W[/K^)'\&?\
M"<7=OX@^%>E0Z5>Q>,HI/"%SX$U:>Q^(EIXKCD\.77A.'64:R'XO_&S]ES]H
MC]J3_@M!HOQ0CTG]I7]E?X<_$'_@A_X:^"FN_%3X?>#8-0\*^'OCKJ'[54WQ
MFU/]F3QK\1-:^&OB70CHLOA*X%OX^O/!&H_#[Q)J.E6ESX?\,_$;PCK>IO8S
M?4%Y\._B!H/_  <4:E^TBWPG^*2_L_Z=_P $9-1^!=W\5]'^%'C[5/ LWQJ'
M[:$_QIO_  %8:QHGAJ]M=8\3W?@5Y_$R1:7]M74[V9M'MI[KQ-.-+< ^Y?@E
M_P %._V'?VD?@%H/[3WP(^-DGQ5^"?B'XS>%?V?+;Q7X.^&'QBU34M(^,/C;
MQCX8\!^%O!GC+P-'\/E^(/@"XUCQ-XV\&6\&K>.?"WAWP_%IGBWPSXCNM6@\
M-Z]I6KW3K;_@IA^QYJ/CKXV_#'1?&OQ.\3?$3]G;XH>"?@S\6_!/A']F']J;
MQAXGT'XD?$33/$FO>$_#VBZ-X8^"^K7WCU+[PUX1\1>+;_7/A]#XI\.^'O!N
MG'QCXCU;2?#%U9:M<_@]X*_X)=_'/X-^(O\ @FM^UG^RUX4\6^"]%^/F@_\
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M3_A)\!_#G[,][\,/"GQ#\-ZC\8-3\4^)_BMXMU[7KCE_VDO^"//[3'QDU/\
M;VU7X:VW[(OP#@^.7[''[/W[)'[,7A?X2>(_'_PY\->!_ASJ?[06H?M*_P#!
M0+X8_$.U\(? ^SMM$T']JGQAXK\8^%M3^)O@O3=?\2>*-(N(?%'BWP+I^K:G
M=:-IH!^YNA?M@_LH^*-'UKQ#X:_:3^!?B#0_#WBSP%X#UG5M%^*?@K5-/L/&
MOQ5M=#O?A;X4DNK+69X7U_XF6?B?PY<_#O2H6DO/&\.NZ3)X8BU5;^V,GS1^
MS+_P4D^&WQH_8@^(/_!07XK6'AOX%?LV>#_$7[0>H:)X['C75?B-IGBOX&_
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MWQ^\:?&#Q_XXLA\#SX?\5_\ !6S]E']NZP;4_''C./7(_@U\"/V3?V??V?\
MQ'HE_I\7P>OK)/B>OBOX)WGBKP?X?AUJY\*W.G^(H&OO'GA[4].E6\\=U?\
MX)R_M5Z==?#CQCI^@?LN_%Z?3_'O_!63PY\6?V?_ (F_&[XY> OA7XU^ _\
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M\/06#ZQX:\-:EINOZQ96>D:A9WD_Q3XP_8I_:4^(W_!,7Q3^R/XV^.^C:_\
MM)S3:WXB\*?&'Q/;6.OZ%JFM^$?VB+GXX_ [PY\9+[PG\//A;'\2+"XT#0O
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M S^ _B#XB\7CXC6GA&^TBW\/_!_XUZGJ'AJW\=_%C7_@5X5/Q9TNU^'<FI?
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M6>E:?XSN_C9XCU#X;-XN^->A^)_A!X-T[P=9?"F70] >3Q!XRTK5[V_XQ_\
M@J/^RYIWQ ^-?A+Q1=_$GPIX6^"4W[+&E:O\4M5^#7QAN? NO>)?VO-2\.:3
M\)='T?5-&\ ZG;V\.JZG\0?AGI,>HZS/IHDU7Q5J@FM+31_!GB#6XO/OC%_P
M36D^+&J?M.W.O>(?@OXTT+]HS]JGP!^T]9^'?B/\(?'-QK'PCU[X=_LA?#7]
MECPMJGPK^*/P]^./P^^(/P\^+GA;6/A/X4^+/A7XV?#K4O!?BW0[#4/'/PJT
MR'3G\4Z?\4/"_"W7_!+OXM/<?$J.7]K*P\61_$J__P""8/CK7O%_Q*^#6I>)
MOB=KOQ>_X)P?$?X-^/)/&7BOQ%H/Q@\':#J^F?':+X,6D'B;2;#PMHVK>&_$
M?C;6_$MCXDU.PT2P\+:F ;'[0G_!1^]\$:#XW\??"7Q1X5N-"\(:Q_P3!N=5
M^&GQD_9?_:?^&'Q3\)?#G]MK]MW5OV8O&WCGQ.OQ"N_AE=7AU/PQI7B:;X9>
M&M+\"P^*OA[X\^%WBZ+XGZ%XCT_Q/X6T>V^K/A[_ ,%"?V3OBCJ7P^T+PEX]
M\7#Q/\3?BM\2O@9X:\&^*_@=\>_AYXZL/C#\(_A3>_'/QW\-O'O@7X@_#'PO
MXO\ A3XPT_X06$OQ$T?1?BCHO@Z\\8^%Y]-U+P9'X@CUC21>^0?M._L"^,/C
M]\0?CO\ $70?C-X9\$ZI\4?"?_!.;3/!VGZU\*]6\8:=X0\4?\$Z/VQ_B/\
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MV/?@'I'[/OQ1TC1_ VEZ=X;_ &J/"W@>+X:>+O@_<>+[;5-8\0:WX)'P6_:
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M=$?3]1O/$_VJ?^"H_P %O /[$?Q;_:4_9L\<Z-\5_'-E^R+\??VF?@MHUO\
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M_#K5OA/J'@7XL_MJ?M!:3X=\'>+?%WQ<TJZ^&GB'P3I6OZOK/BKX=W/BCQT
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M?A3P3\#?AK\<] \3_ 3QSJF@^!O#6EZ%H_@;XE^'?&-]=7_@7XGI\7['6/\
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M8_;4\>?$W]HA-5\*1:%X1TGP[X[\7>+H-'U/P;<Z#\-O!/A#PUX/^$FC3:R
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB!9DTR/5WSKEUJ.I7O&?$#_@G3^S?X\M?V=(K$_&#X3ZA^RY\.G^"OPM\2_
M/X\?%OX&>+A\";ZP\$Z=KWP1\5^*?AEXM\-ZYXK^'/B"/X;^ [VXLM5O9-=T
M+7O"ND^*/!>O^%_$T4NKS %O]K']KCQC^S[IG[,:?#KX&7'QB\9?M5?&&7X&
M^!/!WB#Q];_!N?0O&^H?L^?&KX[^&KCQEJ&N>$_$YT;P\8_@QJ/A[QM*FGW7
MB7PI!JAU31/"OC?5]/3PEJ7S5X1_;.OO GQ0^/6A>(?A_P"-(/B?X]_X*!_
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M(M+\=V_@QIH?#.D>,M8^''PZ^'/A7Q!J6E:;9V<]EX(TN?2].TF_U;Q==^)
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M?XGV/C_2C\-KKPKX1T7QMXM^G_VJ/VY?&7[+_P"U+HGA7Q+X1\&7'[+WA/\
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MOB1?"\CL[)C#K_Q*\=>+_$ZVCH\&E/K<FD:0MCX?T_1])TX ]FHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#X,_P""J%S/8_\ !,;_ (*+:C:75U8WVE?L+?M:ZOINHV,TMO?Z
M9JFE? 3Q_J&F:IIUS!+!/:ZEIE_;6]_IUY!-#<6=];6]U;30W$,4J?#&G_\
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MSX@^'EE>66G7]C\/O%<VN^"['4-)T;4+30H;W1M+GM #YJ_X*HZKK.E>*/\
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MUOP/JUC=>)?A_8?#_P"-&MKXF^,OPZ\&> /$MYJ_@SX<?#KXO>)8[7Q'\4_
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M?J?Q3_:1T)_'/BKP)X2\4W7P\MK#Q'X8D^(7CO\ :"&A7/PM\,V_PA\'??\
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M0_X+ _M47OP4U'XEZ'\(/@AX=USX?_\ !/C]N?\ ;+^).B>+YO&.JR7?BO\
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M#4HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN>)= UW2_"FMZMX3^)VGV%E::A9>'M7U'0?%4,6FW]S:R@'X#_LO?MY_'/\
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MET;6DTOQ+XE\!^-AXDEU/X;6=CKGH_PQ_:Q^-6C?$/XF>!?$G[1.OSCX^_\
M!:?XM_L5Z=\0O%]G\)[BV_9N^&_A']F_QU\2_AQX:^&NA)X2TC08/&'Q'USX
M6^%/@=X'7QYI/C#0[[Q3XJ@\9:GH7BWXCZIKD/Q'_7;PGI'['OQ83XR>!/ V
ME_LU?$N.S^)8D_:#\&^$[+X7^,DM?C%8PZ+K"O\ &3P]H\6I+!\2[."V\.ZH
M&\;6:^*;>&WT6]!1(K&5;'Q>\&_LH^ ?AU\=/B-\</ WP)\._"_Q%IUEX_\
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M+X8T#5]'UJ#4=42ZM=&MI+*\G:Y\I6E(!^,'Q-_;_P#VLOAS=Z=X7^'?Q/\
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M7B?0/$_C+0O!46J:&GBW4[6'3_$.CZUK=J-9O;>*RU:RN98XX+@?2GCSX?>
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MJ0W5K^ZKE-,_9Y_9_P!%T/P;X6T?X&_!W2?#7P[\9)\1OA]X<TSX9^"K#0_
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M\/\ 5+6.RU_0]7\)ZC?W6JZSH^AZSI"_JSXS^'?['?PCTG0]0\<?#?\ 9Y\
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M=Z5/X=N$UF#3VN;$7/JU '\H'Q-_:)\1_&C]I']E,:C\9O&-K^V/\,?V\O\
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M,>$_'=U\3M9G\"VWBWPIXBUK]??\^G\Z\1E_:+^$,/[0]G^RK)XCU0?'6_\
MA1??'"T\(#P1X];39OA=IOB>S\%W_BC_ (3U/##?#I!:^*-0L=&ET:3Q8GB
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M?2-8TK4EB-EJ-G-, ?S,?!W]H;Q1\7_BA^RCHWC_ .*>A^/K;X-?\%Y_B?\
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M#4E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP/CMK5A\)+CXSW&N?"N#PMXJ\3WMYHB>$= ^(KR6/BNT\*>,+5OA3X^U&_\
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M7P/^WWX0-S-_P5.^&>HP>%/!?[8GB*]U:"X_9;UZX_93\7^&?BYX!AMOA:?
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M:)_X)I>(/VG=%_:2\4^+_ O['7_!2#PT?B-XPM/C9JTV@^&_$7[8?[(7B/\
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M$'R5\4OV7_CW\,+?_@HCIG[*N@_MI:?;_LC>%/V)?A[^Q!\-_#?QA_:L\,^
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MQ^6UGQEX4U2"W\.*(]2^Y* /P0^&?AG_ (*)^,O^"?O[5?QZ\?>#M?\ "O\
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MD91)//(0D,*9DE<A45FXH GHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M  HTSQ;?V?BB:U\/ZA\3=3D&D?#^SU26UN/&.LQSZ-X>CU#5+:XM(O*O'/\
MP4(^$;:?^R_XI_9U\4?"+]I[X=_M"_M@:#^R3K/Q ^&/QGT#7O#W@#6]2\%_
M$+Q?JNKVFH>#=)\<:-XLUO0Y/ UKI=[X-NM;\(R+9^)+7Q -=:*VM-,UH P?
MVD]'U/P[_P %!O\ @G9\;M;TY6^%6G^"_P!L7]G#5?$=Q<E+#P9\9?V@[?\
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M\5_!\FN_#[XF?M,>%/#'B;X2_"C78+Z^TC5+?QG\0F\5:59_#70]4T?1]?\
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MO@)XJ_9;_8A\/^!O&/[/!^"WQ+@\=_M!>+_$OPWTC_A2PU_64\2_'/XF>)_
M#7.L?##QQX@^'5_J=W\.=3\'Z;IC7GC;R]%L8;#0=0NM)ATIK:S_ #M\,_\
M!++Q$_\ P1IC\!>,_@#X\\6?\% /#W_!)/XG?L1> /AK\1/C7X=\<:+\./'O
MCKX16/AO6-(^&%IJWQBUK]F_P*GBOXF^%/ ^O7OQ+T?5M/\ % \*>&/"^B3:
M]I^B^'-)\&Z;_2310!_/_P#M<_L'^+M=UW]IKPQ\(/V-O"GB?X9_M&_\$_=8
M^'?[/5EHFI?"'PG:_LG?MS:I\2OC7\2?'WQ8\3:1K/B+3;?P-XI^,WBOXD_
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M7XFT*XOX+B;2?$&LV#V^HW'6444 %%%% !1110 4444 %%%% !1110 4444
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M2\4>%_&\_C'Q98V/C"R:#6OE_P :_L(?M0?#75+KQMXBU#]GV#X"_ ?]IO\
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MNKQ>-?!FF?#T>-;(:AI;>";SQ/?6D^EZA]W_ /!-+_@H#H/[?^AZK\0/A?\
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MLF\0F"ZU&\L+_P 1ZK;>5(G;_'3_ ()C?&K]IGQ;^PC\0/CI^U?\/O&WB_\
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MXE\.#5?#^I 'ZVT5_-_^U_XS^+/_  38^.__  1CC^!OQ\^.GQLLOVGOVHO
MW[&O[2GA?XT_&KXA?'33?C[X)^*6FZ6FH?'^+2/'>N^+K'X:^+_A=K\^I_$V
MWUGX$V'PT\*RV.M1^"_$UA<?"[3?#7AK0NY/_!:OXQ6/P'_:8_:;UW]A[0K'
MX-?L_?'+XI_LF:-J>G?M36VI^)/B5^T[X2_:L^&?[+_P]T*/P_=? K1W\(_!
MSQ[=?$6?QAK/Q1N+GQ!XJ\$Q>!?&^AGX2^(GC\#:K\0 #^@>BOY>/#G_  4Z
M^)_[(O[0?_!1/2OC?!XG^*&O>,_^"J/[$7[$O[-/PJ@^(_Q'^(/P]^'OB/\
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M. ?U;45^!?Q!_P""TOQ)\%^&O'WF?L3:_P"'/B=\ /V%OC)^WI^T9\.OB_\
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MXS?\%7_VE_@]H'CR;5/V'_!UEXM^$_[%W[7?[:_COP_XZ_:4\4^!5O\ X?\
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M7@.^TZTL?$?PF^&=OX+L/%NO_%O6K7QCH^CH ?L?17X3?!3]L'XI?"+]K_\
M:$^'/B+1;SXH_!+XW?\ !7J[_9>\+>+/$GQS\::WXU^!VK>*_P#@EW^SW^TY
MX:T3P#\.O$?A3Q/X<O/@W=^+/#7CI]0T;0_BMX+L?".K_$:ZUGPEX.U*PM;J
MPU'2\*?\%?O&?B+1/BG<?\,N7^M:YX%^ G[)7[1EK9?!_P 1_$'X]V,/P_\
MVD/V@_%_P-^(EU%=?#7X,:A)\:M/_9IT#P;JOQB\4^-?V5XOCC\/OBKX>TOQ
M;X9^%_BC4'\,:?XL\6@'[CT5^/NG?\%2_$'CT:/;? 3X":-^TCJNF?##]GKX
MX>/$^ WQ9U'XA^#M9^%?[0'QP^,OPGL]1^"?Q23X5Z+X%\2:OX2\)? ;XE?%
M?4K?XTZC^S_I]_-I>B?"C[;IGC'5?%^H?#3Z@_9!_:>^,/[3U]\4M?UWX(>
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MPC^&/B*T^/J:5\/K#X9Z7X#TC6_@EKNK>"/'-KX>L('\&^+_  UXR$D7BRP
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M>&M;U?\ 8T\3>,_B/\*K;X<?#S6?"'PZ^+VA_8?B3>W'PFU77_BF ?06M_\
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M\3$\=Z9I.A?"_P ,^"/"5S\(-6\1>/[SQKX9\9_X)F?MG_'O7?V=/V(OV?\
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MK_9.^#&BV_ACX;>#OB#X=\*Z=XR^'GC;PYX4D_:%_:+USPMX(NOA3XR7XA>
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MX3S?LN6?Q&_X* ?LB_%&U\6:KX$M_'?ASQI^SKIOQ6\,>&;O1KR#X[>*-?\
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M#X%>*KCPI\8?C1\*X/&'PIOM=G\3V_A#QGI_PI^(7@K3?&5CX?\ $EYJ6O\
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MQZ_;"U_PEXF_:$^ 6G67@OXG?MJ_"'XK?L4OXI\/^(?V@?!^A_!;XSZWX*^
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MGPOJR?%'X6_&#XW>//"<7P__ &>/B)X1\.>(YY?VA(? UMH^C:GXJT71IM'
M/T#^'_P-^"'PN^#^E_LL26>A^+O!WB3PY\1+3Q)X4^)S^'_%6L?&L>.-4U'Q
M!\=O%GQ%T74;&'3O'^K?%#Q7\0M=\6?&*[DT#^Q]>\0>/]4N-3TVVM==CLVY
M?PK^PE^Q;X'M+"R\'_LI_L_>&HM,\1?#+QA92Z-\)_!5A>P^,/@K%<1_![Q@
M=2M]'34)O%OPM>]U"]^'WB>>ZDUWPAJFIZMK&@W]CJNJZC>7/SI\:+/3(/\
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MQ*=;\->'O .I:KX;ATSQI\,_!GPP\-?$7XCZ7XZ /UGUSX._\$]O#/QS\?\
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M#Z;^R3XPU/5_VH? /Q&^.W[6WCS]EKP1X>^#'[2GPN^#_P"Q=\2/A1\&+/\
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M5M>:G<:[=WUQJNI37?Y,_P#!0_\ :G^-_P"S#^V1\>?'?PR^(NN^*-?^$O\
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M&?\ @HGJ7P0\!_"_X)ZQ>?M._M):7XI^.6@^+?A/J$MAX"U3Q1X9\(_%?4_
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MS-^$?#?Q0_X)^6O_  4W_9#\/Z3JOP[T#XI_L.:]^V/^R?JWPL\=^+/B-?\
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MOBU:>.?#OP8_:H^-'Q1^"7[0?Q(U[X#:G^Q+\)->\#_L^^+[#Q+\-_B9X)^
MVK^.;6'X*:KJ/C7]FWXG_'O0?B1X<\3_  Z^)/B"Z\!R:F>.?#'[4-Q\0/\
M@J1X_P#@[J?CVX_:8^$7PT_X)D_'_P &V&FKKOPX3]H?QQ^SIX"\9>//BM\
MM8TGX?>);S1;_2_CGI%AXA^#/BKP?I?B?Q;X<\':W\1M&ODO;N]T30=4(!_1
M;::!H5AJ-_K%AHNDV6K:KL_M35+33K.VU'4O+_U?]H7L,*7-YY?\'VF639_#
MBO)?B;XZ^!/PQ\;_  =U+XF'PUHOC_XH>.W^#'P<U^^\)W&J:_JOCCQ/X:UG
MQ/-X*T?Q)I^B:A/H$FO>&/ .LZE<KJ&HZ3IFH67AB1)[B5K*&-?PJ_:9^+?[
M0MY8? 35_&'QH_:0_96^#O[9GPR_:2^+7A;Q_P"$O@7^U/\ &KQ[\'/C]XW\
M3_!27]C'X/Z_X#_9]\90>(OAS\5/!?[/=SK%Y;_ _P 1:AXX_9M^,'[0.G_&
MOP_XB\ ?$G5[CP!97/V5_P %"?#7B3Q?I/\ P2M\/>+-1\81:Y)^WI\&[OXE
MZ[X7A3P;XHTVQ/[,7[1^B>,];N;SP9JOB6/X:6VH:WKUGX9O?$GA/Q:9_!VI
M^*M-A\"_$+3/%+^%/%$0!^M<NDZ7/J=EK<^FV$VLZ;9ZCIVG:M+9V\FIZ?I^
MKS:=<:M8V5^\9NK2SU2?1](FU&U@EC@O9=*TV2Y25[&U,7/V/P]\ Z7X>D\(
MZ9X'\(:=X4FU&75Y?#%AX:T6S\/2ZM-JPUZ;4Y-%M[*/39-0EUU5UJ6]>V-S
M)JRKJ3RF\ F'\Q5M^T-^T7X*_9Z\%77B7XH?M/7][??L8_\ !>3X'>!=>MY_
MC/XS\8>*OB]^S]^UC\.-/_X)]7FK77A>QU;6M>^.\G[+7A+Q]XT\"_$[6;9O
MB%\5/ ]IXU^(NK^(_%5HVJZR.MLOB7^T3?\ CCQ5\0M9^-/[2FG7GPZ^(7_!
M S4?"GAN]\;_ !"\+^!VLOCK\0?ASX,_;F?Q%X"F&DZ/XPTK4/@IXF\?:U\8
M?#OC6PUWPY\+[C2&^*0T+P-XW\*#Q;8@'] 7C/QA\ ?!WQ,^&OPU\:0>$].^
M)7[0NN>.D^'FEWG@V6\N?B!XB\)_#9]3\=E];M]"NM*CU>U^%OA<Q7\FOZI9
M76J>&-#AT>V:]MK*"R3/_:"_9M\%_M"?";3_ (.:QJ.K>"/"NE_$SX&_%6PD
M\#6?ANTN[;Q%^SY\;? /[0/@2QBM-=T'7O#_ /8-[\0/AKX;A\5Z=)HDLNK>
M&)M;TFQN]&U#4+?6]/\ YO/$WQ*^(_Q-^-G[,OC;XA7W[2NB?M:_"SXR_P#!
M7/0?V@?!E_9_&K3? WP,L+;]GK]J?2OV9]5\)V5KIJ_!WP#X9O/A?%\+M._9
M\^+_ ,/[CP_>?'S0-4D\9ZMKWQ&^*.H^,=:L=";QC^TOX)^$O[&NE>/_ -J?
M]LKX>Z)^UG^Q3X)^*NB?M"77PI_:A_:I\4>'/^"B][\+/@IHFI_"^[\'? KQ
MCX&O_ ^J:3%X07XF_"W]F_XQ>&?$/P'^,WQ(UW]I7PKXU\">)M2^R>$+8 _H
M^\=^)_V>_@O9?!/X?>-K+P=X/T?QW\4?"_PR^!_A6/P4TOAV3XJ6^G:YXU\(
M:'X;T_1="O-$\+:O967@_7/$&A7]PNC6MA-HD]Q9WT%Y%'N[+5KGX5_#O5/!
MIOK+PKX=U_Q3J6G_  W\!P6&AVB^(=:NQIMU?0>%O#5EI5C+J]S8Z/X<T+4]
M?U6WL(3I?ACP=X<UOQ1K3:9X8\.ZKJ=A_.Y\3_'OC_XF?M7_  !L/C3:?'[3
MOVA?A1_P66T%(?A39Z3\6+WX-^'/V.H_@A\;O#?P)^*7AKPKX8B\1_"2[\&^
M.["ZT;QAXL^,.IWNJ^,=!^.NN_$GX47GQ#L/"?@ZT^'^D?IM<R>*'_X++:-#
MXJ$Z>"K?_@F3XFD^ S2[DMI_%%[^U1X23]K467S!;F>TTFP_8J.IX4M91WND
M991?J' /LWP)K/[/_P 2IO'6D?#F;X6^,W^$WQ4UGPKX_L_"]KX<U>#P1\9+
MG1O#OQ \1Z5K7V""6VT[QY)I7CGP[XC\0;F&L+-K\$NJ2+?R3HGGM[\3?V.Q
M\4H_V?K[5/@Y)\28]5N_!3>"9M"T6>&Q\9>.?AE<>,[GX6WFH?V5)X:TSXG^
M.?@AIM[X\7X37NIVWQ!\7_!?3+WQQ#X7U/X>:=<ZQ!\L_!_XT?#G]GSQG_P6
M&^-WQ7UG4=#^&GA/]M'P'X\U?7-%\*>+_'FH2>#K#_@G/_P3Z^&U]XAT+PI\
M/]!\4>,/%6FV?Q!\$>-_!-U+X7T'63;^*?!7C'0I534O"NOV^G_F_P".-&U^
M;_@K+I7Q"\(_#S4?%/@G7OV]?@O)XI_9$\2VWB/Q#HWQ%G/[#>C:'X._X+:?
M!OQ1IVK2^%/"VB?"31-8UC]F?QEH5[9>(O@1XQN_A5X?UN_NO"_[;VC_  KM
M=- /WH\$?%_]F'7_ !]\3H_ GBWX6R_$'PG8:G;_ !-UC2DT?3M3DT3X=>*/
M$OA+Q)->^*FMK2'Q5X<^&/Q#TWQOX \9:AINJZSHOPX^)^B>-_A]XGN-!\<Z
M%XET*RH?#7]HK]EO4O NA:G\+?'?@&U^'4OCWPW\+].E\.67]@>&-!\=?$FU
MT?Q'\.] UBU33=.L_!C?%^S\;^"-;^$^H>((-%TCXNQ?%;X47_P]O_%'_"XO
MAM)XM_EH\7_LS?M+?%S]ASX ?LR_!3PSXRTKX^?LL?\ !&+_ (*=?LP_M6^#
MS8:_'J6H?';XC_\ #,O@:R^"M[J=]9?V7X@\2?M1>./@Y\1/BE\-]2DU-K/Q
MI\/+#PY\7]-OO^$*^(7@'Q#XB_2#X]:KX4^*O@S_ (+H?M-:9;ZZG[+_ (Q_
MX)>_#3X<:?\ $J+3-?\ #\/B_P ??!SX,_MN?$OXN:]X/LM3TW3]=DUCX=^#
M_CE\'O!VL>(-/TU[OP_\3O"/B+X97T]I\1?A+XN\,^&0#][]&\)^%O#MQKUW
MX?\ #7A_0KKQ5JLNO>*+K1]&T[3+CQ)KDUO#:3:SK\]E;02ZQJTUK;6]M+J.
MHM<WDEO!#"\QCB15S;'X<_#W2_#VD^$=,\">#=.\)Z#-)<:'X8L?"^B6GA[1
M9YI+N::?2=%M[&/3=.FEEO[Z622SMH7>2\NW9BUQ,7_+O]IGXE_M#?"[]F?_
M ()L_%+XC:[XU\%^,=&_:%_8ZA_;3U7P3!K\FBZ7H'C/P1JOA/XNP_$'2_"5
MK>P-\.9?BKKWA_3]8N]1L)?#WA^>?3=9O;K2;"PEU2T_,#QCXY_:%\>_#'QO
M:P_&C]LGP=/I?[)G_!PGXH\/PZ;X^^/OPT\?GQS\"_\ @HOX1N/^"=ZW=OKK
MZ3\0(?&NA_"BWUV/X8Z+J,%OXK^(OP_\+^(_AUXQL/&GPXM_'O@B_ /VQ^._
MP1^#O[0?Q4?X7Z#\;_B=\"?B+\#_  /8?%#Q_P"&_ACX)^$6J^ ?$O@+]H'6
MO$>@^']>^(/AK]HW]G_XU_ /Q?XB;6OV>?&$/ASQ9HNBI\9/AAIUGXJTV/Q%
MX9\#_%WQ!I7CWZ+^$7[-7P@^#'@3P[X$\,^#] U"WT"35-0EU_5_"O@NWUS6
M_$7B#XD:E\9?$WB6^M_#'AGPWX8TB]U[XP:SJ_Q.?1O!WAOPOX.T#Q=??:O!
MWACPU8V&E6%A^!'[87C;XD?$GPI\7M3\5^,_C'>^$+7X%?\ !OK\>_$^F^"_
M&'Q:T/1_#NN2_P#!0CXJS_MM^+-'\/\ PVU?3[KPS!H'[/</P[\5?'#3?"UE
M80>#_"]OX!^(>OZ?I.I0>&?$:_;'[/OQ)^(NF_\ !1SQ=X&G\2?$;XS?"GQO
MX/\ BPWA?4/^%A?&C1-6_9LA\'0? O3]'\!_M(_LR_%2Q?PO;Z?K[^'/$%S\
M /VJO!6OZ-XP^)5WXB^(?A+X@_#OQ1KR>(_BP #[X^(OQD_99^%'Q#\*>!O'
M=[X0TKX@^*O%_@*:QM;/P'J?B2X\/>*_C7XOF\"_"CQ%\0]=\,^&=9TSX3GX
MT?$7P7<^ OA=XR^)VI^$-.^*/Q#\(W/@KP9K.O\ BSP]-I5G[BOP^\!)+XDG
M3P1X06;QCJ%GJWB^9?#6C"7Q5JNG0PVVGZGXDD%EOUS4+&WMK>"SO=4:ZN;:
M&"&*&5$B15_!G]K^/XP^ OVH?^"H/Q?_ &6K?XL:]\<M+_82_P""=]IX6L?!
M_BWXA^*]5G@T_P#:!_;A3]I8?"#X5ZKKFK> O'?Q<^$_[//BW2?B%\-_AC8^
M#/$ECHWQ,\5>#-2L?!C^)/BYJB^,_+/'&M?'#QI^TCX)^&OPG_:-_:03]@3X
MG_MK_!7P'\/_ (P>!OC/\2-6\8W'A3XC_P#!/O\ ; OOVFO WA[XX^)-1\3>
M,/%'P@T7XX:=^RQ+X8^)NJ:[XAU#X2?M%^/O&/PN^'7Q!\$>,? ^E>#_  $
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M7_%VJWNE^"/%_C7Q3\%_#.J6MC\,)_A]\.?T<H **** "BBB@ HHHH ****
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M=\0_L,?%3X?_ +1_B'X5>"O&FD27DVAZU^SAXW^*J?L\ZMX?^%EUI]SX&O\
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M^"/P,^*W[,?QH^(_[*'[6VB?#_\ 9Y^+7A[P+XZ_X(T^(/@?\3OV=_B)\/\
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D4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex10-1_002.jpg
<TEXT>
begin 644 ex10-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" -C IX# 2(  A$! Q$!_\0
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MA75]:\&^)= UW40#Z%HK\HOV>_\ @JCHO[2GPJU;XP?##]F_Q[XK\/Z=\-O
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M$Z/X:_:9^%$7Q&\26/@/5&\#3ZCKNJ:IIK>%?"/BGQ%I&!XA_P""P?P+\+^
MO&/Q)UWX-?'S0O".BZ;\'/&G@/Q%XNO_ -F;X=>#/C'\&?C[K_Q1T'X3_'SP
MO\4OB7^TGX-^$'PP^%7BZ7X3:W)83_M0_$']G[QO_:7BKX2^!G\$#XG?&?X5
M^!O%P!^L]%?GE\(O^"D_P=^,_P 3/A[\/O#7PX^..C:3\2M2\%>"- ^)?C7P
MQX,\*^$[/XX>._V0M)_;PTO]GKQ!X3U'XA#XWZ)\4=/_ &5=8M?B=K^HWGPB
M7X3Z1/%?> I_B<WQ*L;GP?'^AM !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% 'PW^T+^P[8_'[Q]XO\=VW[2?[
M1_P03XF?!/0_V>_BOX6^"MQ\"-/TGXB_"_0=?^(VNV^EWGB3XC? CXD_$_P+
MK-S'\5_'.C3>*OA!\0/AQXEM-/U6UU#1M4TKQ3H>@^(],\A\2?\ !*3X+>(;
M^X@M_B]\??"WP]\/_$#Q+\:?@7\'?"MW\$M.^&W[,O[0/B?XW>$?VDKGXY_!
M^WNO@?J'B[6O%VF?'/PO?_$'0_"'QS\7?&;X+Z8_C?QKX,3X62?#:_T?P7H7
MZA44 ?F3)_P3&\.:M\1O"_Q-\:?M<?MB^/M<TN3X;WWCBU\0^)_@-IUI\7M<
M^$7Q,^.?Q.^'.O>,=3\%_L]>$_%O@ZZ\(WOQ^\6>&="TKX%>)O@]X7TGPMH'
M@6+3= M?$'AI?$-YYOXP_P""0G@'XB>%/B=8?%SX_?&3]H+QEX]^%.A_!W_A
M+?C'IWPBTJ^\0> O"7@;XN^"=!\,?&37/@-\+_@IX]^+L&JV?QC\0KXK\5ZW
MXTLOB/8VEN1\)_&/PJU/Q1\1M5\<_K]10!^)GP9_X)7>.O&O@3]J:Y_;B^-O
MCOQ=\5?VL?#7[5'PL\7WO@+X@?#;Q9-X<^$O[4G[-_[&W[-7BF/_ (3O2/V0
MOV8_!_B3X@Z-HO[&?A?QAX)UG0OV9_A?X1\*W'C75_#?BSP7\6=4T;_A8WB#
M[G_:&_8VL_CW\3?!7Q=TOX]?&3X'>-O!/P^\8_#*"[^&'AC]F/Q?I^M^%_&O
MB3P;XKU&/6-*_:2_9S^/ME;W]CK/@;19M-OO#<7AYS$UW#J:ZFAM/L?V910!
M^>_B+_@FY\%_%%EXIM=7\=?&&2?Q5X!_;=\"2ZI!K7@6VU30Y?V[OB]\)_CE
M\1/'/ABYB^':QZ'X_P#A?\1/@WX2UKX$Z]:P_9_!-RU_?ZYIOB_6HM$U71OG
M35_^"'/['FK^)?#?BB74O&S:GHGP%\*_ G5M6UOP)^RKX_\ 'GBUO!OPNUKX
M4:)\7;SXV?%#]FKQQ\??!7Q<DTG4=)\3:]J/P@^*GPU\$>*/'7A33/$_B/P'
MJ=QXC^)4'CS]DZ* /R ^,7_!*'3_ !#X?NK#X4_M#?&OPY%8?%*+XG_#/P#K
MVJ_"6+X=?!#QK\1_VH?AE^T3^T;\8?AMJ&G_  $U+XC:K\7?&6K>'_B=XE\&
MP?&#Q9\5OAAX5\9?%/Q#HVD>!- ^'KZ'H'A19?\ @BW^S'J7QG^%W[0OBSQM
M\1_B+\9?A_XB\/\ BKQ/\0?B=\._V.OB)XD^+FM^%?V@?'_[2/A^]\1:KXN_
M93U>]^$5QIWCOXG>,-+:[_9+G_9OOM2\%W'A_P -ZO=7Z>!_ MWX:_7ZB@#X
M0^-7[!'A'XO?%G3_ (Z:/\;_ ([?!CXKZ'\2/A]\4?#?B[X7-\$M1;P_XA^'
MOP+_ &AOV=[:TLM"^,/P3^+/AF]T?Q%\./VFOB1!XBM]<T;5KW^V8?#>J^'M
M0\/-I=S#J/M_P!_9]TS]GKPS'X5T#XA?$/QI9W=[XT\4^*]0\?MX#O-:\=?%
M+XE_$3Q3\4/B/\7/$U_X5\">$1!XL\8^*?%VIJ_ASPM!X:^%'A'P_;:-X6^'
M7PX\&^'=%TS3+;Z HH _,3X;_P#!+[P?\/\ ]GGQ-^RCJ/[3?[2'Q&_9_P#$
MW[/FF_LQS> ?&7AW]C[2I;/X3Z=I&C^$SI;>,_AC^R=\._'WB._U+X?:;J/P
M]U>_\<^*?%G]H^'O%'B'4981XQETOQ3I7MOQ@_8X7XG?$_Q+\3/"?[1/[0?P
M#D^)OP^\)?"SXW>'?@CK7P_\/6OQ4\&^!]6\8:GX<N(O%6O_  [\3?$?X2_$
M*VL?'GBWP;-\6_@=XU^&_P 2?^$+UFUAT_Q)IOC3P#\'/'/PR^SJ* /SCLO^
M":GPVN-;U&U\>?&WX_\ Q6^"EU\6/VF/C7IG[,7C:Y^"-A\&="^('[5VH_&K
M4/B??Q:I\/?@AX$^./B;2K/_ (:'^+T'@SP]X_\ C-XPT/PY/XGT_P 0?8;[
MQ=X(^'WB+PIY'XY_X(W?!'XM_#&Z^&7QM^/'[1/QOCUWQQI_BSQKXT^*6E_L
MI^)/&WC+1-*^#VA? K3/ R72_LN67A[X90Z1\.]'O['P[\7?@5X;^%'[37A#
M5O&WQ'\0>#?CMX>U?Q]XGN=0_7BB@#X<T#]B*W\*?$I_$7A;]I#]H[PK\&_^
M%H_%GXW0_LR>$O$G@?PG\,/^%J?'*7QUK?Q/UG5/&?ASX?Z9\>_$OA?7OB1\
M2_'?QIM/A]XE^,&K>$M'^+/B9]6LK >$O"OPW\%>!O%?A9_P2$_93^$OPA\:
M?#7P\NO-XV\4S?$_4/#?[16F>!_V<_AG\;?@IX@^*OPI\,_!S6?%'[/L7P.^
M _PJ^#7P8U_1O"_A#0=7T"X\$?!_3;-O'T&H?$/Q)8^)/%_B#Q)JVK_J;10!
M^:-Q_P $IOV6?"?BM/'G[,^B)^QEXMTJX^'WB+PC_P ,Q^!/@OX(\$>%?B7\
M-M*^,'@S2/BO;_"[4OA=KWP^UCQWXB^#_P ?_C-\!_'VJZ[H&H'Q9\)O&UK9
M.MAXV^''P?\ '7PZ6\_X)D^"-<U'PKX@\8?M'_M.>-?%:ZQ\.=5^-GBCQ3K/
MP8US5_VF+3X-?M':]^U1\&/"/Q(N=6^"5]-\-O ?P@^*_B[QDWP^\)?LM3?L
M]6&F^$O$TWA?56UNT\/^"YO#/Z6T4 ?G7\,/^";?PP\#:#KOP[\=_$[XA_M%
M_ G7-/U.R_X9]^.WPX_9$U7X;65Q=?$"P^(^BZJVK_#S]F#X;_%CQ'J7A'7+
M*:'P\WCCXF>*K26#4+G4?$5IX@\36^E^(-/X3Q)_P1^_9-O-2^*6M?#F]^+'
MP-U;XHP_L\S/+\-/%^C:IHG@;Q%^SE^V'XA_;G\/>+_ _@7XN^$_BG\/(=;\
M=?'_ ,0SZW\2K/Q3X2\5>%M8TV.\A\/^'/"VK>*_'VM>+OU/HH _-GQ%_P $
MV-!\:+X)_P"$W_:F_:9\3/X=T_Q-X,\<;-)_9-\&6?QO^"_BWQQ\/OB#K/P&
M^*>B?#;]EGP5X>B^'DOB#P#-'%K?PRTCX;_%N+2/'_Q(TL?$XP>)D.G:/PX_
MX)A?LU^"O$UQK?B^'6?CMH&AV?AO0_@M\./C1X;^#>L^ OV=/"7A#QMXS\>^
M&O"WPKL?"'PG\$Z[K,>BZQXUN[;3O%WQG\0_%KXDVNEZ9:00^-DO-:\<W_B_
M]%:* /RE\._\$FOAYX+32;CP5^T]^U-X6\0>"9?@?IOP?\66B_LMZMKGP;^'
MO[.]K^T-I_PO^%GAE/$_[+VNZ+XZ\-Z7IG[3WQ5LM5\8?'72/B[\:/$$^I6>
MOZQ\5+KQ4NI:]JG22?\ !+CX8SW'A._NOCW^TE>ZM_PD,WB+]H+6+S4_@A-?
M_ME2?\+OT?X_:;I'[1P/P*6QMO#_ (?\9:9>Z!X>T?X 67P(M-*^&'B+6_A9
M O\ P@T>@:+H7Z;44 ?!/@W_ ()W?!C3/B+K_P 3OB]XG^(?[5GB2YF^%T?@
M%OVFH_A?X[3X.:1\%/%/Q<\7?"K2_ FH>'_AAX-\0Z]J'@K4?C9XZMM-^(7Q
M?USXH_%RYT^]2+5OB%J-S=:U=ZQYO\//^"7WAKX0Z;>0?";]KK]L+X=:]8^&
M?@G\-_AUXR\/:U^SE-KOPN^"_P"SW#\>K/X8?!2PTW7?V:]9\%?%WP)I-C^T
MA\3!J&I_M/\ A+X]_$C7/$$WAGXB:KX^N?BEX2T'QQ9_I]10!^1I_P"",G[,
ML'AK3?AOI7Q#^/NC_!33/#/@W1(?@E;>(_AI?>"Y->\*?L>^'_\ @GMJ'Q!F
M\2ZY\)]6^,'_  EOC;]AO1+W]FSQ3I\7Q0B^'T'A_P 3Z]\3/"/@7PK\?4T#
MXN:'[SX5_P"":O[*?P[^(?A?QC\*? FE_"#P5X2^(.A_%G3?V>OA7X/^%G@?
M]G=_BCIOP3^//[/FN?$&;X<Z+\/(&A\4^/OAA\<K+1?'FHZ;K.G_ -M-\$/@
M>]O'IT/A[QA;^.OOFB@#X!U__@GUX2\0?%WXC_$2?X]_M 6'P[^+WQW^#?[1
M_P 2OV9]*;X$6GP2\6_$_P" _@?X$>"/A[<7>KGX$R_M Z?X8MX_V:_@]K_B
M#P9HGQUTOPSXKU/PYJ&B>(=-U#P!XK\6>"M;\WT+_@D=^S+\-[B^U?\ 9\\3
M_&C]F_Q59^+OA+XT^&?BGX;^+?#'C"?X':K\'?@M\4/V=?#MI\*O"?[07@;X
MV?#6TT+4?@I\:?BE\/M7T'QGX&\::7:Z5XL6]\*VWAG6_"_@C5/#/ZC44 ?F
M%X'_ ."6'PM^&T>D^$/!/Q[_ &E-$^ %CXB_9F\4:M^S(NJ_!#4?A;XOU3]D
MSX7? 7X3_"6+Q5XSU;X%7_[1U[HKZ#^S1\'[[QSX=L?COIN@^/K_ $#5M*\2
MZ?>^"_&7C3PGX@I:7_P2F^&OAZXTK5?"_P"T=^U%X<\3?#O4OA;'^SGXFM=1
M_9\U>Z_9<\ ?!K1/V@O"'P^^$/PD\.^*OV>/$/@3Q/X"T7P!^TY\5? C7W[0
M7A'XX?$>\T:7P3K-U\0)/'/PS^'WB[PW^I5% 'YI?"?_ ()6?LX?"#XS?LZ?
M&K0=7\=ZSK'[*OP;^'_P9^"^B>)--^#-PGAS2_AK\$?$'[._AS7+KXDZ/\']
M$^/VK(OPL\9>.-/N/A3??&*3]G%/%OC7Q#\4-.^".G?%&:Q\96'Z6T44 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2?M:> /V2/BKIWAK2O"6N>(O$7BKXEZE\+],\,>+?AMHUKXL%QXE\/F;XO\
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M\3ZGHFH_&37-)^&FM^+-&\#?L_\ A[Q;\1?$?BR*>#P1X?\ B#\0_P#!/?\
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MEZM\6M3U+2?#O[-7PPTRVT[XL?$#QCK5OX.^)G@GX(^(_"WQ7T_X:97[//\
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M;0'\+:@-=TVZU^\\O\<?\$6OV;/BA\!/VBO@7\2_BO\ M&^.+K]IWX5?L[?
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M-7M=/\5:/X@\-7TUAJ5E;7*VFO:'JVDW'E^5?:?=6[R1-\2:3_P2/^ HTO\
M8[\.>//BE\=/C%X2_893]GZ[^ GAGXFR? R^AT#Q5^S)J-Y>_"KQS#XD\+?
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MF?$3QWX]T[P%X6^*'BWPAX-MM$\*VWA'1O"P!]WT444 %%%% !1110 4444
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MNU7Q'XFUC0M5UWQ7XGU#6 #Y5^"7_!2'XR?$+XO_  9^'?Q!_9R^''@GP_\
M$3]KK]J[]AKQ1XD\)_'[Q%X[U;1/CG^S7\.OC1\8;;Q'X7\.ZI\!_ EIXA^#
M_BOX?? SQ#9W>N:YX@\(^.=&\=Z_I>CP> =4\-:9-XOU7DOVXYO'6K_MZ_"7
MX;>&I?VN/%&B>*O^"=O[:7C@?"_]EK]HK6/@MX@U+XI?#_XY?L6^&?A?XXTZ
M+6_C/\)OA6/$?AJ#XI^,M#L-1\8W5[X<D/BZ.7Q[I>K>$M)GET?[U\/?L/?L
MS>%?%GAOQOH7@77[3Q)X1_:0^+?[6_AV\E^*_P 8;^TTW]H+XZ>$/%W@'XH^
M.UT;4?'UWHES;^(O!_CWQGH5KX+O-.N/ /AFU\2ZN_A/PMH=S=R3GTS5/V?_
M (6:S\>?"7[3&H:-KDOQF\#?#;QA\(?"WB2+Q]\0;31M-^'?Q U_PEXI\9^'
MG\ 6?BFW^'6H#Q#X@\!>"M4O]5U3PG>ZVUSX5T'RM2CCTRU2, _*7PO_ ,%$
M?VB_V>?AQJWPJ_:J^%_A?XE?M&?LU_##_@D!HWQU\>>&OB)8^'-+^)_Q4_X*
M'_&V[_9B^(VMVN@:%\+$\->$9/A/X[\/ZKXW%MX9_M#PQ\2K2[.F:'8_"JR:
MUCLNQT'_ (*7_&SQ'XZF\.)^S?\ "3P]X5\7?MU_%K_@GE\'/%>K?M*>)+S7
M?$OQJ^$.O_$G7/$'B_Q=X+B_9XT[2?#'PUG^ WP<^)?CK2%L_B)K'C76OC)I
M7AOX$VGAJ/PQXNA^/FE_8?QG_P""?_[*O[0'Q%U[XK?$[P-XOO\ QKXK\/\
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M?CS2?"/QK\$?&3]H#PEH/Q1^'E[IMYHGPD\=ZKI7A*Z3Q-\/_'.@>.? ]_\
M#'XF^&-1\%>/]#E.J:YK_@#X6_IYXF_8^_9Z\<?$'5_B5X]\$:A\0=:UO6-:
M\0WGAWX@^/?B+XZ^%4&N>)/@I)^SEXCU32?@EXL\6ZQ\'-"N_$'P.NM8^&VM
M/HO@6P74O#_BKQX+I)+[XA^.[SQ%Y9X*_P"";'['O@#X;^!_A+X?\!>/KCP+
M\-/B3\%/BIX T_Q7^T3^TEX^U;PAX@_9OU*QUGX#>'=!\6^._BYXD\86'PD^
M$NKV":IX'^ \.O#X(:'J-[K=];?#T7?B+7YM2 /S4\ ?MW>/OV6O#W[5VO\
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MU/XEV7Q,^(%YX[@T'X?Z?IWBOQ%XNUSQ=KEE?>*KZ362 ?FE^WGJ7QN\0?\
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M/WC3P-\8];^&GASPMK]SX>^ MEX^\17VJ>(OBKX%]K_:=^/'QG\"_M=_L#_
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M^,?#/QI\6'XI?M@^"_V-OV9_BC%X-U_X26]KXO\ V:OCIXI\>^%OB#<_M _
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MOPX^"FD?$?Q?^UK\=M$^!'A_PSX_^*Z_">T\#:WXB^!/QC^->GZQXJ\0^&/
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M"^!?B@GQM\%^#_"OP6^'6@^&O"GQDBTB;P_%\5_#^BZ9X=MM/TGXC1>'YY=
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M4:U;P-X&_91^+'[4W[/G[#7["_[06J^+?!?[//Q7\$:E^T-H2_$W]NZ7QO\
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M[NXNM(\,^-G;Q?X>M&31?$Y_MW3]1"_C[\=/^"F'[4WP1TG]KJW\7^"_AO\
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MVAF-K?Q"18[VW\Q&\B[C664)<Q;9D$D@5P';(!_(_P#M/?$[Q)XOTC_@HO\
M$+XUZ/HOPE^*&M_LN?\ !M[XF^,OP]N]9M[>#X3_ !%\5?M??%7Q!XO\!:G/
MJ-X9M/;PWKVO2Z1"FJ3)<SPFTF9I3>122_=</[9/[3?BKXX>'?#WA[XM:M9?
M%&7_ (*K_&3]C#XG_L=6OA'X7V3>"/V3=+\&_$?4/A[\?]+3Q+X U'XL:=KE
MM\&?#WPM_;,TCXCZYXLUOX6>-8OB1JW@ >%]4\/^(/AWH_A+]_MB9#;5W+NV
MMM&5W?>P<9&[^+'7OFJRV%BMX^HK96BZA):Q6+WZV\(O'L8)99X+-[H()VM8
M9YYYHK<N88Y9I9$17D=F /YMOA=^UK_P4.O?'OP.^$?C_P"(/CJ[U3Q1_P -
M&?\ !+CXK_$#1OAC\)="CLO^"B/P^\9:Q\1/ G[:_P /_"?B/X':6FK^#IOV
M'_AO\2?VE9M#MM3\2?L[ZE>ZWX)^$<_ABR\=^%O'\M>H?%3]J3X_6_[4?B/X
M)^#OVE;CX=Z1XA_X+5_#O]DR]U30O!G[/=]XITGX&_$#_@C5X;_:87PE!)XJ
M^&.N6EYKUO\ M 65VW@GQEXHTWQ!XK\^PMO ^K7_ (M\,:*?"+?T"8'''3D>
MQP1D?@2/H33/+C!)"("0P)VKDAVWN"<<AV)9AT9CDY/- '\HWB/_ (*<?M+6
M?[,GP)UG5?VRO@?X#\9?$WX"?\%.O!WPT^*WCOXE?L7?!2[^(O[5O[,W[7.D
M? C]F#QS\2H_CO<^#OA=K?PPU;PAHFNS?&/2?@+X>CU>;6];UO5/#_@'2[./
MPI'X8_H6^ ?B_P )^(O'WQ<TK0/VQH?VDM6T'P]\!Y]>^&,>M?L^ZN_P-@\1
M?#*#5?#_ (ED_P"%._#_ ,%^+8Q^T?I;?\+;CN_B)>:OH6J)/]L^$.F>$/ A
MBT&.+XR?LOZG\4OB-HWQ.\*_M+?M$? C6;/PYI7A+Q)H/PQN/@CXM\!>.] T
M#7M5\2:)#K7@+]HWX(_'KPKX7UJRU+7M82^\:?"G2_ASXZ\5:=-H^D>-?$WB
M72_!/P_M/"GO?P_\ ^$/A9X'\(?#?P#HEOX<\%> O#&@^#?">AVTUW=1Z3X;
M\,Z9;:/HFG?;=0N+S4KXV6G6D$!O=2O+S4+ID:XO;JXNI99G .PHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)6P\.ZD9-026..*7=^"/QV^%?[1?@.+XD?!_Q/)XF\+_ /"0>*O"&I"_\/\
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M+6_!7B/QSX$\.^-_ WBOQ!X;\:Z;?>-_"]]I>@ZUX?U--:3ZA@^+MH_CW5-
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MEX,D_:!_9KUBR^#_ (ITCXEP?"_QO\+O#W[/_ #XR? /0-1_:D^"?@CP;8_
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MR/V?_C?\#+;XB^'_ (E?#C4? WP?L/A[^S'X4_9_T;XP0? 77?VG/!%C\-?
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MQ#X]\%^%5^$>K>)_C0/%OP)^&^H^)M5'AWX[>*O"^C7?@6XTGQSXVN/@OX(
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KY=_;@^"OBW]I/]C#]K7]G/P%>^'-+\:_'_\ 9J^./P1\+:KX
MOOM3T[POI&N?%?X9^)O 6G:QK]YHVC>(=6BTG2;G7X]1O5T[1=0O)H+9X((/
M,D#I]15P7Q0^)_@7X,?#[Q9\4OB7K\?AGP/X*TF;6=?U=K'4]6N4@1XX+6PT
MC0M"LM3\0^)O$6M:A/::+X8\)^&=*U?Q1XL\1:AIGAOPSH^K:]JFGZ=<@'Y%
M^-_^">7[1'B[Q]\;_%T>K?!>RL_BK_P4,_X)F_MA:;9R^-O'%S<:3X(_8O\
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M_P"$I^!*>(/!O[!__!7#]E36]17QG\0#I'_":?\ !07X@?#7QC\+O$>DR_\
M"IEO;_PQX-M?A\UGX]>[L])U:"YU99/#NG:['8$7GHGQ5_X)K_M'^/H_CI)I
M^O\ P4M)OB7\*O\ @C=X'\.VM_XU\=FVL]3_ ."<O[3_ (O_ &@?BW_:UQ!\
M*96L](\<:=XME\-_#V>QL]2N+F_LVU+Q-IWA^"]:UMOUSU?X]?"[PYX8^.OC
M?Q/XAD\,>#/V;#X@?XQ>*]?TG5]-T#PQ8^%/AOH'Q:\3:S:ZE-9>1XCT/0?
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M0Z1KEMX4TIKK3M<CTZ]T/3KG26N]4^0?V=OV"_VN_P!F36?V;/'OAC4_V?\
MX@>)_P!GK1OV_/@/?^"/$GQ-^*7A3PA\0_@5^UK^T3X'_:3\$?%C2O%%A\'O
M%EU\+?C3X;\2_";P1X1\=_#%O 7Q,\)ZWX;UO5KW3?C%]M\(:%::[];? _\
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MUI:Q>%O X\7VGQ.\._"#6O#_ ,.OB+\>OA@FFWVG^(=&O?A-=RZ7\4;*VO\
MP_X'\9'6$N)M/ ,W]J_X >/_ (V_$#]ASQ=X(N_!]O8_LR?M>P?M!^.+;Q5K
M.M:1=:SX37]FS]I#X'2Z3X4_LCPOXDAN_$2:O\<-*UV.WU>31=-ET[0M0MFU
M2&YN;8K\>?L-_L!?'C]FOQ7^PKK'Q!UOX2ZGIW[+_P"P;^T;^RQXZ;P=XK\8
MZK>ZYXZ^,WQW_9R^*.B>(/"EKK?PX\-P77A;3="^!-W::Q=:Q?Z-K']L>)+:
M"ST>ZL]+EU"^]B\)_P#!3O\ 9BTU/AYX$\<_$[Q3XL^(5WX8_8Q7QUX_\*?L
MQ?'WPE\)X-;_ &VTMO#G[/WC'4KZ]T3QMX;^%W@WXS_$%HO#?A[3_$'Q.\41
M^!M>UJW\)>+O%TU[X<\6:MI?T#^T;^V;\#_V6]=^'WA#XFM\4M6\=?%G2OB+
MJWPO\ _"/X$_&KXY>,O'J_"O2-+USQGIOA[0_A!X"\:3S:YI^G:WIEY;Z)=M
M::E?:<^J:[:VTGAWPOXMU?00#\C_ !K^SIXY_:W_ &Q?^"KW[.UKIWPYL?A)
M\2OB-_P37U/XF?$#Q!XC\16WQ%\+Z%\*/!W@;XDZB?A;X-LO >J^'_$WBFZ?
MP?\ V-X,\5ZO\0O"4'PI\>WL7CNYT+QR?#:^#=>[?5_^":'[3WB;QIH7AW4O
M%/P%T7X/>#?C!_P5L\:Z+XPL?$/Q$USXF^(?#_\ P4WO_C/XWT.ZU3P!<> -
M!\*>&M9^"/BWXR:CX2U;P]:?$?Q19?$OPYI-AXULO%OP]U,W7@.[^Z_!?_!2
MK]D[XM:CX%T/X,^,OB%\4[_XG_"7X5_&[PAJWPZ_9S_:&^(?A^R^%?QOTKXL
M7GPQ^(?BZZ\+_#F2+POX>U/5?@QXZ\):U:^)+WP_JOA;Q[IUO\/?%L'AOQ?J
M$&FKY9I'_!53]E+X?_!_X5^(OBQ\:/$/CS5M4_90_9R_:I\:_$[P!^RU^T!H
M7@.3X)_'QY-"\,?M$Z[HMIX?^(%A\&_AKK.L:-XDU[Q!HOB[Q_JNJ?"G0=-O
M1XTU".*RCOKP ^0O'?\ P2J_:&^+'[.7B_P]XJO_ ( ^$?CU;?\ !.?X0?\
M!._X>P^%/&WCW7/A[K&@>!O'/A_QUXP^)_Q+\>7_ ,'O#GBN4ZE?^&]%M_AI
M\.-+^'&HP?#3'Q N[GQUXP?XKM#\/O7/BQ^P%^U3>_'/XZ_M,?!SQ=\";+XE
M_P##>G[/G[:?[/\ X4^(.K^-Y?!/BS3/A_\ L&6/["7Q8^$_QFU72/A_?ZO\
M/7\4^"]>^(_B'P1X[\#:1\3)_#WB"Y\':G?^&;I=+U+3;S["T#_@H!\']0\7
M_M&>#/$>D>-/!FK_  $_:=TS]E+1[37/#NJ6][\9OB5JWP ^&'[05A:?#:&Z
MLK*ROC/X4^(.K:E*+G4DL=&^'_@;7?C1XJU3PY\*&/BBT^=?VH?^"JGPCT?]
MACX[_M(_LA^,[?XK^._!W[(?Q9_:>\#PP_!WXK>/]!\):=X$'C_PQH-Q\?/"
M.@P^$?%?PILM<^+_ ,-O&GPFNM&\<WWA'Q;H6O\ @/XP^(-5\/GP?^SY\=]4
M\! 'T)^T%^SS\9?CA_P3I_:4_9C>3X-Z%\</VAOV;?VAOA67T!=?\+_!;PAX
MS^/WA7QQHH2'4+3PUJ_BG6/#_@NX\:B/4/%[^#-/U_XC7.CW7BR^\)^$M1\3
M7&BZ/\B?&_\ X)S?''XHS_M@:'IVM_"=_!O_  41_8W^"G[+WQZF\8^,/%FM
MZO\ LZ:Y\*-'^)G@*^\;? ?2(OA2EC\7-*U?P1\8]<\3^'O#7C+6O@N?"/Q:
M\"6?B1=0UBR^*.M0?#_]*_V@?VG_ (-_LOZ=\/=1^,.L^*-,7XK_ !"M_A3\
M.M/\(?#/XF_%/7?%OQ$N_"?BWQO8^$M*\/?"WPAXRUU]7U+PWX&\3W>DP3:?
M$-8O=.CT/2GO->U'2],O?#-!_P""EG[(_B'P-+\0;7QCXTL=&L_@E^TO\?M:
MTS7O@_\ %CP_XR\,^!?V-/'7ASX9_M5Z9XJ\"ZSX-LO%_ASXD? OQUXM\.^&
M_%_PHU?1;3XCZA?ZG$/"'AGQ-%%<2P@'RUK/[ G[0*? +]H+PAH5W\%K[XF^
M)O\ @JGX._X*'_"G3]1\<>--!\$^*?#7P^_:V^"G[26B_#WXF^,;+X1:_P"(
M/ 7B/7]$^&&H^!K_ %OPYX#^*=CX<N;C1]7M8_$=G%/I$'#_  L_X)R?M/>"
MOC3H/Q5US7/@5<0:7X]_X*Z^.+C3M$\<?$*.Y+?\%"_B'\./B-\+;"UDO?A0
M%67P'<>"[WP[X[OWD3=%=6WB+PY9Z@[R^'+?T_PA_P %5OA[H_[2?[0_P]^-
M.L7>D_!S1_BI^R%\/_V?OB1X0^ /QXOO"FFZ=^U/\%?ACXO\(W_[1OQ5L-'\
M6_#[X83>,_BK\3M&\!^#M9^(%S\(]-+ZSX<T6\T1KRRU_P 2S]1\#OVT?B#X
M_P#&4GA+XD^/_AUX'UN;_@J%^TU^R%X"TC0_@;\1==T_XL_#SX*_"+XG?$/1
M/ '_  D$'Q$U'2_A?\41X9\&W_Q&U?XH^*=3O/"WB>/X=^)O#7ASX:Z;/XLT
MRT\,@'S'\-_^"6GQK\&^ /"G@OQOHG[.7QBTK0?^"6?_  37_84U7PIK?Q0^
M,W@.PU3XE?L5?%WQOXW\;>/_  SX^\#_  WM_'GPTEDTOQG;^*O@)\5_",D?
MQ&^&OQ?\%^$?%D?A^SFTZUU*Q^[_ -E+PO\ M@_ ]_@S\ ?BWJ7ACXQ^ M)^
M''QMUKQE\:]8\:>/?%/Q8T379OC==ZC\ OA[JGBW5?A9X2\-_&!/"GP.URP\
M">./BYXHU+0/C#\5O&WA&7XH^)_!EM-K^O:A?=7HW_!0K]F7Q'H+>)= UWQW
MJ^D:EI'P5\1^ +RT^$WQ+%I\7_#'[1OQ,;X-_ WQ3\*-1N/#$&E>+O#7Q'^)
MD<FB:5KD=_::=I/AB32?C!XJGT#X&^*/"/Q-U_F?!O\ P46^#?Q-^+/PF^%W
MP[\/_%+6[?XM_!O]K+XH6?C2;X3_ !&MK7PEKW['GQW^'/[.?Q:^&?B/PE<>
M&;7Q._C3P[\3O&FO:+K5A;Q0PV5WX/L[.TNM2/Q#\!W.K@'C6@?L)_$[0?VX
M?BU\6-8\)_LA_%CX _%3X]> _P!K/P]\0OBIX)UC7_VM/@+\7_"7P6\"_!75
M/ WP[AU#PSK/@;7?#=[I_P ,/#6N?#OXPOXV\$>.O@[I7BKQY\/M,\$^+;%O
M#?BC2?+KS_@D[XLLO@=^U_\ !_PA\5?">F6_B_XW^'OB;^Q-IFO>$X=;^'?P
M0\#^$_VC_#_[>5I\(/'/@NPTW0I;KP)XQ_:VU7XB>!OB-HWAC69H_$'[+F@_
M!;PI%/:Z[X)@M;'ZC\)_\%#OV?\ PO\  'X2?$GXE?&1_B-::M^R[\$/VG?B
M1\8?A[\"/BCX<\%^'_@M\9K"2T\$_M$_$+P#"?B#K_P&^&7C_6M*\1WUGIGC
M/Q#JVH>"_#_ACXB>*?%-[;?#WX/_ !7\;^#>\TW_ (*%?LO:I\<A^SS#XE\=
M6GQ!_P"%^>)/V7&N];^#/Q?\.> 5_:"\,_!>W_:&E^%@^)GB#P1IG@*;Q'KO
MP<DN_'/A!K?Q!-I?B[2K!O\ A']0O[C5O#4.N 'Q[X2_84_: 3XN?L__ !SO
M_AQ^Q=\&M<\(>$?VU(_BO\-/V?=2\;:5X8O/'7[07PS_ &?/AMX UNW\=7?P
M:\.ZK\7=7>W^ \-QXV^(/B_P/\/=>\+>%-6\)_#O0O#WCJQ^&MIXB\4^;?#/
M_@FE\?? 7PF\.?"'Q=X4_9C^-'A.3_@E_P#\$R_V,/'6D>)/B[\:_ 7G?%C]
M@'XF_%[7M4\1>!?$O@;X3KXQ\%VOB70/C9J'CKX0?';P_K>B_$[X(?&3X6^!
M=5TOX>ZW)JH\6>"OUI^ O[2?PN_:3\.VGBWX53^*]0\,:OX/\"?$?PQXAUWP
M)XP\*:'XT^''Q2T_4=:^&WCSP9K7B'1M/TKQ/H'C#0=-EUJU32;VXUG0;6XL
M[/QCI/AO6+E-,KWN@#\]?V4_"W[87P,/P5^ 7Q8U'PO\8_ >E^ OCMK'C3XS
M:QXW^(?BWXL>']2E^-=UJ?[/7@+4O&>M_"[POX>^,@\)_!/6['P!X]^*_BW5
M?#_QD^*OC7PT/BAX@\'K)JGBC5+_ ,-^*7[ 'QK\?^//VH_ \7CKP'%^SG^U
M?^V-^QO^VSK/CK^WO'.D_M ?"7QG^R_<?LI2>*/A7X<\-6VBZIX3\=>&OB!:
M?L5_#.P\$_$,?$?X7:S\)&^)WB^\?P1\0(?AIX9TSQU^OE% 'R-^Q+\$_B)^
MS_\ !;Q#X ^)TO@VX\2ZO^TE^V-\9H)O NO:WXAT5?#_ .TI^UK\:OVC_#NG
MSWVO^$O!E\FM>'](^*]KX:UN&/29;&34M&N+VPO[BUO(XX/KFBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *^9/VQ?V;HOVM/V=O'7P-3QYK7PLU[6]0^'_C7P!\3
MM TK2_$&H_#KXL_!KXE>#_C1\'/')\,ZWMTCQ9IOA/XJ_#[P=KVM^#]2GL;/
MQ;HMAJ'AN?4]+35#J-K]-U\>?\%#?B=X]^"'[!'[:OQN^%?B.3PE\2_@M^RC
M^T'\8/ 'B%-+T'7$TWQC\+_A1XK\<^&Y+S1_$VE:WHFIZ;+J^@VEOJEC?:=,
M+K3I;J&"6UN7ANX #X\E_P""9GQ@\5Z_\3O&OQ1_:?\ AMKOC/XN?MQ?L(?M
MK>++GP)^S+XG\"^&+/4OV*=+^!VD/\._#.@:_P#M/?$;5=.T[XFV_P "/#LR
M>(M7\4^(+OP5=:YX@9M+\7P-I5MIG*Z[_P $A];U:^^)?CK0OVA/"'PJ^,/B
M?XG?!+]H?P?XE^"_[/=Y\/\ X80_M4?!KXB>)_%][^TO\9/@6/CEK7@[XJ_%
M3XR>%-?7X9?'/5_!MW\$S\3?#%SKUWXB:ZUC_A7MW\,_4_AS^U5>?#CPQX:^
M+?CWXH?M4?&/P5XN\:?LC_L\:YX1^*/[./@;X.:GX2^,G[5?Q/\ AM\-_ 'Q
M(\#3ZY\,OV7/$?B?X/IXC^+FD:#\1M;L-#^*NG(^FB#X?W;>*_ 'Q3\-W.MJ
M?_!5/P ?$WAGP)X%_9E_:I^+'Q \8?'C]KK]G;P[X)\":?\ L\6FJZAX\_8Q
MNT3XFW3ZMX__ &B_ WA#2_#/B32DU+Q!\/=8UOQ-I9U:RTF?1?$5KX5\;:MX
M5\)^(0#AOVG/^":GQN_:9L8=3\0?M:>"M.^(OC3]B#]N+]A[X[>*+O\ 9HU3
M5O#?B?P5^VC-\-]57Q#\&O!>G_M$^&I?@]<?!S6/ACX?L/"ND^,/$_QQ;Q3X
M+^T:;XQUC4?'=UJ/Q,U#:\3?\$V?'.O_ !EL/CKI_P ;_A-X.^(7AOX3^)_A
M9H7B+P?^S/K6C:IX]\/Z_P#LM6_P.T[P!^U3;C]HB;PG^U;\!O!_Q?DU+]I/
MP9\+/B5X1B\2>$/$-KX5\#^$OBIX?T6Q\::K\0_FC2O^"E7[1OQ/\<?L.^._
M!WP8^*^G:'\3?V@/^"H_P5\5_LQ>#+W]F_6M8^.=E^R3JGQ9\%_#;5].\?>.
MO%^E:)X,U72=6^&#7>NW%_\ %[X6>&I_%J^)]'A_X3KPQ-X U?7?KK2/^"L_
M[./BC3?@EJ_@OPO\5/&5I\9_ ?['_P 2WT_0+'X?W/C'X=^#_P!MI[8_"34/
M%OP]?XB1^.M>N/#>G7^G>*?B_9_"SP_\1)/AKX$O!XXU5KCPY;W-]$ <S\,O
M^"7K?#"V^"6DZ%\7O#NF>"O@[^W%X[_;#TSX1^'?AAXRTSX->$?#7Q!_9)^)
M_P"RKK?[.O[/?@?7/CSXKNOV>_A89/BUXS^-%EHFA^(?%'@WP_\ $KQ+XHM_
M!?@#PGX-U>Q\-:)Y!X@_X(VZSXN_9LT?]G3Q5^TWIFN0?!G]@W]I;_@G=^RG
MXZF^!,EEKGPU^!_[2>B?#CX=ZEXD^,6F:9\8[+2/C;\5?!/P:^#7PV\!^'?$
M7A.'X$>%[_5F^(7C+Q!X)U.?Q=X?T;P'[Y8?\%4?"6HVGPVU2V_9._:R?1_C
M!^TG\0_V1_AKJBI^R]+#XH^//PI\5?M5^#O'WA*.*W_:?FN=,T_0M9_9&\=
M^*M9BT_PS=6/BWP!J<6J#3;SQ7=^$<SP+_P5^_9^\16=KXB\??##X\_ [X>3
M?L[?M>_M&7/Q+^(VA_#77?#6GZ+^P+\0/#_PR_;"\#W6B_!WXI?%/XBR^-O@
MWXK\0I;I+8>!KWP5\2+/2-8U#X5^,?&EJ="DUX ?\5_^":NJ_%7Q1^UMJOB/
MXA_ [QCX1_:Z^*/P4\?^,OAO\7/V9-:^(7AS1=,^$/[-<?P-72]&U+2?VAO
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MAH?B'1-*^!GQTM(?".H>(_AIK>@@ ^0=7_X)5^,8-'O)OAE^U;J7P@^)>O\
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MM]3^&JV7A >*OA'X?^,?AGQ1K/@ZY^(%O\6Q\-?%&C^)K'P9X9^*.G?#G4?
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M8/%WAW4_AWXY\=:%H=_\0K'PG\4],\0>(?!_BWX<]EH7_!-[6-*\5^&M?O\
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MZ-IM^+>1Y+&^2!K'4K6\TZYNK28 Z[XT?LF:%\:OV;?"_P"SGJ?Q2^*/A9O
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M;Z7<>#_&'P>UR]F\06_B*WU_Q'HGCV#2_&WPZ\2^!M0TNU@'+_#W_@E'\(?
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M=V/PO)_P5V^(3Q>+OA3I/[&NO>)/VS_AMK7[5^@^/?V>/"'Q \>^._!5U?\
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M^_$_PMX5@\":'8?$>[UOX<7GA3P[\/='\$:=H/A#PW\/O@GX2^$7AKP/X?\
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M'7B;1?$GARV\"6VF0^(]'$%_K\FCVGC^)/!^I^(9O!?A?YK_ &1O^"BWQ?\
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MK2VO)9]*U/3[](+R'TJOC/\ X*%_M"^/?V3_ -B_]H+]HWX8Z3X0U_QQ\(/
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MX*^-O&7P0M;3XQW%YI&A?%[X+_M ^(KKPWX3\7WWB>]^$_QLT Z#XD\9>/\
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MI_AV/1/._#?[#G[/'A3Q-H_B[1_#WB4:UH/[27Q4_:YTV34O'GC'6K*'X_\
MQL\ ^,OA9\3O&ITO6=9OM->Q\1_#OXB^/?"=OX(:U_X0'PO9>*]1O_!_A?P_
MKEMH^JZ9\M^&?VPOVL?&'[3GB/X<>$OA#X"USX)? 3]I?PA^RU^TAX\UN7PW
M\.KU[_Q/^SM\+_B@OQ?\!W'B'X_7_BG0YKGXE_&3P)X/\)_ &_\ @UX]E\:>
M!K^'QIH?[0,VN:KI_@Q?'/\ @IE!:ZK^TM\.]*^-&F>'_BQ^R=X1_P"";?\
MP4D_:,^(_P"SQ=_#_P 4^*]=\8ZY^SU\0_V#KU/%'@6ZTSXJ^%;#0_C]H_A[
MQYJVC?L[_%72/#UMXX^"NH^(/B(_AK5K^[^)*7/A, ^R+?\ X)F_LA1_";Q%
M\#[_ ,#^*_$7PRUCX)>+OV:?#OA[Q5\5?B9XED^%7[/?C?5]/\0Z_P#!WX-:
MUK'BJ[UWX8>#9=;T3PM<VL?A;4K'6++2/A]\(O!,&KK\/O@A\&/"?@#WSXH?
MLT?"SXQ?#3P=\+?'L'B_5]&^'GBGX=>/O GB$_$'QN/B!X9^(?PEUFP\1_#K
MQ]#X^DUZ;Q1K?B;P[X@TRRU6XF\5:CK^G>*F6ZT[QKIOB31-4U;2[[\7?BO_
M ,%5OVL_A)X)\,ZS+X*_9K^(&K_&K]CO]F[]LGX,:WX6M?B18_#SP[:?$O\
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M5/!^H^"[KP]\1?@)^TE\>_'.J>*OA-\+OVHOC/J7B?2K?P_^RIXETOX)^/\
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MQL+#2])\*+&- TW1K&RT6RT^#2K2WLX_<** /!?'/[+O[/GQ,\<>'/B5X_\
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M^-%UI/QGC\5WY^(NJ)XA_:!_X)RMX^\*Q_"[PKX>T_7O@G\$H?'G[$VI>+O
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M+_Q%^$?PL^'_ (UUSQKX0\9>.OAU\6@#^FRBOR+_ ."@?QD^)7P=_9(_8_\
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M?%'A^*36-'$P'VRQ1IT^45_/AJO[:WB&/2/@]X>_:'_:U^)GP6^ WQ-^-_\
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M%_[;/[/^F?'7XV_$_3CK6G7#1>X_%WXS?'*;PS_P6[^+WPQ_;3^+\>B_L2?
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M !7XA\&PZYXA32K6QTYO$NJZ?H%G?>(KBRT_3K6\UJXOKR#3K"*X2TA /O\
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M^M_#*R^)WCKPSX,^-_PGU#7-(T+P=\3])\ ^(?$?PUT"X\6>'/%'A>[%KXB
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M6Z=X ^)VG7U]J5SX>TW1?%>C7?@K5/&%YXAOO#'A*^TCUFU^"'[5/P@\-?\
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MNA7WP_\ B+X=TKPQ<?%+PR_C+P+%IOC7Q+X3TCP-XW?6?#2?VK*/ 7B3Q/\
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M[PO\;M'^"/Q[^%'AOQ;X"\*^/=8\#^--!\8:?KEY\*/&N@_9?C[PE^WIX/\
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M3]J[]M_P7:R_&#QE\=FL)?V?F_;5^.7Q&_9^B\'_  ^^)&O'P1!X2?X<>,M
MUOP?XK\*^&1<'3-?O]'_ +>#C6=(M@#]1Z*** "BBB@ HHHH **** "BBB@
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MM_%WA2\TVZUBT\3^'KK2+*_U;2KW5;?6M-GTVTU30;J[LM<TVZOHKEK6WO\
M1KVPO[35K.65+C3KJRN[>\CAEMID3^9+X3_\$P/VG?"'PY\ ^#OAC\&M%_9B
M^(NO?L4_\%R?V<M8^+/ASQ-\+?"Y^%OBG]J[]HWX:>+?V##XCU;X1>+M6\9W
M_A7P1\.O!4=QX2@^'^F^+XO@M8Z)H7AO3M.\-RV=A8V?H-_^P)XL^-]Q^SAX
MY\5_\$W-5^$,>L_MM?LV>._VL_@E\4?VAO@Y\?O#<_@3X3?LE_M#? #6?%.E
M^&;;XDW_ ,'-7^$'AK2OB)\+?A3H4WA[1M"^.'Q<^&7@V/2/B=\$]+\-> /
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M>$/!VF6M[J6F:;;^(O%_B/6M%T+1CXAU;0="M;C5;?4O$.N:'X?M]1UFR_G
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M!?B?P]K^F^#-9TROKO["OQ._X6OX-\.']AJ]D_92^)G[/W[-GA7P%\,O@_\
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MKIDMC(/#/BGQ6MRMU" ?HUX(_;,_9>\<>"M7\:Z9^T+\";_3/"/A_P"&FO\
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MN>"]':6T\,:YH'B2!]9\6>$=1MKFPN.N_P""</[$?Q;_ &6++P+X>^.'@_\
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M\8OB=X+\:^#=+\3_  5T./QCI'Q"\-_$O3T\56/B3Q'X,U?X::[IM_IMA?\
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MSK/[+MY\'?AMX'^#%SX\T3QA\4?#7BOQ!:CXQZEXVL+;2/C]\'?%7A:Q\/\
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MI \*ZY_P4YA\(? FX\7>$/\ @FK^RU9?M%ZKXUUCXC#PI8?'S5(K/]I$>+_
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M)^Q'\1/B-\0/V4O$/[1OQN\$?$/X>_L:ZSI/Q,^$_P )_AI\"KCX7:7XA_:
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MG\/7'P\\''58O$NB 'O<'_!4#]A:\^&OB'XP:9\=K?7/AMX4_9R^%O[6FO\
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M6>-?%5_XRLK'XUZG8:'\+O#MG\*?BMK/Q*\7:]J'PY\6?%P>';+X1:-X+O\
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MPQJ/QT\,Z7JOCK]G"3X=Z-X6\2Z'<:WX<TWQQX:\/ZA::1I?Z@_LM?!SQ?\
M!+X9R>&O'VI?!/4?&&L^(;OQ-KJ?L[_ FW_9U^#^FW-QI>C:+;Z9X1^',GC;
MXF^(TCAL-"M)]5\0>,OB-XOU_7=;N=2NK2;PWX67PWX'\+ 'TA1110 4444
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M'4/%_A[QQX3TN/P9XG77?#_Q.M=+T1?$A\2>'4T72]>T!;?5A=:O_!-OQ?\
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M\.?#/@WP-I-W?S;I#8>&/#&C:7;)LBAM,J\L@!V]%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&TCQ5XDB\9>'+C1/&?A?P3XB\,R_"'_@HK\9/@Q\)/!?PF^(GPR\&>*?'"_
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MV-_V<O'.M_$SQ'XG^']S?ZW\8O&OP,^(OQ&U&W\<?$329O$7C7]FG6]$\2?
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M@\8#Q-KG@OXW:AXNNM9^,'PC\8ZKK'PU^)]GJ6GIXX\&:[ID&EPP '!?"O\
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MD;FNCH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX=@N+7P_/\1/%^C:39>(/&TVA6UW=V^C2^)=1U-],@NKB&R:".:16 /P5;X
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MW[,W_"Z_BAX9\3:!<^$YO@;\4?#NG>#]&T75OA[<_$CXR\C_ ,$X/"-YI/\
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M\+>%_AEX@&D>(S;^(%D\/?3=_P#M+?MR-\;OV?OV>M&^._[*EQI?[0/QP_:
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M&O6_V%O$GA_X8_M#>%? _CSX2:9\1++1;G0K[PMXV'BK09]1TEK>:7YN\(>
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MO +1ZCJOP5AL[?X-ZG?1MH!6[U#X2V^G:?!\,[RX$ESX#AL+.+PM)I26L"H
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M65_>VOPS\4^&=271KCP?)#XOT2?Z!\/_ +0_QIT/]M[7/V//$O[<4?@SQ[\
M_C-\!M)\!_#[XV^!/"^I_&#]MC]CCQI^S-X&UCX@?%31?"WAKX;_  R\-_$3
MQ!_PNV\^.LOBW]H'X,R6/A']G2^_9HT^T^('P[L/!5Q\7=*^,/[YT=.E 'X^
M_P#!+G3/%G[7W["?[(_[3_[3_P >/%/[3_B_XK^$/@%^T7_9/BGPS\!=*\!?
M#+XO^"?"TMI<2?#JR^%?PH\&:QI-Y;^,_P#BH?$T'B'Q/XBOM,^(.@3V^@KX
M-\/3ZUX(GM?\$YOVF_B-\6OC+^T;\-?B5\5=/^.%QH.D^'?B%X(^(GPE\5>
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M3_UF44 ?D?\ \%&_B]XS\"_&S_@G[\-;+]KOQ/\ LA?"?]H/Q[^T-X$^+_Q
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M_ ?ANWM;OQ%XVO?#>H:O;ZS:>$=!M+VSNM:\27%G'HVE6]W:S7U[!'/$SO\
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MGBSPSX6@N'US7=+L;H ^B**\>'[0WP!9_B7&/CE\'C)\%UM&^,48^)G@LO\
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M;J+QIX8\0:'IP!]-45X7\4?CCH'A']F[QU^T7X"U?X9^/O#VB_!O7OBY\/\
M5]:^+OA3X>_"'X@6D7@^X\5>");SXZZBFM^"O!W@+QL3I,0^*5S#K/AS1=$U
M9/$YM]4T^ 0W$5E^TW\ #XL\+?#+6OCE\#M'^,7BK48?#>G?"=?C!X$O/&U_
MXU7P7IWQ"U'P?H'AYM6L_$/B+6;#P7JEEXO^QV.B+J$W@^\L?%3:?!HU]!<,
M >\T5YE\1OC7\&O@\WA]?BY\6_AE\+&\67QTSPLOQ&\>^%?!#>)=26[TRP;3
M_#X\3:KIAUF^6^UK1[(VFG?:9Q=ZMIEL8_.O[5)<"+]I;]G&X^(FG_"&#]H#
MX)S?%G5O$WC/P5I?POB^*O@23XB:EXR^''A+0O'_ ,0_"6G^"DUYO$MYXF\!
M^!/%'AKQKXST&VTR35?"_A+Q%H7B37+2QT;5M/O;@ ]LHKS3PE\:/@[X_P!$
M\$>)? GQ8^&GC7PY\3+W6--^''B#PEX[\+^)-$^(&H^'K?6KO7[#P1JNCZK>
M6'BN]T.U\-^(KG6+70;B_GTRWT#6IKV."/2[YH/E+XD?MS:7HG[5:_LA_"GP
M]\//B5\5/!V@?!+XB_&S0O$GQW\)?"WQ%X/^$OQG\:^-?#<WB3X=>&]1T7Q)
M-\4/&7PM\(?#GQA\8OB;\/M8O_AE)IOPN_X1#5= \1^(M<\<^'_#\X!]\45\
M^']K;]E,>"V^))_::_9\'P[36]9\-/X^/QG^' \%KXC\.>%KKQSXA\/MXI/B
M3^PUUO0O!5C>^,-9THWXO]+\+6=UX@OH(-)MYKM,F+]M3]CB>XLK.#]K3]F:
M:[U+2/&6OZ=:Q?'CX627%_H/PZ\$:1\3/B#K=E GBHRW6D>!/AOK^A?$#QEJ
M4"R6?ACP1K>D>*];FL=!U*SOY@#Z9HKF_!WC+PA\1/"?AOQ[\/\ Q7X;\=>!
MO&6AZ9XF\'^-/!VN:7XG\)^*_#>MV<.H:-XA\-^(]$NK[1]=T/5["X@OM,U;
M2[RZL+^SFAN;6XEAD1VZ2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA3QCIGA;Q-JVI>#O$]II(!^-7AK_ ()S_M"6'C/X6:R/"?@#0_[#_P""A_\
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M%_V@?%'Q6T#P9H'P#\22C0?C%J/@C50UHH!^.&D?\$L?VH+[]E[X5? JWM_
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MQ_\ M3?M0?L__!>P^&/AGXKQZ7JE_P#L\W7BC6=:^&_B[5O%F@#3+'XT>"O
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MX6^'VE6=J=2;X4?L_?#[Q9KWBSPKXLU:V^%'PWT9?^"?7QDC^.MKXVM?A_\
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M^'/QO\=_ WPEKWB_7O!FA>/?%_AWQ>\7@;X=R_$_Q9X>T/P1X^\5W^B0^"?
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M#&FW'@O5IK.#0-*\3>,+S2[ZQ\<^*=9T+X<Z5X"U6T^)_BOQAX=^'4.H^)[
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MB\$?#?PGX:L]<\4^,?BUJGAOX6:+I%WXT\6^%-*UNG^Q_P#M'_%GXW?M%?\
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MS_L]]9VUU'+"GP5\3O\ @KE^Q7\)O'/CSP)XG\=W][?> /#O[1NK7VH^%(=
M\6P:OXA_9,\"^*/B5\?OASI.@Z#XDO?'5OXW\">#O GC^_*^(_"/A_PIXAU3
MP%XR\)>%_%6M>,?#]_X?C /-?$?_  3T^,6H?'#QKXZTOQ[\-CX&\1?\%1/@
MC_P4/T^UO;?Q1;>+(M+\#_LI?#[]G#QM\-[T6UG=Z.MZ]W\.+#Q%X8UB"::W
MU&TUR]L]7@TB72X3J?ANJ_\ !*#XUQ:_\/\ QQHVK_L9>/\ 6$\8_M[Z'\6/
MAS^U5\"/$/[1?PAU+X3_ +;G[9'C?]K[1/%7@?3%UWX;ZSIGQ6^"&I^-M5\
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M?PC<:CH&M:)X2\0:?KUU;P?%:7_A7'US^V3^Q7XK^/7_  3X?]BOX4ZW\,?
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ML?!/_@H=^T+\._CSK:S:-!J?A;6M,^,7P=U'X6^$-,T#4+6XN?#GC?1CXO\
M#U]<>$8?%UMK'A;]N/A]X0L?A[X!\$> =,ATBWTWP/X0\->$-/@\/^'-'\'Z
M#!8^&M%LM%M(=$\)>';>T\/^%M(CM[*---\.:':VVCZ)9+#IFF6\-E:P1K\2
M)_P4R_9PC\,7OQ U>Q^*WACX5ZCX6^'OC/X3?&7Q5\.[_P /_!GX_>'_ (L?
M$O3/@_\ #B\^%OQ5U*\A\#6#>,O'_B#PM!H,'Q9USX7RZAX#\5:'\<8%?X"2
MWGQ1LO6OA+^VG\!?C3^SOXX_:;\#:_JFK_#KX73?%W3/B79:%HT_CWQAX/\
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MB7P5!\7;K1O&.B^%P#QUO^"2E[=:/\5- UC]IC5=<L?B-\%/^"J7P/M-0O\
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M(:GI^LZ%X TC4-&^+?QTB\2>*O"&H?#?X*^)-,\5>#6^,FL:5XH\/Z* >O\
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ML]/T.W\(_%[4(O%-SX1\5^"['_A6UU[_ /##]J[1?B/^S/XN_::TGPU;^/\
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MPIKOBWP#HGCZ.?P+]"?MU^-/VI_#?[,^G>/OV6? GC/Q)XVTKQ]\&O$OQ4\
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M_9W@_P")]_/^S[XET'Q[\'OVG?&G[,'Q!\,^-_B;\-?#W@SP[XH\/_!?P_\
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MOC36+_2M!\=6$/AN75M%T<?$*8?#8 ^V(/\ @E'^SJ/!/Q\^$6H^./V@]9^
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MW7_&F@W-GX3TG1]'UKQW>75M+K$_CW@K]O\ ^*DG[3%A^R9X^\"^ _\ A/\
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M?$/X7_&#]F3X?>/]3U"W\<7EUX/^&U]H.A^./!UC?:]\/O&?@35IM:\'^+/
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M3<?\))X\UZRN+GXE^/MN#_@JO\8-$^$'@'XVZU^SKH_C[0OVC_\ @FI\2O\
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M_AAX?\;ZOX7N?CKKO@#2/#'Q+TSXB:W)XT\->)O#_@+P1#XJ_9NU;PO%X/\
MB=/K/Q,;Q1X'\'@'J\'PH_X*37GQ,O\ QYXX^%O[/OQ2\+#Q/X)\>>$?@?X^
M_P""D/CF[^$'P\^('@3PAI/A32O&7AJU\/?\$=/#GQ!UF[DO=+/Q#3PU\1?B
M'X[\ >'_ (N72?%+P5X0\+>--!\(:OX<\Z^+G[('[67Q_P#@5\4/@9\=?V/O
MV+?C%_PM+PU\>_!MU\8?B-_P4 \>^*/CGX)\*?'OQ/\ $#Q'<Z!\./'NH?\
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M7ASX(_"SQ9X@L]#U36/AO\&]-\">"KB?P=\/E&A)#\.O L?A[[.HH ^"8?\
M@F5^QC'X=\6^'I?AQXWU&?QSXN^#_P 0O$OCK6_VAOVD=?\ C+>?$+X!6]I8
M?!_XA6?QXUOXN:A\:]$\?^!=%L+3POI?C;0O'VF^*)_!D"^"M2U:^\)E]&8U
MO_@F#^PEXAT;X<>'M5_9^T:30_A+X]^+WQ$\ :5:>+_B1I=EHFJ?'_Q7J'C?
MXX>%9X-+\962:[\(/BWXHU2\U7XA_ 7Q"-6^!_BUWAM=:^'MY8VEG;0?>U%
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M\8^*/&WBW3?'GB3PMX+\'?#WPUXJ^S>(O$NIIX7\7:!X3^'7P^L-'\5^#/\
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MSXU^)9)/&CVMSXO_ .$&\">%]*U>V2%= UN/1M-;6M)U*6PM9H_8/BE^SO\
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M)_%7@WQ3#HFBG7?"/B:75O#>I3Z1IEU<Z7)=6%K-%[?10!X?\7_V<?@[\=?
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M&5S\.8AXL_X2_1 #^FJBOY/H?^"HO[2WB/\ 9/L/%NA?M4Z%)\;=)_X(D_\
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M/Q,\;78!_1UH7CWP+XHU_P 8^%/#/C3PGXB\4_#O4-,TGX@>&]"\1Z/J^O\
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MG_@FK\.OC5<:=X%\5_L8_$ZP\%?MIWOBKQ?=?%VR\'>&OA^/'OB>]_9S\/\
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M  E'@;X(>(?VEO"/P;T;XF1?"*6'P?\ L\?#SXH_%C6?A=I?P;\-V-KJ?@D
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M?M!ZV?&'QK^%?Q3\/^'-%D^*>E3Z9\&/#&L_6W_!*SPWXV\5_ 'QM\5_BO\
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MGQWH=QX;_:2T3Q]\4?'GQ1\+_%7XB^%(Y/!O2^$?CI^T?X)N=.^$J>(OVD]
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M'I*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP[I\/PL\<_#WXN:M>>$O#6E?$EE^SE^U#J/Q!\"?#71OV:_BMH6E?#7X@?\
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M+P[\+-#?\$OV>?VI?#?_  I'P7HWPM^+7PSC^$'_  5J_;J^+/PRUGXB>%_
M%[X9^&WP/^,?[#?[9_@WX.^.;'PY\([C4/A]HOP\B^,W[0_@&TD\(>&]#T2S
MT[4?$_B#[7X>@_X1GXC7N@@'])-'^?SK\4_^"17P9^(?@/3M?\8?$_X/?M<_
M!;XLW?P>^#GPN_:,TW]HC6_V:'\ _$/X]?#.WUJ+Q-\2?ABW[/\ :7&L?&_Q
M#JUSK6M?\)E^UC\4[^U\6_%WP=<_"/2M0UCQYK_A3Q)I7PD\G^&G[./QVO\
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M#/#7@W]NK0/%_P 8?A)\28_AYXIUK2&U#]@O]I[]F^^^(7A+X,P?%/QM\-O
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M]P/@7^T;X/\ VAO!7Q!\:_#[P[XS6+X;?&/XX_ K7- U^RT#2M>N_B!^S_\
M$;Q)\+?'%KI&/$EUH5QI=UXL\+ZG%X=U:[URPMM3T]K74+@V$,_R>1?L^_\
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MZKJ]]<>%YTU"_FLHM3:U\/\ C?P/XMTJ:&*RD@TU]3O/#WB2RDL;3Y/\"?\
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M3-6\:_"/34T[Q1\.M*\ Z_XCTU?B==^-H" ?1G@']K/]FCXF?#SX+?%/P?\
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M^>>M?L&_M=P^#OB;XA\.?"8>&/VC_$G[2/\ P4M\=_"?Q;X8^+?PH\;?!Q?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC7?'7]G^*_#T'B_7_CCX&O/#<^OZ5H4/A>#X2ZKJ=];QS?$,Z;]GN.)\>_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'FWQD\+^//&
M_P )/B=X*^%WQ#?X1?$CQAX"\6^%O GQ9A\/V'BVY^%WBSQ#H5]I&@_$>S\*
M:K+!I/BF_P# VI7EOXHL/#6K7-KI6OWNEP:3J5W:6-Y/<Q?G5_P3B^'OQ_\
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M,M0\%>%?B3X7\,>*]+^-_BGP/^SOQ4_8U^#GQC_:6_9L_:S\:?\ "6S?&/\
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M?2/!K?#S3-2\+^"(I],\%7_Q"L/ D^I>#;+XQ^+/#WB3XRV?A7Q#XM\-VOQ
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M3X??2O&?BGQ_^BW@7]G3X(_##QC'X[^''PY\/^!-?M_A)X!^ MA%X22[\/\
MAK2?@S\*KG6;SX9?#70_!&EW5MX*T'PC\/9_$?B,^"])T;P_8P>&H_$?B&WT
M<6=OKNJQ7;;7X9_ [6/CSK/QHL-+\,ZA\?/#'@70_A-XFU_3];EN/$&D>#1>
MZUXU\(^'_%/AZTU1M.BNM.?QIXNU;P5JFNZ,?$&BZ/X_\<6_AG4;+1/'GBFV
MUD _,OX5?\%48_BY\=_BU\-O!DO@/Q=X!\/6OPZ_:-^#?CGP9I%[KE]\8_V
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M:A\+?$&J^)/ E]J9O[:\T.\\0^&]4\'>*M,:YTN]L)M6\(^-?">LZCX:\>>
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M7B;Q'\0_AA^SYXA\%ZSX5F;PW>OX=T+]E>Q\=_!KQ-=^)_&_C3XF_%/XN1^
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M)_ GB/4/#'COQ79Z#!K7Q#TRWT*/QU>>(I/"_AF32 #Y!_X*"^%_VCXOC/\
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M[:W\+/C/K_@7XO:#X>T'6/!NJ?$WX<WGB'X1>./#'CVT\-Z=XAUWX:ZG\1?
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MA_C7\)?^"=/PN^#5UJGPF^(OPF\8?\&^G[3'[4G@SX?^./@[I>J>%?!GBO\
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M ?$7X??%S0KSQ'\//'?PH\?^*/#.D^#?B;X<U_2M.O9KB3P7KFL:GX:*6/\
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M\3^%M<MX+F.'5O#GB/2=+U[1+]+C3-8TZRU"UN+:+<H _+[_ (*1>'+/X;?
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MOPO=Z)K_ (1\;ZI<C2?$_K'[3?QW_;Z^!7C;XP+I^L?$OQWX6^%_A_\ 9/\
M^"E[^)= \%:EX'T35OV6_AO$/"'_  40_8_L?#_B-/'$&F>/M0E\%7OQF^$7
MPRU7QO<>/L?&Z3PCI?CO4='^#D.DZG^W?@S]I7X/?$SPC\'OB#\*_$5_\5O
M/QQ\3:GX3\%^-OACX8\3^._"^GZMH>D^-M0UX_$'5O#6D:A;_"VS\.ZM\/\
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M/]L_]HC6?V=O^"A_Q/A_;.U3X:_M3?L[?LH?\%#I_C9^R1I_PH#^(O@+\8?
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MP3X)\*>'KGQP_P 7;GPL=%\::/XLO[#^I&B@#^<E_P!J7XW^-?BE^UI92?\
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M\-1IX7_9ZM/ _P 8/A1XS\(?#_4?!7[9GB+XFZI\(-:A\5^+[?P6GPL_5_\
MX)U_$_3_ (Q?#_XE_$3P)^U?I7[7?P,\6?$.RU[X*>--"\%>*-*T+P!H&H^
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MP=\3KW]K?PS\1OB'X&_:_P#$G@'P#_P7B\;ZSX U63PE^U=XH@\)? 3XJ_\
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MU7_A2GQ!^)>CZI\"-(\5?$?]L'P:OP3^*OP<LOC)X9U?QA<1ZI\3=/\ &?\
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MAE;6GQET7]H_Q/\ &;X/?'+1OAU\>?%&IZE\!O$GP5N-<\<^&_@8W@+]T_\
M/^?S%<1IOC"_OO&GB[PQ=>!_%6C>'_#/ASP;X@TSXFZG<>#V\!^.)/%,WBR/
M5=#\*G3/%>H^+H=6\!Q>&K"[\7OXL\)^%]):U\8^&)?"VJ>)P==_L, _D*N_
M@7^V%XR_8/UKP7XE\&?M[>/?'?QW_P"#>/\ :.'QW\)?%.7]K?Q?J?B3]M3P
M+XB^&G_"HO"-[I'Q(N;[_A'_ ([7=MK/Q@M-+^&OAV/2/%?Q5T"YN[37/#?C
M?2'T19/ZNO@]\5?"'C6XU+P7X2\*?&W0[3P=X,^&?BF'6/BW\*/C/X#L]:T;
MXGZ7K&L^'[/2O$_QB\/Z/J?B?QGH=CI#?\+.\)7-U<>//A;JVIZ1H'Q0TCPS
MXEU&/2AB?$+]IKP3\-_CE^SK\"-8T+Q7J&K_ +2VF_%_5/!WC;1_^$4E\ >'
MK?X,>$-+\:^($\8W]_XKT_Q';-K>BZJC^&KKP]X7\1Z7-+9WHUS4=!0Z>^H>
MP6_CWP9=^.]7^&%IXETBZ^(7A_PEX=\>Z]X.M[R.?7M$\&>+]9\4>'O"7B76
M+"(M+IFD>*=;\#^-=+\.7EZ((]<O?!_BJ'2S=-X>U<68!UM?B;_P3J^"WQCL
M_B9^WQX_OO%'Q]^%NG'_ (*:_M9>/_!GPB\??#1/A[\)OB]X>\6_#/P=X5\(
M?$0WOBKX4:!\5/&W@R?67N=5TC6/"GQ'U+X?ZCJ'AV*[M=+O+VRTN\T_]K&N
M+=;B*T:>%;J>&>XAMFE07$UO:O;Q7,\4)8220V\EY:1SRHI2%[JW21E:>(-\
MQ_#C]J;0?BS\5_&GPZ\ ?#7XG>(/"GP^\=_$'X5>+_CA;P> X/A;H7Q0^&6E
M^#=1\3^";VUO?'EM\4#=O=>,)O#^CZU9_#:[\,7GB'P7XTL[S6M-LX_".H>,
M #^<CXK:1^WGK_[&!UOX?>'/V\O#7[0=I_P2]^/_ (-_;WM?LG[5&E>/O%?_
M  4-T;QQ^SQ:?"+Q1^SUIF@7LOASX@^*M6^(NE?M53:%X[_94L_%7PIO?V8X
M_!_@/Q3<6WP3C_9K\)Z=_4U\,/A]X7^%_@K3?!_@Z7QC-X?M[[Q'KUO-X_\
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MQ\&?BC8_&'X^?!SX2>*]!\6_M ^'_B!\![;X"_!#]K36-)USPWXZ\-^(9O\
M@H?"-;\-^$/$UYK-S^I?[!NK?$[6_P!E'X5ZC\9/AWK_ ,+/B.Q\=6OB'P?X
MC\<?$[XAW:)IWQ)\8:=HGB?3/$GQMT3PW\:8_"/C_P /6FD^/O GA?XP^']%
M^*O@/P1XF\/^!?B+IEEXQ\.:S GMWPG^$_PJ_9V^%GA7X3_";PGH'PU^%7PX
MT-].\/>'=*#6VE:/IL4MSJ6I:A?W]]//>ZEJNJ:A<ZCX@\4^*->O[_7O$FOZ
MAJWB7Q+JNI:WJ>HZC<^DRW%O T*S3PPM<3"WMUEE2-I[@QR2B"$.P,LQBBED
M$2;G,<<CA=J,0 ?S!7/P(^)R^*OC3I'A?PG^V]X%\/\ Q3_X. /#5SXZO_AS
M<?MF?#>;QA^S%KG[./@CPSXO\:W.O>%Y]$N[SX':EXUMM5TO5?B_IUX/!6D:
MCI>C:WI?C71=0\(^#-=T'T3P[\/OVM-!^*%AX TNS_:QTCXV?"#_ (*<^'+#
M0/'FIZK^T;XP^!7C'_@DY!X%T_0H?#VK_&/Q+=>)_ /Q"V?LU6>H:-J>@Z[X
MMU;X]-^WQI,7QDU.W?XA>)K?XE>(OZ.5N+=KB6U6>%KJ&&"XFMEE0W$5O<O<
M1VT\L(8R1PW$EI=1P2NH25[:X2-F:&0*0W%O<1M+!/#/$DMQ"\D,J2QK-:3R
M6UU"SHS*LMM<PS6]Q&2'AGBDBD"R(R@ _CSM?@U^V+J7[)&A:AJ$7_!3"3XT
M:I_P;]?$#XB>)EE\<?MWV'C*7_@I1\)V\)1_ :SFMEURSU#3OV@M#\5ZMXWO
MM"^&NG)9:CXTQ#XJ\3>%/%EIH/A77-*_KD%K:^-/ 8LM6AU62S\6>$?LNI6\
MJZWX1UM[;7=&\F]AD6/^P/$GA?56BNI8W5/[$UO1+LD+_9M_;#R8I/B+X&C^
M(5G\)V\4Z,?B3?\ @S4?B);^"X[M)=?'@;2]<TKPU=>*;FQBWO8Z.^O:S9:3
M87=Z;=-5O4U&'2_MAT;5_L/6M<6Z3QVSSPI<S12S0V[2HL\L,$EO%/-'$6$C
MQ0RW=K'+(JE(Y+FW1RK31A@#^-RW^!'QLUS]C_\ 9H/@;X0?MS>#/BA\!_\
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MQ\$/"FM:5X GN?AUH]Y?Z/I?[9^%_P!KKX1QZ%/K7Q6^+W[-/@B+4_BK\9O
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M'PNTG3?CU\++_4OB/-X^U#Q5I'@2/P)8VGBJ:Y\6OXUU;P+XVTKPB-!CO_\
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MPDLOC?\ $B;X5?$_P1\3-7TKX<:Y;7<W@_7;;2/!VO:K=7T?Q N;0Z3\/_*
MB\7ZS<V.G:+-<SWD < _&VS_ &)_VLM;\0_"KPY^T#^REJ_C+X:^+/@O\//
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M#7QT\->#O@?X^UGXG:K\-OAAH'_"T],\6Z1\='TSX76/Q=DUSX+ZMJWA_P
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MGPP^'>M:YXIG\1^+4\(R6^L@&1^VM\$-:^-/[(OP=\ ?#[]FV>ZN_#W[2O\
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M?_[6<'[.7Q^\ Z?^PKXM\%ZK\2OV3O\ @CQHNE_"^#Q'^Q9IGA#0_CA^QO\
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M  47_8^\?:6^I^&_BCJYE>[^ EII?A[Q#\)_C+X*\;^*1^U#:WE[\ M1\#^
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MZ9X1UW7?^'HGP.FT70O''B27PGX>U._MO@M^T;-!Y^NV_A?QI<V.H6,PBO\
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M$WQ5^'?@G0?'5[H/BCX>^,O"OC?3O!6H^(+_ .'OBG0;OPUX[MO#FN26MA.
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M ."E_P +O@0OC?XJW'BVX\5_"7P%^PM\=?VO#\(-$_9Q^/\ '\</B'H_P?\
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M:?#[2? .IP7'B+XBZC\"AX,T7Q3=_&+1HO#>K>//BQXCFT^YO?AS:^$_BO\
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MSSXR\7_M!ZG\5M:^.^O_ /#4DOCKX?\ P7\2_$'Q-X)^'7C*QU0I97.@6/\
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MX=>&_P"EBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6=5^+_\ PSC^T)\*_P#@F3^S7^S#\,M%N?A'\3_!.M^ =+U34OV5/BU^TAX
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ex10-1_003.jpg
<TEXT>
begin 644 ex10-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" -C IX# 2(  A$! Q$!_\0
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MA75]:\&^)= UW40#Z%HK\HOV>_\ @JCHO[2GPJU;XP?##]F_Q[XK\/Z=\-O
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M$Z/X:_:9^%$7Q&\26/@/5&\#3ZCKNJ:IIK>%?"/BGQ%I&!XA_P""P?P+\+^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3%_3;X6?M(?\%>_AIX\^.GCG4/\ @D-^UY\3X/C;XVT3QI9>!OB1_P %+/\
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M;[7]#U0Q3V>@:QH;-K*?BW\=OV4_VK_VB?A%?> /B#_P0K_:6MOBU>_'F?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%'^?SZ44 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 44=.M% !1110 4444 %%%% !111UZ4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !111_G_ #^8H **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _(_P"/
M7QVTWX<?\%<?V5_"/B^T\$Z-X'F_8+_;+^(^N?%;Q-XQ^(WA:7X;Z!X)\=?
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M"*^)OAW\6_VE_#.G^)O'T"Z5K?P&M)[3]H7X=:?XZ\6>(?!_B[0/"VF:B?\
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MVAZ?X9\.3^+?$$@DU3Q!J.G>'-'T/0?[6U2YN=4O-'\/^'--O[RZM/#VB0V
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M/3OA_+>WTG@NWT)[VZ:8 _+WX8_\%$/VVO&O@+X!:K=^%_@7K?C#]L#XO?M
M?!SX(:5\/?A3K['P#J?[+.O?M<6WQ'UOQII_Q5_:X^%F@?%+4/'7AGX,?"KQ
M)X+\ :!\2OA5J_AK3[CXYZA<Z[XZL? FA/K7S/J?[2W[7?P*^-'_  4,_;%T
M;X=_ '2/B5\*_P!BK_@EU\8?VOOV>+VYU[QW#XYE\,Z_^VGHWQL^%GP&^+7@
M+QAIFD>'_BE9:?HOB*P^&OC#Q1X3^+]GXJ\2:+X,^&FN^$=$%U<^*-%_=_Q3
M^PS^QYXX^"=G^SAXQ_9M^$'B?X$Z9XOOOB#H_P +-=\&:3J?@_0/'NJ:]K?B
MG5/&WAS3+N"5/#OBW4_$GB?Q1KVH^(M$:PU>^U;Q3XGO[J\EN?$>M27W3?\
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MHWP+^-^D/%^S;XY_8HU;X17L_C;QS\(_A;\(?&/Q ^%VD?'7XK^'/CM-X"\
MI\-_$'PU\!:[IT6@?#;XO:3X@^)'PZ],_P""7W[27QT_:/\ VH_B1X[^/WQ,
M\1>'?$GC_P#X)N?\$LOC7'^RT5\):#\./A[XU^-GA#]H7Q1\5;GX?>#+_0KG
MXH:9:6GB?2?M4D_B;QYXI\5VT7B0>%/B!X@U^S\'?#K1_ GZ3^+?V-/@MXX^
M+_P+^*&H>&?!\OAO]GSX3_%KX,^"?A"W@/P=?_#*+0/BMXQ^!7C75;U=!O-,
MGL](UWP5XG_9K^&,G@"?0(-*@\-PKXPMKJTU2YUC1KKPMZYH'C7X.>(_C9\1
M_!V@S>'K[XY_##P3\.C\1O*\/S0^*=!\!_$>^\9ZG\.M/O/%%QI<*7^AZSJ7
MA+QIJ-EHNG:Q?0Z=?65[=WUE8W%_;278!_/;\2OBAK_P(_:<_P""FGQ7U#QP
MWB6U\.?\%+_^":'PA'BSXHZ5\$]5\)_LA^"?VE?@C^R-\-O%/[1GAF]UOX?6
MVH^"/%/PE^'?QI^)G@OX7Z[K>NZA\/=)O?'D_BKXN>#OB387GQ%D\4^IZA^T
M9^V]XK_:G\,_L:>&/VL[?PIIMY^U3^V)\ O#_P"T=;_ [X.^)/%/Q$\'?#3]
MC#X$_M,>#]5DT6^TY/AMJ?Q&^"/QD^)_C;X#_$K4?!WA?PYX0\2:?\,?$>@Z
MAX)\+_$F#6M:\*?O6?AS\/6?Q3*W@3P:9/'-G=Z?XVD/AC1"_C'3[^&:WOK'
MQ4YL=WB&SO8+BXAN[75S>07$4\T<R.DCAO.?&9_9W^ GAGX?Z_XK\._#_P"'
MWA7PIXK\ _"SX:7MIX'LH=.\&>)OB[XS\/\ PK\ ^%O"D>@Z'./!\7C'QMXL
M\.>#K$V$6EZ7)J6MV%G=SPI<J2 ?"G[7OC[Q7H/_  47_8&^'K?''Q-\/OAI
M\0O@#^W7XDUOX<6^H_#_ $[PE\2_B'\-=0_96T;P)I.HQ^*/">JZWK&J:EHW
MQ;\=:1!IV@:U8:ZEK,UQX6FT:[_MF[U'\A?V9OVV_P!H7]DW]B_X,^&K;XF6
M?B7X>Z5_P1H_X(Q_'3PY+XF\!>&)=._90T3XS_$/0_V5?C=\4+ >%-$L/$/B
M[X:_"SX.V"?M%^+D^+>L^+8[#Q5X!\:ZE_PE'A/X4ZS%X+\%?T[_ !+\5?!&
MR\:?!OX>?%-/"U]XR^*GB3QKH7P8T3Q)X8;Q#-K'B71_A9XUUSQS;Z+=2:1J
M-AH5S_PJ6V\=0:K=W]UI46J>'+K6?#HN+S^V'TR\[/3/AS\/=$N$N]&\!^#-
M(NX]#;PS'=:7X7T33[A/#;3O<MX>2>TL895T-KF22X;2586#32/*;<N[,0#\
M#OV@OVR?VR_A3K'[8'PR\->._$_CCPI^R)\4EU2]^*OA.+]EC3_VJ_'WP@U7
M]C/P]\>_B#I'@KX<_%#POX%_9X^+'C']D_Q=X^\)_$#XA>"](L?@]XD\;_L^
M^,?AQ8:)XO'Q*\-^(G^,OJ&B_MV_&7XM_MT7WPY^'_Q[_9W^''@CP)^T+\$?
M!^F?L]_$_P 2KH/QA_:/_9D^,?[)?PK^-!^*'@;X%W'P7U;XY2^/H_''Q*\;
M77AOQWIWQ=\)?#+PQX2^!_B[PM\6/A)I.J>#?B/XZMOU<USP!^S/X5T;X4?"
M3Q#X"^">@^'-6\9R:!\$_AMJGA#P38>'[GQ_I&A>+?B[)I?PW\)3Z;'I:>*=
M-\/>!/&OQ&,/AZPCU*UL/"NO^)L(FEWEW%ZO+X1\*3^*;/QS/X8\/3>-=/T2
M\\-6'C"71=-D\4V/AS4+RVU&_P##]GX@>V.K6VB7VH65G?7FE0W:6%S>6EM=
M30//!$Z 'XL_M^?M(?M+^!/VC_CW\//A+^U-X=_9_P#"_P &_P#@F#XQ_;FT
MBS\0?#OX7>++35_'OP@^*GB#3]3A\5:GXRTF^UJ#X*ZSH-CI/AOXN6^@16_B
MJPL=;TK4? OCSX;^(&BN]:\:\2_MI?MI>'_A[^VW^TIXK^*$WPQ\,_LW_&G]
MF/X3:S\ -?\ A-X%\00_ ?PS^UA^SM_P3.^(WQ:^+'Q+\;Z=H-CXNUG2?V'[
MC]HCX\?$?3K2>WT'1M1\-Z!XKC^,.O>)= TS0;SP%^O&O_L??#GQ;^UQI?[7
M?BUX?%7B;0/@]X?^$?AOP1XD\,>%-;\)^&I?"WQ$U/XFZ!\2_#]SJ6D7/B+2
M/B;I>O:O?65CK]AJ\%G9:(ZP6>E6^J^=K$WTE8>#_"6E76OWVE^%_#NFWWBN
M19O%-Y8:)IMG=>)95%RJR^(+BWMHYM9E47EX%DU%[EP+NY ($\N\ _"KXM?M
MC?M5_L^^(_VFO$NO_$/6?&/[-G_!/#]L3]F>U^/?Q2UGP/X)U#Q/\2OV2OV@
MO@MX"\1_'?1O$^F?"_X0HMI\0?V*]9^+?A/]H:]USX7^$_!\_B?]F^WL?!>N
M:/K?C][KQUK?H_Q1^*_[2WA?Q]\']1U/QC\-?AU\7O'W_!,/_@J%\>="NOVA
M/#?PVT/PK^SS\3]+^,O["FJ_!GP;X_\ BGH_@A_$WA[X=_"#3/C?8?#GXW:S
MI]T_AKX@V?PM\/?$OQ9X1U#7] MG7]?]!^'_ ( \'>"XOA[X5\#>$?#/P]LM
M.U#3+?P)X<\+Z1I/A"WTK4WNY]4TVV\*:580:.EEJ4M[>RWMA!I_DWTMY=--
M#+)<R[_ ?!'QY_9%_:&\0_"N;P9X@^'_ ,3O$/QB^#WQ+^)GPJU4^$KC4[CQ
M7\&OAWXN\'?#GXE:OI>NZMX>6*UT#3/%?Q5\)Z#?:1?7UE<:P?$[SZ?INI:=
M#JUS:@'Y:Z?^UW\6/$&L?L3W=YHGQ3\3?%;P=^W7^U-\"/C'\#_CG\.?V<6^
M+VB>._ W_!,?]J3X^Z7\/?"WQ1^%/AJ^^&.I:K>W^C>#/^$(^.'P"O\ PG:>
M)?AI\2+[X?\ Q&TV/7_^$_\ "UG\P^._^"D_[76G?LI_"C]H7X<_M'^!/&=Q
M^TE_P3C\%?M@Z]-;_#3X<Z]X9_96^/\ _P -%_LC_#/4?AMHR:.NEW<GP:^(
MS?M _&OX=>'?A_\ &;4?%?QLTGQ#^S-XFL[7XSZEXDT'XB7.D_TL:/\ "?X6
M>'=,\)Z+X?\ AKX T+1O ,EU-X%TG1O!WAW2],\%37UP;R]F\)6-EIT%KX;E
MO+LFZNI-'BLGN+DF>4O*=U?+=E\=_P#@G4_B/Q;\.XOB)^RCIWB;Q]\<D^&G
MCKPCJ5]\-=!U#QK^TW<RZ=)#\-O%FEZJE@?$O[05VUWI=U:^!=7CO?B9=P3V
M5];Z1+;O%.0#\\OBK^TY^U]\.-'_ &J?!_A_XN^)?BE>?LS?MV>(/!%W<Z#I
M_P"RWX1_:N\>?LRW?_!/?X&?M<ZSIOPB\/?$?PEX/_9O^)OC_P"!OCKX_G4[
MOPG?Z1\._$_C?]G;X9ZBL7C.[^)VFZAK'C?Z;_:__::^(6E?!#_@G[X^^ GQ
MIM_ ^G_M5?M1?LJ?"_4OB-KGPVT5)/$'PT_:$\+Z[<)<VO@;XEV4%SX.\9Z_
M<2>'YO".FZG'%J6@>+;O3='UOP_XDC6^\*:K^A6L_!;X.>([74;+Q#\)OAIK
MUEJ^L6/B+5K36? GA;5+75/$&EW/VW3-=U&WOM*GBO=8TZ\_TNQU.Y26]M+G
M]_;SQR_/7E'[4?[+'A']JS3?@[HGCC6;VPT+X0_'/P7\=4T.'1O#VNZ1XYU/
MP3IWB+2K?P3XTT[Q+IVJ6=]X$U^P\4:G;^)=.LH;'5KZ-;6*TUK3X5NXKT _
M"7Q!_P %#OVO= ^R_L\>*?VI/V;?@UXJT+5?^"A_ASX7?ML?M)>,OAA\#OA]
M^TYXD_8T^-7PT^'7@\>)+>Z^"WC;X8W#^$X?%?C+0OVK/A=\+M&^$7B_Q?JG
M@#Q7XF^"OCWX,Z+X0\36-ITW[77QP_:\U+X,_P#!0_XA2_M>>,?A+X%_9X_:
MW_9D^ 6F>"_!G@+X4>&+NP\*_M%>!O\ @DY\2_&$VL_$WQU\,4\::7H?P[B^
M/G[0'ASP_:ZMX=\,^+&T+XB74GQ.U?4[WPEX>T_0/Z(;OX>?#R?0O"GA^\\!
M^#[KPY\/+SP]J_@30)/"FCW>D^"M2\&0K%X2U#P=H_\ 9\MKX?U'PM!&D/AJ
MXT*UM+O1HT2'26MP%6O.?A;K'[./Q[^$K_%3X76?PW\??![X_>';K6M1\2V/
MAC3#X:^*WAG5$U*SO;WQ+!J6E6O_  DNEZC#<:K#<_\ "0VMQ%>6MW>>:LEO
M=R&4 _'/1?V^_'M[^WU\&O@MX2_:XT'XF?"/XB?M<?&+]CSQ5INLZ!\"_ VJ
M:/+X%_8#U'X^Z%XC^'F@:7I&O_$+QUXVLOBWX;\.Q^(_C7XHUCX;?!KQ3+\6
MK/P;\,OV8O$/A75_ 'Q2@^'=/_;Z_;#\*_L;Z3\3?A_\:O"?PVL/@+_P0F_8
M#_X*)6_PY\+_  /^">G^"O%GQ:\3>*/C-IWCSX?ZGID'A*UM_!GP(^('A?X8
M6?A?6O"'PXL_"'B?PQ/+8:G\*O'WPZ31]1T?Q'_3?X5/[.OQ(\=?%NU\,^'?
MA[X@^(?PK^(&B>$OB_,_@>QB\2>'_B&WP=T?4?#EIKNI:GH=M=ZAJG_"C/B[
MI4&C:G;W5_"OP^\>2:-97HTC5[VQD[(?!OX0BVFLQ\*OAN+2XTN/0[BU'@;P
MP+:?18M075HM'F@&E^5+I<6J*NI1Z>ZM:)J"K>+"+@"0 'X;_&O]J?XY_#S]
MI;]K#PI\.?'WA+P1/!_P4W_X)3_L[0:Q;_##X7W>O7GPV_:9^'?P7T_XA:%X
MHU*;P];ZOXPUD6OC#5'\%>(/$6H7WB#PO:V>C:9IMW-H&G2Z3><5XB_;Y_:?
M\-?!K0/"4OQ\\,V_Q&3Q!_P67^#_ (#^)/BVX_9<\*_%'XQ?'O\ 8@_:N_X4
M!^QEIWC7PCX[G^%/PFN/A]\1=&GN=)_:)UGX8^$?AO8:;\4]1^$^JGQG\ _A
MGX@\4W-?KMJ_QT_8#TWXIZY\+O$GQ$_9@T3XPZ/\1/A=X-\0^#/%.H_#O0O&
M^G_%CQE9VR_ WPOJFG:Z++4X?B#XXTN]M)_@QHUPH\1>,]&N[>]^']OJNF3Q
MSMS_ .T!^P1X%^./B#PQK>D_$#Q)\(-.T6QUK3]:\"^$?A=^S!\0/AOXN;7]
M4TO5;SQ-J'@C]H+X!_&31-#^(5M/I-O#;^-_"$'A[4-7LQ;6/C>W\96.A>%K
M;00#Q;]O3Q#\5="_8A_9X\42?'_7?AMXW;]JO_@EW8?$WXJ_!O6?!%KH/B#2
M_B+^VO\ LU> ?B:L.O>)O NIZ-)\,=4L/&FK:Q 8-'T"R\1:;I^DZ-XRBUKX
M=ZSXV\"^*_G_ ,*?MN_M&:W\0O /BS1?$T_C&+6/^"L/Q'_X)T^,/V8'\-^#
M;"VTCX*^&?"7Q'\1>&?CY8>)(?!NF?$2\^)NJ?"'P'X._;=?58_$K_"/6OV=
M?'WB'0?#WP^E,O@WXG:1^LNA?"/X-?!WX"0?"F?PQX>?X+> ?"5X-1\/:QX8
MT.^\.'0M*:X\1:K//X,T;0;;PO;V8O$NM6M_#/A?PMI?AS1V$.E^$O#>CZ39
M:7I-IK_#2Z^"OQ8T[P7^T]\,M/\ !7BA?BU\*_"6J^#/C+I7AVQB\1>+_@_X
MNL['QSX/@@\2W.FVOB:3PCJEOJ=CXCL-#OIH;6&XN4NY-/@O0VT _*K]OKP#
MXQN_VH=1^+G[/?C_ /9F^)/QE\"?L1^)O"O[0?[!/[9!TJP^$W[0'[$WC?XH
MW&I>/=3\#_$F^M=3N?@7X@U._P#!GB'P5\1?%>L^$_B+\$/&RS?!W1_V@?#&
MF:/X5\#Z[%\F_$/_ (*2>+/A7\*/$VK?"?QS!\!?AS%^QG_P0N^-O[,/PE^,
M-C\.X_&/@WP_^U[^TA\6OA/\9/ &IMXBLYM7\67-G\(/ 7A+1_$9NM9\0ZEX
M.\36.N:QHWB#35N-L7]%OC7X=?#CX@6VGQ?$7P+X)\;V>A:K8>(]+C\:^&-"
M\2VVC:WHOVF32]>T]-=L;V+3M5TDW=X]AJEL(;NP-S<O;SQ>=*6M:UX"\"^)
M-5MM>\0^"_">O:Y9Z5/H=GK.M>'-'U35K71+G6=$\1W.CVVHWUG/>0:7<>(?
M#7AS79]/BF2TEUGP_HFJ20M?:583VX!^#GA?]JO]L;6/C5>:AIW[0EIXR\,P
M_P#!7;XO_P#!.Z7]GK3/A[\(M,U.'X/W?PTOOB+;_$"P\51^%]5\7S_&?]GC
MPOIU[\:8!J#V_@KQ#\#= \40>./A_P")=6FTCX@VOR#XV_:<_:G^+7_!-CXJ
M:K\6/VAO#W[0OA']L'_@VK_:8_:T^)'A[3/AA\/_  G/^SE\=_"'P!^''A:-
M=(\0?#EM/EB\*_M&#XP?%*35/"GQ*LM=U"/XL?LY?$J_^$>J>#O D'B#X2_#
M_P#H0^ '['G@7]GCQ%\?/'?AF]M?$'Q)^//Q7^)_Q8O_ (@^)?!_A5_%'A.;
MXI7NCZOJGP]T76-&L-(UJ\^%NDZ[H.FZUI7A?5M6N[U[\7-SJ>N:A=/:W%EM
M_LU_LB_!S]F;]G?X>?LW^%O"WAW7_"7@/X9_#/X6:CK.N^$?"R:_\3='^$7@
MGP[\.O!?B'XIMIVE6FF>+_&B^$_"?A^WUC6Y]/M[6ZO[)I]*TK0]-%EH]@ ?
MDE^U+^W'\0_V9/VD?VZ5L=:^&'A7P=H-_P#\$F/!>H_&+QG8^"/A_I'P'\)_
MM-^/?C_X%\8>/_BI\6K?X:^,[W_A$K*[\/Z!X8\"^)OBSH/CKP+\(_%GCU?%
MNM:5=>!H?%.B:AU'P+^/O[7OQ>_:I_9W^ )_;/\ A/KGAB;X"?''X[^+?'?P
M+T/X7?&CPS\9]"_9[_;P^#'@;2?#S?$&[^&'PYT:3Q+XJ^!'C;6_@;^T/XH^
M%/A#PUX2T'XT6VO^)OAAH/PXU70)/ VE_KCIMU^SUJ/Q+^(OP.T[1/ ,GQ)L
M_A5X&U[XF>"!X,LX+J_^#WCNX\;>!? CZ^TVBQ:7XA\&ZS/\._'?A73=,>[U
M&Q@3PSJ^E2V=O#;F%O/=*^//[$.A_$S1OAMIOQ(_9X\+?%OPOK.E_L_>'/"$
MFI^"/"GC;0O$G_".VWB/0/@9X?TV\&F:K8>(KGP9-:>*?#OPLTM(]6O_  7)
M!XFTC0)_#C)J% 'PA^U=K.J_\$X/AY\&?"W[.-WI7PF_9/\ AGX(_:U^,_QS
M\(_!'PS^S]%\9/ 'ARS\;>!_B'=?'?PM^S]XL\+>'?"'Q$_93^$7B?XG>.'_
M &G_  +\#'\"_'*UF^)?P:E^$USJ>HR:OX?U[WK_ (*U?"WQ'XX_8Q\5_%'X
M<>&],\3_ !P_8V\;_#C]NGX#Z;J$>JO-J/Q%_91\56?Q3U'P9I3Z*ZZC%J'Q
MA^&.D_$7X%2-$D\4FE_%'4[>ZMI[6>:-OKKXV:S\ ?#,_P )]=^.NF^"KB[N
MOB]X'\%?!W5/%O@Z'Q7>Z9\9/&VJPZ;X&A\)W1T76+KPQXAU+5K>"*S\0P-I
M4-A+!%-=ZK9I$DJ]Q\4OB3X&^#7PR^(OQ?\ B?KL'A?X:?"GP)XN^)/Q#\2W
M-GJ.HVWA[P-X&\/ZAXG\6:Y<:?I%GJ.K7\&DZ!I>H7\MEIFGWVH74=NT%E9W
M5S)%!( ?S<?L7:YX@^)/[37Q1^ UKX'\.V?[-_\ P4?^+?P^_P""U7PFOO#>
MA:SH5@O[-=OXQNK76[C5EU^:YTNX\;?%[XA?!/\ 80^+OQ:^'^H65AKES8_M
MQ?&.RO?"]AJ?@OQ#JMFW]HC_ (*<_'+PMK7[6C_"C]IRUO+'1?V,_P#@M9\2
M_AM::UX2^ ?A_4O!'QV_X)P?%#P#X?\ AKIW@+X67>A>-/B#+X6TW3+WXA^!
M_'&J?'3QAXDUKX_:W\._B%\5OA]\*/@9\,M/\)-KO]-FEZ;H,-KH\^D:;IEM
M:6&CQZ;H365A;VL>GZ#/'8O'INFI'#&;'3'CL--/V"W6&VVV-D#"/LL CY2Z
M^$7PHO;C4[N]^&'P\N[K6M3U76]9N;KP5X;N+C5M9UVRT33-;U?4YI=,>2_U
M/6=-\,^&]/U6_NFEN]1LO#^B6EW+-!I-A';@'XO_ !D^-/[6/P3_ &G/C9\/
M_&/[>NG^&/A=^S_^PUXG_P""@WC7Q7KG[+'P]\8V-OI&E_M ?'":_P# VH>!
M?!;:3\0M7^"W@?X0^'M.\'7VD>$_%*_''Q=_PB/AK6-,^+6F^+[WQ3)XV^6_
M!/\ P44_:C\1^.[7X.:3^T_X>UIKS]M;_@G+\.+3QI+I_P"S-X]^)Z_!W]KS
M]GK6_&/Q(\*^)+;X1: /@II'B_3/$'AW^W/"-QX-?XFZ1X*\0:O):W'Q-^.W
M@>WT^QNOWI\=_&7]D/X%>,?L_P 0O&_P2^%GC#0? OA>/5-4\07'A?PQ/X%^
M&?B?7M1\*_#V/QGXGGBM;+X=>!?''B[PSK'@_P"&:>+]4\/^'_'?C#PYJOA/
MP0-:\0Z+>Z;:][JOP_\ @3\.O"MQXBO_ (=?#7PQX4^'/A[2]7-U:> ] @L_
M"GASX76&N:AX>ETVSTW1WEL[3P-8ZIXBF\-6NEVV_0TU75DT2"!]2N4G /Q0
M^"'QM^.WQ&_::_8M\'_%;]L+Q_H(OO"/_!;/X*ZI?:99_ /P;:?&3QY^Q/\
M\%%_@K^R7\%?B'K?A+5_A7J7@_4?C%XE^&VH:MK&MV'@[0M'T*+Q,=4E^'?@
M_P %^$=9\:>%O$7VY^P-\<?VA?C/)?>"/CAJ6H6WQ*_9#TOQ1^SG^UI(?!UA
MHOAOXL_M0P^(="U3P[\1_!4[^$?"ESH7A'7/@-I7@O\ :*\*:+X;M[CP[>?#
MS]LCX>:)K%V_B_X<ZS!%]8>&_"_P9^,/P=\*>,_@G<>'?#?AKXA>")_B'\%/
MC%\,O!_@:#7O"2_%WX?366C?&/X91>,?!7B'PYI_BN\\(>)H[S3[WQ'X.UG3
M]2L[E=*\5Z!K6AW.HZ)=;?PZ\$:'^SU\+M3C\0^/?&'CV?28O$'COXF_&#XD
M+H%]\0O'FKK;OJ&O>,_&9\!>$_"7AV6\M-'L+31M&T3PAX-T#PYX6\'Z!X<\
M$>"O#6B^%O#N@Z'8@'\]O[0G_!3WXX^!_BQ\?;'X:?M.^#]=\-V7P._X++C0
M-#U7PQ\%?#US\/OC+_P3[M?"\OP_/@3X<21>+_BB]AX'U2Q\:>!/B)XG^/'C
MF\@^._BK0O'OQ'^'/P.^&OP3N_A-KVL][J?_  4#_:4^"VM?$OP;\4OCE9^(
M?"7B/3_^"._BB]_:"UWX:_#WPQIG[*6C_P#!1#X@?&?X7?&_588M!T>'P?:_
M#?P]>_!71X/@/X@^-=K\09/AM\3OC'INH?&OQ=\9/AQH">&)_P!S_ FG?L^?
M&SP1X8^,_@;PQ\-O'7@KXU^'='^+7AWQQ!X.T:>+Q]H/Q*^'VC:=I?C26XU#
M2(M0OY/%GPQ?0M$EO-4B&HW?A*.PT"_4:?;1V,65\.K[]FGXK-\8]#^'6C?#
M7Q./ WB;5/V<OC9I=AX,TV"*RUS0?"?AO4=2^%?BVUO=%M8M8TRR\&>+_#,@
MTF1-0\/RZ)K-E!;&6W9HD /@C_@D1>V%S8_\%&+:T^)EE\7IM-_X*@?M%V%_
MX]MY/!;7FMW5OX"^"2*VN0_#VRTKPC#X@L8%ATO6SHNBZ%:W.J6%U>#0]'DN
M)-.MOQ9_X)!VFGZ?XP_X(X^*OBO8V/PA^%^D_LZ?M>>%/V/?BK\)K"SB\)?M
M(?&OXB_%SXBQ?$_]F+]I/Q[%=VO_  B]UX7\ >'H_C5\!O@NOAS4?#7QJ\;>
M'O%WQ$TWXD:3XN^!'_"NO$_]?ND>#?"'A_19O#>@>%?#>A^';F(V]QH.CZ'I
MFF:+<0-8P:6T$^EV5K!8RPMIEK:Z<T4D#(;"V@LRIMX8XUR%^%OPR3P[!X03
MX<^!%\)VNI1ZS;>%U\(^'U\.V^L0SFYBU6#1!IXTR'4HK@_:([Z.U6Z2;]ZL
MH?YJ /Y7?B3_ ,%#/VH_C=^R-\6_BG!^UM\(/A.^I_#[P2GQE^ GP^^(7A"_
M_:C_ &0_BC!^VO\  /X0>/\ X;Z]X=UO]G'P?=?!?PYX<\!?$SXI?"[XVM\9
M/%?Q0\7ZKXM\+?#;QI\%/%7AKPN_CV_\1?:/CW_@H5\3_ WQF^(_PGL/VD/!
MFM/X:_X*K_\ !-7]FOX<0:Y'\''\6?$+]FW]I_\ 9U_92\3^/9Q8Z+H6B)X@
MB\9>,_B;\3O$/AKQSX3T?37M=5L9-,\/WO\ PCWARY\/Q?NO<?#7X<W?_"=?
M:O /@JY_X6C:1Z?\3?M'A;0YO^%BV$6C'PY%9>//-L6_X2^TC\/,V@QV_B'^
MT84T9FTM4%D3 9KKX?> K[75\47O@CPA>>)DT[0](3Q%=>&M&N-=72?#&IW^
MM^&M+75YK)]073O#VLZKJFKZ'9"X%MI.IZE?W]A%;W5Y<2R 'X"_ 3X]_MQ?
M%CP/^P[X\UG]L[4;>T_;$_;4_:1_95U_3/#_ ,#/@)&?A[X/^ OP]_X*LZU-
MXJ\(:K>^#=4CO?B5KC_L\? A[6[\36&L>#/#7C/X=W^I:EX!\6>%/&/B?X=7
M7Z>_\$S?CC\1_P!HW]AKX _%OXO:]I?BSXEZUHGBKP[XS\7Z1HMAX;M?&6M?
M#CXA>+OAI/XSG\/Z0[:)H>J^+D\(1>)-=TG0(K/P]I^MZGJ%KX?TS2M&BL=-
MM/K&V^%OPRL[?1K.S^'7@2UM/#FHW.K^'K6V\(^'X+;0=6O)8YKS5-&@BT]8
MM+U&[FBBEN;VQ2"YGECCDEE=D4CH?#_AOP[X3TN'1/"N@Z+X:T6V>>2WTCP_
MI=CHVEV\ES,]Q<R0Z?IT%M:1/<3R23SO'"K2S.\DA9V+$ VJ*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ K\#/VI/A-XT_: _P""L7Q+^"O@WXB^&_AEI_Q9_P"".WB/X/>,_%WB#X72
M?%0VVA^.?VD]5L/$^D>$].O/&OA'PC8_$>+P5JU_K6@#QE8>/]"LR^G:WXB^
M'7BKPS;WVBZQ^^=% '\W/BW5?C+^SIJ/CC]F3X">./C+HGQN_9&^-'_!,[X)
M_P#!/CX*:SK/B.Y\$_'O]A&?PW^RE\-/C'X@\1>&WTBV\+_'X0?;_P!KF#]I
M3XKQZ1K?B[]F3PW\._"_Q*M]2^&%IX=T7Q7XEV/V=O&WQ \":A\(K'P7KFKZ
M(_CK_@O+_P %7M%\8^'6UF_T'0?&_P /M:\ _P#!1?QYX!L/&4&1;3^"_$/Q
MAL?V>]0\.ZY=VLMM-KNM> AH=W++XHTRWU;^BZL?7/$.@>&;*'4O$FMZ3H&G
M7.L>'O#UO?:UJ-GI=G<:]XNU_3/"GA71(;F^F@AEU;Q+XHUK1_#F@:<CM=ZQ
MKNJZ=I.GPW%_>VUO* ?SM?LT^+OCE^U7^QIJOC;X)_'_ /:^U7]O[P-\"/@%
MXX_: ^#?Q5M/B1\*/@]H7[?/P4UU_&?QH^ &LP_$#P[\-+GX;S?M&Z[;^-?V
M?O'OPT^%WB9?@=\,/A&?!GQ@T/X<^$];O_AGXY\??IOX-^+_ (OU[]B'XU_M
M@&P_:'TRX^+OPI^(7[2_PP^&O@SPIHGCS]H#X>_#[_A4%K)\(?"7PH^$7C$Z
MSX5G^-?B#P?X5\/?$(_!_P 2KJGA_P#X7]X\\2>#M9^VZ2TB-]'?M&?!/P!\
M=_AVWA?XEW'Q9_X1+0=6A\::CHWP@^*7Q<^%VM>,(=$TW5;>]\%>(_\ A3?B
MSPEKWQ%\$^*-+U+4-*U_X5Z]/K/A/Q@9[--0T"]U&QTBXL_0_AMXOL_B#\.O
M /CW3O#7B[P9I_C?P5X6\7V/@_X@>%=1\"^//"=GXET*PUFU\->-O!&L16^K
M>#O%VA07J:7XD\*ZI!#J/A[6;6]TB]BCN;.5% /Y=?A[^TS\==9TCXQ:1X?_
M &J+2T^'&D?$']A?XN^ -#^/?QN_:2\*_"SXP> _BK^R=\3M;^)WP>B_X*17
M'@O1/BK\*M%\4?$;X>_\+(\,_'/1O"WACX;7_P ;OAA??LWI\)-$\/\ Q&\?
M^ K[]1/VF_VB/BGX&_X)Z?LG?'/3=!_:/\*?#_Q-JO['VK_MC:GKWA^^?]KC
MX,_LM^,M/\/ZA\;/$?C;0? NBVGB71/B+X?DNM'\,_M$ZU\,/"EMX[^&?@K5
MOBYX]^&</@?Q;X/T#Q;X3_7NO)]"^-'@GQ%\;/B7^S_I[ZPOQ$^%'PY^$'Q4
M\66]WH]W9Z-_PA_QQU_XQ>&? 5[H^LSJMKK,UQK'P)^(=KJD-EYBZ7)IUK'<
M2F:Z,4(!^&'Q0^-GC6TEM?#EA^T%^U+H7[,-]^PO\?/B7^Q1^T'K"^-/#?Q3
M^+7[7VG_ !F\8#P'X%OX9/#.@>-?V@/$GPW^%:_"Q?V1?@]\1/#?C23]M?P#
MJGCWQYX_\)?M1ZKI0\::?XIIWQO_ &W5\=:_\0/C!\5_BKX#^,OP]_;O_P""
M,GP_\2?!#PGXI5_@7X8TC]I?X,?LJ^&OV\?!FG>%/LFJV?CWX;Q:O\0OCGJC
MZIKVO>+M-^%GB3P1_P )OX%U;P;KOA?Q+J=]_2;X ^)%C\0[OXB6EEX4^(GA
M=OAQ\1-6^&][/X_\">(?!%KXKOM(T;P_K4OBOX=W&OV=I'XZ^'5['XBAT[2?
M'?A\W?A[5-9TKQ#I5G=R76B7R1^BT ?QUW?Q4^(/P1_8/\6_#3X9?$C]J3PU
M\=[37O\ @OKX[T$2_$OX_:]-8?M ? S]I'XG>-OV?]&OKUIO%'Q5^)W[0&I>
M#]5\/^+_ (??L\>(/&FB?!KXH?##Q+\>?VHOV@]#^+'B'X=^#=$\<?;'Q1_:
M.^./B/XD?M!WOAKX\_%#PIX6U#6?^#?#7OA]JWAS4ETG3/#%E\?/VN+O0OVL
MM1\(:1XAT6\\/C2];^ TR^)?BCH/B#0M9\.:?X0AM?%'BS0X]!_?2?O#\-?C
MM\)/C!XE^,WA#X:>.-'\7^(?V?/B5'\(/B_IVE&Y<^#?B+)X$\%_$=O#5S<S
M6\5IJ,]MX6\?^&WOKS1I]1TW3]=;6_"-]>6_BSPKXHT71_6Z /Y8O$/[07QY
M\$:5K_PD^(O[1?QK^&/[*6@_MF?\%$?@3/\ M/ZSX?\ CO\ &CX@?#76-/\
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M12R6;1^%X=6DC?7]6\1:MK$_Q@^-/@[X+:5X6NO$HU'5-?\ B%XRL?AO\+_
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M[4NI_$G]M'1/AWXU_;0T/4/'7A[Q5_P4,\&_%3X)^*/$6O\ @76OC?XTT?\
M:5U2X_9&L?@Y\!?'^EV6I^"=-_9Z_96\&?&.Q^+7A_0+7POKNN:I:>&_%^NS
M_M"V'AF]^-&B?OW7R)\$_P!B7X+? *_\-2^!=5^->HZ#X @EL_A7X$^(7[0O
MQL^)_P /_A1I\VDW>A'3_ ?A+Q_XY\0Z99VECHE_=Z%X8&L)K<W@'PU<3>$?
MA[-X4\)2R:&X!^4G[?IO?@W\:/VJOVBOV8?BJUA\>)?ACX)\._'K_@GM\>?
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M'?WGB6YU[2O"/P]EL]?.BZ$VJ:I_1110!_.W\0OV:?$WQ4^+W_!13XD^,_\
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M@O=("?%'PKX6\2_%+PEJOB+P-<Z%XH\0?J=110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%?$G[1/[8=M\!_B;)\.WL_@O,MM^RM^T+^TI?7_
M ,1_VAM)^$NM63?!,>&&TK2G\)W_ (&\2ZA=?#?7X=7\0WWQ ^,^FW=]H_P5
MTOPHU[XM\-7Y\2^&8-1^A?@/\29OC+\#O@S\7[FR\+:;<?%;X4?#OXDW&G>!
MO'EA\4_!-A-XY\(:/XHELO!_Q.TK2]$TOXC>%K635&@\/^/--T72+#Q?I,=I
MX@L]+L+?4([2( ]6HHHH ***_./]K[]LCX]_LO\ BOX56FD_LV?#7QSX$^,_
M[4OP&_98\">*O$?[26O> O$5[XA^-5I*USXUOO!NA?LZ?$ZSTWPEX2U>&YT(
M0W/B\>(]?NM.U.]71-(TH:->ZV ?HY17YJ^%?^"@2>$OVB_&_P"SQ^U]HWP@
M_9H\3:/\.?V8_%?@@67QIN?B-8>-_$'[2?[0/[6OP)\,Z59:YJ?P]^&WV;3M
M3O/V??A[>:%>7^@:>\>N?&;PYX+\0?V7XJN]+TB]^R(OV@O@K-\6(/@8GQ*\
M+#XL7EMKMQIW@J2_\G4M7F\*V&A:OXNTC1)Y433M<\2^#M#\4^$_$/C+PII%
M[>^)O"/AOQ=X1\1^(])TS0_%.@7^H@'L5%?GA\6/VXAX8_:NU_\ 99\&Q?#?
M2=9^$?P7^&?[2WQL\8?&WQ'XF\ > K3X,>.O''Q%\.>(U\/>.-'\,>)M(\.>
M(?A[X%^$WQ$^*FJZ[XWM;?P9J,ND>$/AP;_21XT\5_$;X0^U:C^VY^R1HGAK
M4/%WB;]H3X7^#-$T?Q[X9^%NM-X\\2VG@/5-"^(GC?1K7Q/X'\':]X>\8_V)
MXAT/7?''@^^T[QUX*L=6TNSD\7?#[5-)\?\ AS^T_!NJZ?KER ?4M%?,W@G]
MLS]E;XD>(?!'A;P)\>?AOXJUGXDZ+I.M^ H]'\06]U8>+$UWX5Z1\=M(T+1=
M:4#1;SQOJ'P*U_1?CC;_  [34/\ A/7^"^IV?Q7/AL?#^9?$1[KX5_'_ .#'
MQNN?%5E\*/B/X8\<7_@B70%\4Z=HM\7U'2++Q?I">(O!'B"73[F.WO9_"'Q
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M2WL-(UB\TS4-86ZN+K2X+K3M&U^^TD _.+XV_P#!.G]HSQI\8/VA/C[X)O\
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MJ8!0_9O^$_[5/PR?]NKXD^.?#7[/UM\5_P!I?XS^'OCS\-?!GA/XM?$;Q/\
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M_P %6OA%X(_97\)_$3Q#)^U7\?+_ ,._LG_&7]M#XH:S\0?"G[,WAKXXZ'\
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M?P__ &<_A3X,^(7PU\4V/Q6?2V\//XC\$^-?#VKZKK3:G^C7QG_9E\0?%/\
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M\)]6T3PCX\^ _P 11\2_#.F^*M)^A=:_X*-?#GXF^%-%USPG>_'OX=1^"_\
M@HY^S7^QGXPU#X4R_LF_$_3/%'B_XL:;\%/'GA[3-6\3W_C'XG^$-4_9Y\<>
M'?COX#\._$;Q-\+-1T_X]^$;V7Q#9^%[+0=4\/W&HS:/AK_@KQ^S]>RW6H_$
M+X8_'OX)^ +;X7?MW?%5/BA\0]#^%^N>$I]*_P"";OQ>N/@]^U;H8T_X.?%G
MXK>.;?7_  GJ=M-XJ\+B[\'P:+XZ\(P7,OAW6KGQ'%'X;G /3_\ @GEX=^)_
MAKX6>.[7Q?I/@N/0_$OQ!\0_$7PAX^T?]G+XY_LJ>)_B%KOQ#NKKQ%\0M?\
MB)\"?VD?CM^T%\>(-9B\8W$[)XY^*7Q \&^+/%D5U<>'+'X2>$?!'@;P5X[^
M)_Q'H'_!%WQ3H7[.WB;X ?\ #4_AZZA\2?\ !*34_P#@F WBK_AGK5()+2VU
M3Q1XYU67XV#1O^&@)4GN(M!\;SZ3%\/#J<,7]LV$>OOXU;3[A_#$?V5X9_X*
M4_#'Q3K\_P /K#X5?%]/BWJ'Q@\$?!;P#\/U3X9:SI?Q/\2>.?A#XZ^._P#:
M7@KXR^%?B3XA^ =]I'P[^%_PF^,NL_%VTG^*-OXK\&:O\)/$?A?3/#'BG7?&
MOP+M/C!XM\*_VW?C#X(_X)1?M,_ML_$GPOXP^*_Q+_9WUG_@IWXB3P+XS;X3
M>"?&EWX:_90_:K_:C\%> / _CZ^^%QA^%FGZGX+^''PM\,^&O'?B#P"?$RZB
M/#VLZ[X<'Q"\07MH/$(!]E_M3_LT>(?VBK#]G.]T3XC:+X!\;?LZ?M(_#K]H
MS1M7U;X?WWCCPKXDU+P?X:\;>#-=\,:IX4L_B!X'UBTLM>\-_$'Q"VBZE:>-
MC-X:\06^A:IJ%IXLTNQU+P_K7SM\-/\ @GEXN^'WQ,_9Y^),_P =O#>M7/P'
M^-?_  4K^,K:5%\&=4TJ'Q7<?\%#OC!XW^,PT!+IOC+J;Z!#\(->\<WVEG46
MAUN3X@:/9VJBS\$7K37;^&+_ ,%"_B7\'_VTOVD?"?QE\#?'+Q)\#[9/^"6_
MA#0O#6FZ1^S7%#^RMXX_;7^)OQ:^ QUOQQJ6F?$#1O$GC+PMXQ^*$/PNCUJS
M\#^+OVBM=\%VG]HZSI]EIFA2_9+SU_X@?\%>?V<O "?&+51X(^,OCKP=\&/A
M]^V/XYU[QE\.-&\!>*-.O+[]A/5=7TCX]>"KK3&^(NGZ]\/M?N+KPKX^7X3:
MM\8-+^'/@CXMO\-?&2>$_%DXO?AR_P 0@#A_AO\ \$I-3\$Z;^P-IM_\:_ ,
MVK_L'?"O]F/X6^%OC'X"^ GB'X8?M(>*?#W[/MK?Z7XM\"GXNZ/^T!J=I'\!
M?VA=!A\/Z#\5?@%\1/!/Q<\&"";QUXA\-W&D>/-9^'?C#X1_9OC+]D3PG\7?
MVA/$_P 7?CYIWPF^.'@"+X.:)\)O@]\(_B!\%=%\1I\)7U3Q'J_B3XX^)1XH
M\3^(O$>G>*)/CI+9?"/3/$.DIX(\-PZ/I7P4\'P6]YJ,U]K=Q>>#>-O^"I'P
MQ^&VI7>@^/O@;^T%X5\6:+:?#CQCXF\ W-E\'=?^)&E_!?XP_$_Q-\+?A=\:
M]$^'W@CXQ^*_%?Q!\/\ BJ\\"_$?QG>_#OX>:9XH^._@CP#\,_&%]X_^$_A?
MQ5?_  X\'?$+FO#?_!0;1?"WQ(^(GPSA\$_M;_'SQQXG_;S^.'[*?@?PM?:5
M^R#X=MO"?Q ^%W['^D_M9+\/_ FLV7Q+^%-E=_!K7OAEX?\ $6L_#WQA\5-0
MUWXHKXWU/6_#?Q.U70=)C\*&( Y[]GK_ ()C?$WX&Z/^P[HFJ_M3Z)\1K7]A
M+P/^U1\*?AK+JGP*UG2[O6/A/\;]#\/>&?@WX(U:Z'QZU:>*/]G7PQX7T/P;
M;:N7O;[XC^$-%T:SOAX4\16^H>*M6\W3_@C+<7'PJ\&?##4OVG;BWD^'?_!.
MS]C#]BKP5XR\,?!NPTS7] ^*O["?QAL_CK\$?VEH[#Q-\1?&OAC4[&+XBZ!X
M1U3Q#\$==T+5=(UJUT.[TJ\\=RZ9K5Q:6_ZK?LS_ +0/@;]JW]GWX._M(_#2
MV\16'@7XU_#[PU\0_#FE>,--M]'\6Z)9^(M.AO9- \4Z997^KZ;:>(] NGN-
M&UN/2-9UO13J=C=/HNN:SI3V>J7?N- 'Y@V?[!OQ@U3XD? +XP>/OVA?A7J?
MCOX.^!/VM/!VM:7\/?V7KGX8_#+7I_VD_"7PC\(:#>>"O!L/Q[\3Z_X&TSP-
M%\']+\1^*M-\4>._BIJ_Q%\5>*?%LNB^*/AAX8/A7PIX5^2+O_@BW\2-%_9S
MU;]FSX9?M?\ A/PQX2^)?['?['G[+7QTU/Q=^S1KOCO4O%.O_L8>#X/ ?@;X
MM?"V&S_:8\&67PJD\>>$[+2=%^)/@;7(OBG87D.@:/?>$->\':X^OZQKW[ZT
M4 ?F#X/_ .">?BKPG\4_#OQ,_P"%Z>'[]M#_ ."DOQ>_X*"RZ+_PIW4[5;VU
M^+'[(GQ(_9*E^#T>H?\ "X;DV=QH>D_$W6/&B?$5K*[BU'4K'3M(;P!96JW5
MY<^$?"+_ ())?$3X$W/PAUGX:_M5^$+7Q)H7PDUGX!?'6\\6?LMZ3XWT3XE?
M#(?M ?%SX\_#OQ'\)M#UWXP2W'P*^.OPFO/CY\8M!\*^/]:UGXT_#G7?^$O@
MU/X@?!+Q?;>'M%T.V_;6B@#\P_!/_!/3Q1X.^)WA'XA#XY:!J%MX6_X*3?'[
M_@H*^A_\*?U&TGU"T^-_[,_Q@_9J@^#RZN?B]=1V=SX5TCXR:WXIF^(QTFZB
M\0:GI6EV$?P_T&U-W+/Z)\"_V.O&GP:_X)^>"?V'-3^)OPL^)4GP[^"VC_L_
M:'XP\8?L]2:I\-/%?PN\+:'9>"M&\.?%SX%:]\7?$<7Q L_$_P /M/7PQ\7;
M.S^)'A33?'$NK^)+_P ,V/PYLK_2]$T/[XHH _'7X;_\$I-2^%WB/X3:SX8^
M/NE6/A_X2^ OV[/ /A;X90_"GQ7<?#;P-X?_ &RE^#"Z%X.^#.DZ[\>=>U[X
M8?"?X+R?!72[_2/A?/XF\8Z1?W?BWQ;I?@;4/A)X(B\&>#/!_%>$O^"-LO@W
MX.>*O@#I7[1-@?AC\>OV(_V6/V*OVMX)O@YJ<GBKXG:+^S'\.9?@DOQ&^#>N
MO\:&TOX$^)/B7\%-5UOP3XGTO7O#7QKTO2M4L? GB[PZUAJ/A[Q3:_$#]OZ*
M /RM\.?\$Z?'WA/]HK2OBQH_[17AQOA?X<_;Z\>_M[>'_A;J7P,O+KQ<GBOX
MP?LI?&#]F/XI> ]<^*MM\9K#3]4T:1_B[J'CCX;:QI_PQT*Z\&I8S>%_%EA\
M3?MECXAT3YNTW_@C;\3_  7\(M.^'/PO_;$\-^&M;\4?L1_&#]@WX\Z_XF_9
MIU'QEX9^(?PL\>^/OB3\0OA[XW\ >#+?]HGPO?\ PJ^+/PDU3XP?$K3[76=4
M\9_$[P9XVTGQ5/#XE\!?:=(\-76B?O'10!\%?&#]C+Q)\2_V?/V6OA1HWQ;T
M3PM\0/V5OB3^S;\5/"_C_4/AC?>)O!GB;Q)^SZEI926?B#X:0?$WPUKL6@>+
M]+.JQ1V6G?%:WU+P]J-UIM\^L>(+73;O2]8^<=1_X);>+=$^(GA;X^?"3]H?
MP?X2_:(U3Q9^T5KG[0?BKX@?LY67Q:^%/QFTK]I'7/AWK^KV>@?!Z[^+/A23
MX6>)?@_+\'_A=I'P(\86OCWQ?-H_A_PWJ=I\7M)^-FI>+?$.L7?[!T4 9^DZ
M>NDZ5IFE)<W5XFF:?9Z>EY?/%)>W:V5M';+<WCP0VT#W4XC$MP\-O!$TKN8X
M8D*HNA110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %?F=^T]_P2_\ AK^TUXJ^//B-_CQ^T5\%-/\ VH?A
MY\+? '[0'@WX.7GP./A;XES?!;6]3U7X:^.KU?BY\#/BSKOASQWH.GZK)X4O
M]2\&:YX<TGQ7X5TOPWI7C#0]>'AK2)K;],:* /S>G_X)E?"C4A^TQX*\0_&+
M]HGQ-^S/^U-/\;=<\=?L@:QXU\)_\*,\.>/?VD-)U*Q^./CKP%K&G^ ;#X[Z
M!-XZU[Q'XY^):> +CXT:E\'O"OQA^(OB_P"*OA#X<:'XTA\%:KX,Z[PI^PF-
M-NOV?-:^(W[5W[4_QX\9?LV?&H_&?P)XW^+&I? =]<U6:'X#_%O]G73_  +X
MOL?A_P# 3P%X6U7PO;> ?CA\2;Z^\0Z=X=T;XL>)?&&NPZ]XI^)6M0Z'X<TS
M1_O.B@#\O/#?_!)C]G?2?AMX)^$7BCQQ\:OB=\._"/[-/[9?[*&I>'/&VM?#
MBRC\>_"G]NCXD^!_B?\ &D>+=2^'WPN\"ZQ9>)[+6OASX0T[P%K_ ("U#P3+
MX:TC2R]Q;ZOKUU=ZY-T__#NZ2_\ "WPDA\6_MF_M>^/OC)\ OB3%\0O@M^TU
MXQNOV:=3^,O@.U7X7^,/@W?>!$TV#]FNS^"_BOPQXI\ ?$'QM8^/-;\<_"/Q
M-\3/&VLZ];^)M;^(,VM^"_AG=^!OT<HH _/JT_X)R_"B#]AWXD?L%7?Q+^-6
ML?#/XH:M\:]=\1^/=2UCX>Q?%,ZK\>?C3XO^/?CEA<:-\--'^'&J://X]\<:
M_"WA/Q+\-M=\(Z_X/NIO!/CC0O%GAJ^U;3]1]>_9H_97TG]F?5?C[KFG_%?X
MK?%;6/VC?B[9?&_Q]J?Q3/PQ^TP^/H/A3\-OA!J%_H47PS^&7PUL;"RUKPQ\
M*?"$U]I4UG=Z;9:A:3'P_:Z)8SRV3_4]% 'Y_P!I_P $T?V7[+XA^'_B7#I'
MBLZ_X8_;)\6_MQ:-!<>(8KNPL/BSXV\!^/?"^O\ A73VNM+FU71O@[=^.OB5
MXP_:(D^&>A:KI>CS_M%ZUJGQ*O9+M];\0Z3K' Z;_P $M?A[I'QM_P"%W:;^
MT1^TE::A:?&C]IOXXZ'X-\S]GZ]\*Z/XG_:T\'W'A+XK:=+J6K_ #4OB'XGT
M:UCEL[KP /&?CKQ%JG@'2O#_ (7\ >'M3MOACH=OX+D_3ZB@#X'\,_\ !./]
MG[PWX;_X)^^'3>>/M>;_ ()O^%-&\!_!#7-=UK0GUCQ=X(T+X7:)\.+#PI\8
M8M(\,:1H/B_14UKP/\(?C0MMH^A^%C;?&_X'?"7QU8/9KX8FTG4>;N/^";7@
MSSOVG] TK]HW]J/P]\$_VH_^%\Z[KO[.FE>+?AG<_"CX9_$_]IGPKK'ASXT?
M%3X67/B'X2Z[\3+#4?%6K>*/&_Q-B^%_C/XA^-OV>M-^,/Q \8_$N#X./XBG
M\.S^&OT<HH ^7?%O[(OPH^(G['MY^Q'\2F\0_$#X0:M\"M.^ &O:CK]SHMGX
MVUSPSI?A"S\(VOB>XU/PQH/A[0=*\=PKI]IXCL]:\,^&="T_2/%5O;ZKH6C:
M5%:6EG;^"_$G_@FWX(^,GP\^-/A7XH_'S]H'Q1\0_CQH?[-?@_QS\?HW^!VC
M_$\>!_V3O'U[\4OA#X4T3PWIWP1C^!&DVH^(WB3XC^./&6HP_!E]7\1:_P#%
M?QM:6=[H7@_3?ACX1^''Z.44 ?+_ .T9^R[I7[1=Q^SYK%W\4OB?\+_%O[-?
MQNL/COX \7?#J+X77U_>^)XOA?\ $WX.ZOI'BC0/BK\,OB;X&U30M>\"?%SQ
ME:RS6GA/3/$V@:Q+I>O>#_$?AS4-.#S?"VB?\$6?@-HGP(\6?L_)\??VH;[P
MIXO_ &*O@K^P9>:[>:E^SVOBO3?@A^S_ /$GXG?$;X9W>DW%E^SM9Z"OCK2Q
M\6O%7@K4/$&I^'M4LM:\))I5SJNBW7CFSE\:W7[$T4 ? /PS^#_B[XA_MF>.
MOVI_BO\  @?!K4?A5X0\0?LU?"K5KCXHZ!X\U#]H;P7:^,;_ ,4>%_CQXA\'
M^%89_#?@6'P5I'B'QOX<^!YUB_A^+7ANT^/W[4GACQ!H7ASPKXHTN[\;>YW'
M[-?A>X_:PT_]KT^,/'<7C?3?V>M:_9O@\$12^#/^%;OX4USXBZ)\2[KQ1-;R
M^"Y?'9\;0ZSH%EIUM/'X^C\*+HSW$4_A&XU-X]5B^BZ* /YZOBK_ ,$ZOB'\
M)KW]FOX.?!W2/VP?B?\ "GX'?"_4_#7PU^-/P^C_ ."2OQ!\<>&O&GCGXW^(
M/BK\0Y/C-X5_;E^ >GZ9X+T.QO-(^#&J>"O'7[*FAZKXG\1OX3NK?XC?#^?6
M?AQ\/->\3_<^E?\ !.?3?$T&F^,?C!\9_B5??%WQ'^U5^S!^W3\6IO "?#+2
M?A[J_P"TA^SM\!_A-\#I=#\'Z7KWPHU7Q)I'P/\ &6E?"'PQ=ZMX=OM;N/'T
M4UJT^A>/O#3W^HP3_I=10!^6^O?\$H_A!XD^ FN_LMZU\9/CCK/[//B;QG^T
M!XPUCX6:_9_ #7])A;]H'XOV?QSN[7P[K>J? B?Q?X7UOX2?$%O%.I? WXGZ
M/XBA^,7P_/C_ ,3:G_PL+5_%>B_##Q-\.OJ+X_?LH^%/CM\1?V??C-%XV\>_
M"KXR_LS^(_&^K?#/XC_#J7PE+J3^&_BCX1D\&_%#X9^*]$\=^$_&OA;Q)\/?
M'EC;^&M9U;3)]$MM9L/%W@/P)XFT#7M(O_#_ /I?U-10!\-?!O\ 8"^$GP&\
M:_L]^,?AQXO^)NEP_LY_!/XY?!/PYX3N;OP!>>&_&EO^TI\3_AG\9_CC\2/B
M)._P[3Q;JGQ.^(?Q0^$_A;QEJ^J^'O%/A?PS;ZK-KQTKPGI]OKE] ^+\9_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^%6E>)O"'AOXM>#_ !9I.H^%-(^*=W:ZS/\ $W3/"'PUN;2Q\,>/_AE;>/\
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MT;^V%\:/C+H/@7PCXIT.'X0?&3X7?\%(O^"9MTWP*O[3XN_"'QOX>\-_$/\
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M9/\ @I/JOBC1OA->>&]:USQC\(OA[^P)\8?BSX4U$^"/#_Q-^+,7P^\<>+/
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M[QIX=^)>L>$FN9-0^'GCS6/ 7Q?TG4OAU;?//[9W_!4I-:_8>\>?%S]BQ?C
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MX^OS)IJ>WW__  4X_9J'Q(\"?#?PO-XG^(%YXVUS]GS0)]5\(S> 1<>$+O\
M:>TS1=9^$]WXA^&_B?Q[X:^.&J:/<:1XP^'FL>,M8\ _"KQK8?#KP]\0M%\6
M>.)M"\(^'/B7KW@, ].M?^"?G[$=@OQ>73?V6O@GI/\ POSQCX:^('QE?1_
MFBZ/-\1?&/@WQ9#\0?">O>)9],M[2:\NO#GQ$A/Q(T:-7BM=/^(]UJ7Q MH(
M_&.JZGK=WW'BG]D7]ESQQ\;M!_:4\9?L_?"+Q3\?/#/A?4/!6A?%O7_ ?AW5
M?'.G^%]3L]0TVZTA-=O;&:[F@32M9U_1[&6Y::YTO1?$_BS1M,GM-+\5^(K3
M4_SQU3_@LW\.F^#7Q+^+GA[]EW]I*.V\*?LE_MK_ +5_P_M_']S\!O".B?%7
M2/V"/B'HOPI_: \#V&J^&?C3\1O$WA/6O#/C/Q1X8N$UOQ'X$B\.>)/!FJR^
M)OAS?>/[NR;0)_O?4/VFM&\!_LX^!OCO\7/"_B7P?J7C,_";PQIOPY@B\+ZK
MXP\0?%?XU>,/#'PT^%_PZ\.IH'C/Q)X,75/B+\1_&/A?P_X>U#5?B!!X2\.V
MNOVNN?$/Q?X2\.Z1XGUS1 #CO#'_  3L_8D\#+:/X!_9Q^'WP]U+3M)\!:)I
M/B7X>6^J> O&NA:9\+8/&EE\.[?P]XZ\(:GHOC'P\W@W2/B'XQ\.:#<Z)KEA
M=6'A/63X1BG'AFQTS2;+L-)_8E_8^T#XJ?#CXW^'_P!F+X%^'_BS\'_ 6F?"
M[X5>.]!^&/A'1==^'7P^T+09O"GASPGX,FTO2K2'P[I'A;PC=ZCX/\)PZ7#;
M/X5\'ZSK_A3P[)IGA[Q!K6FW_P '?LF_\%']4\1>(/B=X$^/FB_$4^/M>_:X
M_;R^'OP:\*-X1^'VE:KX8\ ?LC:!X-\67GP]\87WAWQ2/"T_BB/1M>O(_#GB
MJUUS7O#?B^2'[=+XRATRZTB]O-3Q?_P5?^#GCKX5>/+SX2Z)^TKHK3?L.>$O
MVQHOC=X:^"OA+QOHGP2^$OQV_9G^/WQY^#OQ3\5:#K_C6#3;K5HH/@-XI\-V
M?@G7+62QUCXJ2^$?!5_*VA>)9]?LP#[V^*7[)/[,_P ;?$>O>+_BU\#_ (<^
M/_%'BKX67'P0\4:]XD\.65_JGB3X076M7?B&;X;:_=LBRZSX..K:GKEQ'H>H
MM<V,$7B?Q=8P11V'B_Q-;:MSGQ2_8<_9%^-^A>,O#?QB_9\^&OQ/T;X@?$/P
MM\7?%]KX[T)/$\NK_%?P3X4T_P  ^$_B;]NU>2ZO[#X@Z!X TG2_ &G>,M,N
MK+Q%#X#TVP\%_P!HMX8M+?2H_FW1O^"G'P8T+Q+X0^%?B'1/CGXKU:S\1?L9
M_"WQ_P#&-/AOX6TKP)HGC;]MOPQ8']GO7O%-OI_C%=0M[/XF>.KW2? .K6OP
M_P##?BR'X<^-?%.B'Q?;>'OA[<IXVC]D^#7[>OP9^.WQ.\-_#+P!HGQ'N3XY
MTW]HG6_AWXZU#P_H]IX$\>Z%^R?\9K+]G[X_ZUH5[#XDNO$.GV'@+XM:]X+\
M+Q_\)9X:\-77C"'QYX9\2>!+;Q/X57Q!KF@@'NGC/]GCX&_$'X3Z1\"/%WPK
M\$ZK\%= @\%6FA_"A=#M--^'ND6/PVO-)U'X=Z;IWA+24L=$L]+\!:GH'A[5
MO!FEP62:?X8U?P[X=U71+:RU#0=(N;/I?$GPK^'WC#Q!\-O%?BCPQ9:[XE^#
M^M:CXD^&6NZE+>W&J>"_$6L>&=4\%:MKNBWCW7G0ZQJG@W7O$'A+4=3D>6\O
M?#/B3Q+H-S-+I7B+6K6^_)+]J'_@HQ\4-!\>?$?X>?"WP'XP^'[?LY?\%#/^
M";W[-'CWQCJEE\-_&EC\7O#'[4GC[X(7_P 0O"OA;PY9:]K_ (HT:YU;X5?&
MK1O^$9U:;1-&U*SU6*6Y?6-*OXIM&@]H\4_\%<OV6_ _PT\*?$/QC8?$'PSJ
MFM0?M!7OBOX4ZQ)\*;3XK?#+3OV4?C!JOP&_:+N/$>A-\53H7CC4?AO\4]"U
MSPQI_A#X$>)OC!X\^+TVC:K=? /PK\5K33[J:( ^AO'?[ '[$_Q2\-6_@WXE
M_LN_!;XA>%;;XL>+OCE%H'C;P-H_BG2_^%L?$+4+K5?B-XTEM=;@OHY]1^).
MH7^I7/Q(MYQ)IOQ ;5=73QC9:U'J^I)=:_B7]AS]CKQC\8_%7[0GBK]F3X)>
M(/C?XY\%W_P]\9?%'5?AWX:O/&7BGPCJG@^]^'>H:9K^LRV#7&JSW7PYU+4?
MAQ)J]Z9M:_X5WJ%[X#745\)7<^CR9_[0'[4=[\$_BO\ L7_#71_A/XD^)MC^
MUU\;O%?PB?QEX;\2^ M+T?X<6OAG]GKXP?'D>(KZU\3>*-'U3Q*VH:9\*=0E
MAL]!LY[&+PQIOBW4I-9'BZW\ > _B1\P>'/^"Q7[)'C#2=7\0>$+;XG>,= M
MI?V6[_PSJ_@O0_"'C:#X@>"OVQ?C1H7P$^"7CKPK:>$/'>N:K8C4/B!XH\+P
M>+/A1XXT_P &_M%>!M(\3>'=6\4?!?38=:T];@ _0?X>?!?X7_"OP_K_ (8\
M#>#].TK2O%NIOK/C%[V:_P#$6L>-M6/AO0_!4.H^-_$GB:\UCQ%XRO+#P+X6
M\)_#_2;CQ/JNJR:-\/?"'A#P%I+67A#PIX>T73?)C^P_^R2_PR\3_!BX^ 7P
M[OOA5XRT+P?X1\2> ]3TAM4\-ZGX#^'6HWVJ_#7X9M8:C/=):_"CX8WVJ:E)
M\,?A39&V^'/PXBU"]M?!/AC0K2ZF@?Y@MO\ @JY\*6\2>'O!^J_L[_M;>&_%
M&L_&3P!^SGJ^AZ_\./ 5K>>!?V@?BY^R[X-_:P^$WPA\;O;?%:\M-+\2>.O!
M'C?3?"$VM6-SJO@/X:?$.UN-/^-OB_X8>%;_ ,.>,-=^B? O[</P*\:?LC7'
M[:=W=^*O WPCTC2O'=QXLTOQIX:N(/B)X1\5?##QKXB^&'C[X8ZAX/\ #D_B
M6;Q!\2]"^*GA37OAEI_AOP#>^,8_'7C6ULM,^&^H>,H==\/7>K 'NGQ&^#OP
MU^+OA2P\#?$WPI9^./">FZSX7\1VNA^(KG4M0M#XB\$:SI_B3P=K]T9+WSK_
M %OPKXGTC2/%7A[5K^6YU#2/%>D:3XGL+B#7M,L=0M^5^,/[,7[._P"T'<>!
M;OXZ?!;X;_%ZY^&=UXBN_ TWQ%\)Z3XND\/?\)CX9O/!WC&RMFUNVO#<:/XO
M\,WTVD>+-"OOM6B^);:*Q;6["^GTS3I;7X/_ &CO^"BNL>'_ (;_ ! T'X6_
M"3XL^&/VB/A_^TQ^PU\ ?B?\+O%UC\&D^('PY\"_MJ_M$_"[X1^&/C'X6NKK
MXL:K\'_&-GXQ\+^+O&&D_!'Q5I7BSXA>"=.^.WAX^&_C%X8MM%^'WQ>T3P]Z
MMXA_:&^)W[._C7]A_P#9>\>Z5\2/V@?B)^U5XV^,GA&^^.MEI?P-^'%QX!\*
M^ ? WC;XF:9K7C[PI;>,K;P_KWQ*T#PQ#X1TKQ3-\,O!Z_#_ ,72^&_B/XZ\
M/^'/"%W=^ O@OXA /8K3]AO]DC3_  U8^#K'X"^ K/PIIO@WX/?#VQ\/6MC=
M0:1!X*_9\\4S>._@9X<%A%>+;OIOPD\>W>H^/_A['(COX4\>ZOKGC;1Y+7Q3
MKFKZM>[UY^R'^S5?3ZY?2_!_PI!K7B#XH:G\;[SQ1IR:AI/C.R^-6L^$8/A_
MJ?QA\.>-=*OK/Q9X1^*EYX!MH/ LGQ$\*ZSHWC >"XE\*1ZRF@#^SS^/_P -
M?^"KEUXT_P"";)\8_$OQ/\;O@U^TEX5_X)E?LL_MG>-?CE8? ;X;>)K7Q7I/
MQH\-#1_&'QA^#'PPUGQ+IGACQ'8>$OBAX:\9Z3K/@WQ[I'PY6\TU]$\6> M(
M\5?#KQ-X.\4ZU^N/PX_:L\"_%;X]?%KX!^"O#7C?4]2^"-WJ&A_$;Q^L7@X^
M O#OC;3](^&GB%/ &K6\'C*?XCZ!XHUKP]\4=(\0^$7\4?#S0?#?C?0M"\7:
MOX/\0ZYI^A-/< &E%^R/^S7;V6CZ=;?!SP=:V.@^#OBMX TRVM+.XM8HO"7Q
MYUR+Q1\=-*N!;W41OS\;?%EO:>+_ (P:AJ!NM4^)_C#3],\6>.+W7?$6F:?J
M5M3N?V-?V5K[1-9\,ZG\!?AKK/AGQ%\%_"O[.>O>&M>\.6FN^'-8^ _@2;4K
MKP/\(]1T'6!>Z3=^ /!EWK.MWOA/PU-9OIOAN]US7+W1H+*ZUG4Y;KY@_:9_
M;NU+X#_MD_LE_!J$> 9/@K\3/B9I?P'^/WB?6=0OW\7^#?B[^T!X,\=:S^R7
MIG@ZUT87UBR:OXU^%-SX$^*%GXM&B76D7'[07[.6H^'X];LO%FKW>@=+\3/^
M"EWP4^%GQD\4_!?7/AY\=]6U/P-\;/@?^SYXS\9>&? ^A:KX&\/?$_\ :8\&
MV/BG]G_2);R3QE9^(]7L_BAK.K:)\.K/5/#?AC6[+P9XWUW1F^*$G@7P;?Q>
M,* /?_ _['?[+GPSTKX*Z'\/?@5\.?!>C_LYW'BJ]^!^G>&O#]OI%K\-M3\>
M:=JND^/=;\.1V9B$/B#QYI^O^(+;QQXAN/M.M^,%\1>(7\27^IRZ]JSWF#\,
M/V$/V,/@M>ZYJ/PI_9<^!O@2\\1^!=7^%FLR^'_AQX9M%N_A5KNN:EXCU/X5
M)"=/>"T^%TVKZOJ%Q#\.;*.V\%64,ZV%CH=MI\%O:Q?-OB[_ (*W_LN^ _A5
MX.^)GC#3?B-X>U7Q+;?M&7VN?"'5D^&%C\6_ 5E^R'\6;GX%_M,'6M&NOBC%
MX7\;:S\+/BM:R^#K;P5\$O&'Q8\?_%R]CN+OX!>%/BQI=AJ5]9][X?\ ^"DW
MP(\0?&-_A$/#?Q1T2TA^/'Q0_9INOB]XAT7PCI?P=L_C#\+OV<X_VM+OP]<>
M)#XXFUX:7XJ_9ZMO%'Q'\,>,8O"LO@VWM/!/B'0O&>O>$/%-UX5T/Q* ?5/@
M_P" WPD\":_!XI\->#+.WU_3K"^T7PWJ6IW^L^(YO OAK4UTU=0\&_#-/$FH
MZM!\+_ EX-&T?S_ ?P[B\,>#I#I&E$Z'G3;(P>??&C]BO]DG]HSQ++XR^._[
M.?PA^+/BN?P38_#FX\0^.O!&B>(-7N/!.D>,;;X@^'_#]Q>WUK)/<6GA7QO;
MR^*O!TLSO=^#M;U7Q%?^%[C2)O%'B-M5_-5/^"KUIHG[17Q&\<^,-!^+VC?L
M;P_L8_L3_&KX7Z-=?#+PM=^/O&6K?M<?M8?$/X#>"/BUX=T7P]K^J?$"'PIX
MRTV7X9SO\-_'MOX6^*_@N!-5N/$OPMT37KN/16^K?A[_ ,%-?@OXX\?>&_A[
MK7PV^.?PIU'6/C)\=/V<_$6O?%#PWX$TOP?\./V@/@'\.O%/QL\2?"GQMXE\
M-?$CQ7I[7_B;X ^"_$WQR\%^._!K>+_A!>^!M,DTK7OB/X<^(\MOX"E /K+P
M%^SK\$?AAXMUCQUX"^&_ASPSXJUN3QH\VJ6$-PPTL?$OQF?B1\38/"EA<W$^
MF^"+/XG_ !'V?$3XFV/@VST&R^(GCZ&V\:>,X-;\36MMJD7SI\ ?V%?!_P )
M_BY^T;\:/&UUH'Q&\9_&?]J/QA^TIX$U"/0M9T$_!^X\6? WP%\ 5T_2;2Y\
M5Z]I>H_$72_ WA/Q5HT'QOTK3_"GC)?!OQ4\;?#C2K30_">HZ]!XI\G\.?\
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M_%6K>(O$FK:C=:UXF\0WVI_0%%% !1110 4444 %%%% !1110 4444 %%%%
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M/P[X1NOV?-4?XJ^&?V1;&'P_\#OB7XAO?B%^S]XW;P_\8-+\&6]OX,\7Z_X
M@\(^$_'.B:;H"ZUX'\_P]I$MK^T%% 'YOG_@FC\.+E_VF_!FL?'+]H_7/V8_
MVJ(_CQJ/CG]D&^\9>$8/@MX?\:_M1:/XCTS]H/QCX+\1:;X"L?CQI,/Q#U3Q
MEXX\?Q_#F[^,>H_"'PK\5OB!XR^)/AGX?Z=XF'@J[\$>I_L^?L@7_P #OBEX
MW^,WB/\ :5^._P"T#\0?'GP5^$'P'UK5_C%9? ^V2;P;\"/&?QM\9?#;5)XO
MA+\&OA=->>,+6Y^/?CRW\2:Y<736WB:2_P#MMSI5M)!ID6F?9M% 'YT^-?\
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M1]=N;"'2?&MK=2V.K^'?%^AZI:F[E^4? '_!+_PQX!^"V@?LZC]JC]JKQ?\
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M#VO_  3;^#R^,KOQ=K'C?XF^*8-2_;%^,7[:FJ^$O$#_  ]E\*ZEX_\ C?\
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MT\)^%O#?AJWU&]N(="T#1]+2UTZWZ6BB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY^TO^UK\$]8U6V\5>*]:^$MM\.OV4_"/PY\?:[\2?#B2:5X6\9:[XE\1Z?\
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M>ZU%K_Q)XOBMO&.J:YI5]XAN]3T^7Q1'8ZEXFTOQ)I<>H:#JFQX0_:I^.'P
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MA#\*?!'Q?UK]GS]D+]LK]O#XG^(_BM^TA\4]5\2:[HGP;_;P_:1\+_$'X/\
MASQ3JWPG\6>(_$NH6OP_\"7>C?#+XB>,[NQ>_P!4N=%G\4^%-#TO19M.U?\
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MYY_V]OV^/VHO!?P6_:\^!4ND^"OA7\:]/_8Q^"7[4/PX^+_PA\8^,=8T2S\
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M_P -/#_ABT\?W&IZ?J'_  KN31H[+P_)J^C:'^K'[(?[0?[07QRDU'5?B_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%$A/V/2+1/DKK*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M44 %%(P)5@&*D@@,NTLI(P&4,K+D=1N5ER.5(R*_!+]G[_@H1^TU\7_V2_\
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M[JT=T*K<VZ7]K>V330DB2-;NSNK<NH$T$J;D(!8HK^?/_@G?_P %D]7^+/[
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M_"'5[%=-^.O@/X87=[IT5V ?-OP__P""1/@SX9_L6?L/?LG^&OC-XBE\3?\
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M;XE\7P^"_$/A"?Q7X)_X23X9ZIXXU/Q7HMCXI\/Z]J=OI^FZW ML <;\&O\
M@EI<_ 3Q_P# KXI?#7]H?4K#QU^SS_P2[TO_ ()B> -3UCX8:1K-@GA?P[XE
M\*>*/#7QHU/2)?%4$%]XXTZ_\!>$#>>'I9#X3U-K?7-]G;6^L6EKHW">"?\
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M9WFG72QZ1XGT?6/#>N_V;KFFW>GQ@'V]17YX_$'_ (*@?LJ_"F#XLW_Q#O\
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M1?J;P=^P?<>#/CU^W3\?]*^/GCNP\9?MR?!WX$?"O7=;T/P]X7T?Q9\*M6^
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MO$B:+\#?@_IGPMU30-.T&#QCX^%K'K'C$ \M_8!_X)9V7["GQ7\7?%^/X_\
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M'X?_  CU+PMH7@CP!/9>&-?U>Y^(7Q"O_BO8ZKX+L;VW\$W'A3QZ >@?$_\
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M\1?&WXZ>--,^'OA*?Q7\$_AKX<\&_$SQ?\;;S4/A" >+?L[_ /!%[P[^S?\
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M?W*BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KQ'XL>$_CYXDUSP1<?!SXS^!OA9X<LHO%
M%A\2])\6?!6Z^*FM>*+'68=&'A_5/A_X@@^*GP]LOAWXP\'W%AJDEEJ7B;PW
M\6/"&KP:[-!K?@*\DL+"YA]NKYH^/O[1R_ OQ=^SWX)3X:>+OB-KW[2GQ/\
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MJN?AIX&D\#_";X910^)+?Q)]^44 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7YV_MW
M?!KQM\6O'W[#&O\ A_X1>*/B[X.^ O[3?C'XR_%'1/"7B[P/X2UV3PO?_LA_
MM/\ P*T.TT"X\8_$CX:K>ZZ?B#\;/!FL26L>O:?8KX6T/Q1<76H27T.E^'_$
M'Z)44 ?E1_PI;XM:EXK_ &(;WPO^SEK/PM^&O[.?[=_QD^-DOA;6_B;X%\5>
M.+#X4_$#]BO]K+X7ZEXF\6S)\0_$VD-XM\1_M(?M/:I>:5X4\)^-O'%M8?"S
M3(-=U+5M&\0/_P (-:_E!H7_  28_:,T_P#91^'OPJ7]GSX=Z=\1_#G_  00
M_;,_8&U.\MM8^$T,4?[5GQKU/X<K\/UMM<L]3%Q<:!*^C_$;7=0\=$1KI<?C
M&\F>)M9\2^(K*#^K:B@#\?\ P-^SW^T7X0_;<L?C3X3\!>*_#_PQ\1WNF>-_
MVC?#7Q&\3_!'XC^ _B9XMT7]BKPC\&_#GQF^ =TFHR?&WX(_MAV?B?PWX)_9
MS\<>&KS7V_99^(7[.7@KQCX_N_$EG\6-<T,:U\N_ /\ 8<_:B^#OPK_8/M_B
M1\"](^/N@_#'_@E-\3/^";'QY_9AU7QW\-4TS2?%WC1O@?JMU\0+'6O$.N2>
M"/%/P0^*MG\%YOAQ\9+6&YOOB!I^CQ_"G5=!^&OC&UM_&6E:%_1%7PAI7[3W
MQ\^-;7WB+]D?]GKX=?$/X.VFH7NDZ+\:/CU\?_$'P(\-?%673+R>PO\ Q+\$
M=!\"? +]HGQ/XR^&BW]K=6&D?$3QA8?#32/'"VX\5?#*#QU\-M4\,^.O$(!^
M1'A?_@D1\=]/^!W[9OPUUO0/A-XN^.7B+]FS]@GX3_!S]H7X@6V@ZW!\:-6_
M9T_9.\&_ CX_^%?$NM2GQ'\4/ 7@O]H;3]"^(/P?\>:KJ5E+JMY\+OC!XAEF
MLO$D<VJZ)<?8GP;D_:A^#'[4/[0_[1GBG]CB[T#1/VZ?V@OV(O!4G@^'XR_!
M^]^)O@#P]X?_ &?]9^&_Q,^*WBS2?!]]XBT/QW=_#+Q)X6\/0ZMX=\)>*]=U
MBZ^":7'Q*BU6SL? /B#P=I'V3)XX_P""C@C<Q?LP?L2M*$8QK)^W=\=HXVD"
M_(KNO_!.:1D0MPS+'(RKR$8_+7P+XF_:@_X* > /V@/CT_A_P#\;_BM\/O#?
MBSQ_HNH^$O$W[+WB@?#+X1_#F;XQ_LL>"OA9\9?@AXF\!_"[PCX^_:IU/0/A
M3X__ &D?C+\1/@3X"^(?Q9\9_$ZT^$5OX+\+^(?@9XLN]$T_QD ?>?[3G[.6
MD?M'_%3P#X*^*/PGB^*7[-_B_P#9[_:>^"_QNL-0U31;316LOBSJWP&U/0=/
MU"R;Q)HOC!OM(^&FM7%AK_@VVGUGPIXAM?#NM:=>Z5J,%MJVF^=_L$_LH?&+
M]G#P'^U;\+OVCOB'-^T]I7C?X^SW_P ./B/X_6PU[XD_%W]GC3/V7?V<_@MX
M)M/VA'OBFA>+_C!9:=\,]8^'OQ)\73V6D6'Q:N_#X^)NL:)HUYXYU+3K;Y^L
M_P#@H#^W#:^'M>\4>,OV$?'WARYT+P_\$]4U3X>:'\,?CQ\1/$.F+\1O@CX,
M\5ZWJNB^*?"'@FYTCXG-;?'GQIK/P5U'P!X&T&3Q]\&M$^$VN_%+XTV6@^&/
M'NG)X'\;US]L[_@I!\/=8_:'\<:O\!/B1X_T'PCHNE_$OPWX#F\-Q?!;X?>$
M[/0?"E[XD/PEU/XC?$S]GK3?#VCZ?XR@D^R^(_C!X=_:"_:F\/6\&@:EXU^*
M4_[ 7B&+3?V<O&0!]M_\$COV9O'?[(_[#OPZ^"?Q4\#KX'^(_AOQ-\2DUVVD
M\5:?X]U'4/"=MX\UW1?@5;:CXYM->\37_B.+X?\ [-^C_!SX.^&H-:UJ\N/!
M?@GX:^%_AMHGD^#/!?A>"/V;QQ\-/B!JG[?G[-?QITWPM<WGPQ^'O[)_[9'P
MA\6^*$U;PW"NF>,_CI\5_P!B/QSX'MUT6[UNW\1WU@-(_9J\<P:S?Z?H]U%I
M^H:QX1AC%U;WVM76@?F#\/\ _@J3^VQ\6? ?_"U_@9^R3I7[1OPN/A;XUGPE
MXW^'WA#XQ>$M+^,OBCX>R?\ !3_3?!VI^%T\36VJW/P^T[7_ !'^Q%^S7X<\
M3>!/$D7BCQ1X<U[]M3PGH$>O7FM:%X7L_B1])?!C]J?]N#XG_M)_L_>"O'7P
M,O\ X9?"?6/">O\ B'XB:YIWP<^.UKH_B_2Y?AMKVH^$/'5]XS^*/P[\)Z?\
M$7UOQS':^';K]FGQC-#\?/AYXC\/73>([_QI\//&'@SQAK(!\]_ [_@G_P#M
M _ RS_8V\-)X&T?QQX?_ ."6/AC]O;5O@]"?&GAW08/VK_$GQIL/$_@K]E;P
M=H&I7=UK5YX%AM?@7XU\6:#^T?K_ ,4/#7A33_"7QN?P]:_"ZQ^+?PQDU3QW
MIGT1X2^#_P 9OV<[;]IOX^_LI_LES>"?$W[5WB+X+Z@O[(4?Q ^#OA+1_A[\
M1-#T?Q-I?QG_ &L?'4>C^,=3^"VF?%;X@:'J/A3PIXA^'_PH\4>,M,^)#_ _
MX1>+/%/C[2M>^)GQ,N_A?\V?LS?\%&/VZ]6\/_LI?"[X^_L]'0OC+\8/ ^M1
M^*/%7B[X7?%'P)XSTW5?@?\ LW_LJ?&GX^_$;Q!^S+%I=E\3M4\'VGCGXE_'
M_P#9NT;Q/\,-"N_ /B#X_>!?@U#X?N+#P]^T'X0T'2?WOT.[GO\ 1=(O[K/V
MF]TO3[NXSINIZ,?/N;2&:;.CZTD6L:4?,=LZ;JT<>IV/_'K?HEU%*H /R;G^
M&'Q,\0?L@)^RMXQ_8 \?OX,^+=M\:O#OC#0_"_[8_@'1?%&G:_XJU>Q\7S?%
MC]H+XM^%=8^'/B.SO_C[\4_&7Q1^(7Q1\5_ RP^-WC+2-0C_ .$MO/A_XKUW
MQM>^#/#OZ1_ GP3XT^&GP0^#?PY^)'Q$U#XO?$3P!\*OA[X)\>_%G5[0V&J_
M%#QIX5\(Z1H7BGXB:G8M=7S6>H>-M<L+[Q+>VC7MXUO<ZG+"UU<%#*_JM% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^6/[4?[
M%OB?]N+XB?M$>%OC)J/Q%^&_P'F_97\0_LP?#9? ;? 75]1^)6C_ +0+_P#"
M0?M*:Y='QSX8^(&K:#-)?^ /V?=(\!"YMO FN>$O$'PUU;Q;H7B8IXND_L7Y
M=U?X!_\ !0/XG_#3]BGX@>,?AOJ7@K]N;X5?"OX3_#KXM>-KKX@_ CXN?LV_
M$/5?"OQG^%WBKXK)^T-\,?%$EKJ=UX)\9O\ "G1/C7\*/B7^SO'8?M$_!_XA
M:C-I>B:E966D7MKXX_?"B@#\%_A[^R-^US\+/B;\*_B=<_#^3QCX2_9R_P""
MD7_!2OX\O\)O#OCOP!/J'QG^&?[>/B?XZ>*OAO\ &[X9#Q;XE\(^%O#OQ'^
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M=#T'X/?#/1=&TJPA2WL=,TK2_!>B6.G:?9P1A8X+2RLX(;:WA152*&-$4!5
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MI$/&'PWU'6;74K3PA\0=+C?PI\0-.T__ (2_P'J?B3P)K'AKQ3KG\OO[ W[
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MRH]_G>29=^P;O--N!!YF[._R (=V?+ 3:*EHHH **** "BBB@ HHHH ****
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M;S-9V]W<R65K/=+&QMX;F\AM+^:TMY9@B37,5C>R01LTJ6ERR"%_Y[?V:O\
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M&X7T^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVF_LV:#\4_AA:6OA_P"*MWJ.M@'W/1110 4444 %%%% !1110 4444 %%%%
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ME\3_ (9^(KKPE\%[7P5XR\0?&#7;;P+\+O$'@7]H/XZ^-OC)<^/O@]!^T?\
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MV>OC'\/OAI\0M0^.?CCQQX;\ _%?7/B=^W9J7PX\?^+]:3XH?!Z;3KZ'P/\
M%G]FG^V-=\(_LI?$*[L6\%6WA3PGHW@S2OAYX*NM%_1O]G72/B;\/?A3X7\&
M_$#1?&WB'7K34_%MX->U_P :Z7XS\1Q>&/$OQ4U^]\$V/CWQ!K?C74)K[XA>
M&_AQK6@W7Q,M_![W?PTTSQ!H_B70/@S]H\&V7@?09?GW_@G!^T!\8_VLOA,/
MV@OBE8>)/A_'>>'O!GP:U#X,:UI7ARWM_"WQ\^!\6N^%_P!KSQ,FI0>&M%\8
M_P!I6O[25YX__9WO-#U>\N?!W]G_ +-&C?$#P!I^GV?Q)U6XU']%Z "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "O'_BK^T+\ O@2+$_&[XW_  B^#HU/
M0/%GBS3C\4_B1X.^'XO_  KX#;04\<^)[0^+-9TD7'AWP6WBKPNGBW7(MVE^
M'&\2Z NLW5DVLZ<+GV"OSP_X*SPZ7'_P3%_X*+W4\.GIK.I_L'_M:>#]$N98
M[9=3U#4_%GP/\::3HGA;2IG NKN_\2^(Y]'TW2M$M&DN-9UN;3;.TM;F^DM8
MR ?1NC?M4_LS>*M8\(Z!X3^.?PJ\;:OXZ^)5S\'_  S9^"?&6A>-FO/BCIGP
MDUW]H";P->2^%[O5[?1/$</P;\-ZI\38;'79=-DE\+#3M5MC(FMZ)_:'H5_\
M3OASH?Q$\(_"&_\ %>B6'Q)\?^'/''C3P=X*>8)K7B+PU\/M1\+V'C[7]/M8
MT*RV/AK5?'?A.UUJY=T\B\\1Z;&^Z6Z KX=_:-\;M:_%K_@F2?!WQ"GTKP[\
M?OV@O%OPU^)\G@WQ)9:;%\3_ (0_\,!_MH>-O"\>H>*M#>+Q'-H_A[XR6/PV
MU+P9K.@>(M/@TKQKXET@V%PVM^(=)9_PL^%'C[XJ^&OV<_\ @EW\0?V>-1\7
M_$_]J/P+_P $+?\ @IZ_A^RU^[\4?%;Q;=?MG^&/AU_P3YGN?AC-I/BB76M0
MUCQWI/QE\ ^,O"M_\)X@'MO&_@CQOX N].TS6/#GBFUTH _KS=$D1XY$62.1
M622-U#HZ."K(ZL"K*RDAE((()!!!KQ_XG_M!? #X)ZKX4TOXS_&OX1?"36O&
M\7B,^!K#XG?$3P?X#U'QA#X5TU-<\8?\(E;^*M7TJX\0Q^%]&CBUOQ4-&6\7
M0-)$&JZR+.Q,5P?R3_92^,?@GXAZ+;_$-_\ @I5\2/BC\"?B%^U=\ !^S_/X
M+^#/Q0^&$-K\4-2\+ZY8>,OV2_%GCGX]:Q\<?B3\0?!_Q \3:2?%?Q)\ ^(O
M^$"\0? KQA>:I\-H/%OA#2;?2OAYX"[/_@HQ+XJG_;X_X(XZ=\/_ !9X0\(>
M-O\ A=7[8<^DZYXX\*ZIX\\+Z+)?_L/_ !D\/Z=J/B+P;H?CSX::MJNG7NN:
MMIWA^Q2'QOX<^U:[J^F:9;W[WU]:VLX!^O7A'Q?X3^('A7PWXZ\!^)_#OC;P
M1XRT+2O%'A#QCX1UK3?$GA7Q5X9UVQ@U/0_$7AOQ#HUS>Z1KFA:SIMS;:AI6
MKZ7>76GZC8W$%W9W$UO+'(W0U_.!X&_9V^-_[*7QU\ ?L0_ +]I?XQZYI_P6
M_84^*_[8.B^ =!'PA^&/A+]H']K36/VV]?\ C9KOA[Q7I,/@.[M?!?P>^)_B
MKQ]XB^&NJ?#WPUKVE3^&?@OK>FZ)8>-K;Q'HG_"P+SS#X;_M/?%_QM^S_;?%
M;PM^WYI'CJYU/Q-^S]IWQJ^"7[2/@WX]?L->%M!_:'\/>&?C;>?M$?L\?$/]
ML ^)_B%XK_9+^,OCR?3/#GBB_P#AE\-M!TCX/?"KQS\ _ '@BT^&_@CX9_ME
MV6E?$< _I-M?B7\.]0^*FO?!RU\2:5<?%CPC\/\ PE\3-=\'A9?[;TGX>?$3
MQ'XT\+>$_$KL\"P'2O$'B7X7>,],A6WN9)EO/#$QO(($:PDN+'A'XE^ _'NL
M_$7P]X.\4:7XAUKX2>,X?AW\2=-T^5Y;CP=XWN/!OA'XA0^&=9#1HL.J2>"O
M'G@[Q((8VE4:9XATZ4N&E*+_ #[^+_VV/CQHVB?$?QEX:\8_M$:+X*M_^"<'
M_!';XSZ_I'CCP+I'BO\ :#^"_@_XY?M7?&CP5^W9\;M1^'?@CP3J6GR?M ?"
MO]E.'3/B=XYM=.\!>)?"OA'Q;X7\.Z[-\.K_ ,+W,/A;6/!;G]HW0?AE\0/V
MH;CP#^TW?>$_V*/BW_P4;\/)\3/VQH];^(OQGM=&\+>)/^"4/[!5E^S-)KOQ
MB^'GQ.\%_$C1?@M\0?B+IWBG0_#?[2=I\1+C2=6\9_#3X;^"O'/C;Q3X3^(7
MC"S\7@']7=-5E8L%9248*X4@E&*JX5@/NML=& .#M96QA@3_ "Z?$7]H+]K/
MP+XJ^*.IZM^UQ\8?'.J_L_>&?^"!>JVEWJ?PZTCX >&/B1XF_:#_ &JO%'PB
M_:S\:?$#X"'0;;Q%X C^)WP*G7QG\0_@GX@URSM_A-+XJLO$>J>&O!_B/PCX
M%D\#_IE_P2WN(Q??\%!-(UKQ3X[USXAZ'_P47_:@L_%.C?$#QKX\\5:SX7\)
M3^,I;[X*VD.G^-]6U-O#NB:C\(;CPEJ'@F'38[2VU+X9R>!+O3_/\)IX2= #
M]6(XHX8UBAC2*.-52..-%2-$10B(J* JJB*J*J@!54*   *^?O@/^S=X/_9^
MU/XYZMX7\0^,?$EY\??COXT_:"\4-XRG\,70\/>*O'.A^#?#^K>'O!S>'?"W
MAF2Q\&P67@70Y;*PUJ3Q!K9O!=7.H>(-0,D*V_T)10!Y7\;?AA=_&;X7>+?A
MG8?%'XJ?!:\\4VUA;V_Q0^"6O:)X9^*/A*2PUC3M7%YX2UOQ'X;\8:'97-W_
M &>=+OQJ?AK5[6ZT>^U&R>V!N%ECZGP+X)\._#?P=X;\!^$K6[M/#GA32+/1
M=)CU+6-9\1ZO+;6<0C-[KGB7Q'?ZMXD\4>(-2E\S4-?\4>)=6U;Q'XDUFZOM
M<U_5=2U>_O;V?JZ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-3\7^./$.B^#_"NCMK6K:=X?T2TO==UV[T_2;!]7UW4M)T/2;::ZB?4=7O\
M3M+LDFO;NU@D\B'[8W[)J>'?&'BR[_:4^!ND>'/AUKWA7PM\1]5U[XH>#?#U
MM\-O%'CNYMK3P1X9^(XUS6-/E\ >(_&5[>V-GX5T/Q?'HNJ^(KR_L+72+2\G
MOK2.;XC_ ."C5OK'A/\ :5_X)A_M#^.Y6'[(?[._[07QH\2_M$WTVB:GK^A?
M#/Q?XY_9I^(_PW_9]^/7CN#2]'U8:!\._AMXM\3>(_#?B7XB:Q]A\*_"NY^)
M.C?$CQAJWA[PKX7UCQ9X<\4_X*F?%'X!_%K]B;XC?%?X'>-?A]XEU#6?C_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHR,XSSUQWP<X/XX/Y&B@ HHR!C) R<#W."<
M#U. 3] 3VHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ;IO@_\ :1UNV\+_  *\>_$KX"_M#_!?X<?$[Q?J-QJ5IH/@GPO\1OC'\*?
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M^TO_ .)H_MB__/WKZ7HH ^:/^&3?A;_T-7[2_P#XFC^V+_\ /WH_X9-^%O\
MT-7[2_\ XFC^V+_\_>OI>B@#YH_X9-^%O_0U?M+_ /B:/[8O_P _>O4_AY\+
M_#7PPM-3L_#>I_$34H=6N8;NZ?XA_%[XL_%V[BEMX3!&FF7_ ,5_&OC6^T6V
M9"6GLM'N+"SN9L7%Q!+.!*/1** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
*BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>naov-20230930.xsd
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaeDebP9z5Z86ekhvWB/bTkaLyoo6+7MCS7bJLlGoWkF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:NAOV="http://nanovibronix.com/20230930" elementFormDefault="qualified" targetNamespace="http://nanovibronix.com/20230930">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://nanovibronix.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
          <link:definition>00000002 - Statement -  Condensed Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
          <link:definition>00000003 - Statement -  Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
          <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/StatementOfStockholdersEquity" id="StatementOfStockholdersEquity">
          <link:definition>00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/DescriptionOfBusiness" id="DescriptionOfBusiness">
          <link:definition>00000007 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertainties" id="GoingConcernLiquidityAndOtherUncertainties">
          <link:definition>00000008 - Disclosure - GOING CONCERN, LIQUIDITY AND OTHER UNCERTAINTIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>00000010 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/LossPerShareApplicableToCommonStockholder" id="LossPerShareApplicableToCommonStockholder">
          <link:definition>00000011 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDER</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerData" id="GeographicInformationAndMajorCustomerData">
          <link:definition>00000012 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/Leases" id="Leases">
          <link:definition>00000013 - Disclosure - LEASES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/OtherAssets" id="OtherAssets">
          <link:definition>00000014 - Disclosure - OTHER ASSETS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/RelatedPartyTransaction" id="RelatedPartyTransaction">
          <link:definition>00000016 - Disclosure - RELATED PARTY TRANSACTION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>00000017 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
          <link:definition>00000019 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/LossPerShareApplicableToCommonStockholderTables" id="LossPerShareApplicableToCommonStockholderTables">
          <link:definition>00000020 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDER (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataTables" id="GeographicInformationAndMajorCustomerDataTables">
          <link:definition>00000021 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/LeasesTables" id="LeasesTables">
          <link:definition>00000022 - Disclosure - LEASES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/OtherAssetsTables" id="OtherAssetsTables">
          <link:definition>00000023 - Disclosure - OTHER ASSETS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertaintiesDetailsNarrative" id="GoingConcernLiquidityAndOtherUncertaintiesDetailsNarrative">
          <link:definition>00000024 - Disclosure - GOING CONCERN, LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails" id="ScheduleOfOptionsActivityDetails">
          <link:definition>00000026 - Disclosure - SCHEDULE OF OPTIONS ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails" id="ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails">
          <link:definition>00000027 - Disclosure - SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails" id="ScheduleOfWarrantsActivityDetails">
          <link:definition>00000028 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>00000029 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails" id="SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails">
          <link:definition>00000030 - Disclosure - SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails" id="SummaryOfRevenueWithinGeographicAreasDetails">
          <link:definition>00000031 - Disclosure - SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative" id="GeographicInformationAndMajorCustomerDataDetailsNarrative">
          <link:definition>00000032 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails" id="ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails">
          <link:definition>00000033 - Disclosure - SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>00000034 - Disclosure - LEASES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails" id="ScheduleOfWarrantsAssumptionsDetails">
          <link:definition>00000035 - Disclosure - SCHEDULE OF WARRANTS ASSUMPTIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" id="ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails">
          <link:definition>00000036 - Disclosure - SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilityMeasuredAtFairValueDetails" id="ScheduleOfAssetsAndLiabilityMeasuredAtFairValueDetails">
          <link:definition>00000037 - Disclosure - SCHEDULE OF ASSETS AND LIABILITY MEASURED AT FAIR VALUE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/OtherAssetsDetailsNarrative" id="OtherAssetsDetailsNarrative">
          <link:definition>00000038 - Disclosure - OTHER ASSETS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>00000039 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/RelatedPartyTransactionDetailsNarrative" id="RelatedPartyTransactionDetailsNarrative">
          <link:definition>00000040 - Disclosure - RELATED PARTY TRANSACTION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://nanovibronix.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>00000041 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="naov-20230930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="naov-20230930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="naov-20230930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="naov-20230930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="NAOV_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_A1WarrantsMember" name="A1WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_A2WarrantsMember" name="A2WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_WainwrightMember" name="WainwrightMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_EmployeeOptionsMember" name="EmployeeOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_PrivateInvestorsMember" name="PrivateInvestorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_StockOptionsEmployeeAndNonEmployeeMember" name="StockOptionsEmployeeAndNonEmployeeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_OtherCountryMember" name="OtherCountryMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_TwoCustomersMember" name="TwoCustomersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_CustomersOneMember" name="CustomersOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_CustomersTwoMember" name="CustomersTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_LicensingAgreementMember" name="LicensingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_SanuwaveHealthIncMember" name="SanuwaveHealthIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_PriceAtValuationMember" name="PriceAtValuationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_DerivativeAssetMember" name="DerivativeAssetMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_ArbitratorMember" name="ArbitratorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_PrefundedWarrantMember" name="PrefundedWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_SeveranceAssetsNoncurent" name="SeveranceAssetsNoncurent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_FinancialExpensesNet" name="FinancialExpensesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants" name="AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_NoncashInterestExpense" name="NoncashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_IncreaseDecreaseInAccruedSeverancePayNet" name="IncreaseDecreaseInAccruedSeverancePayNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_DisclosureGoingConcernLiquidityAndOtherUncertaintiesAbstract" name="DisclosureGoingConcernLiquidityAndOtherUncertaintiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_GoingConcernAndLiquidityTextBlock" name="GoingConcernAndLiquidityTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_ScheduleOfWarrantsAssumptionsTableTextBlock" name="ScheduleOfWarrantsAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_ValueOfListedSecurites" name="ValueOfListedSecurites" nillable="true" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_StockIssuedDuringPeriodSharesStockOptionsExpired" name="StockIssuedDuringPeriodSharesStockOptionsExpired" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>naov-20230930_cal.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://nanovibronix.com/role/Cover" xlink:href="naov-20230930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets" xlink:href="naov-20230930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="naov-20230930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="naov-20230930.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StatementOfStockholdersEquity" xlink:href="naov-20230930.xsd#StatementOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StatementsOfCashFlows" xlink:href="naov-20230930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/DescriptionOfBusiness" xlink:href="naov-20230930.xsd#DescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertainties" xlink:href="naov-20230930.xsd#GoingConcernLiquidityAndOtherUncertainties" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="naov-20230930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StockholdersEquity" xlink:href="naov-20230930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LossPerShareApplicableToCommonStockholder" xlink:href="naov-20230930.xsd#LossPerShareApplicableToCommonStockholder" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerData" xlink:href="naov-20230930.xsd#GeographicInformationAndMajorCustomerData" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/Leases" xlink:href="naov-20230930.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/OtherAssets" xlink:href="naov-20230930.xsd#OtherAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/CommitmentsAndContingencies" xlink:href="naov-20230930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/RelatedPartyTransaction" xlink:href="naov-20230930.xsd#RelatedPartyTransaction" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SubsequentEvents" xlink:href="naov-20230930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="naov-20230930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StockholdersEquityTables" xlink:href="naov-20230930.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LossPerShareApplicableToCommonStockholderTables" xlink:href="naov-20230930.xsd#LossPerShareApplicableToCommonStockholderTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataTables" xlink:href="naov-20230930.xsd#GeographicInformationAndMajorCustomerDataTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LeasesTables" xlink:href="naov-20230930.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/OtherAssetsTables" xlink:href="naov-20230930.xsd#OtherAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertaintiesDetailsNarrative" xlink:href="naov-20230930.xsd#GoingConcernLiquidityAndOtherUncertaintiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="naov-20230930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails" xlink:href="naov-20230930.xsd#ScheduleOfOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails" xlink:href="naov-20230930.xsd#ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="naov-20230930.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" xlink:href="naov-20230930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails" xlink:href="naov-20230930.xsd#SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails" xlink:href="naov-20230930.xsd#SummaryOfRevenueWithinGeographicAreasDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative" xlink:href="naov-20230930.xsd#GeographicInformationAndMajorCustomerDataDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails" xlink:href="naov-20230930.xsd#ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LeasesDetailsNarrative" xlink:href="naov-20230930.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails" xlink:href="naov-20230930.xsd#ScheduleOfWarrantsAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" xlink:href="naov-20230930.xsd#ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilityMeasuredAtFairValueDetails" xlink:href="naov-20230930.xsd#ScheduleOfAssetsAndLiabilityMeasuredAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/OtherAssetsDetailsNarrative" xlink:href="naov-20230930.xsd#OtherAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="naov-20230930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/RelatedPartyTransactionDetailsNarrative" xlink:href="naov-20230930.xsd#RelatedPartyTransactionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SubsequentEventsDetailsNarrative" xlink:href="naov-20230930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement -  Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_SeveranceAssetsNoncurent" xlink:label="loc_NAOVSeveranceAssetsNoncurent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_NAOVSeveranceAssetsNoncurent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherAccruedLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="loc_us-gaapDeferredIncomeNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredIncomeNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement -  Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_FinancialExpensesNet" xlink:label="loc_NAOVFinancialExpensesNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_NAOVFinancialExpensesNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StatementOfStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statement of Stockholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_NoncashInterestExpense" xlink:label="loc_NAOVNoncashInterestExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NAOVNoncashInterestExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaapEquitySecuritiesFvNiGainLoss" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapEquitySecuritiesFvNiGainLoss" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_IncreaseDecreaseInAccruedSeverancePayNet" xlink:label="loc_NAOVIncreaseDecreaseInAccruedSeverancePayNet" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NAOVIncreaseDecreaseInAccruedSeverancePayNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/DescriptionOfBusiness" xlink:title="00000007 - Disclosure - DESCRIPTION OF BUSINESS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertainties" xlink:title="00000008 - Disclosure - GOING CONCERN, LIQUIDITY AND OTHER UNCERTAINTIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StockholdersEquity" xlink:title="00000010 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LossPerShareApplicableToCommonStockholder" xlink:title="00000011 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDER" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerData" xlink:title="00000012 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/Leases" xlink:title="00000013 - Disclosure - LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/OtherAssets" xlink:title="00000014 - Disclosure - OTHER ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/CommitmentsAndContingencies" xlink:title="00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/RelatedPartyTransaction" xlink:title="00000016 - Disclosure - RELATED PARTY TRANSACTION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SubsequentEvents" xlink:title="00000017 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StockholdersEquityTables" xlink:title="00000019 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LossPerShareApplicableToCommonStockholderTables" xlink:title="00000020 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDER (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataTables" xlink:title="00000021 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LeasesTables" xlink:title="00000022 - Disclosure - LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/OtherAssetsTables" xlink:title="00000023 - Disclosure - OTHER ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertaintiesDetailsNarrative" xlink:title="00000024 - Disclosure - GOING CONCERN, LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails" xlink:title="00000026 - Disclosure - SCHEDULE OF OPTIONS ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails" xlink:title="00000027 - Disclosure - SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000028 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000029 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails" xlink:title="00000030 - Disclosure - SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails" xlink:title="00000031 - Disclosure - SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative" xlink:title="00000032 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails" xlink:title="00000033 - Disclosure - SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LeasesDetailsNarrative" xlink:title="00000034 - Disclosure - LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails" xlink:title="00000035 - Disclosure - SCHEDULE OF WARRANTS ASSUMPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilityMeasuredAtFairValueDetails" xlink:title="00000037 - Disclosure - SCHEDULE OF ASSETS AND LIABILITY MEASURED AT FAIR VALUE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/OtherAssetsDetailsNarrative" xlink:title="00000038 - Disclosure - OTHER ASSETS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000039 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/RelatedPartyTransactionDetailsNarrative" xlink:title="00000040 - Disclosure - RELATED PARTY TRANSACTION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000041 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>naov-20230930_def.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://nanovibronix.com/role/Cover" xlink:href="naov-20230930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets" xlink:href="naov-20230930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="naov-20230930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="naov-20230930.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StatementOfStockholdersEquity" xlink:href="naov-20230930.xsd#StatementOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StatementsOfCashFlows" xlink:href="naov-20230930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/DescriptionOfBusiness" xlink:href="naov-20230930.xsd#DescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertainties" xlink:href="naov-20230930.xsd#GoingConcernLiquidityAndOtherUncertainties" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="naov-20230930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StockholdersEquity" xlink:href="naov-20230930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LossPerShareApplicableToCommonStockholder" xlink:href="naov-20230930.xsd#LossPerShareApplicableToCommonStockholder" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerData" xlink:href="naov-20230930.xsd#GeographicInformationAndMajorCustomerData" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/Leases" xlink:href="naov-20230930.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/OtherAssets" xlink:href="naov-20230930.xsd#OtherAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/CommitmentsAndContingencies" xlink:href="naov-20230930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/RelatedPartyTransaction" xlink:href="naov-20230930.xsd#RelatedPartyTransaction" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SubsequentEvents" xlink:href="naov-20230930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="naov-20230930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StockholdersEquityTables" xlink:href="naov-20230930.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LossPerShareApplicableToCommonStockholderTables" xlink:href="naov-20230930.xsd#LossPerShareApplicableToCommonStockholderTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataTables" xlink:href="naov-20230930.xsd#GeographicInformationAndMajorCustomerDataTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LeasesTables" xlink:href="naov-20230930.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/OtherAssetsTables" xlink:href="naov-20230930.xsd#OtherAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertaintiesDetailsNarrative" xlink:href="naov-20230930.xsd#GoingConcernLiquidityAndOtherUncertaintiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="naov-20230930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails" xlink:href="naov-20230930.xsd#ScheduleOfOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails" xlink:href="naov-20230930.xsd#ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="naov-20230930.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" xlink:href="naov-20230930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails" xlink:href="naov-20230930.xsd#SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails" xlink:href="naov-20230930.xsd#SummaryOfRevenueWithinGeographicAreasDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative" xlink:href="naov-20230930.xsd#GeographicInformationAndMajorCustomerDataDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails" xlink:href="naov-20230930.xsd#ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LeasesDetailsNarrative" xlink:href="naov-20230930.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails" xlink:href="naov-20230930.xsd#ScheduleOfWarrantsAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" xlink:href="naov-20230930.xsd#ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilityMeasuredAtFairValueDetails" xlink:href="naov-20230930.xsd#ScheduleOfAssetsAndLiabilityMeasuredAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/OtherAssetsDetailsNarrative" xlink:href="naov-20230930.xsd#OtherAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="naov-20230930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/RelatedPartyTransactionDetailsNarrative" xlink:href="naov-20230930.xsd#RelatedPartyTransactionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SubsequentEventsDetailsNarrative" xlink:href="naov-20230930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement -  Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesDPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaapSeriesEPreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesEPreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaapSeriesFPreferredStockMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesFPreferredStockMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_110" xlink:to="loc_us-gaapAssetsCurrentAbstract_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_110" xlink:to="loc_us-gaapCash_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_110" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_110" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_110" xlink:to="loc_us-gaapInventoryNet_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_110" xlink:to="loc_us-gaapAssetsCurrent_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_110" xlink:to="loc_us-gaapAssetsNoncurrentAbstract_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_110" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_110" xlink:to="loc_us-gaapOtherAssetsNoncurrent_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_SeveranceAssetsNoncurent" xlink:label="loc_NAOVSeveranceAssetsNoncurent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_110" xlink:to="loc_NAOVSeveranceAssetsNoncurent_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_110" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsNoncurrentAbstract_110" xlink:to="loc_us-gaapAssetsNoncurrent_110" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_110" xlink:to="loc_us-gaapAssets_110" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_110" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_110" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_110" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_110" xlink:to="loc_us-gaapAccountsPayableCurrent_110" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_110" xlink:to="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities_110" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_110" xlink:to="loc_us-gaapDeferredRevenue_110" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_110" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_110" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_110" xlink:to="loc_us-gaapLiabilitiesCurrent_110" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_110" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract_110" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesNoncurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_110" xlink:to="loc_us-gaapOtherAccruedLiabilitiesNoncurrent_110" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="loc_us-gaapDeferredIncomeNoncurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_110" xlink:to="loc_us-gaapDeferredIncomeNoncurrent_110" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_110" xlink:to="loc_us-gaapLiabilities_110" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_110" xlink:to="loc_us-gaapCommitmentsAndContingencies_110" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_110" xlink:to="loc_us-gaapStockholdersEquityAbstract_110" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_110" xlink:to="loc_us-gaapPreferredStockValue_110" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_110" xlink:to="loc_us-gaapCommonStockValue_110" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_110" xlink:to="loc_us-gaapAdditionalPaidInCapital_110" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_110" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_110" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_110" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_110" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_110" xlink:to="loc_us-gaapStockholdersEquity_110" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_110" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_110" xlink:type="arc" order="33" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement -  Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesDPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaapSeriesEPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesEPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaapSeriesFPreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesFPreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_110" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StatementOfStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statement of Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesDPreferredStockMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaapSeriesEPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesEPreferredStockMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaapSeriesFPreferredStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesFPreferredStockMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants" xlink:label="loc_NAOVAdjustmentsToAdditionalPaidInCapitalReversalOfWarrants_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NAOVAdjustmentsToAdditionalPaidInCapitalReversalOfWarrants_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_100" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/DescriptionOfBusiness" xlink:title="00000007 - Disclosure - DESCRIPTION OF BUSINESS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertainties" xlink:title="00000008 - Disclosure - GOING CONCERN, LIQUIDITY AND OTHER UNCERTAINTIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StockholdersEquity" xlink:title="00000010 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LossPerShareApplicableToCommonStockholder" xlink:title="00000011 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDER" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerData" xlink:title="00000012 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/Leases" xlink:title="00000013 - Disclosure - LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/OtherAssets" xlink:title="00000014 - Disclosure - OTHER ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/CommitmentsAndContingencies" xlink:title="00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/RelatedPartyTransaction" xlink:title="00000016 - Disclosure - RELATED PARTY TRANSACTION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SubsequentEvents" xlink:title="00000017 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StockholdersEquityTables" xlink:title="00000019 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LossPerShareApplicableToCommonStockholderTables" xlink:title="00000020 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDER (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataTables" xlink:title="00000021 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LeasesTables" xlink:title="00000022 - Disclosure - LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/OtherAssetsTables" xlink:title="00000023 - Disclosure - OTHER ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertaintiesDetailsNarrative" xlink:title="00000024 - Disclosure - GOING CONCERN, LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_ValueOfListedSecurites" xlink:label="loc_NAOVValueOfListedSecurites_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NAOVValueOfListedSecurites_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInventoryNet_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails" xlink:title="00000026 - Disclosure - SCHEDULE OF OPTIONS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_EmployeeOptionsMember" xlink:label="loc_NAOVEmployeeOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVEmployeeOptionsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:label="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_150" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_150" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_150" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_150" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_StockIssuedDuringPeriodSharesStockOptionsExpired" xlink:label="loc_NAOVStockIssuedDuringPeriodSharesStockOptionsExpired_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NAOVStockIssuedDuringPeriodSharesStockOptionsExpired_150" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_150" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm" xlink:label="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm_150" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xlink:label="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_150" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails" xlink:title="00000027 - Disclosure - SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaapSellingAndMarketingExpenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingAndMarketingExpenseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_170" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000028 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_PrivateInvestorsMember" xlink:label="loc_NAOVPrivateInvestorsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_NAOVPrivateInvestorsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000029 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_PurchaseAgreementMember" xlink:label="loc_NAOVPurchaseAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NAOVPurchaseAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_A1WarrantsMember" xlink:label="loc_NAOVA1WarrantsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVA1WarrantsMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_A2WarrantsMember" xlink:label="loc_NAOVA2WarrantsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVA2WarrantsMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_EmployeeOptionsMember" xlink:label="loc_NAOVEmployeeOptionsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVEmployeeOptionsMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_WainwrightMember" xlink:label="loc_NAOVWainwrightMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_NAOVWainwrightMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_280" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_280" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_280" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_280" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_280" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_280" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="loc_us-gaapWarrantExercisePriceIncrease_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantExercisePriceIncrease_280" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_280" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_280" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_280" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice_280" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_280" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_280" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_280" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_280" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_280" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_280" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_280" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_280" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails" xlink:title="00000030 - Disclosure - SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_StockOptionsEmployeeAndNonEmployeeMember" xlink:label="loc_NAOVStockOptionsEmployeeAndNonEmployeeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_NAOVStockOptionsEmployeeAndNonEmployeeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails" xlink:title="00000031 - Disclosure - SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_countryUS_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AU" xlink:label="loc_countryAU_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryAU_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="loc_srtEuropeMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtEuropeMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AsiaMember" xlink:label="loc_srtAsiaMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtAsiaMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_OtherCountryMember" xlink:label="loc_NAOVOtherCountryMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_NAOVOtherCountryMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_250" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative" xlink:title="00000032 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaapEntityWideRevenueMajorCustomerLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaapScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEntityWideRevenueMajorCustomerLineItems" xlink:to="loc_us-gaapScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_TwoCustomersMember" xlink:label="loc_NAOVTwoCustomersMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NAOVTwoCustomersMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_CustomersOneMember" xlink:label="loc_NAOVCustomersOneMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NAOVCustomersOneMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_CustomersTwoMember" xlink:label="loc_NAOVCustomersTwoMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NAOVCustomersTwoMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEntityWideRevenueMajorCustomerLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails" xlink:title="00000033 - Disclosure - SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LeasesDetailsNarrative" xlink:title="00000034 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_60" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails" xlink:title="00000035 - Disclosure - SCHEDULE OF WARRANTS ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_PriceAtValuationMember" xlink:label="loc_NAOVPriceAtValuationMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_NAOVPriceAtValuationMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_SanuwaveHealthIncMember" xlink:label="loc_NAOVSanuwaveHealthIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_NAOVSanuwaveHealthIncMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_110" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_DerivativeAssetMember" xlink:label="loc_NAOVDerivativeAssetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_NAOVDerivativeAssetMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_150" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilityMeasuredAtFairValueDetails" xlink:title="00000037 - Disclosure - SCHEDULE OF ASSETS AND LIABILITY MEASURED AT FAIR VALUE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapOtherAssetsNoncurrent_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/OtherAssetsDetailsNarrative" xlink:title="00000038 - Disclosure - OTHER ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_LicensingAgreementMember" xlink:label="loc_NAOVLicensingAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NAOVLicensingAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_SanuwaveHealthIncMember" xlink:label="loc_NAOVSanuwaveHealthIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_NAOVSanuwaveHealthIncMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000039 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_ArbitratorMember" xlink:label="loc_NAOVArbitratorMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_NAOVArbitratorMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaapLossContingencyDamagesSoughtValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapLossContingencyDamagesSoughtValue_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaapLossContingencyDamagesAwardedValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapLossContingencyDamagesAwardedValue_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="loc_us-gaapLossContingencyDamagesPaidValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapLossContingencyDamagesPaidValue_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/RelatedPartyTransactionDetailsNarrative" xlink:title="00000040 - Disclosure - RELATED PARTY TRANSACTION (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000041 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_PrefundedWarrantMember" xlink:label="loc_NAOVPrefundedWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVPrefundedWarrantMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_SecuritiesPurchaseAgreementMember" xlink:label="loc_NAOVSecuritiesPurchaseAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NAOVSecuritiesPurchaseAgreementMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_30" xlink:type="arc" order="2" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>naov-20230930_lab.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xml:lang="en-US">Series D Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesEPreferredStockMember" xlink:to="us-gaap_SeriesEPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesEPreferredStockMember_lbl" xml:lang="en-US">Series E Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="us-gaap_SeriesFPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesFPreferredStockMember" xlink:to="us-gaap_SeriesFPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesFPreferredStockMember_lbl" xml:lang="en-US">Series F Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_PurchaseAgreementMember" xlink:label="NAOV_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_PurchaseAgreementMember" xlink:to="NAOV_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_A1WarrantsMember" xlink:label="NAOV_A1WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_A1WarrantsMember" xlink:to="NAOV_A1WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_A1WarrantsMember_lbl" xml:lang="en-US">A-1 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_A2WarrantsMember" xlink:label="NAOV_A2WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_A2WarrantsMember" xlink:to="NAOV_A2WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_A2WarrantsMember_lbl" xml:lang="en-US">A-2 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_WainwrightMember" xlink:label="NAOV_WainwrightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_WainwrightMember" xlink:to="NAOV_WainwrightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_WainwrightMember_lbl" xml:lang="en-US">Wainwright [Membe</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_EmployeeOptionsMember" xlink:label="NAOV_EmployeeOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_EmployeeOptionsMember" xlink:to="NAOV_EmployeeOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_EmployeeOptionsMember_lbl" xml:lang="en-US">Employee Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xml:lang="en-US">Selling and Marketing Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_PrivateInvestorsMember" xlink:label="NAOV_PrivateInvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_PrivateInvestorsMember" xlink:to="NAOV_PrivateInvestorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_PrivateInvestorsMember_lbl" xml:lang="en-US">Private Investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_StockOptionsEmployeeAndNonEmployeeMember" xlink:label="NAOV_StockOptionsEmployeeAndNonEmployeeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_StockOptionsEmployeeAndNonEmployeeMember" xlink:to="NAOV_StockOptionsEmployeeAndNonEmployeeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_StockOptionsEmployeeAndNonEmployeeMember_lbl" xml:lang="en-US">Stock Options Employee And Non Employee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AU" xlink:label="country_AU" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_AU" xlink:to="country_AU_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_AU_lbl" xml:lang="en-US">AUSTRALIA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EuropeMember_lbl" xml:lang="en-US">Europe [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AsiaMember" xlink:label="srt_AsiaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AsiaMember" xlink:to="srt_AsiaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_AsiaMember_lbl" xml:lang="en-US">Asia [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_OtherCountryMember" xlink:label="NAOV_OtherCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_OtherCountryMember" xlink:to="NAOV_OtherCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_OtherCountryMember_lbl" xml:lang="en-US">Other Country [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_TwoCustomersMember" xlink:label="NAOV_TwoCustomersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_TwoCustomersMember" xlink:to="NAOV_TwoCustomersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_TwoCustomersMember_lbl" xml:lang="en-US">Two Customers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_CustomersOneMember" xlink:label="NAOV_CustomersOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_CustomersOneMember" xlink:to="NAOV_CustomersOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_CustomersOneMember_lbl" xml:lang="en-US">Customers One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_CustomersTwoMember" xlink:label="NAOV_CustomersTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_CustomersTwoMember" xlink:to="NAOV_CustomersTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_CustomersTwoMember_lbl" xml:lang="en-US">Customers Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_LicensingAgreementMember" xlink:label="NAOV_LicensingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_LicensingAgreementMember" xlink:to="NAOV_LicensingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_LicensingAgreementMember_lbl" xml:lang="en-US">Licensing Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_SanuwaveHealthIncMember" xlink:label="NAOV_SanuwaveHealthIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SanuwaveHealthIncMember" xlink:to="NAOV_SanuwaveHealthIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_SanuwaveHealthIncMember_lbl" xml:lang="en-US">Sanuwave Health, Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_PriceAtValuationMember" xlink:label="NAOV_PriceAtValuationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_PriceAtValuationMember" xlink:to="NAOV_PriceAtValuationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_PriceAtValuationMember_lbl" xml:lang="en-US">Price at Valuation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US">Measurement Input, Exercise Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_DerivativeAssetMember" xlink:label="NAOV_DerivativeAssetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_DerivativeAssetMember" xlink:to="NAOV_DerivativeAssetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_DerivativeAssetMember_lbl" xml:lang="en-US">Derivative Asset [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_ArbitratorMember" xlink:label="NAOV_ArbitratorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_ArbitratorMember" xlink:to="NAOV_ArbitratorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_ArbitratorMember_lbl" xml:lang="en-US">Arbitrator [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_PrefundedWarrantMember" xlink:label="NAOV_PrefundedWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_PrefundedWarrantMember" xlink:to="NAOV_PrefundedWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_PrefundedWarrantMember_lbl" xml:lang="en-US">Prefunded Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_SecuritiesPurchaseAgreementMember" xlink:label="NAOV_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SecuritiesPurchaseAgreementMember" xlink:to="NAOV_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity address, address line one</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity ddress, city or town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity address, state or province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Trade receivables, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Noncurrent assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Fixed assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_SeveranceAssetsNoncurent" xlink:label="NAOV_SeveranceAssetsNoncurent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SeveranceAssetsNoncurent" xlink:to="NAOV_SeveranceAssetsNoncurent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_SeveranceAssetsNoncurent_lbl" xml:lang="en-US">Severance pay fund</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total non-current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Trade payables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other payables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">Accrued severance pay</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeNoncurrent" xlink:to="us-gaap_DeferredIncomeNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeNoncurrent_lbl" xml:lang="en-US">Deferred licensing income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock of $0.001 par value - Authorized: 40,000,000 shares at September 30, 2023 and December 31, 2022, respectively; Issued and outstanding: 1,842,331 and 1,641,146 shares at September 30, 2023 and December 31, 2022, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Selling and marketing</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_FinancialExpensesNet" xlink:label="NAOV_FinancialExpensesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_FinancialExpensesNet" xlink:to="NAOV_FinancialExpensesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_FinancialExpensesNet_lbl" xml:lang="en-US">Financial expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before taxes on income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic net loss available for holders of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted net loss available for holders of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding, Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding, Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Comprehensive loss:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss available to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl" xml:lang="en-US">Change in foreign currency translation adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss available to common stockholders</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants" xlink:label="NAOV_AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants" xlink:to="NAOV_AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants_lbl" xml:lang="en-US">Reversal of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_lbl" xml:lang="en-US">Currency translation adjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Rounding up of fractional shares due to stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Rounding up of fractional shares due to stock split, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_NoncashInterestExpense" xlink:label="NAOV_NoncashInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_NoncashInterestExpense" xlink:to="NAOV_NoncashInterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_NoncashInterestExpense_lbl" xml:lang="en-US">Noncash interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss_lbl" xml:lang="en-US">Change in fair value of equity investment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Trade receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Trade payables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Other accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_IncreaseDecreaseInAccruedSeverancePayNet" xlink:label="NAOV_IncreaseDecreaseInAccruedSeverancePayNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_IncreaseDecreaseInAccruedSeverancePayNet" xlink:to="NAOV_IncreaseDecreaseInAccruedSeverancePayNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_IncreaseDecreaseInAccruedSeverancePayNet_lbl" xml:lang="en-US">Accrued severance pay, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effects of currency translation on cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">DESCRIPTION OF BUSINESS</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_DisclosureGoingConcernLiquidityAndOtherUncertaintiesAbstract" xlink:label="NAOV_DisclosureGoingConcernLiquidityAndOtherUncertaintiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_DisclosureGoingConcernLiquidityAndOtherUncertaintiesAbstract" xlink:to="NAOV_DisclosureGoingConcernLiquidityAndOtherUncertaintiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_DisclosureGoingConcernLiquidityAndOtherUncertaintiesAbstract_lbl" xml:lang="en-US">Going Concern Liquidity And Other Uncertainties</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_GoingConcernAndLiquidityTextBlock" xlink:label="NAOV_GoingConcernAndLiquidityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_GoingConcernAndLiquidityTextBlock" xlink:to="NAOV_GoingConcernAndLiquidityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_GoingConcernAndLiquidityTextBlock_lbl" xml:lang="en-US">GOING CONCERN, LIQUIDITY AND OTHER UNCERTAINTIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDER</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_DisclosureLeasesAbstract" xlink:label="NAOV_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_DisclosureLeasesAbstract" xlink:to="NAOV_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="us-gaap_OtherAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">OTHER ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation and principles of consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign currency translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently adopted accounting standards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OPTIONS ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WARRANTS ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xml:lang="en-US">SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_ScheduleOfWarrantsAssumptionsTableTextBlock" xlink:label="NAOV_ScheduleOfWarrantsAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_ScheduleOfWarrantsAssumptionsTableTextBlock" xlink:to="NAOV_ScheduleOfWarrantsAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_ScheduleOfWarrantsAssumptionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WARRANTS ASSUMPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ASSETS AND LIABILITY MEASURED AT FAIR VALUE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from issuance sale of equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholder's equity</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_ValueOfListedSecurites" xlink:label="NAOV_ValueOfListedSecurites" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_ValueOfListedSecurites" xlink:to="NAOV_ValueOfListedSecurites_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_ValueOfListedSecurites_lbl" xml:lang="en-US">Value of listed securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net income from continuing operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">Inventory, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_lbl" xml:lang="en-US">Gains and losses from foreign currency translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Shares Under Options Outstanding, Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price per Share, Outstanding Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Life (Years), Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Shares Under Options, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price per Share, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:label="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:to="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Life (Years), Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Shares Under Options, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price per Share, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Life (Years), Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Shares Under Options Outstanding, Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price per Share, Outstanding Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_StockIssuedDuringPeriodSharesStockOptionsExpired" xlink:label="NAOV_StockIssuedDuringPeriodSharesStockOptionsExpired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_StockIssuedDuringPeriodSharesStockOptionsExpired" xlink:to="NAOV_StockIssuedDuringPeriodSharesStockOptionsExpired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_StockIssuedDuringPeriodSharesStockOptionsExpired_lbl" xml:lang="en-US">Shares Under Options, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price per Share, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm" xlink:label="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm" xlink:to="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Life (Years), Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xlink:label="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xlink:to="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Life (Years), Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Warrants, Outstanding, Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Warrants, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Warrants, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xml:lang="en-US">Warrants, Canceled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Warrants, Outstanding, Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Fractional shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of new share issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of securities called by warrants or rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of warrant or right exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="us-gaap_WarrantExercisePriceIncrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl" xml:lang="en-US">Warrant exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US">Class of warrant or right expire date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares issued, price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from issuance of private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xml:lang="en-US">Number of employee options expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Number of employee options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of employee options expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Non-vested stock options granted, unrecognized estimated compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Non-vested stock options granted, weighted average period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xml:lang="en-US">Warrants, granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_2_lbl" xml:lang="en-US">Warrants, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Dilutive loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xml:lang="en-US">Revenues geographic areas</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_lbl" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_EntityWideRevenueMajorCustomerLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems_lbl" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk, percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_DisclosureLeasesAbstract" xlink:to="NAOV_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NAOV_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Liabilities Arising From Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted operating lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US">Lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease, expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrants and rights outstanding, measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Expected term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsTable" xlink:label="us-gaap_OffsettingAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="us-gaap_OffsettingAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsTable_lbl" xml:lang="en-US">Offsetting Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="us-gaap_OffsettingAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsLineItems" xlink:to="us-gaap_OffsettingAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsLineItems_lbl" xml:lang="en-US">Offsetting Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_lbl" xml:lang="en-US">Balance beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value adjustments - Sanuwave warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_2_lbl" xml:lang="en-US">Balance ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="srt_PlatformOperatorCryptoAssetTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="srt_PlatformOperatorCryptoAssetTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetTable_lbl" xml:lang="en-US">Platform Operator, Crypto-Asset [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="srt_PlatformOperatorCryptoAssetLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetLineItems" xlink:to="srt_PlatformOperatorCryptoAssetLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetLineItems_lbl" xml:lang="en-US">Platform Operator, Crypto-Asset [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xml:lang="en-US">Warrants and rights outstanding term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Warrants issued to purchase common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Exercise price of warrants per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants leaving balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesSoughtValue" xlink:to="us-gaap_LossContingencyDamagesSoughtValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_lbl" xml:lang="en-US">Loss contingency damages sought value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="us-gaap_LossContingencyDamagesAwardedValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesAwardedValue" xlink:to="us-gaap_LossContingencyDamagesAwardedValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesAwardedValue_lbl" xml:lang="en-US">Damages awarded value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="us-gaap_LossContingencyDamagesPaidValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesPaidValue" xlink:to="us-gaap_LossContingencyDamagesPaidValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesPaidValue_lbl" xml:lang="en-US">Loss contingency damages paid value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal fees paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xml:lang="en-US">Exercised warrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Warrant price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Purchase warrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SeveranceAssetsNoncurent" xlink:to="NAOV_SeveranceAssetsNoncurent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_SeveranceAssetsNoncurent_doc" xml:lang="en-US">Severance assets, noncurrent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_FinancialExpensesNet" xlink:to="NAOV_FinancialExpensesNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_FinancialExpensesNet_doc" xml:lang="en-US">Financial expenses net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_NoncashInterestExpense" xlink:to="NAOV_NoncashInterestExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_NoncashInterestExpense_doc" xml:lang="en-US">Non cash interest expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_IncreaseDecreaseInAccruedSeverancePayNet" xlink:to="NAOV_IncreaseDecreaseInAccruedSeverancePayNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_IncreaseDecreaseInAccruedSeverancePayNet_doc" xml:lang="en-US">Increase decrease in accrued severance pay net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_GoingConcernAndLiquidityTextBlock" xlink:to="NAOV_GoingConcernAndLiquidityTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_GoingConcernAndLiquidityTextBlock_doc" xml:lang="en-US">Going Concern And Liquidity [TextBlock]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_ValueOfListedSecurites" xlink:to="NAOV_ValueOfListedSecurites_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_ValueOfListedSecurites_doc" xml:lang="en-US">Value of listed securites.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_EmployeeOptionsMember" xlink:to="NAOV_EmployeeOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_EmployeeOptionsMember_doc" xml:lang="en-US">Employee Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_PurchaseAgreementMember" xlink:to="NAOV_PurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_PurchaseAgreementMember_doc" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_A1WarrantsMember" xlink:to="NAOV_A1WarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_A1WarrantsMember_doc" xml:lang="en-US">A1 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_A2WarrantsMember" xlink:to="NAOV_A2WarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_A2WarrantsMember_doc" xml:lang="en-US">A2 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_WainwrightMember" xlink:to="NAOV_WainwrightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_WainwrightMember_doc" xml:lang="en-US">Wainwright [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_StockIssuedDuringPeriodSharesStockOptionsExpired" xlink:to="NAOV_StockIssuedDuringPeriodSharesStockOptionsExpired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_StockIssuedDuringPeriodSharesStockOptionsExpired_doc" xml:lang="en-US">Stock issued during period shares stock options expired.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:to="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xlink:to="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Weighted average remaining contractual term for option awards exercised, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_PrivateInvestorsMember" xlink:to="NAOV_PrivateInvestorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_PrivateInvestorsMember_doc" xml:lang="en-US">Private Investors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_TwoCustomersMember" xlink:to="NAOV_TwoCustomersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_TwoCustomersMember_doc" xml:lang="en-US">Two Customers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_LicensingAgreementMember" xlink:to="NAOV_LicensingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_LicensingAgreementMember_doc" xml:lang="en-US">Licensing Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SanuwaveHealthIncMember" xlink:to="NAOV_SanuwaveHealthIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_SanuwaveHealthIncMember_doc" xml:lang="en-US">Sanuwave Health, Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_ScheduleOfWarrantsAssumptionsTableTextBlock" xlink:to="NAOV_ScheduleOfWarrantsAssumptionsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_ScheduleOfWarrantsAssumptionsTableTextBlock_doc" xml:lang="en-US">Schedule Of Warrants Assumptions [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_PriceAtValuationMember" xlink:to="NAOV_PriceAtValuationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_PriceAtValuationMember_doc" xml:lang="en-US">Price at Valuation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_CustomersOneMember" xlink:to="NAOV_CustomersOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_CustomersOneMember_doc" xml:lang="en-US">Customers One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_CustomersTwoMember" xlink:to="NAOV_CustomersTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_CustomersTwoMember_doc" xml:lang="en-US">Customers Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_DerivativeAssetMember" xlink:to="NAOV_DerivativeAssetMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_DerivativeAssetMember_doc" xml:lang="en-US">Derivative Asset [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_ArbitratorMember" xlink:to="NAOV_ArbitratorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_ArbitratorMember_doc" xml:lang="en-US">Arbitrator [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants" xlink:to="NAOV_AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants_doc" xml:lang="en-US">Reversal of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_OtherCountryMember" xlink:to="NAOV_OtherCountryMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NAOV_OtherCountryMember_doc" xml:lang="en-US">Other Country [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_2_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiGainLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss_2_lbl" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_3_lbl" xml:lang="en-US">Weighted Average Remaining Life (Years), Outstanding - ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_3_lbl" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>naov-20230930_pre.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://nanovibronix.com/role/Cover" xlink:href="naov-20230930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets" xlink:href="naov-20230930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="naov-20230930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="naov-20230930.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StatementOfStockholdersEquity" xlink:href="naov-20230930.xsd#StatementOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StatementsOfCashFlows" xlink:href="naov-20230930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/DescriptionOfBusiness" xlink:href="naov-20230930.xsd#DescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertainties" xlink:href="naov-20230930.xsd#GoingConcernLiquidityAndOtherUncertainties" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="naov-20230930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StockholdersEquity" xlink:href="naov-20230930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LossPerShareApplicableToCommonStockholder" xlink:href="naov-20230930.xsd#LossPerShareApplicableToCommonStockholder" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerData" xlink:href="naov-20230930.xsd#GeographicInformationAndMajorCustomerData" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/Leases" xlink:href="naov-20230930.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/OtherAssets" xlink:href="naov-20230930.xsd#OtherAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/CommitmentsAndContingencies" xlink:href="naov-20230930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/RelatedPartyTransaction" xlink:href="naov-20230930.xsd#RelatedPartyTransaction" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SubsequentEvents" xlink:href="naov-20230930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="naov-20230930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StockholdersEquityTables" xlink:href="naov-20230930.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LossPerShareApplicableToCommonStockholderTables" xlink:href="naov-20230930.xsd#LossPerShareApplicableToCommonStockholderTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataTables" xlink:href="naov-20230930.xsd#GeographicInformationAndMajorCustomerDataTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LeasesTables" xlink:href="naov-20230930.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/OtherAssetsTables" xlink:href="naov-20230930.xsd#OtherAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertaintiesDetailsNarrative" xlink:href="naov-20230930.xsd#GoingConcernLiquidityAndOtherUncertaintiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="naov-20230930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails" xlink:href="naov-20230930.xsd#ScheduleOfOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails" xlink:href="naov-20230930.xsd#ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="naov-20230930.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" xlink:href="naov-20230930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails" xlink:href="naov-20230930.xsd#SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails" xlink:href="naov-20230930.xsd#SummaryOfRevenueWithinGeographicAreasDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative" xlink:href="naov-20230930.xsd#GeographicInformationAndMajorCustomerDataDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails" xlink:href="naov-20230930.xsd#ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/LeasesDetailsNarrative" xlink:href="naov-20230930.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails" xlink:href="naov-20230930.xsd#ScheduleOfWarrantsAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" xlink:href="naov-20230930.xsd#ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilityMeasuredAtFairValueDetails" xlink:href="naov-20230930.xsd#ScheduleOfAssetsAndLiabilityMeasuredAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/OtherAssetsDetailsNarrative" xlink:href="naov-20230930.xsd#OtherAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="naov-20230930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/RelatedPartyTransactionDetailsNarrative" xlink:href="naov-20230930.xsd#RelatedPartyTransactionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanovibronix.com/role/SubsequentEventsDetailsNarrative" xlink:href="naov-20230930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement -  Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesDPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaapSeriesEPreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesEPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaapSeriesFPreferredStockMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesFPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_SeveranceAssetsNoncurent" xlink:label="loc_NAOVSeveranceAssetsNoncurent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_NAOVSeveranceAssetsNoncurent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="loc_us-gaapDeferredIncomeNoncurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapDeferredIncomeNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement -  Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesDPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaapSeriesEPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesEPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaapSeriesFPreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesFPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_FinancialExpensesNet" xlink:label="loc_NAOVFinancialExpensesNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_NAOVFinancialExpensesNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaapNetIncomeLossAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLossAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLossAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLossAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StatementOfStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statement of Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapSeriesDPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="loc_us-gaapSeriesEPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapSeriesEPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaapSeriesFPreferredStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapSeriesFPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants" xlink:label="loc_NAOVAdjustmentsToAdditionalPaidInCapitalReversalOfWarrants" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NAOVAdjustmentsToAdditionalPaidInCapitalReversalOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_NoncashInterestExpense" xlink:label="loc_NAOVNoncashInterestExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NAOVNoncashInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaapEquitySecuritiesFvNiGainLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapEquitySecuritiesFvNiGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_IncreaseDecreaseInAccruedSeverancePayNet" xlink:label="loc_NAOVIncreaseDecreaseInAccruedSeverancePayNet" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_NAOVIncreaseDecreaseInAccruedSeverancePayNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/DescriptionOfBusiness" xlink:title="00000007 - Disclosure - DESCRIPTION OF BUSINESS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertainties" xlink:title="00000008 - Disclosure - GOING CONCERN, LIQUIDITY AND OTHER UNCERTAINTIES">
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_DisclosureGoingConcernLiquidityAndOtherUncertaintiesAbstract" xlink:label="loc_NAOVDisclosureGoingConcernLiquidityAndOtherUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_GoingConcernAndLiquidityTextBlock" xlink:label="loc_NAOVGoingConcernAndLiquidityTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NAOVDisclosureGoingConcernLiquidityAndOtherUncertaintiesAbstract" xlink:to="loc_NAOVGoingConcernAndLiquidityTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StockholdersEquity" xlink:title="00000010 - Disclosure - STOCKHOLDERS&#8217; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LossPerShareApplicableToCommonStockholder" xlink:title="00000011 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDER">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerData" xlink:title="00000012 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/Leases" xlink:title="00000013 - Disclosure - LEASES">
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_DisclosureLeasesAbstract" xlink:label="loc_NAOVDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NAOVDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/OtherAssets" xlink:title="00000014 - Disclosure - OTHER ASSETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaapOtherAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/CommitmentsAndContingencies" xlink:title="00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/RelatedPartyTransaction" xlink:title="00000016 - Disclosure - RELATED PARTY TRANSACTION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SubsequentEvents" xlink:title="00000017 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StockholdersEquityTables" xlink:title="00000019 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LossPerShareApplicableToCommonStockholderTables" xlink:title="00000020 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDER (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataTables" xlink:title="00000021 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="loc_us-gaapRevenueFromExternalCustomersByGeographicAreasTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapRevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LeasesTables" xlink:title="00000022 - Disclosure - LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_DisclosureLeasesAbstract" xlink:label="loc_NAOVDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NAOVDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/OtherAssetsTables" xlink:title="00000023 - Disclosure - OTHER ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_ScheduleOfWarrantsAssumptionsTableTextBlock" xlink:label="loc_NAOVScheduleOfWarrantsAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_NAOVScheduleOfWarrantsAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertaintiesDetailsNarrative" xlink:title="00000024 - Disclosure - GOING CONCERN, LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_DisclosureGoingConcernLiquidityAndOtherUncertaintiesAbstract" xlink:label="loc_NAOVDisclosureGoingConcernLiquidityAndOtherUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NAOVDisclosureGoingConcernLiquidityAndOtherUncertaintiesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_ValueOfListedSecurites" xlink:label="loc_NAOVValueOfListedSecurites" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NAOVValueOfListedSecurites" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails" xlink:title="00000026 - Disclosure - SCHEDULE OF OPTIONS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_EmployeeOptionsMember" xlink:label="loc_NAOVEmployeeOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVEmployeeOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:label="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_StockIssuedDuringPeriodSharesStockOptionsExpired" xlink:label="loc_NAOVStockIssuedDuringPeriodSharesStockOptionsExpired" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NAOVStockIssuedDuringPeriodSharesStockOptionsExpired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm" xlink:label="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xlink:label="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_NAOVSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails" xlink:title="00000027 - Disclosure - SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaapSellingAndMarketingExpenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingAndMarketingExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000028 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_PrivateInvestorsMember" xlink:label="loc_NAOVPrivateInvestorsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_NAOVPrivateInvestorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000029 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_PurchaseAgreementMember" xlink:label="loc_NAOVPurchaseAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NAOVPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_A1WarrantsMember" xlink:label="loc_NAOVA1WarrantsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVA1WarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_A2WarrantsMember" xlink:label="loc_NAOVA2WarrantsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVA2WarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_EmployeeOptionsMember" xlink:label="loc_NAOVEmployeeOptionsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVEmployeeOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_WainwrightMember" xlink:label="loc_NAOVWainwrightMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_NAOVWainwrightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="loc_us-gaapWarrantExercisePriceIncrease" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantExercisePriceIncrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails" xlink:title="00000030 - Disclosure - SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_StockOptionsEmployeeAndNonEmployeeMember" xlink:label="loc_NAOVStockOptionsEmployeeAndNonEmployeeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_NAOVStockOptionsEmployeeAndNonEmployeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails" xlink:title="00000031 - Disclosure - SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AU" xlink:label="loc_countryAU" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryAU" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="loc_srtEuropeMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtEuropeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AsiaMember" xlink:label="loc_srtAsiaMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtAsiaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_OtherCountryMember" xlink:label="loc_NAOVOtherCountryMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_NAOVOtherCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative" xlink:title="00000032 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaapScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaapEntityWideRevenueMajorCustomerLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="loc_us-gaapEntityWideRevenueMajorCustomerLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="loc_srtMajorCustomersAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_TwoCustomersMember" xlink:label="loc_NAOVTwoCustomersMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NAOVTwoCustomersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_CustomersOneMember" xlink:label="loc_NAOVCustomersOneMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NAOVCustomersOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_CustomersTwoMember" xlink:label="loc_NAOVCustomersTwoMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NAOVCustomersTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEntityWideRevenueMajorCustomerLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails" xlink:title="00000033 - Disclosure - SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES (Details)">
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_DisclosureLeasesAbstract" xlink:label="loc_NAOVDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NAOVDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NAOVDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NAOVDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NAOVDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NAOVDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/LeasesDetailsNarrative" xlink:title="00000034 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_DisclosureLeasesAbstract" xlink:label="loc_NAOVDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NAOVDisclosureLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails" xlink:title="00000035 - Disclosure - SCHEDULE OF WARRANTS ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_PriceAtValuationMember" xlink:label="loc_NAOVPriceAtValuationMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_NAOVPriceAtValuationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_SanuwaveHealthIncMember" xlink:label="loc_NAOVSanuwaveHealthIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_NAOVSanuwaveHealthIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_DerivativeAssetMember" xlink:label="loc_NAOVDerivativeAssetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_NAOVDerivativeAssetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilityMeasuredAtFairValueDetails" xlink:title="00000037 - Disclosure - SCHEDULE OF ASSETS AND LIABILITY MEASURED AT FAIR VALUE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/OtherAssetsDetailsNarrative" xlink:title="00000038 - Disclosure - OTHER ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_LicensingAgreementMember" xlink:label="loc_NAOVLicensingAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NAOVLicensingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_SanuwaveHealthIncMember" xlink:label="loc_NAOVSanuwaveHealthIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_NAOVSanuwaveHealthIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000039 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_ArbitratorMember" xlink:label="loc_NAOVArbitratorMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_NAOVArbitratorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaapLossContingencyDamagesSoughtValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapLossContingencyDamagesSoughtValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaapLossContingencyDamagesAwardedValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapLossContingencyDamagesAwardedValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="loc_us-gaapLossContingencyDamagesPaidValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="loc_us-gaapLossContingencyDamagesPaidValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/RelatedPartyTransactionDetailsNarrative" xlink:title="00000040 - Disclosure - RELATED PARTY TRANSACTION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanovibronix.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000041 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_PrefundedWarrantMember" xlink:label="loc_NAOVPrefundedWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_NAOVPrefundedWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="naov-20230930.xsd#NAOV_SecuritiesPurchaseAgreementMember" xlink:label="loc_NAOVSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NAOVSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183414080912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Nov. 13, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NanoVibronix,
Inc<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001326706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">01-0801232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity address, address line one</a></td>
<td class="text">525
    Executive Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity ddress, city or town</a></td>
<td class="text">Elmsford<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity address, state or province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(914)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">233-3004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NAOV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,046,308<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183413491040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 3,787<span></span>
</td>
<td class="nump">$ 2,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">3,179<span></span>
</td>
<td class="nump">2,175<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">7,168<span></span>
</td>
<td class="nump">5,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Noncurrent assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_SeveranceAssetsNoncurent', window );">Severance pay fund</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">270<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">7,361<span></span>
</td>
<td class="nump">5,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade payables</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other payables</a></td>
<td class="nump">2,311<span></span>
</td>
<td class="nump">2,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,392<span></span>
</td>
<td class="nump">2,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesNoncurrent', window );">Accrued severance pay</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeNoncurrent', window );">Deferred licensing income</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,671<span></span>
</td>
<td class="nump">2,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock of $0.001 par value - Authorized: 40,000,000 shares at September 30, 2023 and December 31, 2022, respectively; Issued and outstanding: 1,842,331 and 1,641,146 shares at September 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">70,025<span></span>
</td>
<td class="nump">65,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(65,283)<span></span>
</td>
<td class="num">(62,385)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">4,690<span></span>
</td>
<td class="nump">3,233<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">7,361<span></span>
</td>
<td class="nump">5,879<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember', window );">Series E Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember', window );">Series F Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_SeveranceAssetsNoncurent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Severance assets, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_SeveranceAssetsNoncurent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481174/470-10-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183416322336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">1,842,331<span></span>
</td>
<td class="nump">1,641,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">1,842,331<span></span>
</td>
<td class="nump">1,641,146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">506<span></span>
</td>
<td class="nump">506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember', window );">Series E Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,999,494<span></span>
</td>
<td class="nump">1,999,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember', window );">Series F Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesEPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183413502048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 458<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
<td class="nump">$ 1,106<span></span>
</td>
<td class="nump">$ 854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">306<span></span>
</td>
<td class="nump">387<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">349<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="nump">631<span></span>
</td>
<td class="nump">760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">796<span></span>
</td>
<td class="nump">738<span></span>
</td>
<td class="nump">2,780<span></span>
</td>
<td class="nump">2,835<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,019<span></span>
</td>
<td class="nump">1,004<span></span>
</td>
<td class="nump">3,534<span></span>
</td>
<td class="nump">3,771<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(670)<span></span>
</td>
<td class="num">(924)<span></span>
</td>
<td class="num">(2,734)<span></span>
</td>
<td class="num">(3,304)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(35)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_FinancialExpensesNet', window );">Financial expense, net</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes on income</a></td>
<td class="num">(724)<span></span>
</td>
<td class="num">(940)<span></span>
</td>
<td class="num">(2,880)<span></span>
</td>
<td class="num">(3,351)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (727)<span></span>
</td>
<td class="num">$ (955)<span></span>
</td>
<td class="num">$ (2,898)<span></span>
</td>
<td class="num">$ (3,389)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss available for holders of common stock</a></td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (0.68)<span></span>
</td>
<td class="num">$ (1.73)<span></span>
</td>
<td class="num">$ (2.42)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss available for holders of common stock</a></td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (0.68)<span></span>
</td>
<td class="num">$ (1.73)<span></span>
</td>
<td class="num">$ (2.42)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, Basic</a></td>
<td class="nump">1,721,026<span></span>
</td>
<td class="nump">1,399,890<span></span>
</td>
<td class="nump">1,678,684<span></span>
</td>
<td class="nump">1,399,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, Diluted</a></td>
<td class="nump">1,721,026<span></span>
</td>
<td class="nump">1,399,890<span></span>
</td>
<td class="nump">1,678,684<span></span>
</td>
<td class="nump">1,399,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common stockholders</a></td>
<td class="num">$ (727)<span></span>
</td>
<td class="num">$ (955)<span></span>
</td>
<td class="num">$ (2,898)<span></span>
</td>
<td class="num">$ (3,389)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Change in foreign currency translation adjustments</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss available to common stockholders</a></td>
<td class="num">$ (726)<span></span>
</td>
<td class="num">$ (961)<span></span>
</td>
<td class="num">$ (2,934)<span></span>
</td>
<td class="num">$ (3,446)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_FinancialExpensesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial expenses net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_FinancialExpensesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183408454272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series C Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series D Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series E Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series F Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 63,162<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="num">$ (56,937)<span></span>
</td>
<td class="nump">$ 6,313<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,399,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">287<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants', window );">Reversal of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(135)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent', window );">Currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,389)<span></span>
</td>
<td class="num">(3,389)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">63,449<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(60,326)<span></span>
</td>
<td class="nump">3,154<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,399,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">63,468<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="num">(59,371)<span></span>
</td>
<td class="nump">4,134<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,399,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants', window );">Reversal of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(135)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(135)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent', window );">Currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(955)<span></span>
</td>
<td class="num">(955)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">63,449<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(60,326)<span></span>
</td>
<td class="nump">3,154<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,399,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">65,634<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(62,385)<span></span>
</td>
<td class="nump">3,233<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,641,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">65,634<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(62,385)<span></span>
</td>
<td class="nump">3,233<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,641,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent', window );">Currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,898)<span></span>
</td>
<td class="num">(2,898)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,215<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Rounding up of fractional shares due to stock split</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Rounding up of fractional shares due to stock split, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">70,025<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="num">(65,283)<span></span>
</td>
<td class="nump">4,690<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,842,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">65,774<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="num">(64,556)<span></span>
</td>
<td class="nump">1,165<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,662,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent', window );">Currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(727)<span></span>
</td>
<td class="num">(727)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,215<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 70,025<span></span>
</td>
<td class="num">$ (54)<span></span>
</td>
<td class="num">$ (65,283)<span></span>
</td>
<td class="nump">$ 4,690<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,842,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reversal of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, on foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183414119680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,898)<span></span>
</td>
<td class="num">$ (3,389)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_NoncashInterestExpense', window );">Noncash interest expense</a></td>
<td class="nump">102<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Change in fair value of equity investment</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivable</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other accounts receivable</a></td>
<td class="nump">542<span></span>
</td>
<td class="num">(1,008)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(1,004)<span></span>
</td>
<td class="num">(1,378)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Trade payables</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Other accounts payable and accrued expenses</a></td>
<td class="nump">61<span></span>
</td>
<td class="num">(77)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_IncreaseDecreaseInAccruedSeverancePayNet', window );">Accrued severance pay, net</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(3,111)<span></span>
</td>
<td class="num">(5,704)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of equipment</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">4,215<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">7<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">4,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effects of currency translation on cash and cash equivalents</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash</a></td>
<td class="nump">1,074<span></span>
</td>
<td class="num">(5,765)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash at beginning of period</a></td>
<td class="nump">2,713<span></span>
</td>
<td class="nump">7,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash at end of period</a></td>
<td class="nump">$ 3,787<span></span>
</td>
<td class="nump">$ 1,972<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_IncreaseDecreaseInAccruedSeverancePayNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued severance pay net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_IncreaseDecreaseInAccruedSeverancePayNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_NoncashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_NoncashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183414796544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">DESCRIPTION OF BUSINESS</a></td>
<td class="text"><p id="xdx_805_eus-gaap--NatureOfOperations_zvtoRsJwU95f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 &#8211; <span id="xdx_827_zgAAM6YqGzga">DESCRIPTION OF BUSINESS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NanoVibronix,
Inc. (the &#8220;Company&#8221;), a Delaware corporation, commenced operations on October 20, 2003 and is a medical device company focusing
on noninvasive biological response-activating devices that target wound healing and pain therapy and can be administered at home, without
the assistance of medical professionals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s principal research and development activities are conducted in Israel through its wholly owned subsidiary, NanoVibronix
(Israel 2003) Ltd., a company registered in Israel, which commenced operations in October 2003.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183418494960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOING CONCERN, LIQUIDITY AND OTHER UNCERTAINTIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_DisclosureGoingConcernLiquidityAndOtherUncertaintiesAbstract', window );"><strong>Going Concern Liquidity And Other Uncertainties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_GoingConcernAndLiquidityTextBlock', window );">GOING CONCERN, LIQUIDITY AND OTHER UNCERTAINTIES</a></td>
<td class="text"><p id="xdx_801_ecustom--GoingConcernAndLiquidityTextBlock_zMmT5rxIC1cc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 &#8211; <span id="xdx_820_zk2DvL6R2hZ7">GOING CONCERN, LIQUIDITY AND OTHER UNCERTAINTIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity
and Going Concern</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s ability to continue to operate is dependent mainly on its ability to successfully market and sell its products and the
receipt of additional financing until profitability is achieved. In August 2023, the Company received net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20230801__20230831_zhqmgj7jqGVd" title="Proceeds from issuance sale of equity">4,215,000</span> from
the sale of our equity securities. During the three and nine months ended September 30, 2023, the Company has incurred losses as well
as negative cash outflows from operating activities and expects to incur losses and negative cash outflows from operating activities
through at least fiscal year 2024. Because the Company does not have sufficient resources to fund its operations for the next twelve
months from the date of this filing and there could be a significant arbitration payment due (see Note 9), substantial doubt exists as
to the Company&#8217;s ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will need to raise additional capital to finance its losses and negative cash flows from operations and may continue to be dependent
on additional capital raising as long as our products do not reach commercial profitability. If the Company is unable to obtain additional
financing, the development of its product candidates and the Company&#8217;s commercial strategy may be impacted and there could be a
material adverse effect on the Company&#8217;s business and financial condition. These financial statements do not include any adjustments
that may result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Uncertainties</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 23, 2023, we received a letter from the Listing Qualifications Department of Nasdaq indicating that we no longer comply with the
minimum stockholders&#8217; equity requirement under Nasdaq Listing Rule 5550(b)(1) (the &#8220;Rule&#8221;) for continued listing on
Nasdaq because our stockholders&#8217; equity of approximately $<span id="xdx_90C_eus-gaap--StockholdersEquity_iI_pn5n6_c20230331_zYwx4zz4VUVe" title="Stockholder's equity">2.2</span> million as reported in our Quarterly Report on Form 10-Q for the
period ended March 31, 2023, is below the required minimum of $<span id="xdx_902_eus-gaap--StockholdersEquity_iI_pn5n6_c20230331__srt--RangeAxis__srt--MinimumMember_zUklhW6vLmca" title="Stockholder's equity">2.5</span> million, and as of May 22, 2023, we did not meet the alternative compliance
standards relating to the market value of listed securities of $<span id="xdx_901_ecustom--ValueOfListedSecurites_iI_pn6n6_c20230522_zdfmiMlumnsk" title="Value of listed securities">35</span> million or net income from continuing operations of $<span id="xdx_900_eus-gaap--NetIncomeLoss_pn3d_c20230522__20230522_zV3rMQU4XvHb" title="Net income from continuing operations">500,000</span> in the
most recently completed fiscal year or in two of the last three most recently completed fiscal years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Nasdaq Listing Rules, we had 45 calendar days, or until July 7, 2023, to submit a plan to regain compliance. On July
7, 2023, we submitted our plan to regain compliance with the Nasdaq minimum stockholders&#8217; equity standard. On July 19, 2023, the
Staff granted the Company&#8217;s plan and granted our request for continued listing pursuant to an extension through November 20, 2023
to evidence compliance with the Rule. We believe that upon filing of this Form 10-Q, we should have provided sufficient evidence of compliance
with Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian
and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s
border with the Gaza Strip and in other areas within the State of Israel. Following the attack, Israel&#8217;s security cabinet declared
war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror
attacks. Moreover, the clash between Israel and Hezbollah in Lebanon, may escalate in the future into a greater regional conflict</span>,
especially in the northern part of Israel where our Israel office is located which stores approximately $<span id="xdx_906_eus-gaap--InventoryNet_iI_pn5n6_c20231031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zg5GePQ0Qte7">2.1</span> million worth of our inventory.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This conflict could cause a<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n
inability to receive supplies and materials, shortages of materials or difficulties in procuring our materials, among others, or
conversely, our ability to ship products to our US facilities or overseas customers, may adversely impact our ability to
commercialize and manufacture our product candidates and products in a timely manner. This could also cause delays the review of our product candidates by regulatory agencies, which in turn would have a material adverse impact on our ability to
commercialize those  product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_DisclosureGoingConcernLiquidityAndOtherUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_DisclosureGoingConcernLiquidityAndOtherUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_GoingConcernAndLiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Going Concern And Liquidity [TextBlock]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_GoingConcernAndLiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183408872672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_802_eus-gaap--SignificantAccountingPoliciesTextBlock_zbQvJSucPhWc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 &#8211; <span id="xdx_827_zTpsvuW9FIKf">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zBY09KwdrUt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zuuL4Fa8DtHb">Basis
of presentation and principles of consolidation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts
and transactions have been eliminated in consolidation. The Company&#8217;s condensed consolidated financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for the interim
financial information and with instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the accompanying
unaudited interim consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary
to state fairly the financial position and results of operations of the Company. These condensed consolidated financial statements and
notes thereto are unaudited and should be read in conjunction with the Company&#8217;s audited financial statements for the year ended
December 31, 2022, as found in the Company&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the
&#8220;SEC&#8221;) on April 17, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
balance sheet for December 31, 2022 was derived from the Company&#8217;s audited financial statements for the year ended December 31,
2022. The results of operations for the periods presented are not necessarily indicative of results that could be expected for the entire
fiscal year due to seasonality and other factors. Certain information and footnote disclosures normally included in the consolidated
financial statements in accordance with U.S. GAAP have been omitted in accordance with the rules and regulations of the SEC for interim
reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_843_eus-gaap--UseOfEstimates_z5P9bh2OVXV3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zqp2oKoziQlc">Use
of estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and
assumptions. The Company believes that the estimates, judgments and assumptions used are reasonable based upon information available
at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during
the reporting period. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zzV043tV41G9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zyFn95UYln8">Foreign
currency translation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-U.S.
dollar denominated transactions and balances have been re-measured to U.S. dollars. All gains and losses from re-measurement of monetary
balance sheet items denominated in non-U.S. dollar currencies are reflected in the statements of operations as other comprehensive income,
as appropriate. The cumulative translation gains for the periods ended September 30, 2023 and 2022 were $<span id="xdx_901_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_pn3n3_c20230101__20230930_zbWCWbb4IAS8" title="Gains and losses from foreign currency translation">36</span> and $<span id="xdx_905_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_pn3n3_c20220101__20220930_zchb15iSrutd" title="Gains and losses from foreign currency translation">57</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zBAmZ7iek945" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_z6mPWqtr7zX9">Revenue
recognition</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
from product sales are recognized in accordance with ASC 606 &#8220;Revenue Recognition.&#8221; Five basic steps must be followed before
revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying
the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction
price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised
goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires
the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of
each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance
obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the
satisfied performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from product sales is recorded at the net sales price, or &#8220;transaction price,&#8221; which includes estimates of variable consideration
that result from coupons, discounts and distributor fees, processing fees, as well as allowances for returns and government rebates.
The Company constrains revenue by considering factors that could otherwise lead to a probable reversal of revenue. Collectability of
revenue is reasonably assured based on historical evidence of collectability between the Company and its customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
from sales to distributors are recognized at the time the products are delivered to the distributors (&#8220;sell-in&#8221;). The Company
does not grant rights of return, credits, rebates, price protection, or other privileges on its products to distributors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zDSs0khjhCVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zueI98NmfDe1">Recently
adopted accounting standards</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13,
Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;)
and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, and ASU 2019-05 (collectively, &#8220;Topic
326&#8221;). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. This ASU is effective
for interim and annual reporting periods beginning after December 15, 2022, including interim periods within those fiscal years. The
Company adopted ASU 2016-13 as of January 1, 2023, and there was no material impact on its condensed consolidated financial statements
upon adoption.</span></p>

<p id="xdx_85A_zKL4xcse8Vd5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183417747136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zUC6nYDaty42" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 &#8211;<span id="xdx_822_zM2k2FhcpeY6"> STOCKHOLDERS&#8217; EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common
stock</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
common stock confers upon the holders the right to receive notice to participate and vote in general meetings of the Company, and the
right to receive dividends, if declared, and to participate in the distribution of the surplus assets and funds of the Company in the
event of liquidation, dissolution or winding up of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reverse
stock split</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2023, the Company effected a reverse stock split of its common stock at a ratio of 1 post-split share for every 20 pre-split
shares. The Company&#8217;s common stock begin trading on a split-adjusted basis when the market opened on February 9, 2023 (the &#8220;Reverse
Stock Split&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the effective time of the Reverse Stock Split, every 20 shares of the Company&#8217;s issued and outstanding common stock were converted
automatically into one issued and outstanding share of common stock without any change in the par value per share. Stockholders holding
shares through a brokerage account had their shares automatically adjusted to reflect the <span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20230208__20230208_zLC1i1LhWeOj" title="Reverse stock split">1-for-20 Reverse Stock Split</span>. The Reverse Stock
Split affected all stockholders uniformly and did not alter any stockholder&#8217;s percentage interest in the Company&#8217;s equity,
except to the extent that the Reverse Stock Split resulted in a stockholder owning a fractional share. Any fractional share of a stockholder
resulting from the Reverse Stock Split was rounded up to the nearest whole number of shares. Proportional adjustments were made to the
number of shares of the Company&#8217;s common stock issuable upon exercise or conversion of the Company&#8217;s equity awards, warrants
and other convertible securities, as well as the applicable exercise or conversion price thereof. On February 16, 2023, the Company rounded
up fractional shares to its nearest whole number of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20230215__20230216_z2wwKcccHXd6" title="Fractional shares">15,726</span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references in this Report to number of shares, price per share and weighted average number of shares of common stock outstanding prior
to the Reverse Stock Split have been adjusted to reflect the Reverse Stock Split on a retroactive basis, unless otherwise noted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Issuance
of common stock for cash through private placement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 30, 2023, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with an institutional
investor for the issuance and sale in a private placement (the &#8220;Private Placement&#8221;) of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlFv0NaUbej4" title="Number of new share issued">180,000</span> shares (the &#8220;Common
Shares&#8221;) of common stock, par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXkviiOOVyCi" title="Common stock, par value">0.001</span> per share (the &#8220;Common Stock&#8221;), pre-funded warrants (&#8220;Pre-Funded Warrants&#8221;)
to purchase up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGBfViebVFS4" title="Number of securities called by warrants or rights">2,726,977</span> shares of common stock, with an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrXBo42AE23k" title="Class of warrant or right, exercise price of warrants">0.0001</span> per share, A-1 Warrants (the &#8220;A-1 Warrants&#8221;)
to purchase up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zw3vbYxYjMF6" title="Number of securities called by warrants or rights">2,906,977</span> shares of Common Stock, with an exercise price of $<span id="xdx_908_eus-gaap--WarrantExercisePriceIncrease_pid_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zHPPujQoM1H" title="Warrant exercise price">1.47</span> per share, and A-2 Warrants (the &#8220;A-2 Warrants&#8221;
and together with the A-1 Warrants, the &#8220;Warrants<b><i>&#8221;</i></b> ) to purchase up to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_z1OTkJGj2wRk" title="Number of securities called by warrants or rights">2,906,977</span> shares of Common Stock with
an exercise price of $<span id="xdx_90D_eus-gaap--WarrantExercisePriceIncrease_pid_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zPDC2CFwamLj" title="Warrant exercise price">1.47</span> per share. The A-1 Warrants are exercisable immediately upon issuance and expire <span id="xdx_909_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zLVai5Gpwz62" title="Class of warrant or right expire date">March 1, 2029</span>. The A-2 Warrants
are exercisable immediately upon issuance and expire <span id="xdx_906_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zPS1XQ2gnNSd" title="Class of warrant or right expire date">October 1, 2024</span>. The combined purchase price for one Common Share and the accompanying
Warrants was $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zlm50Hz5cl7e" title="Class of warrant or right exercise price">1.72</span>, and the combined purchase price for one Pre-Funded Warrant and the accompanying Warrants was $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zILTh77GSs2l" title="Shares issued, price per share">1.7199</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net proceeds to the Company from the Private Placement are approximately $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20230830__20230830__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zswqXNxNBuil" title="Proceeds from issuance of private placement">4,215,000</span>, after deducting placement agent fees and expenses
and estimated offering expenses payable by the Company. The Company intends to use the net proceeds received from the Private Placement
for general corporate purposes, including funding of our development programs, commercial planning and sales and marketing expenses,
potential strategic acquisitions, general and administrative expenses and working capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;) served as the Company&#8217;s exclusive placement agent in connection with the Private
Placement, pursuant to that certain engagement letter, dated as of July 5, 2023, as amended, between us and Wainwright (the &#8220;Engagement
Letter&#8221;). As part of Wainwright&#8217;s compensation, we issued to Wainwright or its designees warrants (the &#8220;Placement Agent
Warrants&#8221;) to purchase up to an aggregate of <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230705__srt--TitleOfIndividualAxis__custom--WainwrightMember_zzMwmkvEsIik" title="Number of securities called by warrants or rights">218,023 </span>shares of Common Stock at an exercise price equal to $<span id="xdx_908_eus-gaap--SharePrice_iI_pid_c20230705__srt--TitleOfIndividualAxis__custom--WainwrightMember_zAzEnEDVXIwk" title="Share price">2.15 </span>per share. The
Placement Agent Warrants are exercisable immediately upon issuance and expire <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20230705__20230705__srt--TitleOfIndividualAxis__custom--WainwrightMember_zdOA1L7DcnRk" title="Class of warrant or right expire date">March 1, 2029</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-based
compensation and Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and nine-month period ended September 30, 2023, <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zwU73p1gvLgb" title="Number of options, exercised">0</span> and<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zq8u4ttHowbi" title="Number of options, exercised"> 5,459</span> employee options were exercised respectively. During the three
and nine-month period ended September 30, 2022, <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_ztRgjbj3PONa" title="Number of options, exercised"><span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z9Vw6YBYG04l" title="Number of options, exercised">no</span></span> employee options were exercised. During the three and nine-month period ended September
30, 2023, <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_dxL_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zLWXgG66SCm9" title="Number of employee options granted::XDX::-"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_dxL_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zQR2mJdHWk8" title="Number of employee options granted::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0913"><span style="-sec-ix-hidden: xdx2ixbrl0915">no</span></span></span></span> employee options were granted. During the three and nine-month period ended September 30, 2022, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_dxL_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zEob1MEI8nm1" title="Number of employee options granted::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0917">0</span></span> and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zateONgWrs7c" title="Number of employee options granted">6,000</span> employee options
were granted, respectively. During the three and nine-month period ended September 30, 2023, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zPxxhvlvH9g6" title="Number of employee options expired">0</span> and <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zgX9q3tgJCG4" title="Number of employee options expired">3,000</span> employee options expired. During
the three and nine-month period ended September 30, 2022, <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zcqLjKaA47nc" title="Number of employee options expired"><span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zDu5BGUxuKu6" title="Number of employee options expired">no</span></span> employee options expired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The options granted to employees and board members
were recorded at a fair value and vested over three years. During the three and nine-month period ended September 30, 2023, stock-based
compensation expense of $<span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_znkmRBm3AN02" title="Stock-based compensation expense">36</span> and $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zRLWYT3exfm8" title="Stock-based compensation expense">169</span> was recorded for options that vested, respectively. During the three and nine-month period ended
September 30, 2022, stock-based compensation expense of $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z1tdMI9wGC77" title="Stock-based compensation expense">116</span> and $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zfBERijeiVAb" title="Stock-based compensation expense">285</span> was recorded for options that vested, respectively.</p>

<p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zEFWXkHaWf5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zhm3L1Jach92" style="display: none">SCHEDULE
OF OPTIONS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Shares Under</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Options</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise Price</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>per Share</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Remaining</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Life (Years)</b></p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%">Outstanding &#8211; December 31, 2021</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zNYffLFvX0Uc" style="width: 14%; text-align: right" title="Shares Under Options Outstanding, Balance">127,000</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zgSkhIkOChO" style="width: 14%; text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance">31.86</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 14%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zDt92FjsGQp3" title="Weighted Average Remaining Life (Years), Outstanding">7.77</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zlnZXpA0aVik" style="text-align: right" title="Shares Under Options, Granted">6,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z8RyMpLwyUr9" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted">15.56</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_dtY_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zuZ0btfr18r3" title="Weighted Average Remaining Life (Years), Granted">9.89</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z1knTaIsHKY1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Under Options, Exercised">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zUTR0v6d3qyl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding &#8211; March 31, 2022</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zMVdeEOodzCf" style="text-align: right" title="Shares Under Options Outstanding, Balance">133,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zQl75Nkjlwkg" style="text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance">26.00</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zr5TxapXQV4a" title="Weighted Average Remaining Life (Years), Outstanding">7.63</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Granted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zCUkBXnTWWyc" style="text-align: right" title="Shares Under Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0961">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z7XmzNglk7ze" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0963">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zBpqS1kVzeWc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Under Options, Exercised">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zLJTMOxelFuh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding &#8211; June 30, 2022</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zqJCIWFX3hnd" style="text-align: right" title="Shares Under Options Outstanding, Balance">133,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zo5qK40TN7U1" style="text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance">26.00</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zrboyDLisHW2" title="Weighted Average Remaining Life (Years), Outstanding">7.63</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9.9pt">Granted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zuAB7KtmwOgc" style="text-align: right" title="Shares Under Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0975">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zzpgR4r4mgj5" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9.9pt">Exercised</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z2jdDHBBrw8h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Under Options, Exercised">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zDQELXuJ2IQa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding &#8211; September 30, 2022</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zsOdobhd7Pg8" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Under Options Outstanding, Balance">133,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2d_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z0CCFpvoNyBl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance">26.00</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z3pE2Gl58YG6" title="Weighted Average Remaining Life (Years), Outstanding">7.63</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding &#8211; December 31, 2022</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zhoB7bKlR414" style="text-align: right" title="Shares Under Options Outstanding, Balance">147,619</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zZTMNuwfXMNd" style="text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance">24.42</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zVuDGsTgBHac" title="Weighted Average Remaining Life (Years), Outstanding">7.24</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Granted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zwxCNY9xMY36" style="text-align: right" title="Shares Under Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0995">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zc8I37J80Oh8" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0997">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesStockOptionsExpired_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zu0ljdrBE1Yj" style="text-align: right" title="Shares Under Options, Expired">(3,000</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pp2d_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zdsxMDbbetIc" style="text-align: right" title="Weighted Average Exercise Price per Share, Expired">39.20</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm_dtY_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zZYIkwfFvCKg" title="Weighted Average Remaining Life (Years), Expired">0.51</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zKKlmfoL5fgh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Under Options, Exercised">(5,459</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zHwArBRA0DI1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised">1.40</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_dtY_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zGoCC7x1TOGd" title="Weighted Average Remaining Life (Years), Exercised">0.51</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding &#8211; March 31, 2023</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zzICRKZrDv99" style="text-align: right" title="Shares Under Options Outstanding, Balance">139,160</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zxY9fQSGAIP8" style="text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance">25.01</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_znvzozuZiFNh" title="Weighted Average Remaining Life (Years), Outstanding">6.91</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 7.1pt">Granted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zQPtlU2u1WR3" style="text-align: right" title="Shares Under Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1017">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zqgXorGAlGqi" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1019">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 7.1pt">Expired</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--StockIssuedDuringPeriodSharesStockOptionsExpired_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zZ5ViEPywVh7" style="text-align: right" title="Shares Under Options, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1021">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pp2d_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zyNPEuuCmYKd" style="text-align: right" title="Weighted Average Exercise Price per Share, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1023">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 7.1pt">Exercised</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zWIMiZpYYdgk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Under Options, Exercised">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zy5ROLzGpry6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding &#8211; June 30, 2023</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zlXYWrrCA7l" style="text-align: right" title="Shares Under Options Outstanding, Balance">139,160</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zbXorH9UYMq6" style="text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance">25.01</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zPFowipxeFCh" title="Weighted Average Remaining Life (Years), Outstanding">6.91</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 7.1pt">Granted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zaUnOBFzx8ei" style="text-align: right" title="Shares Under Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1035">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z7pFjnUsTmXi" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1037">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 7.1pt">Expired</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--StockIssuedDuringPeriodSharesStockOptionsExpired_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zETeSBLjgvJb" style="text-align: right" title="Shares Under Options, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1039">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pp2d_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zIkf0SEaFru3" style="text-align: right" title="Weighted Average Exercise Price per Share, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1041">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 7.1pt">Exercised</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zg3uTmKbCKyh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Under Options, Exercised">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zrbsjjr17xX7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding &#8211; September 30, 2023</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zHePMHa2Oby7" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Under Options Outstanding, Balance">139,160</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2d_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zE9Ci5cTdJlf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance">25.01</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z9vxGd4z7K27" title="Weighted Average Remaining Life (Years), Outstanding">6.91</span></td>
    <td style="text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8AC_zaOEmmrGypkh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_89C_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zExjcrz8ZHZb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total stock-based expense recognized in the financial statements for services received from employees and non-employees is shown in the
following table.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zC3XcNGR5IIa" style="display: none">SCHEDULE
OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20230701__20230930_zJPm9rJ3YLul" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20220701__20220930_z8Ayol1U9W37" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20230101__20230930_z4eXWo6J0sv8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20220930_zkau9nLXEj64" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zpm9UNQIDlji" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">2</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">5</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">5</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zxAO96Pf7cfe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Selling and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zJLrHJnV5C3g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">108</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">146</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">264</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zQ1JG9Blffpd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">116</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">169</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">287</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zhCI0bKjvrfd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Stock based compensation expense</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">116</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">169</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">287</td><td style="text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A7_zsDGAXzQJCxk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2023, the total unrecognized estimated compensation cost related to non-vested stock options granted prior to that date
was $<span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20230930_zKVv5POdawNb" title="Non-vested stock options granted, unrecognized estimated compensation cost">159</span>, which is expected to be recognized over a weighted average period of approximately <span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20230930_zzNUxds7L2pa" title="Non-vested stock options granted, weighted average period">1.19</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 30, 2023, the Company granted (a) Pre-Funded Warrants to purchase up to <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgLlKrYWqyi1">2,906,977 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of Common Stock with an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8sDOiEjMW87">0.0001 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share, (b) A-1 Warrants to purchase up to <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zYyu2zjnwsX7">2,906,977 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of Common Stock with an exercise price of $<span id="xdx_906_eus-gaap--WarrantExercisePriceIncrease_pid_c20230830__20230830__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zAAhcBrwMzPh" title="Warrant exercise price">1.47 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share and (c) A-2 Warrants to purchase up to <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zGGqxRjfGPrj">2,906,977 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of Common Stock with an exercise price of $<span id="xdx_907_eus-gaap--WarrantExercisePriceIncrease_pid_c20230830__20230830__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zMkGtiS8shcg">1.47 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share, or a total of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230830__20230830__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zoAtEc7xw6Y1">8,540,931 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants,
in conjunction with the Private Placement disclosed above. The A-1 Warrants and A-2 Warrants are exercisable immediately upon
issuance and expire on <span id="xdx_909_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zHLF7G5BJiG9">March
1, 2029</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_906_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zcKEkV8QAEa3">October
1, 2024</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the same Private
Placement, the Company granted Placement Agent Warrants to Wainwright, or its designees, to purchase up to an aggregate of <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__srt--TitleOfIndividualAxis__custom--WainwrightMember_ziJKg2u1UTi3">218,023 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of Common Stock at an exercise price equal to $<span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20230830__srt--TitleOfIndividualAxis__custom--WainwrightMember_z6j9oBc7RhZ3">2.15 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share. The Placement Agent Warrants are exercisable immediately upon issuance and expire <span id="xdx_904_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20230830__20230830__srt--TitleOfIndividualAxis__custom--WainwrightMember_z4hE5HGKB5Yl">March
1, 2029</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the nine months ended September 30, 2023 and 2022, there were <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNUT0NLSE9MREVSU5IgRVFVSVRZIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgkwpILmJbUg" title="Warrants, granted">8,758,954</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNUT0NLSE9MREVSU5IgRVFVSVRZIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwSCyeSMHzKc" title="Warrants, granted">12,500</span> warrants granted, respectively. For the nine months
ended September 30, 2023 and 2022, there were <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNUT0NLSE9MREVSU5IgRVFVSVRZIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_do_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoqf0PEG2xNi" title="Warrants, exercised">0</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNUT0NLSE9MREVSU5IgRVFVSVRZIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_do_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zn3A0mi9JvT5" title="Warrants, exercised">12,500</span> warrants exercised and/ or cancelled.</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z8XvFRFCbLxj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zDfgzzEvrEod" style="display: none">SCHEDULE
OF WARRANTS ACTIVITY</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Outstanding &#8211; December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zddE0YuW9FJ9" style="width: 16%; text-align: right" title="Warrants, Outstanding, Balance">115,467</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_ziHWn2I0kot6" style="text-align: right" title="Warrants, Granted">12,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zDDixifz4nae" style="text-align: right" title="Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1111">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Cancelled</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zXwywzl08eMb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants, Canceled">(12,500</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding &#8211; September 30, 2022</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zSmCVZnG2QMh" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding, Balance">115,467</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding &#8211; December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zYiwyjNql9n7" style="text-align: right" title="Warrants, Outstanding, Balance">78,252</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zfiMd1yDDYh" style="text-align: right" title="Warrants, Granted">8,758,954</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_z5MSJuCusr78" style="text-align: right" title="Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1121">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Cancelled</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zzRrVoAVykbj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants, Canceled"><span style="-sec-ix-hidden: xdx2ixbrl1123">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding &#8211; September 30, 2023</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_z9fjFUmp2Q8d" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding, Balance">8,837,206</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zpzRfliPdog7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183416620256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDER<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDER</a></td>
<td class="text"><p id="xdx_802_eus-gaap--EarningsPerShareTextBlock_zqoQOBemvow3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 &#8211; <span id="xdx_820_zupmYl9Pvvxb">LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDER</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of shares
of common stock outstanding during the period. All outstanding stock options and warrants for the nine months ended September 30, 2023
and 2022 have been excluded from the calculation of the diluted net loss per share because all such securities are anti-dilutive for
all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z69lLnUAhqbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the Company&#8217;s
securities, in common stock equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would
be anti-dilutive:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zkvBOAvkpBB" style="display: none">SUMMARY
OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20230930_zC12P28pi2oi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,<br/>
2023</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20220930_zIQsFF93BkCa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,<br/>
2022</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsEmployeeAndNonEmployeeMember_zn8H6Gp4XC4j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: justify">Stock Options &#8211; employee and non-employee</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 16%; text-align: right">139,160</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 16%; text-align: right">133,000</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_ziANJ0ezVMC3" style="vertical-align: bottom; background-color: White">
    <td>Warrants</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">8,758,954</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">115,467</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_z2j1vvNZGx24" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">8,898,114</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">248,467</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_z504HyESbaM7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Dilutive loss per share</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">8,898,114</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">248,467</td>
    <td style="text-align: left">&#160;</td></tr>
</table>
<p id="xdx_8AA_zuDvMg26a6hb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183413937392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--SegmentReportingDisclosureTextBlock_zgAWaOPuLZHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6 &#8211; <span id="xdx_82E_z9zV6bnxXrA4">GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company manages its business on the basis of one reportable segment and derives revenues from selling its products directly to patients
as well as through distributor agreements. The following is a summary of revenues within geographic areas:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_z3DOMyvmdXR3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zJfCAPWGswq" style="display: none">SUMMARY
OF REVENUE WITHIN GEOGRAPHIC AREAS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20230701__20230930_z02zv56I2Oeh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20220701__20220930_zc4W7I99Nx02" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20230930_z7dl2fup9kt3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20220930_z14epOvXBal9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--US_zeeLV1M7X788" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">445</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">90</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,037</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">828</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--AU_zQ5o3QuASst2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Australia/New Zealand</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__srt--EuropeMember_zgKVvqvUx6Se" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Europe</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1157">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__srt--AsiaMember_zUPESZMg6uOk" style="vertical-align: bottom; background-color: White">
    <td>Asia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1162">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1163">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__custom--OtherCountryMember_z5DkMGZVzMbg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Other</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1168">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1170">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zDD5KOjit4q1" style="vertical-align: bottom; background-color: White">
    <td>Total</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">458</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">97</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,106</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">854</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zeKUERsx4vca" style="display: none; vertical-align: bottom; background-color: White">
    <td>Revenues geographic areas</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">458</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">97</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,106</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">854</td><td style="text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AB_zjLEUTX1HQv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
both the three and nine months ended September 30, 2023, our two largest customers comprised approximately <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zqDGPKtskgz6" title="Concentration risk, percentage">96</span>% and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zIboCg8ok9o2" title="Concentration risk, percentage">93</span>% of total revenues,
respectively. Customer one comprised <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersOneMember_zCbf7zbUyi8j" title="Concentration risk, percentage">49</span>% and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersOneMember_zIkYM4B4l9F6" title="Concentration risk, percentage">58</span>% while customer two comprised <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersTwoMember_zdwuFN4T0lu8" title="Concentration risk, percentage">46</span>% and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersTwoMember_zAH4mCwxs8jf" title="Concentration risk, percentage">35</span>%, respectively. During the three and nine months
ended September 30, 2022, our two largest customers comprised approximately <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zxo5GYHm9ZNe" title="Concentration risk, percentage">76</span>% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zqguEbFWrnq9" title="Concentration risk, percentage">92</span>% of total revenues, respectively. Customer one
comprised <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersOneMember_zgx6JE4b0Yrg" title="Concentration risk, percentage">76</span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersOneMember_zvi1NAzf53Be" title="Concentration risk, percentage">35</span>% while customer two comprised <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersTwoMember_zC1YU8Q1A9Y3" title="Concentration risk, percentage">0</span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersTwoMember_zFitgrlE5DQ3" title="Concentration risk, percentage">57</span>%, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//280/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183416620256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--LesseeOperatingLeasesTextBlock_zhCvuBgKUHz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7 &#8211; <span id="xdx_829_z6Y42CuujNgj">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has operating lease agreements with terms up to <span id="xdx_900_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20230930__srt--RangeAxis__srt--MinimumMember_zjwnJ90Ks2d5" title="Lease term">2</span>-<span id="xdx_907_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20230930__srt--RangeAxis__srt--MaximumMember_zx38Ce9sGZ5a" title="Lease term">3</span> years, including car and office space leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s weighted-average remaining lease term relating to its operating leases is <span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230930_zO7QWleLsBbb" title="Weighted-average remaining lease term">0.56</span> years, with a weighted-average discount
rate of <span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20230930_zPCMvoyJLg01" title="Weighted-average discount rate">10</span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company incurred $<span id="xdx_90B_eus-gaap--OperatingLeaseExpense_pn3n3_c20230101__20230930_zZ5R5BISVhNa" title="Operating lease, expense">36</span> and $<span id="xdx_90B_eus-gaap--OperatingLeaseExpense_pn3n3_c20220101__20220930_zlh1HbBKPgTd" title="Operating lease, expense">14</span> of lease expense for its operating leases for the nine months ended September 30, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zLxqwPJ6zV63" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the amount and timing of liabilities arising from the Company&#8217;s operating leases as
of September 30, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zfexwvnadMd5" style="display: none">SCHEDULE
OF LIABILITIES ARISING FROM OPERATING LEASES</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20230930_zdSdZyzWgiV6" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzL7T_zraQzhGcZhwk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">17</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzL7T_zj93CSK5ksjd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzL7T_zQ90fMenEHQd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total undiscounted operating lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_z2KyuYjpTUU8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: Imputed interest</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zXGsFqHDIzfe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Present value of operating lease liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">19</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zo0XuwuHb8v1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183417543312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER ASSETS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">OTHER ASSETS</a></td>
<td class="text"><p id="xdx_800_eus-gaap--OtherAssetsDisclosureTextBlock_zzvdBBB6okJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8 &#8211; <span id="xdx_828_zVDSaOwCJKcj">OTHER ASSETS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2020, pursuant to a licensing agreement entered into in March 2020, the Company received <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20200409__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zLQHvBfS1ZMa" title="Warrants and rights outstanding term">10</span>-year warrants to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20200409__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zunQsrt2zHn9" title="Warrants issued to purchase common stock">127,000</span>
shares of Sanuwave Health, Inc. at a price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200409__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zO7kLut3k8ql" title="Exercise price of warrants per share">0.19</span> per share. The fair value for warrants received was estimated at the date of grant
and at each reporting period using a Black-Scholes-Merton pricing model with the following underlying assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_ecustom--ScheduleOfWarrantsAssumptionsTableTextBlock_zFCDePnuDPP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zNrs91gyCtqa" style="display: none">SCHEDULE
OF WARRANTS ASSUMPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, <br/> 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/>2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Price at valuation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20230930__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zbLmK52CByL1" title="Warrants and rights outstanding, measurement input">0.02</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20221231__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zRNhRtck9nX3" title="Warrants and rights outstanding, measurement input">0.02</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zFEjQwQNjodc" title="Warrants and rights outstanding, measurement input">0.19</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_znqqZEmcGNg9" title="Warrants and rights outstanding, measurement input">0.19</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zxaqRMIL5P1k" title="Warrants and rights outstanding, measurement input">4.61</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zkNFvV1yFqpg" title="Warrants and rights outstanding, measurement input">3.96</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230930__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zGLILhGZdGPd" title="Expected term (in years)">7</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zVnNidrWcmA" title="Expected term (in years)">8</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zeiIrl805H45" title="Warrants and rights outstanding, measurement input">147.8</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zN2OgJdmeXhi" title="Warrants and rights outstanding, measurement input">155.6</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A3_zP9heDp8HHDk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers this to be Level 3 inputs and is valued at each reporting period. For the three and nine months ended September 30,
2023, changes in the fair value of these warrants amounted to $(<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230701__20230930_zWWnjdbmOxHk" title="Fair value of warrants"><span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20230930_zB1DUsEnYvVd" title="Fair value of warrants">1</span></span>) for both periods, leaving a balance of $<span id="xdx_904_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_c20230930_zYemgK95da5a" title="Warrants leaving balance">2</span> as of September 30, 2023.
For the three and nine months ended September 30, 2022, changes in the fair value of these warrants amounted to $(<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220701__20220930_zI12FiNSGqM5" title="Fair value of warrants">2</span>) and $(<span id="xdx_903_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20220930_zEVXpQljD4Ue" title="Fair value of warrants">12</span>), respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financial
Instruments Measured at Fair Value on a Recurring Basis</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability
in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants
would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 inputs: Inputs, other than quoted prices included in Level 1, that are observable either directly or indirectly; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own
    assumptions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers between Level 3 during the three and nine months ended September 30, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zpo1qsKTo0kj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents changes in Level 3 asset and liability measured at fair value for the quarters ended September 30, 2023 and
2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_z0NEQTYj6Gn2" style="display: none">SCHEDULE
OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Asset</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Balance &#8211; December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zUxKh6Ddht2g" style="width: 16%; text-align: right" title="Balance beginning">19</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Fair value adjustments &#8211; Sanuwave warrants</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zdCZPYVEy2Sk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants">(2</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance &#8211; March 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zMclxCGl37vi" style="text-align: right" title="Balance beginning">17</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Fair value adjustments &#8211; Sanuwave warrants</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zNkfGvDw4OKg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants">(8</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance &#8211; June 30, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zpY4Ffqob7T5" style="text-align: right" title="Balance beginning">9</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 7.1pt">Fair value adjustments &#8211; Sanuwave warrants</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zmI0PKlZa9gb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants">(2</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance &#8211; September 30, 2022</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_pn3n3_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zpnfSRk84IZ6" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance ending">7</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance &#8211; December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20230101__20230331__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_z6jsim1FAC46" style="text-align: right" title="Balance beginning">3</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Fair value adjustments &#8211; Sanuwave warrants</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20230331__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zDESfAW8F5Gi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants">2</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance &#8211; March 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20230401__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zN2AtoAvA57b" style="text-align: right" title="Balance beginning">5</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Fair value adjustments &#8211; Sanuwave warrants</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230401__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_z31cVTHyhSq5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants">(2</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance &#8211; June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20230701__20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zctTQIEQJghh" style="text-align: right" title="Balance beginning">3</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Fair value adjustments &#8211; Sanuwave warrants</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230701__20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_z3UfqnDNCVE9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants">(1</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance &#8211; September 30, 2023</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_pn3n3_c20230701__20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zJetDClqh2pj" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance ending">2</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zURpUu5fA6Jc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z9La9bA9cEh2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the Company&#8217;s assets and liabilities which are measured at fair value on a recurring basis by level
within the fair value hierarchy:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zfe70fG0cZua" style="display: none">SCHEDULE
OF ASSETS AND LIABILITY MEASURED AT FAIR VALUE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z1aYneIPZOB8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level I</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9nEX2WzvbPc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level II</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ztsGne2KXYCe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level III</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20230930_zF5sobBJeuff" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of September 30, 2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level I</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level II</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level III</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Asset:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherAssetsNoncurrent_iI_pn3n3_zpoGgf4YjdN5" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">Other assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1304">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1305">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zPLK0zFyOA6a" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level I</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zj1jCnxhtmJl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level II</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zLa4v91soDf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level III</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20221231_z8eM9y6jLsZk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of December 31, 2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level I</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level II</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level III</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Asset:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherAssetsNoncurrent_iI_pn3n3_zvA3TpYOPNy2" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">Other assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1309">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1310">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183418518128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zl13PQJ7QnCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 &#8211; <span id="xdx_82B_zB7bL6g6XZKe">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pending
litigation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2021, Protrade Systems, Inc. (&#8220;Protrade&#8221;) filed a Request for Arbitration (the &#8220;Request&#8221;) with the
International Court of Arbitration (the &#8220;ICA&#8221;) of the International Chamber of Commerce alleging the Company is in breach
of an Exclusive Distribution Agreement dated March 7, 2019 (the &#8220;Exclusive Distribution Agreement&#8221;) between Protrade and
the Company. Protrade alleges, in part, that the Company has breached the Exclusive Distribution Agreement by discontinuing the manufacture
of the DV0057 Painshield MD device in favor of an updated 10-100-001 Painshield MD device. Protrade claims damages estimated at $<span id="xdx_90C_eus-gaap--LossContingencyDamagesSoughtValue_pn6n6_c20210225__20210226_zb3LWKzJb3b1" title="Litigation damages sought value">3</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 15, 2022, the arbitrator issued a final award, which, determined that (i) the Company had the right to terminate the Exclusive
Distribution Agreement; (ii) the Company did not breach the duty of good faith and fair dealing with regard to the Exclusive Distribution
Agreement; and (iii) the Company did not breach any confidentiality obligations to Protrade. Nevertheless, the arbitrator determined
that the Company did not comply with the obligation to supply Protrade with a year&#8217;s supply of patches, and awarded Protrade $<span id="xdx_901_eus-gaap--LossContingencyDamagesSoughtValue_c20230314__20230315_z8CbTyi4HHsf" title="Loss contingency damages sought value">1,500,250</span>,
which consists of $<span id="xdx_90C_eus-gaap--LossContingencyDamagesAwardedValue_c20230314__20230315_zduAhMSb5p14" title="Loss contingency damages sought value">1,432,000</span> for &#8220;lost profits&#8221; and $<span id="xdx_900_eus-gaap--LossContingencyDamagesPaidValue_c20230314__20230315_zZXat2vCa801" title="Loss contingency damages paid value">68,250</span> as reimbursement of arbitration costs, on the grounds that the
Company allegedly failed to supply Protrade with certain patches utilized by users of DV0057 Painshield MD device. The arbitrator based
the decision on the testimony of Protrade&#8217;s president who asserted that a user would use in excess of 33 patches per each device.
The Company believes that the number of patches per device alleged by Protrade is grossly inflated, and that these claims were not properly
raised before the arbitrator. Accordingly, on April 13, 2022, the Company submitted an application for the correction of the award which
the arbitrator denied on June 22, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 5, 2022, Protrade filed a Petition with the Supreme Court of New York Nassau County seeking to confirm the Award. On April 13,
2022, the Company submitted an application to the ICA seeking to correct an error in the award based on the evidence that the Company
only sold 2-3 reusable patches per device contrary to the 33 reusable patches claimed by Protrade. The same arbitrator who issued the
award, denied the application.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2022, the Company filed a cross-motion seeking to vacate arbitration award on the grounds that the arbitrator exceeded her authority,
that the award was procured by fraud, and that the arbitrator failed to follow procedures established by New York law. In particular,
the Company averred in its motion that Protrade&#8217;s witness made false statements in arbitration, and that the arbitrator resolved
a claim that was never raised by Protrade and that has no factual basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2022, the court issued a decision granting Protrade its petition to confirm the award and denying the cross-motion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 9, 2022, the Company filed a motion to re-argue and renew its cross-motion to vacate the arbitration decision based on newer
information that was not available during the initial hearing. On the same day, the Company also filed a notice of appeal with the Appellate
Division, Second Department. On March 21, 2023, the court denied the motion to re-argue and renew.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 10, 2023, the Company filed its appeal with the Appellate Division, Second Department. The Company intends to continue to vigorously
pursue its opposition to the award in all appropriate fora.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2023 and December 31, 2022, the Company accrued the amount of the arbitration award to Protrade of
approximately $<span id="xdx_906_eus-gaap--LossContingencyDamagesAwardedValue_pn5n6_c20230101__20230930__srt--TitleOfIndividualAxis__custom--ArbitratorMember_zvbJTCy0uhFj" title="Damages awarded value"><span id="xdx_902_eus-gaap--LossContingencyDamagesAwardedValue_pn5n6_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ArbitratorMember_ztRJewDVAizj" title="Damages awarded value">1.9</span></span>
million, including interest which is classified in &#8220;Other accounts payable and accrued expenses&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183416620256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTION</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z1kmIKpinJW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10 &#8211; <span id="xdx_826_z2HYDhJVn8J8">RELATED PARTY TRANSACTION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
firm of FisherBroyles LLP is handling the Company&#8217;s Protrade litigation and appeals. For the three and nine months ended September
30, 2023, the Company have been billed and paid legal fees from FisherBroyles amounting to $<span id="xdx_90F_eus-gaap--LegalFees_pn3n3_c20230701__20230930_zwWshmzeO7hd" title="Legal fees paid">176</span> and $<span id="xdx_903_eus-gaap--LegalFees_pn3n3_c20230101__20230930_zfl67S9IbOb1" title="Legal fees paid">264</span>, respectively, which have been
recorded as part of &#8220;General and administrative expenses&#8221; in the condensed consolidated statements of operations. As has
been previously disclosed, one of the Company&#8217;s board members, Aurora Cassirer, is a partner at FisherBroyles. Ms. Cassirer does
not provide any legal services or legal advice to the Company<b>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183414826464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_zqHZWXrJQ6x" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11 &#8211; <span id="xdx_829_zakteqd6uyKe">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 6, 2023, an investor exercised <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zhezIuGQ2XNh" title="Exercised warrant">203,977</span> pre-funded warrants at $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zndWSw7PhBpj" title="Warrant price per share">0.001</span> per share to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfZual2q9C2j" title="Purchase warrant">203,977</span> shares of common
stock from the Securities Purchase Agreement entered into by the Company on August 30, 2023.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183418769040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation and principles of consolidation</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zBY09KwdrUt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zuuL4Fa8DtHb">Basis
of presentation and principles of consolidation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts
and transactions have been eliminated in consolidation. The Company&#8217;s condensed consolidated financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for the interim
financial information and with instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the accompanying
unaudited interim consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary
to state fairly the financial position and results of operations of the Company. These condensed consolidated financial statements and
notes thereto are unaudited and should be read in conjunction with the Company&#8217;s audited financial statements for the year ended
December 31, 2022, as found in the Company&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the
&#8220;SEC&#8221;) on April 17, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
balance sheet for December 31, 2022 was derived from the Company&#8217;s audited financial statements for the year ended December 31,
2022. The results of operations for the periods presented are not necessarily indicative of results that could be expected for the entire
fiscal year due to seasonality and other factors. Certain information and footnote disclosures normally included in the consolidated
financial statements in accordance with U.S. GAAP have been omitted in accordance with the rules and regulations of the SEC for interim
reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p id="xdx_843_eus-gaap--UseOfEstimates_z5P9bh2OVXV3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zqp2oKoziQlc">Use
of estimates</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and
assumptions. The Company believes that the estimates, judgments and assumptions used are reasonable based upon information available
at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during
the reporting period. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency translation</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zzV043tV41G9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zyFn95UYln8">Foreign
currency translation</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-U.S.
dollar denominated transactions and balances have been re-measured to U.S. dollars. All gains and losses from re-measurement of monetary
balance sheet items denominated in non-U.S. dollar currencies are reflected in the statements of operations as other comprehensive income,
as appropriate. The cumulative translation gains for the periods ended September 30, 2023 and 2022 were $<span id="xdx_901_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_pn3n3_c20230101__20230930_zbWCWbb4IAS8" title="Gains and losses from foreign currency translation">36</span> and $<span id="xdx_905_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_pn3n3_c20220101__20220930_zchb15iSrutd" title="Gains and losses from foreign currency translation">57</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p id="xdx_847_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zBAmZ7iek945" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_z6mPWqtr7zX9">Revenue
recognition</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
from product sales are recognized in accordance with ASC 606 &#8220;Revenue Recognition.&#8221; Five basic steps must be followed before
revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying
the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction
price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised
goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires
the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of
each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance
obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the
satisfied performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
from product sales is recorded at the net sales price, or &#8220;transaction price,&#8221; which includes estimates of variable consideration
that result from coupons, discounts and distributor fees, processing fees, as well as allowances for returns and government rebates.
The Company constrains revenue by considering factors that could otherwise lead to a probable reversal of revenue. Collectability of
revenue is reasonably assured based on historical evidence of collectability between the Company and its customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues
from sales to distributors are recognized at the time the products are delivered to the distributors (&#8220;sell-in&#8221;). The Company
does not grant rights of return, credits, rebates, price protection, or other privileges on its products to distributors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted accounting standards</a></td>
<td class="text"><p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zDSs0khjhCVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zueI98NmfDe1">Recently
adopted accounting standards</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13,
Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;)
and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, and ASU 2019-05 (collectively, &#8220;Topic
326&#8221;). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. This ASU is effective
for interim and annual reporting periods beginning after December 15, 2022, including interim periods within those fiscal years. The
Company adopted ASU 2016-13 as of January 1, 2023, and there was no material impact on its condensed consolidated financial statements
upon adoption.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183414084528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF OPTIONS ACTIVITY</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zEFWXkHaWf5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B2_zhm3L1Jach92" style="display: none">SCHEDULE
OF OPTIONS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Shares Under</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Options</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exercise Price</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>per Share</b></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Weighted</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Average</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Remaining</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Life (Years)</b></p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%">Outstanding &#8211; December 31, 2021</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zNYffLFvX0Uc" style="width: 14%; text-align: right" title="Shares Under Options Outstanding, Balance">127,000</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zgSkhIkOChO" style="width: 14%; text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance">31.86</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 14%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zDt92FjsGQp3" title="Weighted Average Remaining Life (Years), Outstanding">7.77</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zlnZXpA0aVik" style="text-align: right" title="Shares Under Options, Granted">6,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z8RyMpLwyUr9" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted">15.56</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_dtY_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zuZ0btfr18r3" title="Weighted Average Remaining Life (Years), Granted">9.89</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z1knTaIsHKY1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Under Options, Exercised">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zUTR0v6d3qyl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding &#8211; March 31, 2022</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zMVdeEOodzCf" style="text-align: right" title="Shares Under Options Outstanding, Balance">133,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zQl75Nkjlwkg" style="text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance">26.00</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zr5TxapXQV4a" title="Weighted Average Remaining Life (Years), Outstanding">7.63</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Granted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zCUkBXnTWWyc" style="text-align: right" title="Shares Under Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0961">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z7XmzNglk7ze" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0963">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zBpqS1kVzeWc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Under Options, Exercised">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zLJTMOxelFuh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding &#8211; June 30, 2022</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zqJCIWFX3hnd" style="text-align: right" title="Shares Under Options Outstanding, Balance">133,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zo5qK40TN7U1" style="text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance">26.00</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zrboyDLisHW2" title="Weighted Average Remaining Life (Years), Outstanding">7.63</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9.9pt">Granted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zuAB7KtmwOgc" style="text-align: right" title="Shares Under Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0975">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zzpgR4r4mgj5" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9.9pt">Exercised</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z2jdDHBBrw8h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Under Options, Exercised">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zDQELXuJ2IQa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding &#8211; September 30, 2022</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zsOdobhd7Pg8" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Under Options Outstanding, Balance">133,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2d_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z0CCFpvoNyBl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance">26.00</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z3pE2Gl58YG6" title="Weighted Average Remaining Life (Years), Outstanding">7.63</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding &#8211; December 31, 2022</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zhoB7bKlR414" style="text-align: right" title="Shares Under Options Outstanding, Balance">147,619</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zZTMNuwfXMNd" style="text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance">24.42</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zVuDGsTgBHac" title="Weighted Average Remaining Life (Years), Outstanding">7.24</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Granted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zwxCNY9xMY36" style="text-align: right" title="Shares Under Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0995">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zc8I37J80Oh8" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0997">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesStockOptionsExpired_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zu0ljdrBE1Yj" style="text-align: right" title="Shares Under Options, Expired">(3,000</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pp2d_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zdsxMDbbetIc" style="text-align: right" title="Weighted Average Exercise Price per Share, Expired">39.20</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm_dtY_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zZYIkwfFvCKg" title="Weighted Average Remaining Life (Years), Expired">0.51</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zKKlmfoL5fgh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Under Options, Exercised">(5,459</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zHwArBRA0DI1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised">1.40</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_dtY_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zGoCC7x1TOGd" title="Weighted Average Remaining Life (Years), Exercised">0.51</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding &#8211; March 31, 2023</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zzICRKZrDv99" style="text-align: right" title="Shares Under Options Outstanding, Balance">139,160</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zxY9fQSGAIP8" style="text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance">25.01</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_znvzozuZiFNh" title="Weighted Average Remaining Life (Years), Outstanding">6.91</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 7.1pt">Granted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zQPtlU2u1WR3" style="text-align: right" title="Shares Under Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1017">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zqgXorGAlGqi" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1019">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 7.1pt">Expired</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98A_ecustom--StockIssuedDuringPeriodSharesStockOptionsExpired_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zZ5ViEPywVh7" style="text-align: right" title="Shares Under Options, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1021">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pp2d_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zyNPEuuCmYKd" style="text-align: right" title="Weighted Average Exercise Price per Share, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1023">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 7.1pt">Exercised</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zWIMiZpYYdgk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Under Options, Exercised">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zy5ROLzGpry6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding &#8211; June 30, 2023</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zlXYWrrCA7l" style="text-align: right" title="Shares Under Options Outstanding, Balance">139,160</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zbXorH9UYMq6" style="text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance">25.01</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zPFowipxeFCh" title="Weighted Average Remaining Life (Years), Outstanding">6.91</span></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 7.1pt">Granted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zaUnOBFzx8ei" style="text-align: right" title="Shares Under Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1035">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z7pFjnUsTmXi" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1037">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 7.1pt">Expired</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98B_ecustom--StockIssuedDuringPeriodSharesStockOptionsExpired_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zETeSBLjgvJb" style="text-align: right" title="Shares Under Options, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1039">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pp2d_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zIkf0SEaFru3" style="text-align: right" title="Weighted Average Exercise Price per Share, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1041">-</span></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 7.1pt">Exercised</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zg3uTmKbCKyh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Under Options, Exercised">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zrbsjjr17xX7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding &#8211; September 30, 2023</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zHePMHa2Oby7" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Under Options Outstanding, Balance">139,160</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2d_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zE9Ci5cTdJlf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance">25.01</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z9vxGd4z7K27" title="Weighted Average Remaining Life (Years), Outstanding">6.91</span></td>
    <td style="text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zExjcrz8ZHZb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total stock-based expense recognized in the financial statements for services received from employees and non-employees is shown in the
following table.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zC3XcNGR5IIa" style="display: none">SCHEDULE
OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20230701__20230930_zJPm9rJ3YLul" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20220701__20220930_z8Ayol1U9W37" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20230101__20230930_z4eXWo6J0sv8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20220930_zkau9nLXEj64" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zpm9UNQIDlji" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">2</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">5</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">5</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zxAO96Pf7cfe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Selling and marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zJLrHJnV5C3g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">108</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">146</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">264</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zQ1JG9Blffpd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">116</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">169</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">287</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zhCI0bKjvrfd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Stock based compensation expense</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">116</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">169</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">287</td><td style="text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">SCHEDULE OF WARRANTS ACTIVITY</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z8XvFRFCbLxj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zDfgzzEvrEod" style="display: none">SCHEDULE
OF WARRANTS ACTIVITY</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Outstanding &#8211; December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zddE0YuW9FJ9" style="width: 16%; text-align: right" title="Warrants, Outstanding, Balance">115,467</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_ziHWn2I0kot6" style="text-align: right" title="Warrants, Granted">12,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zDDixifz4nae" style="text-align: right" title="Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1111">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Cancelled</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zXwywzl08eMb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants, Canceled">(12,500</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding &#8211; September 30, 2022</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zSmCVZnG2QMh" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding, Balance">115,467</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding &#8211; December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zYiwyjNql9n7" style="text-align: right" title="Warrants, Outstanding, Balance">78,252</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zfiMd1yDDYh" style="text-align: right" title="Warrants, Granted">8,758,954</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_z5MSJuCusr78" style="text-align: right" title="Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1121">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Cancelled</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zzRrVoAVykbj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants, Canceled"><span style="-sec-ix-hidden: xdx2ixbrl1123">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding &#8211; September 30, 2023</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_z9fjFUmp2Q8d" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding, Balance">8,837,206</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183408388960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDER (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z69lLnUAhqbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the Company&#8217;s
securities, in common stock equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would
be anti-dilutive:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zkvBOAvkpBB" style="display: none">SUMMARY
OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20230930_zC12P28pi2oi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,<br/>
2023</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20220930_zIQsFF93BkCa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,<br/>
2022</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsEmployeeAndNonEmployeeMember_zn8H6Gp4XC4j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: justify">Stock Options &#8211; employee and non-employee</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 16%; text-align: right">139,160</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 16%; text-align: right">133,000</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_ziANJ0ezVMC3" style="vertical-align: bottom; background-color: White">
    <td>Warrants</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">8,758,954</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">115,467</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_z2j1vvNZGx24" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">8,898,114</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">248,467</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_z504HyESbaM7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Dilutive loss per share</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">8,898,114</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">248,467</td>
    <td style="text-align: left">&#160;</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183414866752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_z3DOMyvmdXR3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zJfCAPWGswq" style="display: none">SUMMARY
OF REVENUE WITHIN GEOGRAPHIC AREAS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20230701__20230930_z02zv56I2Oeh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20220701__20220930_zc4W7I99Nx02" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20230930_z7dl2fup9kt3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20220930_z14epOvXBal9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--US_zeeLV1M7X788" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">445</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">90</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,037</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">828</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--AU_zQ5o3QuASst2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Australia/New Zealand</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__srt--EuropeMember_zgKVvqvUx6Se" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Europe</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1157">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__srt--AsiaMember_zUPESZMg6uOk" style="vertical-align: bottom; background-color: White">
    <td>Asia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1162">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1163">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__custom--OtherCountryMember_z5DkMGZVzMbg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Other</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1168">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1170">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zDD5KOjit4q1" style="vertical-align: bottom; background-color: White">
    <td>Total</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">458</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">97</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,106</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">854</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zeKUERsx4vca" style="display: none; vertical-align: bottom; background-color: White">
    <td>Revenues geographic areas</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">458</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">97</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,106</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">854</td><td style="text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -SubTopic 10<br> -Topic 280<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183418479232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES</a></td>
<td class="text"><p id="xdx_892_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zLxqwPJ6zV63" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about the amount and timing of liabilities arising from the Company&#8217;s operating leases as
of September 30, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zfexwvnadMd5" style="display: none">SCHEDULE
OF LIABILITIES ARISING FROM OPERATING LEASES</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20230930_zdSdZyzWgiV6" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzL7T_zraQzhGcZhwk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">17</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzL7T_zj93CSK5ksjd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzL7T_zQ90fMenEHQd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total undiscounted operating lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_z2KyuYjpTUU8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: Imputed interest</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zXGsFqHDIzfe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Present value of operating lease liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">19</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183418753088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_ScheduleOfWarrantsAssumptionsTableTextBlock', window );">SCHEDULE OF WARRANTS ASSUMPTIONS</a></td>
<td class="text"><p id="xdx_899_ecustom--ScheduleOfWarrantsAssumptionsTableTextBlock_zFCDePnuDPP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zNrs91gyCtqa" style="display: none">SCHEDULE
OF WARRANTS ASSUMPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, <br/> 2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/>2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Price at valuation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20230930__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zbLmK52CByL1" title="Warrants and rights outstanding, measurement input">0.02</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20221231__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zRNhRtck9nX3" title="Warrants and rights outstanding, measurement input">0.02</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zFEjQwQNjodc" title="Warrants and rights outstanding, measurement input">0.19</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_znqqZEmcGNg9" title="Warrants and rights outstanding, measurement input">0.19</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zxaqRMIL5P1k" title="Warrants and rights outstanding, measurement input">4.61</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zkNFvV1yFqpg" title="Warrants and rights outstanding, measurement input">3.96</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230930__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zGLILhGZdGPd" title="Expected term (in years)">7</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zVnNidrWcmA" title="Expected term (in years)">8</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zeiIrl805H45" title="Warrants and rights outstanding, measurement input">147.8</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zN2OgJdmeXhi" title="Warrants and rights outstanding, measurement input">155.6</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE</a></td>
<td class="text"><p id="xdx_893_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zpo1qsKTo0kj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents changes in Level 3 asset and liability measured at fair value for the quarters ended September 30, 2023 and
2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_z0NEQTYj6Gn2" style="display: none">SCHEDULE
OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Asset</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Balance &#8211; December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zUxKh6Ddht2g" style="width: 16%; text-align: right" title="Balance beginning">19</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Fair value adjustments &#8211; Sanuwave warrants</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zdCZPYVEy2Sk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants">(2</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance &#8211; March 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zMclxCGl37vi" style="text-align: right" title="Balance beginning">17</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Fair value adjustments &#8211; Sanuwave warrants</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zNkfGvDw4OKg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants">(8</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance &#8211; June 30, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zpY4Ffqob7T5" style="text-align: right" title="Balance beginning">9</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 7.1pt">Fair value adjustments &#8211; Sanuwave warrants</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zmI0PKlZa9gb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants">(2</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance &#8211; September 30, 2022</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_pn3n3_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zpnfSRk84IZ6" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance ending">7</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance &#8211; December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20230101__20230331__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_z6jsim1FAC46" style="text-align: right" title="Balance beginning">3</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Fair value adjustments &#8211; Sanuwave warrants</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20230331__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zDESfAW8F5Gi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants">2</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance &#8211; March 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20230401__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zN2AtoAvA57b" style="text-align: right" title="Balance beginning">5</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Fair value adjustments &#8211; Sanuwave warrants</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230401__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_z31cVTHyhSq5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants">(2</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance &#8211; June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20230701__20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zctTQIEQJghh" style="text-align: right" title="Balance beginning">3</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Fair value adjustments &#8211; Sanuwave warrants</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230701__20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_z3UfqnDNCVE9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants">(1</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance &#8211; September 30, 2023</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_pn3n3_c20230701__20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zJetDClqh2pj" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance ending">2</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">SCHEDULE OF ASSETS AND LIABILITY MEASURED AT FAIR VALUE</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z9La9bA9cEh2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the Company&#8217;s assets and liabilities which are measured at fair value on a recurring basis by level
within the fair value hierarchy:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zfe70fG0cZua" style="display: none">SCHEDULE
OF ASSETS AND LIABILITY MEASURED AT FAIR VALUE</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z1aYneIPZOB8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level I</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9nEX2WzvbPc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level II</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ztsGne2KXYCe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level III</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20230930_zF5sobBJeuff" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of September 30, 2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level I</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level II</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level III</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Asset:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherAssetsNoncurrent_iI_pn3n3_zpoGgf4YjdN5" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">Other assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1304">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1305">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zPLK0zFyOA6a" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level I</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zj1jCnxhtmJl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level II</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zLa4v91soDf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level III</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20221231_z8eM9y6jLsZk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of December 31, 2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level I</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level II</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level III</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Asset:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherAssetsNoncurrent_iI_pn3n3_zvA3TpYOPNy2" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">Other assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1309">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1310">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_ScheduleOfWarrantsAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Warrants Assumptions [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_ScheduleOfWarrantsAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183407669744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOING CONCERN, LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 22, 2023</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance sale of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholder's equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,690,000<span></span>
</td>
<td class="nump">$ 3,154,000<span></span>
</td>
<td class="nump">$ 4,690,000<span></span>
</td>
<td class="nump">$ 3,154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,165,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">$ 3,233,000<span></span>
</td>
<td class="nump">$ 4,134,000<span></span>
</td>
<td class="nump">$ 6,313,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_ValueOfListedSecurites', window );">Value of listed securities</a></td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income from continuing operations</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(727,000)<span></span>
</td>
<td class="num">$ (955,000)<span></span>
</td>
<td class="num">(2,898,000)<span></span>
</td>
<td class="num">$ (3,389,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,179,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,179,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholder's equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_ValueOfListedSecurites">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of listed securites.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_ValueOfListedSecurites</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183414820160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax', window );">Gains and losses from foreign currency translation</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481839/830-10-45-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183407572528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF OPTIONS ACTIVITY (Details) - Employee Options [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares Under Options Outstanding, Balance</a></td>
<td class="nump">139,160<span></span>
</td>
<td class="nump">139,160<span></span>
</td>
<td class="nump">147,619<span></span>
</td>
<td class="nump">133,000<span></span>
</td>
<td class="nump">133,000<span></span>
</td>
<td class="nump">127,000<span></span>
</td>
<td class="nump">147,619<span></span>
</td>
<td class="nump">127,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Outstanding Balance</a></td>
<td class="nump">$ 25.01<span></span>
</td>
<td class="nump">$ 25.01<span></span>
</td>
<td class="nump">$ 24.42<span></span>
</td>
<td class="nump">$ 26.00<span></span>
</td>
<td class="nump">$ 26.00<span></span>
</td>
<td class="nump">$ 31.86<span></span>
</td>
<td class="nump">$ 24.42<span></span>
</td>
<td class="nump">$ 31.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Life (Years), Outstanding</a></td>
<td class="text">6 years 10 months 28 days<span></span>
</td>
<td class="text">6 years 10 months 28 days<span></span>
</td>
<td class="text">7 years 2 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 7 months 17 days<span></span>
</td>
<td class="text">7 years 9 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares Under Options, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 15.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Life (Years), Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 10 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares Under Options, Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
<td class="num">(5,459)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
<td class="nump">5,459<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Exercised</a></td>
<td class="nump">$ (0)<span></span>
</td>
<td class="nump">$ (0)<span></span>
</td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="nump">$ (0)<span></span>
</td>
<td class="nump">$ (0)<span></span>
</td>
<td class="nump">$ (0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Life (Years), Outstanding</a></td>
<td class="text">6 years 10 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares Under Options Outstanding, Balance</a></td>
<td class="nump">139,160<span></span>
</td>
<td class="nump">139,160<span></span>
</td>
<td class="nump">139,160<span></span>
</td>
<td class="nump">133,000<span></span>
</td>
<td class="nump">133,000<span></span>
</td>
<td class="nump">133,000<span></span>
</td>
<td class="nump">139,160<span></span>
</td>
<td class="nump">133,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Outstanding Balance</a></td>
<td class="nump">$ 25.01<span></span>
</td>
<td class="nump">$ 25.01<span></span>
</td>
<td class="nump">$ 25.01<span></span>
</td>
<td class="nump">$ 26.00<span></span>
</td>
<td class="nump">$ 26.00<span></span>
</td>
<td class="nump">$ 26.00<span></span>
</td>
<td class="nump">$ 25.01<span></span>
</td>
<td class="nump">$ 26.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_StockIssuedDuringPeriodSharesStockOptionsExpired', window );">Shares Under Options, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 39.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Life (Years), Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Life (Years), Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards exercised, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_StockIssuedDuringPeriodSharesStockOptionsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares stock options expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_StockIssuedDuringPeriodSharesStockOptionsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=NAOV_EmployeeOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=NAOV_EmployeeOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183414051136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 116<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
<td class="nump">$ 287<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Selling and Marketing Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
<td class="nump">$ 146<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183416300480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WARRANTS ACTIVITY (Details) - Warrant [Member] - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants, Granted</a></td>
<td class="nump">8,758,954<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Warrants, Canceled</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Private Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants, Outstanding, Balance</a></td>
<td class="nump">78,252<span></span>
</td>
<td class="nump">115,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants, Granted</a></td>
<td class="nump">8,758,954<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Warrants, Canceled</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(12,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants, Outstanding, Balance</a></td>
<td class="nump">8,837,206<span></span>
</td>
<td class="nump">115,467<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=NAOV_PrivateInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=NAOV_PrivateInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183409122240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 30, 2023</div></th>
<th class="th"><div>Jul. 05, 2023</div></th>
<th class="th"><div>Feb. 16, 2023</div></th>
<th class="th"><div>Feb. 08, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-20 Reverse Stock Split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Fractional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169,000<span></span>
</td>
<td class="nump">$ 287,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Non-vested stock options granted, unrecognized estimated compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Non-vested stock options granted, weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 2 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=NAOV_WainwrightMember', window );">Wainwright [Membe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights</a></td>
<td class="nump">218,023<span></span>
</td>
<td class="nump">218,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Class of warrant or right expire date</a></td>
<td class="text">Mar.  01,  2029<span></span>
</td>
<td class="text">Mar.  01,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 2.15<span></span>
</td>
<td class="nump">$ 2.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of new share issued</a></td>
<td class="nump">8,540,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="nump">$ 4,215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of new share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights</a></td>
<td class="nump">2,906,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right exercise price</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of employee options expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Warrants, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,758,954<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Warrants, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=NAOV_A1WarrantsMember', window );">A-1 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights</a></td>
<td class="nump">2,906,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrant exercise price</a></td>
<td class="nump">$ 1.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=NAOV_A2WarrantsMember', window );">A-2 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights</a></td>
<td class="nump">2,906,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrant exercise price</a></td>
<td class="nump">$ 1.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=NAOV_EmployeeOptionsMember', window );">Employee Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of employee options expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
<td class="num">(5,459)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
<td class="nump">5,459<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of employee options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of employee options expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169,000<span></span>
</td>
<td class="nump">$ 285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NAOV_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of new share issued</a></td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NAOV_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights</a></td>
<td class="nump">2,726,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right exercise price</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NAOV_PurchaseAgreementMember', window );">Purchase Agreement [Member] | A-1 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights</a></td>
<td class="nump">2,906,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrant exercise price</a></td>
<td class="nump">$ 1.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Class of warrant or right expire date</a></td>
<td class="text">Mar.  01,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NAOV_PurchaseAgreementMember', window );">Purchase Agreement [Member] | A-2 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights</a></td>
<td class="nump">2,906,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of warrant or right exercise price</a></td>
<td class="nump">$ 1.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrant exercise price</a></td>
<td class="nump">$ 1.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Class of warrant or right expire date</a></td>
<td class="text">Oct.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="nump">$ 1.7199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=NAOV_WainwrightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=NAOV_WainwrightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=NAOV_A1WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=NAOV_A1WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=NAOV_A2WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=NAOV_A2WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=NAOV_EmployeeOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=NAOV_EmployeeOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=NAOV_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=NAOV_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183414233648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive loss per share</a></td>
<td class="nump">8,898,114<span></span>
</td>
<td class="nump">248,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NAOV_StockOptionsEmployeeAndNonEmployeeMember', window );">Stock Options Employee And Non Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive loss per share</a></td>
<td class="nump">139,160<span></span>
</td>
<td class="nump">133,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive loss per share</a></td>
<td class="nump">8,758,954<span></span>
</td>
<td class="nump">115,467<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NAOV_StockOptionsEmployeeAndNonEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NAOV_StockOptionsEmployeeAndNonEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183407705872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues geographic areas</a></td>
<td class="nump">$ 458<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
<td class="nump">$ 1,106<span></span>
</td>
<td class="nump">$ 854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues geographic areas</a></td>
<td class="nump">445<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">1,037<span></span>
</td>
<td class="nump">828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AU', window );">AUSTRALIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues geographic areas</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues geographic areas</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaMember', window );">Asia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues geographic areas</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=NAOV_OtherCountryMember', window );">Other Country [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues geographic areas</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=NAOV_OtherCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=NAOV_OtherCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183416302912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Details Narrative) - Revenue Benchmark [Member] - Customer Concentration Risk [Member]<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Two Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">96.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Customers One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Customers Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">46.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">57.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NAOV_TwoCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NAOV_TwoCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NAOV_CustomersOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NAOV_CustomersOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NAOV_CustomersTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NAOV_CustomersTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183414024704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NAOV_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted operating lease payments</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NAOV_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NAOV_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NAOV_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183408422976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">6 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease, expense</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lease term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lease term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183414027888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF WARRANTS ASSUMPTIONS (Details) - Sanuwave Health, Inc. [Member]<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=NAOV_PriceAtValuationMember', window );">Price at Valuation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">0.02<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember', window );">Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">0.19<span></span>
</td>
<td class="nump">0.19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">4.61<span></span>
</td>
<td class="nump">3.96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected term (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">147.8<span></span>
</td>
<td class="nump">155.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=NAOV_PriceAtValuationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=NAOV_PriceAtValuationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=NAOV_SanuwaveHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=NAOV_SanuwaveHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183414224144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustments - Sanuwave warrants</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=NAOV_DerivativeAssetMember', window );">Derivative Asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Balance beginning</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustments - Sanuwave warrants</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Balance ending</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=NAOV_DerivativeAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=NAOV_DerivativeAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183415603216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ASSETS AND LIABILITY MEASURED AT FAIR VALUE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183414053760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER ASSETS (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Apr. 09, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants leaving balance</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NAOV_LicensingAgreementMember', window );">Licensing Agreement [Member] | Sanuwave Health, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=NAOV_LicensingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=NAOV_LicensingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=NAOV_SanuwaveHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=NAOV_SanuwaveHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183417772000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 15, 2023</div></th>
<th class="th"><div>Feb. 26, 2021</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency damages sought value</a></td>
<td class="nump">$ 1,500,250<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded value</a></td>
<td class="nump">1,432,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Loss contingency damages paid value</a></td>
<td class="nump">$ 68,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=NAOV_ArbitratorMember', window );">Arbitrator [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesPaidValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages paid to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesPaidValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=NAOV_ArbitratorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=NAOV_ArbitratorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183407624848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTION (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees paid</a></td>
<td class="nump">$ 176<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140183413480112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - $ / shares<br></strong></div></th>
<th class="th"><div>Nov. 06, 2023</div></th>
<th class="th"><div>Aug. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Exercised warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,906,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Prefunded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Exercised warrant</a></td>
<td class="nump">203,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant price per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Purchase warrant</a></td>
<td class="nump">203,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=NAOV_PrefundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=NAOV_PrefundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=NAOV_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=NAOV_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>form10-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:NAOV="http://nanovibronix.com/20230930"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="naov-20230930.xsd" xlink:type="simple"/>
    <context id="From2023-01-01to2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2023-11-13</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_SeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_SeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-07-012023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-08-012023-08-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-05-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2023-05-22</instant>
        </period>
    </context>
    <context id="From2023-05-222023-05-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2023-05-22</startDate>
            <endDate>2023-05-22</endDate>
        </period>
    </context>
    <context id="AsOf2023-10-31_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="From2023-02-082023-02-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2023-02-08</startDate>
            <endDate>2023-02-08</endDate>
        </period>
    </context>
    <context id="From2023-02-152023-02-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2023-02-15</startDate>
            <endDate>2023-02-16</endDate>
        </period>
    </context>
    <context id="From2023-08-302023-08-30_custom_PurchaseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-30</startDate>
            <endDate>2023-08-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-30_custom_PurchaseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="AsOf2023-08-30_custom_PurchaseAgreementMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A1WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A1WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="From2023-08-302023-08-30_custom_PurchaseAgreementMember_custom_A1WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A1WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-30</startDate>
            <endDate>2023-08-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A2WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="From2023-08-302023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A2WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-30</startDate>
            <endDate>2023-08-30</endDate>
        </period>
    </context>
    <context id="From2023-08-302023-08-30_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-30</startDate>
            <endDate>2023-08-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-05_custom_WainwrightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:WainwrightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-05</instant>
        </period>
    </context>
    <context id="From2023-07-052023-07-05_custom_WainwrightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:WainwrightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-05</startDate>
            <endDate>2023-07-05</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_EmployeeOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_EmployeeOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_EmployeeOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_EmployeeOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="AsOf2023-08-30_custom_A1WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A1WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="From2023-08-302023-08-30_custom_A1WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A1WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-30</startDate>
            <endDate>2023-08-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-30_custom_A2WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A2WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="From2023-08-302023-08-30_custom_A2WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:A2WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-30</startDate>
            <endDate>2023-08-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-30_custom_WainwrightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:WainwrightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="From2023-08-302023-08-30_custom_WainwrightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:WainwrightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-30</startDate>
            <endDate>2023-08-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_EmployeeOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_EmployeeOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_EmployeeOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_custom_EmployeeOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_EmployeeOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_EmployeeOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_EmployeeOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_EmployeeOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_EmployeeOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_EmployeeOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_EmployeeOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_EmployeeOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:EmployeeOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_SellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_SellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_SellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_SellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_WarrantMember_custom_PrivateInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_WarrantMember_custom_PrivateInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_WarrantMember_custom_PrivateInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember_custom_PrivateInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_WarrantMember_custom_PrivateInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_WarrantMember_custom_PrivateInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PrivateInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_StockOptionsEmployeeAndNonEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NAOV:StockOptionsEmployeeAndNonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_StockOptionsEmployeeAndNonEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NAOV:StockOptionsEmployeeAndNonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_WarrantMember33335218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_WarrantMember33335218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_country_AU">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_country_AU">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_country_AU">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_country_AU">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_srt_AsiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_srt_AsiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_srt_AsiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_srt_AsiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_OtherCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NAOV:OtherCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_OtherCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NAOV:OtherCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_OtherCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NAOV:OtherCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_OtherCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NAOV:OtherCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:TwoCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:TwoCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:CustomersOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:CustomersOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:CustomersTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:CustomersTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:TwoCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:TwoCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:CustomersOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:CustomersOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:CustomersTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:CustomersTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-04-09_custom_LicensingAgreementMember_custom_SanuwaveHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:LicensingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-09</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_PriceAtValuationMember_custom_SanuwaveHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">NAOV:PriceAtValuationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_PriceAtValuationMember_custom_SanuwaveHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">NAOV:PriceAtValuationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_MeasurementInputExercisePriceMember_custom_SanuwaveHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_SanuwaveHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_SanuwaveHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_SanuwaveHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_SanuwaveHealthIncMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SanuwaveHealthIncMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_MeasurementInputPriceVolatilityMember_custom_SanuwaveHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_SanuwaveHealthIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:SanuwaveHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_DerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_DerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_DerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_custom_DerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_DerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_DerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_DerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_DerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_DerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_DerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_DerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_DerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_DerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_DerivativeAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">NAOV:DerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2021-02-252021-02-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-02-26</endDate>
        </period>
    </context>
    <context id="From2023-03-142023-03-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2023-03-14</startDate>
            <endDate>2023-03-15</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ArbitratorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:ArbitratorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ArbitratorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:ArbitratorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-06_us-gaap_SubsequentEventMember_custom_PrefundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PrefundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-06</instant>
        </period>
    </context>
    <context id="AsOf2023-11-06_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-06</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2023-01-01to2023-09-30">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-01-01to2023-09-30">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-01-01to2023-09-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="From2023-01-01to2023-09-30">0001326706</dei:EntityCentralIndexKey>
    <us-gaap:DeferredRevenue
      contextRef="AsOf2023-09-30"
      id="xdx2ixbrl0095"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-09-30"
      id="xdx2ixbrl0116"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0117"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-09-30_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0122"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0123"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-09-30_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0141"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0142"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-09-30_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0160"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0161"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-09-30_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0179"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0180"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-09-30_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0198"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0199"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="From2022-07-012022-09-30"
      id="xdx2ixbrl0281"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0283"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0360"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0367"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0369"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0371"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0373"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0378"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0380"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-07-012022-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0390"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0391"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants
      contextRef="From2022-07-012022-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0398"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0399"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0400"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0401"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0402"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0408"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0410"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0427"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0429"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0431"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0433"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0437"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0438"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0439"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0440"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0447"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0449"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0451"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0453"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0457"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0458"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0459"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0460"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0461"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0463"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0464"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0467"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0468"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0470"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0473"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0474"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants
      contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0477"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants
      contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0478"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants
      contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0479"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants
      contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0480"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants
      contextRef="From2022-01-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0481"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants
      contextRef="From2022-01-012022-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0483"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants
      contextRef="From2022-01-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0484"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0487"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0488"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0489"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0490"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2022-01-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0491"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2022-01-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0492"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2022-01-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0494"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0497"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0498"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0499"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0500"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0501"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0502"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0503"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0507"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0508"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0509"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0510"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0517"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0519"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0521"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0523"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0527"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0528"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0529"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0530"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0537"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0539"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0541"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0543"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0547"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0548"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0549"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0550"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0551"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0553"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0554"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0557"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0558"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0559"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0560"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0561"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0563"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0564"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0569"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0570"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0571"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0572"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0573"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0574"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0576"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0579"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0580"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0581"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0582"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0583"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0584"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0585"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0589"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0590"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0591"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0592"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0599"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0601"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0603"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0605"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0609"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0610"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0611"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0612"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0619"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0621"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0623"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0625"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0629"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0630"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0631"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0632"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0639"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0641"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0643"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0645"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0649"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0650"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0651"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0652"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0653"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0655"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0656"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0659"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0660"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0661"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0662"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0663"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0665"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0666"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0671"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0672"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0673"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0674"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0675"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0676"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0678"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0681"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0682"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0683"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0684"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0685"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0687"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0688"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0693"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0694"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0695"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0696"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0697"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0698"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0699"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0700"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-01to2023-09-30"
      id="xdx2ixbrl0701"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0705"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0706"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0707"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0708"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0709"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0710"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0711"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0715"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0716"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0717"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0718"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0725"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0727"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0729"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0731"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0735"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0736"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0737"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0738"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0745"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesDPreferredStockMember"
      id="xdx2ixbrl0747"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesEPreferredStockMember"
      id="xdx2ixbrl0749"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesFPreferredStockMember"
      id="xdx2ixbrl0751"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:NoncashInterestExpense
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0771"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0816"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0819"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-07-012023-09-30_custom_EmployeeOptionsMember"
      id="xdx2ixbrl0913"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-09-30_custom_EmployeeOptionsMember"
      id="xdx2ixbrl0915"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-07-012022-09-30_custom_EmployeeOptionsMember"
      id="xdx2ixbrl0917"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-04-012022-06-30_custom_EmployeeOptionsMember"
      id="xdx2ixbrl0961"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-04-012022-06-30_custom_EmployeeOptionsMember"
      id="xdx2ixbrl0963"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-07-012022-09-30_custom_EmployeeOptionsMember"
      id="xdx2ixbrl0975"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-07-012022-09-30_custom_EmployeeOptionsMember"
      id="xdx2ixbrl0977"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-03-31_custom_EmployeeOptionsMember"
      id="xdx2ixbrl0995"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-03-31_custom_EmployeeOptionsMember"
      id="xdx2ixbrl0997"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-04-012023-06-30_custom_EmployeeOptionsMember"
      id="xdx2ixbrl1017"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-04-012023-06-30_custom_EmployeeOptionsMember"
      id="xdx2ixbrl1019"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodSharesStockOptionsExpired
      contextRef="From2023-04-012023-06-30_custom_EmployeeOptionsMember"
      id="xdx2ixbrl1021"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-04-012023-06-30_custom_EmployeeOptionsMember"
      id="xdx2ixbrl1023"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-07-012023-09-30_custom_EmployeeOptionsMember"
      id="xdx2ixbrl1035"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-07-012023-09-30_custom_EmployeeOptionsMember"
      id="xdx2ixbrl1037"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodSharesStockOptionsExpired
      contextRef="From2023-07-012023-09-30_custom_EmployeeOptionsMember"
      id="xdx2ixbrl1039"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-07-012023-09-30_custom_EmployeeOptionsMember"
      id="xdx2ixbrl1041"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_custom_PrivateInvestorsMember"
      id="xdx2ixbrl1111"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember_custom_PrivateInvestorsMember"
      id="xdx2ixbrl1121"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember_custom_PrivateInvestorsMember"
      id="xdx2ixbrl1123"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-07-012023-09-30_srt_EuropeMember"
      id="xdx2ixbrl1157"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-07-012023-09-30_srt_AsiaMember"
      id="xdx2ixbrl1162"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-07-012022-09-30_srt_AsiaMember"
      id="xdx2ixbrl1163"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-07-012022-09-30_custom_OtherCountryMember"
      id="xdx2ixbrl1168"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-09-30_custom_OtherCountryMember"
      id="xdx2ixbrl1170"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2023-09-30_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1304"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2023-09-30_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1310"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2023-01-01to2023-09-30">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2023-01-01to2023-09-30">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-01-01to2023-09-30">2023-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2023-01-01to2023-09-30">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2023-01-01to2023-09-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-01-01to2023-09-30">001-36445</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-01-01to2023-09-30">NanoVibronix, Inc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-01-01to2023-09-30">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-01-01to2023-09-30">01-0801232</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-01-01to2023-09-30">525     Executive Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2023-01-01to2023-09-30">Elmsford</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-01-01to2023-09-30">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-01-01to2023-09-30">10523</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-01-01to2023-09-30">(914)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-01-01to2023-09-30">233-3004</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-01-01to2023-09-30">Common     stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-01-01to2023-09-30">NAOV</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-01-01to2023-09-30">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2023-01-01to2023-09-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-01-01to2023-09-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-01-01to2023-09-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-01-01to2023-09-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-01-01to2023-09-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2023-01-01to2023-09-30">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-11-13" decimals="INF" unitRef="Shares">2046308</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Cash contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">3787000</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2713000</us-gaap:Cash>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">32000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">9000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">170000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">712000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">3179000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2175000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">7168000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">5609000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">7000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">7000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">2000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">3000</us-gaap:OtherAssetsNoncurrent>
    <NAOV:SeveranceAssetsNoncurent contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">165000</NAOV:SeveranceAssetsNoncurent>
    <NAOV:SeveranceAssetsNoncurent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">179000</NAOV:SeveranceAssetsNoncurent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">19000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">81000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">193000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">270000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">7361000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">5879000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">62000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">66000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">2311000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2148000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:DeferredRevenue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">21000</us-gaap:DeferredRevenue>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">19000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">81000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">2392000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2316000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">206000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">223000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeNoncurrent contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">73000</us-gaap:DeferredIncomeNoncurrent>
    <us-gaap:DeferredIncomeNoncurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">107000</us-gaap:DeferredIncomeNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">2671000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2646000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-09-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      unitRef="Shares">3000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      unitRef="Shares">3000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-09-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-09-30_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      unitRef="Shares">506</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      unitRef="Shares">506</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-09-30_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_SeriesDPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-09-30_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1999494</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      unitRef="Shares">1999494</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-09-30_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_SeriesEPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30_us-gaap_SeriesFPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_SeriesFPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-09-30_us-gaap_SeriesFPreferredStockMember"
      decimals="INF"
      unitRef="Shares">40000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_SeriesFPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-09-30_us-gaap_SeriesFPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_SeriesFPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_SeriesFPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_SeriesFPreferredStockMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">1842331</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">1842331</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">1641146</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">1641146</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">2000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">70025000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">65634000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">-54000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">-18000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">-65283000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">-62385000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">4690000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">3233000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">7361000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">5879000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">458000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">97000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">1106000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">854000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">109000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">17000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">306000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">387000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">349000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">80000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">800000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">467000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">33000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">49000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">123000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">176000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">190000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">217000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">631000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">760000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">796000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">738000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">2780000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">2835000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">1019000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">1004000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">3534000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">3771000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">-670000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">-924000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">-2734000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">-3304000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">35000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">102000</us-gaap:InterestExpense>
    <NAOV:FinancialExpensesNet
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">-19000</NAOV:FinancialExpensesNet>
    <NAOV:FinancialExpensesNet
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">-16000</NAOV:FinancialExpensesNet>
    <NAOV:FinancialExpensesNet
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">-44000</NAOV:FinancialExpensesNet>
    <NAOV:FinancialExpensesNet
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">-47000</NAOV:FinancialExpensesNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">-724000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">-940000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">-2880000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">-3351000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">3000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">15000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">18000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">38000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">-727000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">-955000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">-2898000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">-3389000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-07-012022-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.68</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-07-012022-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.68</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="USDPShares">-1.73</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="USDPShares">-1.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-09-30"
      decimals="INF"
      unitRef="USDPShares">-2.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-09-30"
      decimals="INF"
      unitRef="USDPShares">-2.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      unitRef="Shares">1721026</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      unitRef="Shares">1721026</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-07-012022-09-30"
      decimals="INF"
      unitRef="Shares">1399890</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-07-012022-09-30"
      decimals="INF"
      unitRef="Shares">1399890</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="Shares">1678684</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="Shares">1678684</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-09-30"
      decimals="INF"
      unitRef="Shares">1399890</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-09-30"
      decimals="INF"
      unitRef="Shares">1399890</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">-727000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">-955000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">-2898000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">-3389000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">-1000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">6000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">36000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">57000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">-726000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">-961000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">-2934000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">-3446000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1399890</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">63468000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-59371000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="-3" unitRef="USD">4134000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">116000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">116000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">-135000</NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants>
    <NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">-135000</NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2022-07-012022-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-6000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">-6000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-955000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">-955000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1399890</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">63449000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-60326000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-09-30" decimals="-3" unitRef="USD">3154000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1399890</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">63162000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">60000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-56937000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">6313000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">287000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">287000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">135000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">135000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants
      contextRef="From2022-01-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">-135000</NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants>
    <NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">135000</NAOV:AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2022-01-012022-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-57000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">-57000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-3389000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">-3389000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1399890</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">63449000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-60326000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-09-30" decimals="-3" unitRef="USD">3154000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1662330</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">65774000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-55000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-64556000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-06-30" decimals="-3" unitRef="USD">1165000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">36000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">36000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">180000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">4215000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">4215000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">1000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-727000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">-727000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1842330</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">70025000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-54000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-65283000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">4690000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1641146</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">65634000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-62385000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">3233000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1641146</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">65634000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-62385000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">3233000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">169000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">169000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">180000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">4215000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">4215000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2023-01-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-36000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">-36000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">5458</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">15726</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-2898000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">-2898000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1842330</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">70025000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-54000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-65283000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">4690000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1842330</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">70025000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      unitRef="USD">-54000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-65283000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">4690000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">-2898000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">-3389000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">1000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">1000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">169000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">287000</us-gaap:ShareBasedCompensation>
    <NAOV:NoncashInterestExpense
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">102000</NAOV:NoncashInterestExpense>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">-1000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">-12000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">23000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">26000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">-542000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">1008000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">1004000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">1378000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">-4000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">-46000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">61000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">-77000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">-55000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">-78000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <NAOV:IncreaseDecreaseInAccruedSeverancePayNet
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">-3000</NAOV:IncreaseDecreaseInAccruedSeverancePayNet>
    <NAOV:IncreaseDecreaseInAccruedSeverancePayNet
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">-2000</NAOV:IncreaseDecreaseInAccruedSeverancePayNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">-3111000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">-5704000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">1000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">4000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">-1000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">-4000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">4215000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">7000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">4222000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">-36000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">-57000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">1074000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">-5765000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">2713000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="-3" unitRef="USD">7737000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">3787000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-09-30" decimals="-3" unitRef="USD">1972000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:NatureOfOperations contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_805_eus-gaap--NatureOfOperations_zvtoRsJwU95f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1 &#x2013; &lt;span id="xdx_827_zgAAM6YqGzga"&gt;DESCRIPTION OF BUSINESS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NanoVibronix,
Inc. (the &#x201c;Company&#x201d;), a Delaware corporation, commenced operations on October 20, 2003 and is a medical device company focusing
on noninvasive biological response-activating devices that target wound healing and pain therapy and can be administered at home, without
the assistance of medical professionals.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s principal research and development activities are conducted in Israel through its wholly owned subsidiary, NanoVibronix
(Israel 2003) Ltd., a company registered in Israel, which commenced operations in October 2003.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <NAOV:GoingConcernAndLiquidityTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_801_ecustom--GoingConcernAndLiquidityTextBlock_zMmT5rxIC1cc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 &#x2013; &lt;span id="xdx_820_zk2DvL6R2hZ7"&gt;GOING CONCERN, LIQUIDITY AND OTHER UNCERTAINTIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Liquidity
and Going Concern&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s ability to continue to operate is dependent mainly on its ability to successfully market and sell its products and the
receipt of additional financing until profitability is achieved. In August 2023, the Company received net proceeds of $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20230801__20230831_zhqmgj7jqGVd" title="Proceeds from issuance sale of equity"&gt;4,215,000&lt;/span&gt; from
the sale of our equity securities. During the three and nine months ended September 30, 2023, the Company has incurred losses as well
as negative cash outflows from operating activities and expects to incur losses and negative cash outflows from operating activities
through at least fiscal year 2024. Because the Company does not have sufficient resources to fund its operations for the next twelve
months from the date of this filing and there could be a significant arbitration payment due (see Note 9), substantial doubt exists as
to the Company&#x2019;s ability to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company will need to raise additional capital to finance its losses and negative cash flows from operations and may continue to be dependent
on additional capital raising as long as our products do not reach commercial profitability. If the Company is unable to obtain additional
financing, the development of its product candidates and the Company&#x2019;s commercial strategy may be impacted and there could be a
material adverse effect on the Company&#x2019;s business and financial condition. These financial statements do not include any adjustments
that may result from the outcome of this uncertainty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Other
Uncertainties&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 23, 2023, we received a letter from the Listing Qualifications Department of Nasdaq indicating that we no longer comply with the
minimum stockholders&#x2019; equity requirement under Nasdaq Listing Rule 5550(b)(1) (the &#x201c;Rule&#x201d;) for continued listing on
Nasdaq because our stockholders&#x2019; equity of approximately $&lt;span id="xdx_90C_eus-gaap--StockholdersEquity_iI_pn5n6_c20230331_zYwx4zz4VUVe" title="Stockholder's equity"&gt;2.2&lt;/span&gt; million as reported in our Quarterly Report on Form 10-Q for the
period ended March 31, 2023, is below the required minimum of $&lt;span id="xdx_902_eus-gaap--StockholdersEquity_iI_pn5n6_c20230331__srt--RangeAxis__srt--MinimumMember_zUklhW6vLmca" title="Stockholder's equity"&gt;2.5&lt;/span&gt; million, and as of May 22, 2023, we did not meet the alternative compliance
standards relating to the market value of listed securities of $&lt;span id="xdx_901_ecustom--ValueOfListedSecurites_iI_pn6n6_c20230522_zdfmiMlumnsk" title="Value of listed securities"&gt;35&lt;/span&gt; million or net income from continuing operations of $&lt;span id="xdx_900_eus-gaap--NetIncomeLoss_pn3d_c20230522__20230522_zV3rMQU4XvHb" title="Net income from continuing operations"&gt;500,000&lt;/span&gt; in the
most recently completed fiscal year or in two of the last three most recently completed fiscal years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with Nasdaq Listing Rules, we had 45 calendar days, or until July 7, 2023, to submit a plan to regain compliance. On July
7, 2023, we submitted our plan to regain compliance with the Nasdaq minimum stockholders&#x2019; equity standard. On July 19, 2023, the
Staff granted the Company&#x2019;s plan and granted our request for continued listing pursuant to an extension through November 20, 2023
to evidence compliance with the Rule. We believe that upon filing of this Form 10-Q, we should have provided sufficient evidence of compliance
with Nasdaq.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2023, Hamas terrorists infiltrated Israel&#x2019;s southern border from the Gaza Strip and conducted a series of attacks on civilian
and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#x2019;s
border with the Gaza Strip and in other areas within the State of Israel. Following the attack, Israel&#x2019;s security cabinet declared
war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror
attacks. Moreover, the clash between Israel and Hezbollah in Lebanon, may escalate in the future into a greater regional conflict&lt;/span&gt;,
especially in the northern part of Israel where our Israel office is located which stores approximately $&lt;span id="xdx_906_eus-gaap--InventoryNet_iI_pn5n6_c20231031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zg5GePQ0Qte7"&gt;2.1&lt;/span&gt; million worth of our inventory.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;This conflict could cause a&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n
inability to receive supplies and materials, shortages of materials or difficulties in procuring our materials, among others, or
conversely, our ability to ship products to our US facilities or overseas customers, may adversely impact our ability to
commercialize and manufacture our product candidates and products in a timely manner. This could also cause delays the review of our product candidates by regulatory agencies, which in turn would have a material adverse impact on our ability to
commercialize those  product candidates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</NAOV:GoingConcernAndLiquidityTextBlock>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2023-08-012023-08-31"
      decimals="0"
      unitRef="USD">4215000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-03-31" decimals="-5" unitRef="USD">2200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_srt_MinimumMember"
      decimals="-5"
      unitRef="USD">2500000</us-gaap:StockholdersEquity>
    <NAOV:ValueOfListedSecurites contextRef="AsOf2023-05-22" decimals="-6" unitRef="USD">35000000</NAOV:ValueOfListedSecurites>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-05-222023-05-22"
      decimals="-3"
      unitRef="USD">500000</us-gaap:NetIncomeLoss>
    <us-gaap:InventoryNet
      contextRef="AsOf2023-10-31_us-gaap_SubsequentEventMember"
      decimals="-5"
      unitRef="USD">2100000</us-gaap:InventoryNet>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_802_eus-gaap--SignificantAccountingPoliciesTextBlock_zbQvJSucPhWc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3 &#x2013; &lt;span id="xdx_827_zTpsvuW9FIKf"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zBY09KwdrUt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zuuL4Fa8DtHb"&gt;Basis
of presentation and principles of consolidation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts
and transactions have been eliminated in consolidation. The Company&#x2019;s condensed consolidated financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for the interim
financial information and with instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the accompanying
unaudited interim consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary
to state fairly the financial position and results of operations of the Company. These condensed consolidated financial statements and
notes thereto are unaudited and should be read in conjunction with the Company&#x2019;s audited financial statements for the year ended
December 31, 2022, as found in the Company&#x2019;s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the
&#x201c;SEC&#x201d;) on April 17, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
balance sheet for December 31, 2022 was derived from the Company&#x2019;s audited financial statements for the year ended December 31,
2022. The results of operations for the periods presented are not necessarily indicative of results that could be expected for the entire
fiscal year due to seasonality and other factors. Certain information and footnote disclosures normally included in the consolidated
financial statements in accordance with U.S. GAAP have been omitted in accordance with the rules and regulations of the SEC for interim
reporting.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--UseOfEstimates_z5P9bh2OVXV3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_zqp2oKoziQlc"&gt;Use
of estimates&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and
assumptions. The Company believes that the estimates, judgments and assumptions used are reasonable based upon information available
at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during
the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zzV043tV41G9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_868_zyFn95UYln8"&gt;Foreign
currency translation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-U.S.
dollar denominated transactions and balances have been re-measured to U.S. dollars. All gains and losses from re-measurement of monetary
balance sheet items denominated in non-U.S. dollar currencies are reflected in the statements of operations as other comprehensive income,
as appropriate. The cumulative translation gains for the periods ended September 30, 2023 and 2022 were $&lt;span id="xdx_901_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_pn3n3_c20230101__20230930_zbWCWbb4IAS8" title="Gains and losses from foreign currency translation"&gt;36&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_pn3n3_c20220101__20220930_zchb15iSrutd" title="Gains and losses from foreign currency translation"&gt;57&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zBAmZ7iek945" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_869_z6mPWqtr7zX9"&gt;Revenue
recognition&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues
from product sales are recognized in accordance with ASC 606 &#x201c;Revenue Recognition.&#x201d; Five basic steps must be followed before
revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying
the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction
price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised
goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires
the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of
each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance
obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the
satisfied performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
from product sales is recorded at the net sales price, or &#x201c;transaction price,&#x201d; which includes estimates of variable consideration
that result from coupons, discounts and distributor fees, processing fees, as well as allowances for returns and government rebates.
The Company constrains revenue by considering factors that could otherwise lead to a probable reversal of revenue. Collectability of
revenue is reasonably assured based on historical evidence of collectability between the Company and its customers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues
from sales to distributors are recognized at the time the products are delivered to the distributors (&#x201c;sell-in&#x201d;). The Company
does not grant rights of return, credits, rebates, price protection, or other privileges on its products to distributors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zDSs0khjhCVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zueI98NmfDe1"&gt;Recently
adopted accounting standards&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13,
Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU 2016-13&#x201d;)
and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, and ASU 2019-05 (collectively, &#x201c;Topic
326&#x201d;). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. This ASU is effective
for interim and annual reporting periods beginning after December 15, 2022, including interim periods within those fiscal years. The
Company adopted ASU 2016-13 as of January 1, 2023, and there was no material impact on its condensed consolidated financial statements
upon adoption.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_85A_zKL4xcse8Vd5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zBY09KwdrUt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_866_zuuL4Fa8DtHb"&gt;Basis
of presentation and principles of consolidation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts
and transactions have been eliminated in consolidation. The Company&#x2019;s condensed consolidated financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for the interim
financial information and with instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the accompanying
unaudited interim consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary
to state fairly the financial position and results of operations of the Company. These condensed consolidated financial statements and
notes thereto are unaudited and should be read in conjunction with the Company&#x2019;s audited financial statements for the year ended
December 31, 2022, as found in the Company&#x2019;s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the
&#x201c;SEC&#x201d;) on April 17, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
balance sheet for December 31, 2022 was derived from the Company&#x2019;s audited financial statements for the year ended December 31,
2022. The results of operations for the periods presented are not necessarily indicative of results that could be expected for the entire
fiscal year due to seasonality and other factors. Certain information and footnote disclosures normally included in the consolidated
financial statements in accordance with U.S. GAAP have been omitted in accordance with the rules and regulations of the SEC for interim
reporting.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_843_eus-gaap--UseOfEstimates_z5P9bh2OVXV3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_86B_zqp2oKoziQlc"&gt;Use
of estimates&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and
assumptions. The Company believes that the estimates, judgments and assumptions used are reasonable based upon information available
at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during
the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_84F_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zzV043tV41G9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_868_zyFn95UYln8"&gt;Foreign
currency translation&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-U.S.
dollar denominated transactions and balances have been re-measured to U.S. dollars. All gains and losses from re-measurement of monetary
balance sheet items denominated in non-U.S. dollar currencies are reflected in the statements of operations as other comprehensive income,
as appropriate. The cumulative translation gains for the periods ended September 30, 2023 and 2022 were $&lt;span id="xdx_901_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_pn3n3_c20230101__20230930_zbWCWbb4IAS8" title="Gains and losses from foreign currency translation"&gt;36&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_pn3n3_c20220101__20220930_zchb15iSrutd" title="Gains and losses from foreign currency translation"&gt;57&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">36000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">57000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_847_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zBAmZ7iek945" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_869_z6mPWqtr7zX9"&gt;Revenue
recognition&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues
from product sales are recognized in accordance with ASC 606 &#x201c;Revenue Recognition.&#x201d; Five basic steps must be followed before
revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying
the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction
price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised
goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires
the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of
each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance
obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the
satisfied performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
from product sales is recorded at the net sales price, or &#x201c;transaction price,&#x201d; which includes estimates of variable consideration
that result from coupons, discounts and distributor fees, processing fees, as well as allowances for returns and government rebates.
The Company constrains revenue by considering factors that could otherwise lead to a probable reversal of revenue. Collectability of
revenue is reasonably assured based on historical evidence of collectability between the Company and its customers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues
from sales to distributors are recognized at the time the products are delivered to the distributors (&#x201c;sell-in&#x201d;). The Company
does not grant rights of return, credits, rebates, price protection, or other privileges on its products to distributors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zDSs0khjhCVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&lt;span id="xdx_860_zueI98NmfDe1"&gt;Recently
adopted accounting standards&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13,
Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU 2016-13&#x201d;)
and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, and ASU 2019-05 (collectively, &#x201c;Topic
326&#x201d;). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. This ASU is effective
for interim and annual reporting periods beginning after December 15, 2022, including interim periods within those fiscal years. The
Company adopted ASU 2016-13 as of January 1, 2023, and there was no material impact on its condensed consolidated financial statements
upon adoption.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zUC6nYDaty42" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4 &#x2013;&lt;span id="xdx_822_zM2k2FhcpeY6"&gt; STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Common
stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
common stock confers upon the holders the right to receive notice to participate and vote in general meetings of the Company, and the
right to receive dividends, if declared, and to participate in the distribution of the surplus assets and funds of the Company in the
event of liquidation, dissolution or winding up of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Reverse
stock split&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 8, 2023, the Company effected a reverse stock split of its common stock at a ratio of 1 post-split share for every 20 pre-split
shares. The Company&#x2019;s common stock begin trading on a split-adjusted basis when the market opened on February 9, 2023 (the &#x201c;Reverse
Stock Split&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the effective time of the Reverse Stock Split, every 20 shares of the Company&#x2019;s issued and outstanding common stock were converted
automatically into one issued and outstanding share of common stock without any change in the par value per share. Stockholders holding
shares through a brokerage account had their shares automatically adjusted to reflect the &lt;span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20230208__20230208_zLC1i1LhWeOj" title="Reverse stock split"&gt;1-for-20 Reverse Stock Split&lt;/span&gt;. The Reverse Stock
Split affected all stockholders uniformly and did not alter any stockholder&#x2019;s percentage interest in the Company&#x2019;s equity,
except to the extent that the Reverse Stock Split resulted in a stockholder owning a fractional share. Any fractional share of a stockholder
resulting from the Reverse Stock Split was rounded up to the nearest whole number of shares. Proportional adjustments were made to the
number of shares of the Company&#x2019;s common stock issuable upon exercise or conversion of the Company&#x2019;s equity awards, warrants
and other convertible securities, as well as the applicable exercise or conversion price thereof. On February 16, 2023, the Company rounded
up fractional shares to its nearest whole number of &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20230215__20230216_z2wwKcccHXd6" title="Fractional shares"&gt;15,726&lt;/span&gt; shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
references in this Report to number of shares, price per share and weighted average number of shares of common stock outstanding prior
to the Reverse Stock Split have been adjusted to reflect the Reverse Stock Split on a retroactive basis, unless otherwise noted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Issuance
of common stock for cash through private placement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 30, 2023, the Company entered into a securities purchase agreement (the &#x201c;Purchase Agreement&#x201d;) with an institutional
investor for the issuance and sale in a private placement (the &#x201c;Private Placement&#x201d;) of &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlFv0NaUbej4" title="Number of new share issued"&gt;180,000&lt;/span&gt; shares (the &#x201c;Common
Shares&#x201d;) of common stock, par value $&lt;span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXkviiOOVyCi" title="Common stock, par value"&gt;0.001&lt;/span&gt; per share (the &#x201c;Common Stock&#x201d;), pre-funded warrants (&#x201c;Pre-Funded Warrants&#x201d;)
to purchase up to &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGBfViebVFS4" title="Number of securities called by warrants or rights"&gt;2,726,977&lt;/span&gt; shares of common stock, with an exercise price of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrXBo42AE23k" title="Class of warrant or right, exercise price of warrants"&gt;0.0001&lt;/span&gt; per share, A-1 Warrants (the &#x201c;A-1 Warrants&#x201d;)
to purchase up to &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zw3vbYxYjMF6" title="Number of securities called by warrants or rights"&gt;2,906,977&lt;/span&gt; shares of Common Stock, with an exercise price of $&lt;span id="xdx_908_eus-gaap--WarrantExercisePriceIncrease_pid_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zHPPujQoM1H" title="Warrant exercise price"&gt;1.47&lt;/span&gt; per share, and A-2 Warrants (the &#x201c;A-2 Warrants&#x201d;
and together with the A-1 Warrants, the &#x201c;Warrants&lt;b&gt;&lt;i&gt;&#x201d;&lt;/i&gt;&lt;/b&gt; ) to purchase up to &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_z1OTkJGj2wRk" title="Number of securities called by warrants or rights"&gt;2,906,977&lt;/span&gt; shares of Common Stock with
an exercise price of $&lt;span id="xdx_90D_eus-gaap--WarrantExercisePriceIncrease_pid_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zPDC2CFwamLj" title="Warrant exercise price"&gt;1.47&lt;/span&gt; per share. The A-1 Warrants are exercisable immediately upon issuance and expire &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zLVai5Gpwz62" title="Class of warrant or right expire date"&gt;March 1, 2029&lt;/span&gt;. The A-2 Warrants
are exercisable immediately upon issuance and expire &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zPS1XQ2gnNSd" title="Class of warrant or right expire date"&gt;October 1, 2024&lt;/span&gt;. The combined purchase price for one Common Share and the accompanying
Warrants was $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zlm50Hz5cl7e" title="Class of warrant or right exercise price"&gt;1.72&lt;/span&gt;, and the combined purchase price for one Pre-Funded Warrant and the accompanying Warrants was $&lt;span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zILTh77GSs2l" title="Shares issued, price per share"&gt;1.7199&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
net proceeds to the Company from the Private Placement are approximately $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20230830__20230830__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zswqXNxNBuil" title="Proceeds from issuance of private placement"&gt;4,215,000&lt;/span&gt;, after deducting placement agent fees and expenses
and estimated offering expenses payable by the Company. The Company intends to use the net proceeds received from the Private Placement
for general corporate purposes, including funding of our development programs, commercial planning and sales and marketing expenses,
potential strategic acquisitions, general and administrative expenses and working capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;H.C.
Wainwright &amp;amp; Co., LLC (&#x201c;Wainwright&#x201d;) served as the Company&#x2019;s exclusive placement agent in connection with the Private
Placement, pursuant to that certain engagement letter, dated as of July 5, 2023, as amended, between us and Wainwright (the &#x201c;Engagement
Letter&#x201d;). As part of Wainwright&#x2019;s compensation, we issued to Wainwright or its designees warrants (the &#x201c;Placement Agent
Warrants&#x201d;) to purchase up to an aggregate of &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230705__srt--TitleOfIndividualAxis__custom--WainwrightMember_zzMwmkvEsIik" title="Number of securities called by warrants or rights"&gt;218,023 &lt;/span&gt;shares of Common Stock at an exercise price equal to $&lt;span id="xdx_908_eus-gaap--SharePrice_iI_pid_c20230705__srt--TitleOfIndividualAxis__custom--WainwrightMember_zAzEnEDVXIwk" title="Share price"&gt;2.15 &lt;/span&gt;per share. The
Placement Agent Warrants are exercisable immediately upon issuance and expire &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20230705__20230705__srt--TitleOfIndividualAxis__custom--WainwrightMember_zdOA1L7DcnRk" title="Class of warrant or right expire date"&gt;March 1, 2029&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Stock-based
compensation and Options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three and nine-month period ended September 30, 2023, &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zwU73p1gvLgb" title="Number of options, exercised"&gt;0&lt;/span&gt; and&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zq8u4ttHowbi" title="Number of options, exercised"&gt; 5,459&lt;/span&gt; employee options were exercised respectively. During the three
and nine-month period ended September 30, 2022, &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_ztRgjbj3PONa" title="Number of options, exercised"&gt;&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z9Vw6YBYG04l" title="Number of options, exercised"&gt;no&lt;/span&gt;&lt;/span&gt; employee options were exercised. During the three and nine-month period ended September
30, 2023, &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_dxL_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zLWXgG66SCm9" title="Number of employee options granted::XDX::-"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_dxL_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zQR2mJdHWk8" title="Number of employee options granted::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0913"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0915"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; employee options were granted. During the three and nine-month period ended September 30, 2022, &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_dxL_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zEob1MEI8nm1" title="Number of employee options granted::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0917"&gt;0&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zateONgWrs7c" title="Number of employee options granted"&gt;6,000&lt;/span&gt; employee options
were granted, respectively. During the three and nine-month period ended September 30, 2023, &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zPxxhvlvH9g6" title="Number of employee options expired"&gt;0&lt;/span&gt; and &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zgX9q3tgJCG4" title="Number of employee options expired"&gt;3,000&lt;/span&gt; employee options expired. During
the three and nine-month period ended September 30, 2022, &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zcqLjKaA47nc" title="Number of employee options expired"&gt;&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zDu5BGUxuKu6" title="Number of employee options expired"&gt;no&lt;/span&gt;&lt;/span&gt; employee options expired.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The options granted to employees and board members
were recorded at a fair value and vested over three years. During the three and nine-month period ended September 30, 2023, stock-based
compensation expense of $&lt;span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_znkmRBm3AN02" title="Stock-based compensation expense"&gt;36&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zRLWYT3exfm8" title="Stock-based compensation expense"&gt;169&lt;/span&gt; was recorded for options that vested, respectively. During the three and nine-month period ended
September 30, 2022, stock-based compensation expense of $&lt;span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z1tdMI9wGC77" title="Stock-based compensation expense"&gt;116&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zfBERijeiVAb" title="Stock-based compensation expense"&gt;285&lt;/span&gt; was recorded for options that vested, respectively.&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zEFWXkHaWf5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zhm3L1Jach92" style="display: none"&gt;SCHEDULE
OF OPTIONS ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Shares Under&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;per Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Life (Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%"&gt;Outstanding &#x2013; December 31, 2021&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zNYffLFvX0Uc" style="width: 14%; text-align: right" title="Shares Under Options Outstanding, Balance"&gt;127,000&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zgSkhIkOChO" style="width: 14%; text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance"&gt;31.86&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zDt92FjsGQp3" title="Weighted Average Remaining Life (Years), Outstanding"&gt;7.77&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zlnZXpA0aVik" style="text-align: right" title="Shares Under Options, Granted"&gt;6,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z8RyMpLwyUr9" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"&gt;15.56&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_dtY_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zuZ0btfr18r3" title="Weighted Average Remaining Life (Years), Granted"&gt;9.89&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z1knTaIsHKY1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Under Options, Exercised"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zUTR0v6d3qyl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding &#x2013; March 31, 2022&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zMVdeEOodzCf" style="text-align: right" title="Shares Under Options Outstanding, Balance"&gt;133,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zQl75Nkjlwkg" style="text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance"&gt;26.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zr5TxapXQV4a" title="Weighted Average Remaining Life (Years), Outstanding"&gt;7.63&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zCUkBXnTWWyc" style="text-align: right" title="Shares Under Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0961"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z7XmzNglk7ze" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0963"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zBpqS1kVzeWc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Under Options, Exercised"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zLJTMOxelFuh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding &#x2013; June 30, 2022&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zqJCIWFX3hnd" style="text-align: right" title="Shares Under Options Outstanding, Balance"&gt;133,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zo5qK40TN7U1" style="text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance"&gt;26.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zrboyDLisHW2" title="Weighted Average Remaining Life (Years), Outstanding"&gt;7.63&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9.9pt"&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zuAB7KtmwOgc" style="text-align: right" title="Shares Under Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0975"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zzpgR4r4mgj5" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0977"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9.9pt"&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z2jdDHBBrw8h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Under Options, Exercised"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zDQELXuJ2IQa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding &#x2013; September 30, 2022&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zsOdobhd7Pg8" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Under Options Outstanding, Balance"&gt;133,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2d_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z0CCFpvoNyBl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance"&gt;26.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z3pE2Gl58YG6" title="Weighted Average Remaining Life (Years), Outstanding"&gt;7.63&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding &#x2013; December 31, 2022&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zhoB7bKlR414" style="text-align: right" title="Shares Under Options Outstanding, Balance"&gt;147,619&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zZTMNuwfXMNd" style="text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance"&gt;24.42&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zVuDGsTgBHac" title="Weighted Average Remaining Life (Years), Outstanding"&gt;7.24&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zwxCNY9xMY36" style="text-align: right" title="Shares Under Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0995"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zc8I37J80Oh8" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0997"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesStockOptionsExpired_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zu0ljdrBE1Yj" style="text-align: right" title="Shares Under Options, Expired"&gt;(3,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pp2d_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zdsxMDbbetIc" style="text-align: right" title="Weighted Average Exercise Price per Share, Expired"&gt;39.20&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm_dtY_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zZYIkwfFvCKg" title="Weighted Average Remaining Life (Years), Expired"&gt;0.51&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zKKlmfoL5fgh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Under Options, Exercised"&gt;(5,459&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zHwArBRA0DI1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised"&gt;1.40&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_dtY_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zGoCC7x1TOGd" title="Weighted Average Remaining Life (Years), Exercised"&gt;0.51&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding &#x2013; March 31, 2023&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zzICRKZrDv99" style="text-align: right" title="Shares Under Options Outstanding, Balance"&gt;139,160&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zxY9fQSGAIP8" style="text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance"&gt;25.01&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_znvzozuZiFNh" title="Weighted Average Remaining Life (Years), Outstanding"&gt;6.91&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 7.1pt"&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zQPtlU2u1WR3" style="text-align: right" title="Shares Under Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1017"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zqgXorGAlGqi" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1019"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 7.1pt"&gt;Expired&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--StockIssuedDuringPeriodSharesStockOptionsExpired_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zZ5ViEPywVh7" style="text-align: right" title="Shares Under Options, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1021"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pp2d_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zyNPEuuCmYKd" style="text-align: right" title="Weighted Average Exercise Price per Share, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1023"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 7.1pt"&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zWIMiZpYYdgk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Under Options, Exercised"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zy5ROLzGpry6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding &#x2013; June 30, 2023&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zlXYWrrCA7l" style="text-align: right" title="Shares Under Options Outstanding, Balance"&gt;139,160&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zbXorH9UYMq6" style="text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance"&gt;25.01&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zPFowipxeFCh" title="Weighted Average Remaining Life (Years), Outstanding"&gt;6.91&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 7.1pt"&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zaUnOBFzx8ei" style="text-align: right" title="Shares Under Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1035"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z7pFjnUsTmXi" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1037"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 7.1pt"&gt;Expired&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--StockIssuedDuringPeriodSharesStockOptionsExpired_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zETeSBLjgvJb" style="text-align: right" title="Shares Under Options, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1039"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pp2d_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zIkf0SEaFru3" style="text-align: right" title="Weighted Average Exercise Price per Share, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1041"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 7.1pt"&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zg3uTmKbCKyh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Under Options, Exercised"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zrbsjjr17xX7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding &#x2013; September 30, 2023&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zHePMHa2Oby7" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Under Options Outstanding, Balance"&gt;139,160&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2d_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zE9Ci5cTdJlf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance"&gt;25.01&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z9vxGd4z7K27" title="Weighted Average Remaining Life (Years), Outstanding"&gt;6.91&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AC_zaOEmmrGypkh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zExjcrz8ZHZb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
total stock-based expense recognized in the financial statements for services received from employees and non-employees is shown in the
following table.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zC3XcNGR5IIa" style="display: none"&gt;SCHEDULE
OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230701__20230930_zJPm9rJ3YLul" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220701__20220930_z8Ayol1U9W37" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230101__20230930_z4eXWo6J0sv8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20220101__20220930_zkau9nLXEj64" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Nine Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zpm9UNQIDlji" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;2&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zxAO96Pf7cfe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Selling and marketing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zJLrHJnV5C3g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;108&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;264&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zQ1JG9Blffpd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;116&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;169&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;287&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zhCI0bKjvrfd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Stock based compensation expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;116&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;169&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;287&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A7_zsDGAXzQJCxk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2023, the total unrecognized estimated compensation cost related to non-vested stock options granted prior to that date
was $&lt;span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20230930_zKVv5POdawNb" title="Non-vested stock options granted, unrecognized estimated compensation cost"&gt;159&lt;/span&gt;, which is expected to be recognized over a weighted average period of approximately &lt;span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20230930_zzNUxds7L2pa" title="Non-vested stock options granted, weighted average period"&gt;1.19&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 30, 2023, the Company granted (a) Pre-Funded Warrants to purchase up to &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgLlKrYWqyi1"&gt;2,906,977 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares
of Common Stock with an exercise price of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8sDOiEjMW87"&gt;0.0001 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per
share, (b) A-1 Warrants to purchase up to &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zYyu2zjnwsX7"&gt;2,906,977 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares
of Common Stock with an exercise price of $&lt;span id="xdx_906_eus-gaap--WarrantExercisePriceIncrease_pid_c20230830__20230830__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zAAhcBrwMzPh" title="Warrant exercise price"&gt;1.47 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per
share and (c) A-2 Warrants to purchase up to &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zGGqxRjfGPrj"&gt;2,906,977 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares
of Common Stock with an exercise price of $&lt;span id="xdx_907_eus-gaap--WarrantExercisePriceIncrease_pid_c20230830__20230830__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zMkGtiS8shcg"&gt;1.47 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per
share, or a total of &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230830__20230830__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zoAtEc7xw6Y1"&gt;8,540,931 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants,
in conjunction with the Private Placement disclosed above. The A-1 Warrants and A-2 Warrants are exercisable immediately upon
issuance and expire on &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A1WarrantsMember_zHLF7G5BJiG9"&gt;March
1, 2029&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20230830__20230830__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--A2WarrantsMember_zcKEkV8QAEa3"&gt;October
1, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For the same Private
Placement, the Company granted Placement Agent Warrants to Wainwright, or its designees, to purchase up to an aggregate of &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__srt--TitleOfIndividualAxis__custom--WainwrightMember_ziJKg2u1UTi3"&gt;218,023 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares
of Common Stock at an exercise price equal to $&lt;span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20230830__srt--TitleOfIndividualAxis__custom--WainwrightMember_z6j9oBc7RhZ3"&gt;2.15 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per
share. The Placement Agent Warrants are exercisable immediately upon issuance and expire &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_c20230830__20230830__srt--TitleOfIndividualAxis__custom--WainwrightMember_z4hE5HGKB5Yl"&gt;March
1, 2029&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the nine months ended September 30, 2023 and 2022, there were &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNUT0NLSE9MREVSU5IgRVFVSVRZIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgkwpILmJbUg" title="Warrants, granted"&gt;8,758,954&lt;/span&gt; and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNUT0NLSE9MREVSU5IgRVFVSVRZIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwSCyeSMHzKc" title="Warrants, granted"&gt;12,500&lt;/span&gt; warrants granted, respectively. For the nine months
ended September 30, 2023 and 2022, there were &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNUT0NLSE9MREVSU5IgRVFVSVRZIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_do_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoqf0PEG2xNi" title="Warrants, exercised"&gt;0&lt;/span&gt; and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNUT0NLSE9MREVSU5IgRVFVSVRZIChEZXRhaWxzIE5hcnJhdGl2ZSkA" id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_do_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zn3A0mi9JvT5" title="Warrants, exercised"&gt;12,500&lt;/span&gt; warrants exercised and/ or cancelled.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z8XvFRFCbLxj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_zDfgzzEvrEod" style="display: none"&gt;SCHEDULE
OF WARRANTS ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Outstanding &#x2013; December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zddE0YuW9FJ9" style="width: 16%; text-align: right" title="Warrants, Outstanding, Balance"&gt;115,467&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_ziHWn2I0kot6" style="text-align: right" title="Warrants, Granted"&gt;12,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zDDixifz4nae" style="text-align: right" title="Warrants, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1111"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zXwywzl08eMb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants, Canceled"&gt;(12,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding &#x2013; September 30, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zSmCVZnG2QMh" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding, Balance"&gt;115,467&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zYiwyjNql9n7" style="text-align: right" title="Warrants, Outstanding, Balance"&gt;78,252&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zfiMd1yDDYh" style="text-align: right" title="Warrants, Granted"&gt;8,758,954&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_z5MSJuCusr78" style="text-align: right" title="Warrants, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1121"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zzRrVoAVykbj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants, Canceled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1123"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding &#x2013; September 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_z9fjFUmp2Q8d" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding, Balance"&gt;8,837,206&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zpzRfliPdog7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2023-02-082023-02-08">1-for-20 Reverse Stock Split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2023-02-152023-02-16"
      decimals="INF"
      unitRef="Shares">15726</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-08-302023-08-30_custom_PurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">180000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">2726977</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A1WarrantsMember"
      decimals="INF"
      unitRef="Shares">2906977</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2023-08-302023-08-30_custom_PurchaseAgreementMember_custom_A1WarrantsMember"
      decimals="INF"
      unitRef="USDPShares">1.47</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember"
      decimals="INF"
      unitRef="Shares">2906977</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2023-08-302023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember"
      decimals="INF"
      unitRef="USDPShares">1.47</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="From2023-08-302023-08-30_custom_PurchaseAgreementMember_custom_A1WarrantsMember">2029-03-01</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="From2023-08-302023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember">2024-10-01</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember"
      decimals="INF"
      unitRef="USDPShares">1.72</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember"
      decimals="INF"
      unitRef="USDPShares">1.7199</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2023-08-302023-08-30_us-gaap_PrivatePlacementMember"
      decimals="0"
      unitRef="USD">4215000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-07-05_custom_WainwrightMember"
      decimals="INF"
      unitRef="Shares">218023</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharePrice
      contextRef="AsOf2023-07-05_custom_WainwrightMember"
      decimals="INF"
      unitRef="USDPShares">2.15</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="From2023-07-052023-07-05_custom_WainwrightMember">2029-03-01</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-07-012023-09-30_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-09-30_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="Shares">5459</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-07-012022-09-30_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-09-30_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-09-30_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="Shares">6000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2023-07-012023-09-30_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2023-01-012023-09-30_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="Shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-07-012022-09-30_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-09-30_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-07-012023-09-30_custom_EmployeeOptionsMember"
      decimals="-3"
      unitRef="USD">36000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-09-30_custom_EmployeeOptionsMember"
      decimals="-3"
      unitRef="USD">169000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-07-012022-09-30_custom_EmployeeOptionsMember"
      decimals="-3"
      unitRef="USD">116000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-09-30_custom_EmployeeOptionsMember"
      decimals="-3"
      unitRef="USD">285000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zEFWXkHaWf5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B2_zhm3L1Jach92" style="display: none"&gt;SCHEDULE
OF OPTIONS ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Shares Under&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;per Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Life (Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%"&gt;Outstanding &#x2013; December 31, 2021&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zNYffLFvX0Uc" style="width: 14%; text-align: right" title="Shares Under Options Outstanding, Balance"&gt;127,000&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zgSkhIkOChO" style="width: 14%; text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance"&gt;31.86&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zDt92FjsGQp3" title="Weighted Average Remaining Life (Years), Outstanding"&gt;7.77&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zlnZXpA0aVik" style="text-align: right" title="Shares Under Options, Granted"&gt;6,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z8RyMpLwyUr9" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"&gt;15.56&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_dtY_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zuZ0btfr18r3" title="Weighted Average Remaining Life (Years), Granted"&gt;9.89&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z1knTaIsHKY1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Under Options, Exercised"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zUTR0v6d3qyl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding &#x2013; March 31, 2022&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zMVdeEOodzCf" style="text-align: right" title="Shares Under Options Outstanding, Balance"&gt;133,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zQl75Nkjlwkg" style="text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance"&gt;26.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zr5TxapXQV4a" title="Weighted Average Remaining Life (Years), Outstanding"&gt;7.63&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zCUkBXnTWWyc" style="text-align: right" title="Shares Under Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0961"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z7XmzNglk7ze" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0963"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zBpqS1kVzeWc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Under Options, Exercised"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zLJTMOxelFuh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding &#x2013; June 30, 2022&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zqJCIWFX3hnd" style="text-align: right" title="Shares Under Options Outstanding, Balance"&gt;133,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zo5qK40TN7U1" style="text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance"&gt;26.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zrboyDLisHW2" title="Weighted Average Remaining Life (Years), Outstanding"&gt;7.63&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9.9pt"&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zuAB7KtmwOgc" style="text-align: right" title="Shares Under Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0975"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zzpgR4r4mgj5" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0977"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 9.9pt"&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z2jdDHBBrw8h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Under Options, Exercised"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zDQELXuJ2IQa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding &#x2013; September 30, 2022&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zsOdobhd7Pg8" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Under Options Outstanding, Balance"&gt;133,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2d_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z0CCFpvoNyBl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance"&gt;26.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z3pE2Gl58YG6" title="Weighted Average Remaining Life (Years), Outstanding"&gt;7.63&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding &#x2013; December 31, 2022&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zhoB7bKlR414" style="text-align: right" title="Shares Under Options Outstanding, Balance"&gt;147,619&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zZTMNuwfXMNd" style="text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance"&gt;24.42&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zVuDGsTgBHac" title="Weighted Average Remaining Life (Years), Outstanding"&gt;7.24&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zwxCNY9xMY36" style="text-align: right" title="Shares Under Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0995"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zc8I37J80Oh8" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0997"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesStockOptionsExpired_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zu0ljdrBE1Yj" style="text-align: right" title="Shares Under Options, Expired"&gt;(3,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pp2d_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zdsxMDbbetIc" style="text-align: right" title="Weighted Average Exercise Price per Share, Expired"&gt;39.20&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm_dtY_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zZYIkwfFvCKg" title="Weighted Average Remaining Life (Years), Expired"&gt;0.51&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zKKlmfoL5fgh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Under Options, Exercised"&gt;(5,459&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zHwArBRA0DI1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised"&gt;1.40&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_dtY_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zGoCC7x1TOGd" title="Weighted Average Remaining Life (Years), Exercised"&gt;0.51&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding &#x2013; March 31, 2023&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zzICRKZrDv99" style="text-align: right" title="Shares Under Options Outstanding, Balance"&gt;139,160&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zxY9fQSGAIP8" style="text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance"&gt;25.01&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_znvzozuZiFNh" title="Weighted Average Remaining Life (Years), Outstanding"&gt;6.91&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 7.1pt"&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zQPtlU2u1WR3" style="text-align: right" title="Shares Under Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1017"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zqgXorGAlGqi" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1019"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 7.1pt"&gt;Expired&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--StockIssuedDuringPeriodSharesStockOptionsExpired_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zZ5ViEPywVh7" style="text-align: right" title="Shares Under Options, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1021"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pp2d_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zyNPEuuCmYKd" style="text-align: right" title="Weighted Average Exercise Price per Share, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1023"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 7.1pt"&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zWIMiZpYYdgk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Under Options, Exercised"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zy5ROLzGpry6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding &#x2013; June 30, 2023&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zlXYWrrCA7l" style="text-align: right" title="Shares Under Options Outstanding, Balance"&gt;139,160&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zbXorH9UYMq6" style="text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance"&gt;25.01&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zPFowipxeFCh" title="Weighted Average Remaining Life (Years), Outstanding"&gt;6.91&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 7.1pt"&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zaUnOBFzx8ei" style="text-align: right" title="Shares Under Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1035"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z7pFjnUsTmXi" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1037"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 7.1pt"&gt;Expired&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--StockIssuedDuringPeriodSharesStockOptionsExpired_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zETeSBLjgvJb" style="text-align: right" title="Shares Under Options, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1039"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pp2d_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zIkf0SEaFru3" style="text-align: right" title="Weighted Average Exercise Price per Share, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1041"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 7.1pt"&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_d0_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zg3uTmKbCKyh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Under Options, Exercised"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_d0_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zrbsjjr17xX7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding &#x2013; September 30, 2023&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zHePMHa2Oby7" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares Under Options Outstanding, Balance"&gt;139,160&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2d_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zE9Ci5cTdJlf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price per Share, Outstanding Balance"&gt;25.01&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z9vxGd4z7K27" title="Weighted Average Remaining Life (Years), Outstanding"&gt;6.91&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="Shares">127000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_custom_EmployeeOptionsMember"
      decimals="2"
      unitRef="USDPShares">31.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-03-31_custom_EmployeeOptionsMember">P7Y9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-03-31_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="Shares">6000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-03-31_custom_EmployeeOptionsMember"
      decimals="2"
      unitRef="USDPShares">15.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm contextRef="From2022-01-012022-03-31_custom_EmployeeOptionsMember">P9Y10M20D</NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-03-31_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="Shares">-0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-03-31_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="USDPShares">-0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-03-31_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="Shares">133000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-03-31_custom_EmployeeOptionsMember"
      decimals="2"
      unitRef="USDPShares">26.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-04-012022-06-30_custom_EmployeeOptionsMember">P7Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-04-012022-06-30_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="Shares">-0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-04-012022-06-30_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="USDPShares">-0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-06-30_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="Shares">133000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-06-30_custom_EmployeeOptionsMember"
      decimals="2"
      unitRef="USDPShares">26.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm contextRef="From2022-07-012022-09-30_custom_EmployeeOptionsMember">P7Y7M17D</NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-07-012022-09-30_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="Shares">-0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-07-012022-09-30_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="USDPShares">-0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-09-30_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="Shares">133000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_custom_EmployeeOptionsMember"
      decimals="2"
      unitRef="USDPShares">26.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm contextRef="From2022-07-012022-09-30_custom_EmployeeOptionsMember">P7Y7M17D</NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="Shares">147619</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_custom_EmployeeOptionsMember"
      decimals="2"
      unitRef="USDPShares">24.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2023-01-012023-03-31_custom_EmployeeOptionsMember">P7Y2M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <NAOV:StockIssuedDuringPeriodSharesStockOptionsExpired
      contextRef="From2023-01-012023-03-31_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="Shares">-3000</NAOV:StockIssuedDuringPeriodSharesStockOptionsExpired>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-03-31_custom_EmployeeOptionsMember"
      decimals="2"
      unitRef="USDPShares">39.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm contextRef="From2023-01-012023-03-31_custom_EmployeeOptionsMember">P0Y6M3D</NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-03-31_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="Shares">-5459</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-03-31_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="USDPShares">1.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm contextRef="From2023-01-012023-03-31_custom_EmployeeOptionsMember">P0Y6M3D</NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-03-31_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="Shares">139160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-03-31_custom_EmployeeOptionsMember"
      decimals="2"
      unitRef="USDPShares">25.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2023-04-012023-06-30_custom_EmployeeOptionsMember">P6Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-04-012023-06-30_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="Shares">-0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-04-012023-06-30_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="USDPShares">-0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-06-30_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="Shares">139160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_custom_EmployeeOptionsMember"
      decimals="2"
      unitRef="USDPShares">25.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2023-07-012023-09-30_custom_EmployeeOptionsMember">P6Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-07-012023-09-30_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="Shares">-0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-07-012023-09-30_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="USDPShares">-0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-09-30_custom_EmployeeOptionsMember"
      decimals="INF"
      unitRef="Shares">139160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-09-30_custom_EmployeeOptionsMember"
      decimals="2"
      unitRef="USDPShares">25.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm contextRef="From2023-07-012023-09-30_custom_EmployeeOptionsMember">P6Y10M28D</NAOV:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_89C_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zExjcrz8ZHZb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
total stock-based expense recognized in the financial statements for services received from employees and non-employees is shown in the
following table.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zC3XcNGR5IIa" style="display: none"&gt;SCHEDULE
OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230701__20230930_zJPm9rJ3YLul" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220701__20220930_z8Ayol1U9W37" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230101__20230930_z4eXWo6J0sv8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20220101__20220930_zkau9nLXEj64" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Nine Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zpm9UNQIDlji" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;2&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zxAO96Pf7cfe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Selling and marketing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zJLrHJnV5C3g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;108&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;264&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zQ1JG9Blffpd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;116&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;169&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;287&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zhCI0bKjvrfd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Stock based compensation expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;116&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;169&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;287&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-07-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-07-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      unitRef="USD">2000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      unitRef="USD">5000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      unitRef="USD">5000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-07-012023-09-30_us-gaap_SellingAndMarketingExpenseMember"
      decimals="-3"
      unitRef="USD">6000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-07-012022-09-30_us-gaap_SellingAndMarketingExpenseMember"
      decimals="-3"
      unitRef="USD">6000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-09-30_us-gaap_SellingAndMarketingExpenseMember"
      decimals="-3"
      unitRef="USD">18000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-09-30_us-gaap_SellingAndMarketingExpenseMember"
      decimals="-3"
      unitRef="USD">18000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-07-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">29000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-07-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">108000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">146000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      unitRef="USD">264000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">36000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">116000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">169000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">287000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">36000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">116000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">169000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">287000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">159000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2023-01-01to2023-09-30">P1Y2M8D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-08-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2906977</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-08-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-08-30_custom_A1WarrantsMember"
      decimals="INF"
      unitRef="Shares">2906977</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2023-08-302023-08-30_custom_A1WarrantsMember"
      decimals="INF"
      unitRef="USDPShares">1.47</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-08-30_custom_A2WarrantsMember"
      decimals="INF"
      unitRef="Shares">2906977</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2023-08-302023-08-30_custom_A2WarrantsMember"
      decimals="INF"
      unitRef="USDPShares">1.47</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-08-302023-08-30_us-gaap_PrivatePlacementMember"
      decimals="INF"
      unitRef="Shares">8540931</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="From2023-08-302023-08-30_custom_PurchaseAgreementMember_custom_A1WarrantsMember">2029-03-01</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="From2023-08-302023-08-30_custom_PurchaseAgreementMember_custom_A2WarrantsMember">2024-10-01</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-08-30_custom_WainwrightMember"
      decimals="INF"
      unitRef="Shares">218023</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharePrice
      contextRef="AsOf2023-08-30_custom_WainwrightMember"
      decimals="INF"
      unitRef="USDPShares">2.15</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="From2023-08-302023-08-30_custom_WainwrightMember">2029-03-01</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">8758954</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">12500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">12500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z8XvFRFCbLxj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B5_zDfgzzEvrEod" style="display: none"&gt;SCHEDULE
OF WARRANTS ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Outstanding &#x2013; December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zddE0YuW9FJ9" style="width: 16%; text-align: right" title="Warrants, Outstanding, Balance"&gt;115,467&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_ziHWn2I0kot6" style="text-align: right" title="Warrants, Granted"&gt;12,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zDDixifz4nae" style="text-align: right" title="Warrants, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1111"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zXwywzl08eMb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants, Canceled"&gt;(12,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding &#x2013; September 30, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zSmCVZnG2QMh" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding, Balance"&gt;115,467&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding &#x2013; December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zYiwyjNql9n7" style="text-align: right" title="Warrants, Outstanding, Balance"&gt;78,252&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zfiMd1yDDYh" style="text-align: right" title="Warrants, Granted"&gt;8,758,954&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_z5MSJuCusr78" style="text-align: right" title="Warrants, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1121"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zzRrVoAVykbj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants, Canceled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1123"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding &#x2013; September 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_z9fjFUmp2Q8d" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding, Balance"&gt;8,837,206&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember_custom_PrivateInvestorsMember"
      decimals="INF"
      unitRef="Shares">115467</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_custom_PrivateInvestorsMember"
      decimals="INF"
      unitRef="Shares">12500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember_custom_PrivateInvestorsMember"
      decimals="INF"
      unitRef="Shares">-12500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-09-30_us-gaap_WarrantMember_custom_PrivateInvestorsMember"
      decimals="INF"
      unitRef="Shares">115467</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember_custom_PrivateInvestorsMember"
      decimals="INF"
      unitRef="Shares">78252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember_custom_PrivateInvestorsMember"
      decimals="INF"
      unitRef="Shares">8758954</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-09-30_us-gaap_WarrantMember_custom_PrivateInvestorsMember"
      decimals="INF"
      unitRef="Shares">8837206</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_802_eus-gaap--EarningsPerShareTextBlock_zqoQOBemvow3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5 &#x2013; &lt;span id="xdx_820_zupmYl9Pvvxb"&gt;LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDER&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of shares
of common stock outstanding during the period. All outstanding stock options and warrants for the nine months ended September 30, 2023
and 2022 have been excluded from the calculation of the diluted net loss per share because all such securities are anti-dilutive for
all periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z69lLnUAhqbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table summarizes the Company&#x2019;s
securities, in common stock equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would
be anti-dilutive:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zkvBOAvkpBB" style="display: none"&gt;SUMMARY
OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230101__20230930_zC12P28pi2oi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;br/&gt;
2023&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220101__20220930_zIQsFF93BkCa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;br/&gt;
2022&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsEmployeeAndNonEmployeeMember_zn8H6Gp4XC4j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%; text-align: justify"&gt;Stock Options &#x2013; employee and non-employee&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;139,160&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;133,000&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_ziANJ0ezVMC3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,758,954&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;115,467&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_z2j1vvNZGx24" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Total&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,898,114&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;248,467&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_z504HyESbaM7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Dilutive loss per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,898,114&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;248,467&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p id="xdx_8AA_zuDvMg26a6hb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z69lLnUAhqbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table summarizes the Company&#x2019;s
securities, in common stock equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would
be anti-dilutive:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zkvBOAvkpBB" style="display: none"&gt;SUMMARY
OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230101__20230930_zC12P28pi2oi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;br/&gt;
2023&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220101__20220930_zIQsFF93BkCa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;br/&gt;
2022&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsEmployeeAndNonEmployeeMember_zn8H6Gp4XC4j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%; text-align: justify"&gt;Stock Options &#x2013; employee and non-employee&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;139,160&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%; text-align: right"&gt;133,000&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_ziANJ0ezVMC3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,758,954&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;115,467&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_z2j1vvNZGx24" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Total&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,898,114&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;248,467&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_z504HyESbaM7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Dilutive loss per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,898,114&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;248,467&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-09-30_custom_StockOptionsEmployeeAndNonEmployeeMember"
      decimals="INF"
      unitRef="Shares">139160</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-09-30_custom_StockOptionsEmployeeAndNonEmployeeMember"
      decimals="INF"
      unitRef="Shares">133000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember33335218"
      decimals="INF"
      unitRef="Shares">8758954</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember33335218"
      decimals="INF"
      unitRef="Shares">115467</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="Shares">8898114</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-09-30"
      decimals="INF"
      unitRef="Shares">248467</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="Shares">8898114</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-09-30"
      decimals="INF"
      unitRef="Shares">248467</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_80A_eus-gaap--SegmentReportingDisclosureTextBlock_zgAWaOPuLZHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6 &#x2013; &lt;span id="xdx_82E_z9zV6bnxXrA4"&gt;GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company manages its business on the basis of one reportable segment and derives revenues from selling its products directly to patients
as well as through distributor agreements. The following is a summary of revenues within geographic areas:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_z3DOMyvmdXR3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zJfCAPWGswq" style="display: none"&gt;SUMMARY
OF REVENUE WITHIN GEOGRAPHIC AREAS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230701__20230930_z02zv56I2Oeh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20220701__20220930_zc4W7I99Nx02" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230101__20230930_z7dl2fup9kt3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20220930_z14epOvXBal9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Three Months Ended &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Nine Months Ended &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--US_zeeLV1M7X788" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;445&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;90&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;1,037&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;828&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--AU_zQ5o3QuASst2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Australia/New Zealand&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__srt--EuropeMember_zgKVvqvUx6Se" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Europe&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1157"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__srt--AsiaMember_zUPESZMg6uOk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Asia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1162"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1163"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__custom--OtherCountryMember_z5DkMGZVzMbg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1168"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1170"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zDD5KOjit4q1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;458&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,106&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;854&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zeKUERsx4vca" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Revenues geographic areas&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;458&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,106&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;854&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AB_zjLEUTX1HQv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
both the three and nine months ended September 30, 2023, our two largest customers comprised approximately &lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zqDGPKtskgz6" title="Concentration risk, percentage"&gt;96&lt;/span&gt;% and &lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zIboCg8ok9o2" title="Concentration risk, percentage"&gt;93&lt;/span&gt;% of total revenues,
respectively. Customer one comprised &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersOneMember_zCbf7zbUyi8j" title="Concentration risk, percentage"&gt;49&lt;/span&gt;% and &lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersOneMember_zIkYM4B4l9F6" title="Concentration risk, percentage"&gt;58&lt;/span&gt;% while customer two comprised &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersTwoMember_zdwuFN4T0lu8" title="Concentration risk, percentage"&gt;46&lt;/span&gt;% and &lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersTwoMember_zAH4mCwxs8jf" title="Concentration risk, percentage"&gt;35&lt;/span&gt;%, respectively. During the three and nine months
ended September 30, 2022, our two largest customers comprised approximately &lt;span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zxo5GYHm9ZNe" title="Concentration risk, percentage"&gt;76&lt;/span&gt;% and &lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zqguEbFWrnq9" title="Concentration risk, percentage"&gt;92&lt;/span&gt;% of total revenues, respectively. Customer one
comprised &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersOneMember_zgx6JE4b0Yrg" title="Concentration risk, percentage"&gt;76&lt;/span&gt;% and &lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersOneMember_zvi1NAzf53Be" title="Concentration risk, percentage"&gt;35&lt;/span&gt;% while customer two comprised &lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersTwoMember_zC1YU8Q1A9Y3" title="Concentration risk, percentage"&gt;0&lt;/span&gt;% and &lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersTwoMember_zFitgrlE5DQ3" title="Concentration risk, percentage"&gt;57&lt;/span&gt;%, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_89D_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_z3DOMyvmdXR3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zJfCAPWGswq" style="display: none"&gt;SUMMARY
OF REVENUE WITHIN GEOGRAPHIC AREAS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230701__20230930_z02zv56I2Oeh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20220701__20220930_zc4W7I99Nx02" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20230101__20230930_z7dl2fup9kt3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20220930_z14epOvXBal9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Three Months Ended &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Nine Months Ended &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--US_zeeLV1M7X788" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;445&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;90&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;1,037&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;828&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--AU_zQ5o3QuASst2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Australia/New Zealand&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__srt--EuropeMember_zgKVvqvUx6Se" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Europe&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1157"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__srt--AsiaMember_zUPESZMg6uOk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Asia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1162"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1163"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__custom--OtherCountryMember_z5DkMGZVzMbg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1168"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1170"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zDD5KOjit4q1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;458&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,106&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;854&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zeKUERsx4vca" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Revenues geographic areas&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;458&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,106&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;854&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-07-012023-09-30_country_US"
      decimals="-3"
      unitRef="USD">445000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-07-012022-09-30_country_US"
      decimals="-3"
      unitRef="USD">90000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-09-30_country_US"
      decimals="-3"
      unitRef="USD">1037000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-09-30_country_US"
      decimals="-3"
      unitRef="USD">828000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-07-012023-09-30_country_AU"
      decimals="-3"
      unitRef="USD">2000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-07-012022-09-30_country_AU"
      decimals="-3"
      unitRef="USD">1000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-09-30_country_AU"
      decimals="-3"
      unitRef="USD">15000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-09-30_country_AU"
      decimals="-3"
      unitRef="USD">4000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-07-012022-09-30_srt_EuropeMember"
      decimals="-3"
      unitRef="USD">6000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-09-30_srt_EuropeMember"
      decimals="-3"
      unitRef="USD">19000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-09-30_srt_EuropeMember"
      decimals="-3"
      unitRef="USD">13000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-09-30_srt_AsiaMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-09-30_srt_AsiaMember"
      decimals="-3"
      unitRef="USD">9000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-07-012023-09-30_custom_OtherCountryMember"
      decimals="-3"
      unitRef="USD">11000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-09-30_custom_OtherCountryMember"
      decimals="-3"
      unitRef="USD">34000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">458000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">97000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">1106000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">854000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">458000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">97000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">1106000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">854000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember"
      decimals="INF"
      unitRef="Pure">0.96</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember"
      decimals="INF"
      unitRef="Pure">0.93</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersOneMember"
      decimals="INF"
      unitRef="Pure">0.49</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersOneMember"
      decimals="INF"
      unitRef="Pure">0.58</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-07-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersTwoMember"
      decimals="INF"
      unitRef="Pure">0.46</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersTwoMember"
      decimals="INF"
      unitRef="Pure">0.35</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-07-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember"
      decimals="INF"
      unitRef="Pure">0.76</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember"
      decimals="INF"
      unitRef="Pure">0.92</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-07-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersOneMember"
      decimals="INF"
      unitRef="Pure">0.76</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersOneMember"
      decimals="INF"
      unitRef="Pure">0.35</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-07-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersTwoMember"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomersTwoMember"
      decimals="INF"
      unitRef="Pure">0.57</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_80C_eus-gaap--LesseeOperatingLeasesTextBlock_zhCvuBgKUHz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
7 &#x2013; &lt;span id="xdx_829_z6Y42CuujNgj"&gt;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has operating lease agreements with terms up to &lt;span id="xdx_900_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20230930__srt--RangeAxis__srt--MinimumMember_zjwnJ90Ks2d5" title="Lease term"&gt;2&lt;/span&gt;-&lt;span id="xdx_907_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20230930__srt--RangeAxis__srt--MaximumMember_zx38Ce9sGZ5a" title="Lease term"&gt;3&lt;/span&gt; years, including car and office space leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s weighted-average remaining lease term relating to its operating leases is &lt;span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230930_zO7QWleLsBbb" title="Weighted-average remaining lease term"&gt;0.56&lt;/span&gt; years, with a weighted-average discount
rate of &lt;span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20230930_zPCMvoyJLg01" title="Weighted-average discount rate"&gt;10&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company incurred $&lt;span id="xdx_90B_eus-gaap--OperatingLeaseExpense_pn3n3_c20230101__20230930_zZ5R5BISVhNa" title="Operating lease, expense"&gt;36&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--OperatingLeaseExpense_pn3n3_c20220101__20220930_zlh1HbBKPgTd" title="Operating lease, expense"&gt;14&lt;/span&gt; of lease expense for its operating leases for the nine months ended September 30, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zLxqwPJ6zV63" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information about the amount and timing of liabilities arising from the Company&#x2019;s operating leases as
of September 30, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zfexwvnadMd5" style="display: none"&gt;SCHEDULE
OF LIABILITIES ARISING FROM OPERATING LEASES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20230930_zdSdZyzWgiV6" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzL7T_zraQzhGcZhwk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;17&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzL7T_zj93CSK5ksjd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzL7T_zQ90fMenEHQd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total undiscounted operating lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_z2KyuYjpTUU8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: Imputed interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zXGsFqHDIzfe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Present value of operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zo0XuwuHb8v1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="AsOf2023-09-30_srt_MinimumMember">P2Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="AsOf2023-09-30_srt_MaximumMember">P3Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2023-09-30">P0Y6M21D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2023-09-30" decimals="INF" unitRef="Pure">0.10</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">36000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">14000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_892_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zLxqwPJ6zV63" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information about the amount and timing of liabilities arising from the Company&#x2019;s operating leases as
of September 30, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zfexwvnadMd5" style="display: none"&gt;SCHEDULE
OF LIABILITIES ARISING FROM OPERATING LEASES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20230930_zdSdZyzWgiV6" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzL7T_zraQzhGcZhwk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;17&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzL7T_zj93CSK5ksjd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzL7T_zQ90fMenEHQd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total undiscounted operating lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_z2KyuYjpTUU8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: Imputed interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zXGsFqHDIzfe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Present value of operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">17000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">3000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">20000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">1000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">19000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OtherAssetsDisclosureTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_800_eus-gaap--OtherAssetsDisclosureTextBlock_zzvdBBB6okJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
8 &#x2013; &lt;span id="xdx_828_zVDSaOwCJKcj"&gt;OTHER ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 9, 2020, pursuant to a licensing agreement entered into in March 2020, the Company received &lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20200409__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zLQHvBfS1ZMa" title="Warrants and rights outstanding term"&gt;10&lt;/span&gt;-year warrants to purchase &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20200409__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zunQsrt2zHn9" title="Warrants issued to purchase common stock"&gt;127,000&lt;/span&gt;
shares of Sanuwave Health, Inc. at a price of $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200409__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zO7kLut3k8ql" title="Exercise price of warrants per share"&gt;0.19&lt;/span&gt; per share. The fair value for warrants received was estimated at the date of grant
and at each reporting period using a Black-Scholes-Merton pricing model with the following underlying assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_ecustom--ScheduleOfWarrantsAssumptionsTableTextBlock_zFCDePnuDPP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zNrs91gyCtqa" style="display: none"&gt;SCHEDULE
OF WARRANTS ASSUMPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;September 30, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, &lt;br/&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Price at valuation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20230930__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zbLmK52CByL1" title="Warrants and rights outstanding, measurement input"&gt;0.02&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20221231__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zRNhRtck9nX3" title="Warrants and rights outstanding, measurement input"&gt;0.02&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zFEjQwQNjodc" title="Warrants and rights outstanding, measurement input"&gt;0.19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_znqqZEmcGNg9" title="Warrants and rights outstanding, measurement input"&gt;0.19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zxaqRMIL5P1k" title="Warrants and rights outstanding, measurement input"&gt;4.61&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zkNFvV1yFqpg" title="Warrants and rights outstanding, measurement input"&gt;3.96&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230930__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zGLILhGZdGPd" title="Expected term (in years)"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zVnNidrWcmA" title="Expected term (in years)"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zeiIrl805H45" title="Warrants and rights outstanding, measurement input"&gt;147.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zN2OgJdmeXhi" title="Warrants and rights outstanding, measurement input"&gt;155.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zP9heDp8HHDk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers this to be Level 3 inputs and is valued at each reporting period. For the three and nine months ended September 30,
2023, changes in the fair value of these warrants amounted to $(&lt;span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230701__20230930_zWWnjdbmOxHk" title="Fair value of warrants"&gt;&lt;span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20230930_zB1DUsEnYvVd" title="Fair value of warrants"&gt;1&lt;/span&gt;&lt;/span&gt;) for both periods, leaving a balance of $&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_c20230930_zYemgK95da5a" title="Warrants leaving balance"&gt;2&lt;/span&gt; as of September 30, 2023.
For the three and nine months ended September 30, 2022, changes in the fair value of these warrants amounted to $(&lt;span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220701__20220930_zI12FiNSGqM5" title="Fair value of warrants"&gt;2&lt;/span&gt;) and $(&lt;span id="xdx_903_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20220930_zEVXpQljD4Ue" title="Fair value of warrants"&gt;12&lt;/span&gt;), respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Financial
Instruments Measured at Fair Value on a Recurring Basis&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability
in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants
would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2 inputs: Inputs, other than quoted prices included in Level 1, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own
    assumptions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no transfers between Level 3 during the three and nine months ended September 30, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zpo1qsKTo0kj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents changes in Level 3 asset and liability measured at fair value for the quarters ended September 30, 2023 and
2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_z0NEQTYj6Gn2" style="display: none"&gt;SCHEDULE
OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Asset&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Balance &#x2013; December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zUxKh6Ddht2g" style="width: 16%; text-align: right" title="Balance beginning"&gt;19&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Fair value adjustments &#x2013; Sanuwave warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zdCZPYVEy2Sk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants"&gt;(2&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance &#x2013; March 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zMclxCGl37vi" style="text-align: right" title="Balance beginning"&gt;17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Fair value adjustments &#x2013; Sanuwave warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zNkfGvDw4OKg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants"&gt;(8&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance &#x2013; June 30, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zpY4Ffqob7T5" style="text-align: right" title="Balance beginning"&gt;9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 7.1pt"&gt;Fair value adjustments &#x2013; Sanuwave warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zmI0PKlZa9gb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants"&gt;(2&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance &#x2013; September 30, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_pn3n3_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zpnfSRk84IZ6" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance ending"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance &#x2013; December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20230101__20230331__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_z6jsim1FAC46" style="text-align: right" title="Balance beginning"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Fair value adjustments &#x2013; Sanuwave warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20230331__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zDESfAW8F5Gi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance &#x2013; March 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20230401__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zN2AtoAvA57b" style="text-align: right" title="Balance beginning"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Fair value adjustments &#x2013; Sanuwave warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230401__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_z31cVTHyhSq5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants"&gt;(2&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance &#x2013; June 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20230701__20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zctTQIEQJghh" style="text-align: right" title="Balance beginning"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Fair value adjustments &#x2013; Sanuwave warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230701__20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_z3UfqnDNCVE9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants"&gt;(1&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance &#x2013; September 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_pn3n3_c20230701__20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zJetDClqh2pj" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance ending"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zURpUu5fA6Jc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z9La9bA9cEh2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth the Company&#x2019;s assets and liabilities which are measured at fair value on a recurring basis by level
within the fair value hierarchy:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zfe70fG0cZua" style="display: none"&gt;SCHEDULE
OF ASSETS AND LIABILITY MEASURED AT FAIR VALUE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z1aYneIPZOB8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level I&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9nEX2WzvbPc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level II&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ztsGne2KXYCe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level III&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230930_zF5sobBJeuff" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements as of September 30, 2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level I&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level II&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level III&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Asset:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OtherAssetsNoncurrent_iI_pn3n3_zpoGgf4YjdN5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Other assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1304"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1305"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;2&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;2&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zPLK0zFyOA6a" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level I&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zj1jCnxhtmJl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level II&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zLa4v91soDf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level III&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20221231_z8eM9y6jLsZk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements as of December 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level I&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level II&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level III&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Asset:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OtherAssetsNoncurrent_iI_pn3n3_zvA3TpYOPNy2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Other assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1309"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1310"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OtherAssetsDisclosureTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2020-04-09_custom_LicensingAgreementMember_custom_SanuwaveHealthIncMember">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2020-04-09_custom_LicensingAgreementMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      unitRef="Shares">127000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-04-09_custom_LicensingAgreementMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      unitRef="USDPShares">0.19</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <NAOV:ScheduleOfWarrantsAssumptionsTableTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_899_ecustom--ScheduleOfWarrantsAssumptionsTableTextBlock_zFCDePnuDPP5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zNrs91gyCtqa" style="display: none"&gt;SCHEDULE
OF WARRANTS ASSUMPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;September 30, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, &lt;br/&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Price at valuation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20230930__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zbLmK52CByL1" title="Warrants and rights outstanding, measurement input"&gt;0.02&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20221231__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zRNhRtck9nX3" title="Warrants and rights outstanding, measurement input"&gt;0.02&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zFEjQwQNjodc" title="Warrants and rights outstanding, measurement input"&gt;0.19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_znqqZEmcGNg9" title="Warrants and rights outstanding, measurement input"&gt;0.19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zxaqRMIL5P1k" title="Warrants and rights outstanding, measurement input"&gt;4.61&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zkNFvV1yFqpg" title="Warrants and rights outstanding, measurement input"&gt;3.96&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230930__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zGLILhGZdGPd" title="Expected term (in years)"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zVnNidrWcmA" title="Expected term (in years)"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20230930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zeiIrl805H45" title="Warrants and rights outstanding, measurement input"&gt;147.8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zN2OgJdmeXhi" title="Warrants and rights outstanding, measurement input"&gt;155.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</NAOV:ScheduleOfWarrantsAssumptionsTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-09-30_custom_PriceAtValuationMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      unitRef="USDPShares">0.02</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_custom_PriceAtValuationMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      unitRef="USDPShares">0.02</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-09-30_us-gaap_MeasurementInputExercisePriceMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      unitRef="Pure">0.19</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      unitRef="Pure">0.19</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      unitRef="Pure">4.61</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      unitRef="Pure">3.96</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2023-09-30_custom_SanuwaveHealthIncMember_us-gaap_MeasurementInputExpectedTermMember">P7Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2022-12-31_custom_SanuwaveHealthIncMember_us-gaap_MeasurementInputExpectedTermMember">P8Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-09-30_us-gaap_MeasurementInputPriceVolatilityMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      unitRef="Pure">147.8</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_SanuwaveHealthIncMember"
      decimals="INF"
      unitRef="Pure">155.6</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">1000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">1000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">2000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-07-012022-09-30"
      decimals="-3"
      unitRef="USD">2000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-09-30"
      decimals="-3"
      unitRef="USD">12000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_893_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zpo1qsKTo0kj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents changes in Level 3 asset and liability measured at fair value for the quarters ended September 30, 2023 and
2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_z0NEQTYj6Gn2" style="display: none"&gt;SCHEDULE
OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Asset&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Balance &#x2013; December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zUxKh6Ddht2g" style="width: 16%; text-align: right" title="Balance beginning"&gt;19&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Fair value adjustments &#x2013; Sanuwave warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zdCZPYVEy2Sk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants"&gt;(2&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance &#x2013; March 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zMclxCGl37vi" style="text-align: right" title="Balance beginning"&gt;17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Fair value adjustments &#x2013; Sanuwave warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220401__20220630__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zNkfGvDw4OKg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants"&gt;(8&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance &#x2013; June 30, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zpY4Ffqob7T5" style="text-align: right" title="Balance beginning"&gt;9&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 7.1pt"&gt;Fair value adjustments &#x2013; Sanuwave warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zmI0PKlZa9gb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants"&gt;(2&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance &#x2013; September 30, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_pn3n3_c20220701__20220930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zpnfSRk84IZ6" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance ending"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance &#x2013; December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20230101__20230331__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_z6jsim1FAC46" style="text-align: right" title="Balance beginning"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Fair value adjustments &#x2013; Sanuwave warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230101__20230331__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zDESfAW8F5Gi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance &#x2013; March 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20230401__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zN2AtoAvA57b" style="text-align: right" title="Balance beginning"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Fair value adjustments &#x2013; Sanuwave warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230401__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_z31cVTHyhSq5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants"&gt;(2&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance &#x2013; June 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20230701__20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zctTQIEQJghh" style="text-align: right" title="Balance beginning"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Fair value adjustments &#x2013; Sanuwave warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20230701__20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_z3UfqnDNCVE9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants"&gt;(1&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance &#x2013; September 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_pn3n3_c20230701__20230930__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zJetDClqh2pj" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance ending"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="AsOf2021-12-31_custom_DerivativeAssetMember"
      decimals="-3"
      unitRef="USD">19000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-03-31_custom_DerivativeAssetMember"
      decimals="-3"
      unitRef="USD">-2000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="AsOf2022-03-31_custom_DerivativeAssetMember"
      decimals="-3"
      unitRef="USD">17000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-04-012022-06-30_custom_DerivativeAssetMember"
      decimals="-3"
      unitRef="USD">-8000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="AsOf2022-06-30_custom_DerivativeAssetMember"
      decimals="-3"
      unitRef="USD">9000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-07-012022-09-30_custom_DerivativeAssetMember"
      decimals="-3"
      unitRef="USD">-2000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="AsOf2022-09-30_custom_DerivativeAssetMember"
      decimals="-3"
      unitRef="USD">7000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="AsOf2022-12-31_custom_DerivativeAssetMember"
      decimals="-3"
      unitRef="USD">3000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-03-31_custom_DerivativeAssetMember"
      decimals="-3"
      unitRef="USD">2000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="AsOf2023-03-31_custom_DerivativeAssetMember"
      decimals="-3"
      unitRef="USD">5000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-04-012023-06-30_custom_DerivativeAssetMember"
      decimals="-3"
      unitRef="USD">-2000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="AsOf2023-06-30_custom_DerivativeAssetMember"
      decimals="-3"
      unitRef="USD">3000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-07-012023-09-30_custom_DerivativeAssetMember"
      decimals="-3"
      unitRef="USD">-1000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="AsOf2023-09-30_custom_DerivativeAssetMember"
      decimals="-3"
      unitRef="USD">2000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_890_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z9La9bA9cEh2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth the Company&#x2019;s assets and liabilities which are measured at fair value on a recurring basis by level
within the fair value hierarchy:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zfe70fG0cZua" style="display: none"&gt;SCHEDULE
OF ASSETS AND LIABILITY MEASURED AT FAIR VALUE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z1aYneIPZOB8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level I&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9nEX2WzvbPc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level II&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ztsGne2KXYCe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level III&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230930_zF5sobBJeuff" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements as of September 30, 2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level I&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level II&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level III&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Asset:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OtherAssetsNoncurrent_iI_pn3n3_zpoGgf4YjdN5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Other assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1304"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1305"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;2&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;2&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zPLK0zFyOA6a" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level I&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zj1jCnxhtmJl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level II&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zLa4v91soDf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level III&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20221231_z8eM9y6jLsZk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements as of December 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level I&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level II&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level III&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Asset:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OtherAssetsNoncurrent_iI_pn3n3_zvA3TpYOPNy2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Other assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1309"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1310"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2023-09-30_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      unitRef="USD">2000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2023-09-30" decimals="-3" unitRef="USD">2000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      unitRef="USD">3000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2022-12-31" decimals="-3" unitRef="USD">3000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zl13PQJ7QnCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9 &#x2013; &lt;span id="xdx_82B_zB7bL6g6XZKe"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Pending
litigation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 26, 2021, Protrade Systems, Inc. (&#x201c;Protrade&#x201d;) filed a Request for Arbitration (the &#x201c;Request&#x201d;) with the
International Court of Arbitration (the &#x201c;ICA&#x201d;) of the International Chamber of Commerce alleging the Company is in breach
of an Exclusive Distribution Agreement dated March 7, 2019 (the &#x201c;Exclusive Distribution Agreement&#x201d;) between Protrade and
the Company. Protrade alleges, in part, that the Company has breached the Exclusive Distribution Agreement by discontinuing the manufacture
of the DV0057 Painshield MD device in favor of an updated 10-100-001 Painshield MD device. Protrade claims damages estimated at $&lt;span id="xdx_90C_eus-gaap--LossContingencyDamagesSoughtValue_pn6n6_c20210225__20210226_zb3LWKzJb3b1" title="Litigation damages sought value"&gt;3&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 15, 2022, the arbitrator issued a final award, which, determined that (i) the Company had the right to terminate the Exclusive
Distribution Agreement; (ii) the Company did not breach the duty of good faith and fair dealing with regard to the Exclusive Distribution
Agreement; and (iii) the Company did not breach any confidentiality obligations to Protrade. Nevertheless, the arbitrator determined
that the Company did not comply with the obligation to supply Protrade with a year&#x2019;s supply of patches, and awarded Protrade $&lt;span id="xdx_901_eus-gaap--LossContingencyDamagesSoughtValue_c20230314__20230315_z8CbTyi4HHsf" title="Loss contingency damages sought value"&gt;1,500,250&lt;/span&gt;,
which consists of $&lt;span id="xdx_90C_eus-gaap--LossContingencyDamagesAwardedValue_c20230314__20230315_zduAhMSb5p14" title="Loss contingency damages sought value"&gt;1,432,000&lt;/span&gt; for &#x201c;lost profits&#x201d; and $&lt;span id="xdx_900_eus-gaap--LossContingencyDamagesPaidValue_c20230314__20230315_zZXat2vCa801" title="Loss contingency damages paid value"&gt;68,250&lt;/span&gt; as reimbursement of arbitration costs, on the grounds that the
Company allegedly failed to supply Protrade with certain patches utilized by users of DV0057 Painshield MD device. The arbitrator based
the decision on the testimony of Protrade&#x2019;s president who asserted that a user would use in excess of 33 patches per each device.
The Company believes that the number of patches per device alleged by Protrade is grossly inflated, and that these claims were not properly
raised before the arbitrator. Accordingly, on April 13, 2022, the Company submitted an application for the correction of the award which
the arbitrator denied on June 22, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 5, 2022, Protrade filed a Petition with the Supreme Court of New York Nassau County seeking to confirm the Award. On April 13,
2022, the Company submitted an application to the ICA seeking to correct an error in the award based on the evidence that the Company
only sold 2-3 reusable patches per device contrary to the 33 reusable patches claimed by Protrade. The same arbitrator who issued the
award, denied the application.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 22, 2022, the Company filed a cross-motion seeking to vacate arbitration award on the grounds that the arbitrator exceeded her authority,
that the award was procured by fraud, and that the arbitrator failed to follow procedures established by New York law. In particular,
the Company averred in its motion that Protrade&#x2019;s witness made false statements in arbitration, and that the arbitrator resolved
a claim that was never raised by Protrade and that has no factual basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 3, 2022, the court issued a decision granting Protrade its petition to confirm the award and denying the cross-motion.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 9, 2022, the Company filed a motion to re-argue and renew its cross-motion to vacate the arbitration decision based on newer
information that was not available during the initial hearing. On the same day, the Company also filed a notice of appeal with the Appellate
Division, Second Department. On March 21, 2023, the court denied the motion to re-argue and renew.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 10, 2023, the Company filed its appeal with the Appellate Division, Second Department. The Company intends to continue to vigorously
pursue its opposition to the award in all appropriate fora.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2023 and December 31, 2022, the Company accrued the amount of the arbitration award to Protrade of
approximately $&lt;span id="xdx_906_eus-gaap--LossContingencyDamagesAwardedValue_pn5n6_c20230101__20230930__srt--TitleOfIndividualAxis__custom--ArbitratorMember_zvbJTCy0uhFj" title="Damages awarded value"&gt;&lt;span id="xdx_902_eus-gaap--LossContingencyDamagesAwardedValue_pn5n6_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ArbitratorMember_ztRJewDVAizj" title="Damages awarded value"&gt;1.9&lt;/span&gt;&lt;/span&gt;
million, including interest which is classified in &#x201c;Other accounts payable and accrued expenses&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="From2021-02-252021-02-26"
      decimals="-6"
      unitRef="USD">3000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="From2023-03-142023-03-15"
      decimals="0"
      unitRef="USD">1500250</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="From2023-03-142023-03-15"
      decimals="0"
      unitRef="USD">1432000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesPaidValue
      contextRef="From2023-03-142023-03-15"
      decimals="0"
      unitRef="USD">68250</us-gaap:LossContingencyDamagesPaidValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="From2023-01-012023-09-30_custom_ArbitratorMember"
      decimals="-5"
      unitRef="USD">1900000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="From2022-01-012022-12-31_custom_ArbitratorMember"
      decimals="-5"
      unitRef="USD">1900000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_80A_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z1kmIKpinJW6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10 &#x2013; &lt;span id="xdx_826_z2HYDhJVn8J8"&gt;RELATED PARTY TRANSACTION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
firm of FisherBroyles LLP is handling the Company&#x2019;s Protrade litigation and appeals. For the three and nine months ended September
30, 2023, the Company have been billed and paid legal fees from FisherBroyles amounting to $&lt;span id="xdx_90F_eus-gaap--LegalFees_pn3n3_c20230701__20230930_zwWshmzeO7hd" title="Legal fees paid"&gt;176&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--LegalFees_pn3n3_c20230101__20230930_zfl67S9IbOb1" title="Legal fees paid"&gt;264&lt;/span&gt;, respectively, which have been
recorded as part of &#x201c;General and administrative expenses&#x201d; in the condensed consolidated statements of operations. As has
been previously disclosed, one of the Company&#x2019;s board members, Aurora Cassirer, is a partner at FisherBroyles. Ms. Cassirer does
not provide any legal services or legal advice to the Company&lt;b&gt;.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:LegalFees
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      unitRef="USD">176000</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2023-01-01to2023-09-30"
      decimals="-3"
      unitRef="USD">264000</us-gaap:LegalFees>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_zqHZWXrJQ6x" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
11 &#x2013; &lt;span id="xdx_829_zakteqd6uyKe"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 6, 2023, an investor exercised &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zhezIuGQ2XNh" title="Exercised warrant"&gt;203,977&lt;/span&gt; pre-funded warrants at $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zndWSw7PhBpj" title="Warrant price per share"&gt;0.001&lt;/span&gt; per share to purchase &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfZual2q9C2j" title="Purchase warrant"&gt;203,977&lt;/span&gt; shares of common
stock from the Securities Purchase Agreement entered into by the Company on August 30, 2023.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-11-06_us-gaap_SubsequentEventMember_custom_PrefundedWarrantMember"
      decimals="INF"
      unitRef="Shares">203977</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-11-06_us-gaap_SubsequentEventMember_custom_PrefundedWarrantMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-11-06_us-gaap_SubsequentEventMember_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">203977</us-gaap:ClassOfWarrantOrRightOutstanding>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>58
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M75=!M[V#?/I$?A//5ES<RH&BNFQ\YHRMG%WD&]H$'(HGE)+S(W\B=S[ !JO
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M N3W6\;$\XEZ\>?XHM?J/U!+ P04    " "*A6U7.NUG]=4#   %%0  &
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M&EA[SKX3>ZML9@<JL\5VM^TWM+B;X[;*3-C*<['==%\WN+CNIT-O=(EL%YG
ME>%BN^/V'UI<=]/:(-@D)FCEM=ANMJ\=V[J1UFAM$I.VLEG<R6=_ZS>V-S7:
M6V4S.U!9+;ZEU^)N9MLJ,V$KN\5OX;>X;J1X.IWZ4_\2NUUH@E>6BV_MN;C=
M=*T2\XVI<EWR)JY+VEW7*C%I*]<EG5SW<Z_QM>?L.[ZWRF9VX.P5]Y:N6R2;
MF'-9>\UM49FHE>>2M_!<<N4=]I*Y+KOV=%6>2V[MN:3=<ZT2$[3R7/(FGDO:
M/=<JR6G=LSTJO4'XE?)ME H4PT;%>'=C%<SS/;=\(=D^V[9Z8E*R)#O< 0V!
M:X&ZOF%,OBST3EBY\[GX'U!+ P04    " "*A6U7U6 SPT@&  #:'0  &
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MJJBKSE @@0))%,A#@>9<8SLV!P:@6@%9J_X4@,JELVB7CEJ!1J?V4"0*Y*)
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M:1&@_O^4)/F/C>*1M<=G/]__'U!+ P04    " "*A6U7"&XMM- %  "]&
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ML>]DL.5?IQ&N0)9L$T4RAR8CK, G'5#3=F>QR S#GI[N-]SH/T6.&Y 2X4G
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MEMSI'(UWX/,=D3ML?(+C1W/V#U!+ P04    " "*A6U7MS6YWYH'  !2$0
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M#U_-!L*E-_CT(]@FOC4O;$!.X]>*)!B&+^"\M#:L?K"!_L\H1_\%4$L#!!0
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MOL8J!$B<%< '=$,!>PUT@VJ&_Q J5RP/^1%ZOCB^*DQP:_J7L_\96=K+!OG
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MQW/&]F*C7?@K-M7<LTE?Q*7S)JL7 T&F\NI7OM8\=!9\CMY9,*D73 +NRE%
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MSV'O,(<7,/B#Q40E(C>^SD482DJ_98)6QB2@BU7/?0U/%@"E9NY#+5A: 7R
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MH;0.YGPMA#X:]H+ZB8M^ U!+ P04    " "*A6U7FDC$[]D*  !;'0  &0
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MEZHLJ*& (F0=_B@^=\*LK',[$4ZHX>KLX4'. ST6VC#-D7,LWUPWC4[3M5P
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MZ>F<T.L:@?(LE)Z-6*9<&^H&:N?F>KE]5]^KKKYW\-6_'<YFP_%\?]G;"W=
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M[3+3[Q,*HZ#/4\[586,<'%^\WM]02P,$%     @ BH5M5^XHFPCC @  .@8
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M]>JZM?;SCO+I>-Z74]K/>*K(Y5,2K98;]&#)O-?-)UIDMK\<"TW=JAU&]/,
MI3E ^U,A]&IB%*Q_<+3^!U!+ P04    " "*A6U7K4?M64,%  #<*0  &0
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MA-GE&KO)I))F2)XO">&[FS1 >:!S\ -02P,$%     @ BH5M5Y)0;AF/ @
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MI!>@RK3O\,DP3O'7OHX I5F@-!N4YD#1J@6ZZW<K1S:\>5/9]JH]H<797+5
M(+T 57X>F/;KOVJ<XHY3M) T"Y1F@](<*%JU:'<];87?U!:>EO-*]H3>:GM[
M!Y2F=UR^MIT^#UI_GP&-QP2E6: T&Y3F0-&JA;UKJ2M']M3;"YO75H!LXRY
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MIB]?'I;=1;*.H*D^;#]2(8_NNAG(ZQLP!9#/MY2*EXZ:H+@03OX!4$L#!!0
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M\U#-1[4 U4)4BRBM7DJJ<*O^FN%6'0VWHIJ!:B:J6:AFHYJ#:BZJ>:CFHUJ
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MMA[Z3O>LCBZWA"V\D(./<XDQ3L_EWQO;G@:V$T&CN*&>4"';\WBXE"<H9"I
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M"6!H*0,)X"NP_'=OG"[^7,?8D-@.L5<1>[FZM^^0LYF 7QDD$HU7^GKW3<U
MYQ)B44ON-4G>D-@.>;LB;QO/>OP /* "YFBMG^9$UM$:)0ZE+<0ZN9A^AZY\
MMX^[_5YO8*]J0#H52,<(<ELL'Z6<!H!2X(4;ZW",0H?B%&+]+1S<PA@[]33=
MBJ9KI'G^0)8V1'_01+W'LV2NCFS#;/*H,<^AL V)[6Q)K]J27K,>[35)WI#8
M#OE117[T_QX]>FXK[&V[JN P9GHE1[_BZ#=ET4*H]\15SA,88[I7PCCXL3#
MK_9H[5^H&I]"D'$J*0@TR7@0JOH*G2PY0 PO^-B\F$,?YZ;4=K=NJZ9RFO5R
MJ=<4?4-JN_2/Y95CKJ^JDS?8N91XT<_F5(>BV%MULOY(N2!\21.!(E@H>=SJ
MJ?7PHNXO.I*E>>D\8U(5XGDS5-]*P/4$=7_!F-QT=#5>?7WY?P%02P,$%
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( (J%;5>%V >5) 0  +0;   /
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M4')O<',O8V]R92YX;6Q02P$"% ,4    " "*A6U7F5R<(Q &  "<)P  $P
M            @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M (J%;5>]GE ^RP4  ,D>   8              " @0T(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " "*A6U7A]^R4>0&  #T)0  &
M            @($.#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#
M%     @ BH5M5SKM9_75 P  !14  !@              ("!*!4  'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( (J%;5?58#/#2 8  -H=
M   8              " @3,9  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"% ,4    " "*A6U719TZH>,*   '>@  &               @(&Q'P
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ BH5M5PAN+;30
M!0  O1@  !@              ("!RBH  'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;%!+ 0(4 Q0    ( (J%;5=2"<]';P,  $ '   8              "
M@= P  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " "*A6U7
MMS6YWYH'  !2$0  &               @(%U-   >&PO=V]R:W-H965T<R]S
M:&5E=#@N>&UL4$L! A0#%     @ BH5M5[&T"\Z&"@  "1L  !@
M     ("!13P  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (
M (J%;5> 'T,%' H  +X:   9              " @0%'  !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&UL4$L! A0#%     @ BH5M5]H)K SN P  L0@  !D
M             ("!5%$  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M% ,4    " "*A6U7:5?WH+L#  #\!P  &0              @(%Y50  >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( (J%;5>%,GFD#@,
M *\&   9              " @6M9  !X;"]W;W)K<VAE971S+W-H965T,3,N
M>&UL4$L! A0#%     @ BH5M5T4%A.AK!@  #A   !D              ("!
ML%P  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " "*A6U7
M>=M3G?P&  #7$   &0              @(%28P  >&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;%!+ 0(4 Q0    ( (J%;5>U1TN!K (  -@%   9
M      " @85J  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%
M  @ BH5M5^=)U88] @  [@0  !D              ("!:&T  'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " "*A6U7FDC$[]D*  !;'0
M&0              @('<;P  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+
M 0(4 Q0    ( (J%;5=XNT'!N@0  .8,   9              " @>QZ  !X
M;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ BH5M5YM6^+Q/
M P  _08  !D              ("!W7\  'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6Q02P$"% ,4    " "*A6U7[BB;".,"   Z!@  &0
M@(%C@P  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( (J%
M;5? 1DKSP@(   X&   9              " @7V&  !X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL4$L! A0#%     @ BH5M5]8I(@)K!   ? P  !D
M         ("!=HD  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
M    " "*A6U7K4?M64,%  #<*0  &0              @($8C@  >&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( (J%;5>24&X9CP(  -X%
M   9              " @9*3  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
M4$L! A0#%     @ BH5M5Z-7QO("!@  I2P  !D              ("!6)8
M 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " "*A6U7.N50
M9((#   <#@  &0              @(&1G   >&PO=V]R:W-H965T<R]S:&5E
M=#(W+GAM;%!+ 0(4 Q0    ( (J%;5>QFA.@4 ,  "\,   9
M  " @4J@  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @
MBH5M5UNPC\]R$   &@<! !D              ("!T:,  'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6Q02P$"% ,4    " "*A6U77XSYOU<#  #/"P  &0
M            @(%ZM   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4
M Q0    ( (J%;5>ZS1I8@@0  +4=   9              " @0BX  !X;"]W
M;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ BH5M5_]6BV^1 P
M_!$  !D              ("!P;P  'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6Q02P$"% ,4    " "*A6U7/F=79X8"   :!@  &0              @(&)
MP   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( (J%;5<*
M-E(WY0(  .\)   9              " @4;#  !X;"]W;W)K<VAE971S+W-H
M965T,S0N>&UL4$L! A0#%     @ BH5M5W_PHF6V P  /!(  !D
M     ("!8L8  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
M" "*A6U7;OEUIB$$  !0%@  &0              @(%/R@  >&PO=V]R:W-H
M965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( (J%;5<XAJR*$0,  )\-   9
M              " @:?.  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L!
M A0#%     @ BH5M5YMF+)L"!   !A0  !D              ("![]$  'AL
M+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " "*A6U7\C1^,IH#
M  #O#P  &0              @($HU@  >&PO=V]R:W-H965T<R]S:&5E=#,Y
M+GAM;%!+ 0(4 Q0    ( (J%;5<4Q_Z :@(  -L%   9              "
M@?G9  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ BH5M
M5^P1R#$: P  B0T  !D              ("!FMP  'AL+W=O<FMS:&5E=',O
M<VAE970T,2YX;6Q02P$"% ,4    " "*A6U7XA27)#H#  #N$P  #0
M        @ 'KWP  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( (J%;5>7BKL<
MP    !,"   +              "  5#C  !?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( (J%;5>%V >5) 0  +0;   /              "  3GD  !X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " "*A6U7*5V(H),!  #B&   &@
M    @ &*Z   >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" "*A6U7B(RI-Z4!   O&0  $P              @ %5Z@  6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     ,0 Q $X-   K[      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>235</ContextCount>
  <ElementCount>192</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement -  Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement -  Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/StatementOfStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statement of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/DescriptionOfBusiness</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - GOING CONCERN, LIQUIDITY AND OTHER UNCERTAINTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertainties</Role>
      <ShortName>GOING CONCERN, LIQUIDITY AND OTHER UNCERTAINTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDER</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/LossPerShareApplicableToCommonStockholder</Role>
      <ShortName>LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDER</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/GeographicInformationAndMajorCustomerData</Role>
      <ShortName>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - OTHER ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/OtherAssets</Role>
      <ShortName>OTHER ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - RELATED PARTY TRANSACTION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/RelatedPartyTransaction</Role>
      <ShortName>RELATED PARTY TRANSACTION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/StockholdersEquity</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDER (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/LossPerShareApplicableToCommonStockholderTables</Role>
      <ShortName>LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDER (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/LossPerShareApplicableToCommonStockholder</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataTables</Role>
      <ShortName>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/GeographicInformationAndMajorCustomerData</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/Leases</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - OTHER ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/OtherAssetsTables</Role>
      <ShortName>OTHER ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/OtherAssets</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - GOING CONCERN, LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertaintiesDetailsNarrative</Role>
      <ShortName>GOING CONCERN, LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertainties</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - SCHEDULE OF OPTIONS ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails</Role>
      <ShortName>SCHEDULE OF OPTIONS ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails</Role>
      <ShortName>SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails</Role>
      <ShortName>SCHEDULE OF WARRANTS ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/StockholdersEquityTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails</Role>
      <ShortName>SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails</Role>
      <ShortName>SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative</Role>
      <ShortName>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails</Role>
      <ShortName>SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/LeasesDetailsNarrative</Role>
      <ShortName>LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/LeasesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - SCHEDULE OF WARRANTS ASSUMPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails</Role>
      <ShortName>SCHEDULE OF WARRANTS ASSUMPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails</Role>
      <ShortName>SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - SCHEDULE OF ASSETS AND LIABILITY MEASURED AT FAIR VALUE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilityMeasuredAtFairValueDetails</Role>
      <ShortName>SCHEDULE OF ASSETS AND LIABILITY MEASURED AT FAIR VALUE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - OTHER ASSETS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/OtherAssetsDetailsNarrative</Role>
      <ShortName>OTHER ASSETS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/OtherAssetsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - RELATED PARTY TRANSACTION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/RelatedPartyTransactionDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/RelatedPartyTransaction</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanovibronix.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanovibronix.com/role/SubsequentEvents</ParentRole>
      <Position>41</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="form10-q.htm">form10-q.htm</File>
    <File>naov-20230930.xsd</File>
    <File>naov-20230930_cal.xml</File>
    <File>naov-20230930_def.xml</File>
    <File>naov-20230930_lab.xml</File>
    <File>naov-20230930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-q_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="782">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>63
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-q.htm": {
   "nsprefix": "NAOV",
   "nsuri": "http://nanovibronix.com/20230930",
   "dts": {
    "inline": {
     "local": [
      "form10-q.htm"
     ]
    },
    "schema": {
     "local": [
      "naov-20230930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "naov-20230930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "naov-20230930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "naov-20230930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "naov-20230930_pre.xml"
     ]
    }
   },
   "keyStandard": 179,
   "keyCustom": 13,
   "axisStandard": 17,
   "axisCustom": 0,
   "memberStandard": 30,
   "memberCustom": 18,
   "hidden": {
    "total": 266,
    "http://fasb.org/us-gaap/2023": 245,
    "http://xbrl.sec.gov/dei/2023": 4,
    "http://nanovibronix.com/20230930": 17
   },
   "contextCount": 235,
   "entityCount": 1,
   "segmentCount": 49,
   "elementCount": 355,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 782,
    "http://xbrl.sec.gov/dei/2023": 29
   },
   "report": {
    "R1": {
     "role": "http://nanovibronix.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "00000002 - Statement -  Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "00000003 - Statement -  Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss",
     "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://nanovibronix.com/role/StatementOfStockholdersEquity",
     "longName": "00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited)",
     "shortName": "Condensed Consolidated Statement of Stockholders' Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://nanovibronix.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://nanovibronix.com/role/DescriptionOfBusiness",
     "longName": "00000007 - Disclosure - DESCRIPTION OF BUSINESS",
     "shortName": "DESCRIPTION OF BUSINESS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertainties",
     "longName": "00000008 - Disclosure - GOING CONCERN, LIQUIDITY AND OTHER UNCERTAINTIES",
     "shortName": "GOING CONCERN, LIQUIDITY AND OTHER UNCERTAINTIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "NAOV:GoingConcernAndLiquidityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "NAOV:GoingConcernAndLiquidityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://nanovibronix.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://nanovibronix.com/role/StockholdersEquity",
     "longName": "00000010 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://nanovibronix.com/role/LossPerShareApplicableToCommonStockholder",
     "longName": "00000011 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDER",
     "shortName": "LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDER",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerData",
     "longName": "00000012 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA",
     "shortName": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://nanovibronix.com/role/Leases",
     "longName": "00000013 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://nanovibronix.com/role/OtherAssets",
     "longName": "00000014 - Disclosure - OTHER ASSETS",
     "shortName": "OTHER ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://nanovibronix.com/role/CommitmentsAndContingencies",
     "longName": "00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://nanovibronix.com/role/RelatedPartyTransaction",
     "longName": "00000016 - Disclosure - RELATED PARTY TRANSACTION",
     "shortName": "RELATED PARTY TRANSACTION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://nanovibronix.com/role/SubsequentEvents",
     "longName": "00000017 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://nanovibronix.com/role/StockholdersEquityTables",
     "longName": "00000019 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://nanovibronix.com/role/LossPerShareApplicableToCommonStockholderTables",
     "longName": "00000020 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDER (Tables)",
     "shortName": "LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDER (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataTables",
     "longName": "00000021 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)",
     "shortName": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://nanovibronix.com/role/LeasesTables",
     "longName": "00000022 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://nanovibronix.com/role/OtherAssetsTables",
     "longName": "00000023 - Disclosure - OTHER ASSETS (Tables)",
     "shortName": "OTHER ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "NAOV:ScheduleOfWarrantsAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "NAOV:ScheduleOfWarrantsAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertaintiesDetailsNarrative",
     "longName": "00000024 - Disclosure - GOING CONCERN, LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)",
     "shortName": "GOING CONCERN, LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2023-08-012023-08-31",
      "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "NAOV:GoingConcernAndLiquidityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-08-012023-08-31",
      "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "NAOV:GoingConcernAndLiquidityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails",
     "longName": "00000026 - Disclosure - SCHEDULE OF OPTIONS ACTIVITY (Details)",
     "shortName": "SCHEDULE OF OPTIONS ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "AsOf2023-06-30_custom_EmployeeOptionsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012023-09-30_custom_EmployeeOptionsMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails",
     "longName": "00000027 - Disclosure - SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES (Details)",
     "shortName": "SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R28": {
     "role": "http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails",
     "longName": "00000028 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)",
     "shortName": "SCHEDULE OF WARRANTS ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-09-30_us-gaap_WarrantMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_WarrantMember_custom_PrivateInvestorsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
     "longName": "00000029 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2023-02-082023-02-08",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-02-082023-02-08",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails",
     "longName": "00000030 - Disclosure - SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE (Details)",
     "shortName": "SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails",
     "longName": "00000031 - Disclosure - SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS (Details)",
     "shortName": "SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012023-09-30_country_US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative",
     "longName": "00000032 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Details Narrative)",
     "shortName": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012023-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails",
     "longName": "00000033 - Disclosure - SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES (Details)",
     "shortName": "SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://nanovibronix.com/role/LeasesDetailsNarrative",
     "longName": "00000034 - Disclosure - LEASES (Details Narrative)",
     "shortName": "LEASES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails",
     "longName": "00000035 - Disclosure - SCHEDULE OF WARRANTS ASSUMPTIONS (Details)",
     "shortName": "SCHEDULE OF WARRANTS ASSUMPTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30_custom_PriceAtValuationMember_custom_SanuwaveHealthIncMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "NAOV:ScheduleOfWarrantsAssumptionsTableTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30_custom_PriceAtValuationMember_custom_SanuwaveHealthIncMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "NAOV:ScheduleOfWarrantsAssumptionsTableTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails",
     "longName": "00000036 - Disclosure - SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE (Details)",
     "shortName": "SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012023-09-30_custom_DerivativeAssetMember",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilityMeasuredAtFairValueDetails",
     "longName": "00000037 - Disclosure - SCHEDULE OF ASSETS AND LIABILITY MEASURED AT FAIR VALUE (Details)",
     "shortName": "SCHEDULE OF ASSETS AND LIABILITY MEASURED AT FAIR VALUE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:OtherAssetsNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30_us-gaap_FairValueInputsLevel3Member",
      "name": "us-gaap:OtherAssetsNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://nanovibronix.com/role/OtherAssetsDetailsNarrative",
     "longName": "00000038 - Disclosure - OTHER ASSETS (Details Narrative)",
     "shortName": "OTHER ASSETS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2020-04-09_custom_LicensingAgreementMember_custom_SanuwaveHealthIncMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "00000039 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2023-03-142023-03-15",
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-03-142023-03-15",
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://nanovibronix.com/role/RelatedPartyTransactionDetailsNarrative",
     "longName": "00000040 - Disclosure - RELATED PARTY TRANSACTION (Details Narrative)",
     "shortName": "RELATED PARTY TRANSACTION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:LegalFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:LegalFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative",
     "longName": "00000041 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2023-08-30_us-gaap_CommonStockMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-11-06_us-gaap_SubsequentEventMember_custom_PrefundedWarrantMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_OffsettingAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OffsettingAssetsTable",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting Assets [Table]",
        "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66"
     ]
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r23"
     ]
    },
    "us-gaap_SeriesEPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesEPreferredStockMember",
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets",
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series E Preferred Stock [Member]",
        "documentation": "Series E preferred stock."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r526",
      "r548"
     ]
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets",
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r526",
      "r548"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r199",
      "r200",
      "r455",
      "r541"
     ]
    },
    "us-gaap_SeriesDPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesDPreferredStockMember",
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets",
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series D Preferred Stock [Member]",
        "documentation": "Series D preferred stock."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r526",
      "r548"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and rights outstanding, measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_SeriesFPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesFPreferredStockMember",
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets",
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series F Preferred Stock [Member]",
        "documentation": "Series F preferred stock."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r526",
      "r548"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-vested stock options granted, weighted average period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "country_AU": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "AU",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AUSTRALIA"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF WARRANTS ACTIVITY",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_OffsettingAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OffsettingAssetsLineItems",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyDamagesAwardedValue",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Damages awarded value",
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r543",
      "r544"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r408"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/RelatedPartyTransaction"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTION",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r354",
      "r355",
      "r356",
      "r409",
      "r410",
      "r411",
      "r431",
      "r433"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock of $0.001 par value - Authorized: 40,000,000 shares at September 30, 2023 and December 31, 2022, respectively; Issued and outstanding: 1,842,331 and 1,641,146 shares at September 30, 2023 and December 31, 2022, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r329",
      "r486"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r133",
      "r194",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r270",
      "r271",
      "r272",
      "r287",
      "r382",
      "r473",
      "r498",
      "r545",
      "r560",
      "r561"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r384"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r39",
      "r53",
      "r54",
      "r191",
      "r454"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r59",
      "r384",
      "r403",
      "r574",
      "r575"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r56",
      "r326",
      "r383"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Under Options, Granted",
        "verboseLabel": "Number of employee options granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets",
      "http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, net",
        "verboseLabel": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r470",
      "r486"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r39",
      "r53",
      "r54",
      "r191",
      "r347",
      "r454"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r198",
      "r411"
     ]
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_LossContingencyDamagesPaidValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyDamagesPaidValue",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss contingency damages paid value",
        "documentation": "Amount of damages paid to the plaintiff in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r543",
      "r544"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss available to common stockholders",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r119",
      "r121",
      "r126",
      "r321",
      "r336"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r313"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r91",
      "r332",
      "r486",
      "r532",
      "r539",
      "r554"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "NAOV_A1WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "A1WarrantsMember",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "A-1 Warrants [Member]",
        "documentation": "A1 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use assets, net",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r39",
      "r53",
      "r54",
      "r191",
      "r454",
      "r522"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r216"
     ]
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Exercise Price [Member]",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "NAOV_A2WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "A2WarrantsMember",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "A-2 Warrants [Member]",
        "documentation": "A2 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://nanovibronix.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r201",
      "r202",
      "r203",
      "r204",
      "r241",
      "r248",
      "r254",
      "r255",
      "r256",
      "r318",
      "r319",
      "r340",
      "r374",
      "r375",
      "r434",
      "r436",
      "r438",
      "r439",
      "r445",
      "r465",
      "r466",
      "r475",
      "r478",
      "r484",
      "r487",
      "r490",
      "r540",
      "r547",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "NAOV_WainwrightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "WainwrightMember",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Wainwright [Membe",
        "documentation": "Wainwright [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://nanovibronix.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r201",
      "r202",
      "r203",
      "r204",
      "r248",
      "r319",
      "r340",
      "r374",
      "r375",
      "r434",
      "r436",
      "r438",
      "r439",
      "r445",
      "r465",
      "r466",
      "r475",
      "r478",
      "r484",
      "r487",
      "r547",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ]
    },
    "NAOV_EmployeeOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "EmployeeOptionsMember",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Options [Member]",
        "documentation": "Employee Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://nanovibronix.com/role/LeasesDetailsNarrative"
     ],
     "auth_ref": [
      "r201",
      "r202",
      "r203",
      "r204",
      "r241",
      "r248",
      "r254",
      "r255",
      "r256",
      "r318",
      "r319",
      "r340",
      "r374",
      "r375",
      "r434",
      "r436",
      "r438",
      "r439",
      "r445",
      "r465",
      "r466",
      "r475",
      "r478",
      "r484",
      "r487",
      "r490",
      "r540",
      "r547",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase warrant",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "verboseLabel": "Revenues geographic areas",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r176",
      "r180",
      "r181",
      "r187",
      "r189",
      "r191",
      "r239",
      "r240",
      "r320"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://nanovibronix.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r201",
      "r202",
      "r203",
      "r204",
      "r248",
      "r319",
      "r340",
      "r374",
      "r375",
      "r434",
      "r436",
      "r438",
      "r439",
      "r445",
      "r465",
      "r466",
      "r475",
      "r478",
      "r484",
      "r487",
      "r547",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ]
    },
    "NAOV_PrivateInvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "PrivateInvestorsMember",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Investors [Member]",
        "documentation": "Private Investors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_DerivativeAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "DerivativeAssetMember",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Asset [Member]",
        "documentation": "Derivative Asset [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets",
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r112",
      "r113",
      "r114",
      "r133",
      "r151",
      "r152",
      "r155",
      "r157",
      "r163",
      "r164",
      "r194",
      "r205",
      "r207",
      "r208",
      "r209",
      "r212",
      "r213",
      "r216",
      "r217",
      "r219",
      "r222",
      "r228",
      "r287",
      "r349",
      "r350",
      "r351",
      "r352",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r369",
      "r384",
      "r406",
      "r427",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r519",
      "r531",
      "r536"
     ]
    },
    "NAOV_OtherCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "OtherCountryMember",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Country [Member]",
        "documentation": "Other Country [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_StockOptionsEmployeeAndNonEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "StockOptionsEmployeeAndNonEmployeeMember",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options Employee And Non Employee [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsDetailsNarrative",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of securities called by warrants or rights",
        "verboseLabel": "Warrants issued to purchase common stock",
        "terseLabel": "Exercised warrant",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 EQUITY",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r132",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r230",
      "r279",
      "r430",
      "r432",
      "r452"
     ]
    },
    "NAOV_TwoCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "TwoCustomersMember",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Customers [Member]",
        "documentation": "Two Customers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "auth_ref": []
    },
    "NAOV_CustomersOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "CustomersOneMember",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customers One [Member]",
        "documentation": "Customers One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of revenues",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r133",
      "r194",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r287",
      "r545"
     ]
    },
    "NAOV_CustomersTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "CustomersTwoMember",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customers Two [Member]",
        "documentation": "Customers Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_LicensingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "LicensingAgreementMember",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensing Agreement [Member]",
        "documentation": "Licensing Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_SanuwaveHealthIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "SanuwaveHealthIncMember",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsDetailsNarrative",
      "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sanuwave Health, Inc. [Member]",
        "documentation": "Sanuwave Health, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_PriceAtValuationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "PriceAtValuationMember",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Price at Valuation [Member]",
        "documentation": "Price at Valuation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r173"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative"
     ],
     "auth_ref": [
      "r191",
      "r480",
      "r549",
      "r569",
      "r570"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r313"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r39",
      "r53",
      "r54",
      "r191",
      "r454"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r31",
      "r85"
     ]
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r521"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://nanovibronix.com/role/StatementOfStockholdersEquity",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rounding up of fractional shares due to stock split, shares",
        "verboseLabel": "Number of new share issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r58",
      "r59",
      "r85",
      "r349",
      "r427",
      "r448"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of employee options expired",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED SERVICES FROM EMPLOYEES AND NON-EMPLOYEES",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r68"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r77"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued severance pay",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effects of currency translation on cash and cash equivalents",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Shares Under Options Outstanding, Balance",
        "periodEndLabel": "Shares Under Options Outstanding, Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r250"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price per Share, Outstanding Balance",
        "periodEndLabel": "Weighted Average Exercise Price per Share, Outstanding Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r250"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash at beginning of period",
        "periodEndLabel": "Cash at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r77",
      "r130"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r191"
     ]
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://nanovibronix.com/role/StatementOfStockholdersEquity",
      "http://nanovibronix.com/role/StatementsOfCashFlows",
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "verboseLabel": "Net income from continuing operations",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r79",
      "r93",
      "r107",
      "r118",
      "r120",
      "r124",
      "r133",
      "r137",
      "r139",
      "r140",
      "r141",
      "r142",
      "r145",
      "r146",
      "r153",
      "r169",
      "r177",
      "r182",
      "r185",
      "r194",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r282",
      "r287",
      "r335",
      "r405",
      "r425",
      "r426",
      "r474",
      "r496",
      "r545"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss available to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r139",
      "r140",
      "r141",
      "r142",
      "r148",
      "r149",
      "r154",
      "r157",
      "r169",
      "r177",
      "r182",
      "r185",
      "r474"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets",
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r112",
      "r113",
      "r114",
      "r133",
      "r151",
      "r152",
      "r155",
      "r157",
      "r163",
      "r164",
      "r194",
      "r205",
      "r207",
      "r208",
      "r209",
      "r212",
      "r213",
      "r216",
      "r217",
      "r219",
      "r222",
      "r228",
      "r287",
      "r349",
      "r350",
      "r351",
      "r352",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r369",
      "r384",
      "r406",
      "r427",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r519",
      "r531",
      "r536"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails",
      "http://nanovibronix.com/role/StatementOfStockholdersEquity",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of options, shares",
        "verboseLabel": "Shares Under Options, Exercised",
        "terseLabel": "Number of employee options expired",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r58",
      "r59",
      "r85",
      "r252"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets",
      "http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Stockholder's equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r62",
      "r63",
      "r82",
      "r386",
      "r403",
      "r428",
      "r429",
      "r486",
      "r498",
      "r532",
      "r539",
      "r554",
      "r574"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r263",
      "r568"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r117",
      "r133",
      "r194",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r269",
      "r271",
      "r287",
      "r486",
      "r545",
      "r546",
      "r560"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation expense",
        "verboseLabel": "Stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r262"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fractional shares",
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r512",
      "r513"
     ]
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable",
     "presentation": [
      "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]",
        "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r87"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems",
     "presentation": [
      "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Trade receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r327",
      "r368",
      "r392",
      "r486",
      "r498",
      "r523"
     ]
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r94",
      "r125",
      "r172",
      "r299",
      "r412",
      "r496",
      "r573"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails",
      "http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r375",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r401",
      "r415",
      "r416",
      "r417",
      "r418",
      "r421",
      "r422",
      "r423",
      "r424",
      "r441",
      "r442",
      "r443",
      "r444",
      "r488",
      "r490"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets",
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://nanovibronix.com/role/LeasesDetailsNarrative",
      "http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails",
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r162",
      "r320",
      "r348",
      "r369",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r384",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r404",
      "r407",
      "r408",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r427",
      "r491"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently adopted accounting standards",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsDetailsNarrative",
      "http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustments - Sanuwave warrants",
        "verboseLabel": "Fair value of warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r9"
     ]
    },
    "srt_EuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EuropeMember",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]"
       }
      }
     },
     "auth_ref": [
      "r576",
      "r577",
      "r578",
      "r579"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade receivables, net",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r85",
      "r331",
      "r344",
      "r346",
      "r353",
      "r385",
      "r486"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://nanovibronix.com/role/DescriptionOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DESCRIPTION OF BUSINESS",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r103"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilityMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r242",
      "r247",
      "r284",
      "r316",
      "r476",
      "r477",
      "r481",
      "r482",
      "r483"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price per Share, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilityMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r242",
      "r247",
      "r284",
      "r315",
      "r481",
      "r482",
      "r483"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, value",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r328",
      "r486"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price per Share, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r252"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price per Share, Expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilityMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r284",
      "r317",
      "r476",
      "r477",
      "r481",
      "r482",
      "r483"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "auth_ref": []
    },
    "srt_AsiaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "AsiaMember",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asia [Member]"
       }
      }
     },
     "auth_ref": [
      "r576",
      "r577",
      "r578",
      "r579"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive loss per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsDetailsNarrative",
      "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term (in years)",
        "verboseLabel": "Warrants and rights outstanding term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of warrant or right expire date",
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsDetailsNarrative",
      "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r313"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r102",
      "r145",
      "r146",
      "r174",
      "r264",
      "r267",
      "r339"
     ]
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/LossPerShareApplicableToCommonStockholderTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r313"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Life (Years), Outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency translation adjustment",
        "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, on foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r11",
      "r89"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r313"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-vested stock options granted, unrecognized estimated compensation cost",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of presentation and principles of consolidation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails",
      "http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails"
     ],
     "auth_ref": [
      "r189",
      "r190",
      "r370",
      "r371",
      "r372",
      "r435",
      "r437",
      "r440",
      "r446",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r469",
      "r479",
      "r490",
      "r549",
      "r569"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsDetailsNarrative",
      "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade payables",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r486"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r157"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Trade payables",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r468"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
      "http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r489",
      "r492",
      "r493",
      "r494",
      "r495"
     ]
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of equity investment",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r538"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://nanovibronix.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r485"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity ddress, city or town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity address, state or province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants leaving balance",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "us-gaap_OtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER ASSETS",
        "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted operating lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r109",
      "r133",
      "r194",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r270",
      "r271",
      "r272",
      "r287",
      "r486",
      "r545",
      "r560",
      "r561"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_OtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccountsPayableAndAccruedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses and other payables",
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted net loss available for holders of common stock",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r151",
      "r155",
      "r156",
      "r157",
      "r161",
      "r281",
      "r282",
      "r322",
      "r337",
      "r472"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://nanovibronix.com/role/StatementOfStockholdersEquity",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r489",
      "r490",
      "r492",
      "r493",
      "r494",
      "r495",
      "r533",
      "r534",
      "r551",
      "r571",
      "r574"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before taxes on income",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r69",
      "r92",
      "r169",
      "r177",
      "r182",
      "r185",
      "r323",
      "r334",
      "r474"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78",
      "r79"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsDetailsNarrative",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r50",
      "r51",
      "r373",
      "r375",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r401",
      "r415",
      "r416",
      "r417",
      "r418",
      "r421",
      "r422",
      "r423",
      "r424",
      "r441",
      "r442",
      "r443",
      "r444",
      "r471",
      "r488",
      "r490"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease, expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r216"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LegalFees",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/RelatedPartyTransactionDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal fees paid",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsDetailsNarrative",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r384"
     ]
    },
    "NAOV_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement [Member]",
        "documentation": "Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r157"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r384",
      "r403",
      "r574",
      "r575"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r357",
      "r533",
      "r534",
      "r535",
      "r551",
      "r574"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilityMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r315",
      "r316",
      "r317",
      "r476",
      "r477",
      "r481",
      "r482",
      "r483"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r131"
     ]
    },
    "NAOV_ArbitratorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "ArbitratorMember",
     "presentation": [
      "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arbitrator [Member]",
        "documentation": "Arbitrator [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Deferred Revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "NAOV_PrefundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "PrefundedWarrantMember",
     "presentation": [
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prefunded Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r111",
      "r133",
      "r169",
      "r178",
      "r183",
      "r194",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r269",
      "r271",
      "r287",
      "r325",
      "r397",
      "r486",
      "r498",
      "r545",
      "r546",
      "r560"
     ]
    },
    "NAOV_SeveranceAssetsNoncurent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "SeveranceAssetsNoncurent",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance pay fund",
        "documentation": "Severance assets, noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic net loss available for holders of common stock",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r148",
      "r151",
      "r155",
      "r156",
      "r157",
      "r161",
      "r281",
      "r282",
      "r322",
      "r337",
      "r472"
     ]
    },
    "NAOV_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails",
      "http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails",
      "http://nanovibronix.com/role/StatementOfStockholdersEquity",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r31",
      "r106",
      "r122",
      "r123",
      "r124",
      "r134",
      "r135",
      "r136",
      "r138",
      "r144",
      "r146",
      "r162",
      "r195",
      "r196",
      "r230",
      "r259",
      "r260",
      "r261",
      "r265",
      "r266",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r306",
      "r341",
      "r342",
      "r343",
      "r357",
      "r427"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r134",
      "r135",
      "r136",
      "r138",
      "r144",
      "r146",
      "r195",
      "r196",
      "r259",
      "r260",
      "r261",
      "r265",
      "r266",
      "r273",
      "r275",
      "r276",
      "r278",
      "r280",
      "r341",
      "r343",
      "r357",
      "r574"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/LossPerShareApplicableToCommonStockholder"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDER",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r158",
      "r159",
      "r160"
     ]
    },
    "NAOV_FinancialExpensesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "FinancialExpensesNet",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial expense, net",
        "documentation": "Financial expenses net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r489",
      "r492",
      "r493",
      "r494",
      "r495",
      "r571",
      "r574"
     ]
    },
    "us-gaap_DeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenue",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred revenue",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock, shares",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets",
      "http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilityMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "NAOV_NoncashInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "NoncashInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash interest expense",
        "documentation": "Non cash interest expense."
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "AdjustmentsToAdditionalPaidInCapitalReversalOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reversal of warrants",
        "documentation": "Reversal of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r314"
     ]
    },
    "NAOV_DisclosureGoingConcernLiquidityAndOtherUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "DisclosureGoingConcernLiquidityAndOtherUncertaintiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Going Concern Liquidity And Other Uncertainties"
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_IncreaseDecreaseInAccruedSeverancePayNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "IncreaseDecreaseInAccruedSeverancePayNet",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued severance pay, net",
        "documentation": "Increase decrease in accrued severance pay net."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r537",
      "r559"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other accounts receivable",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "NAOV_GoingConcernAndLiquidityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "GoingConcernAndLiquidityTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertainties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GOING CONCERN, LIQUIDITY AND OTHER UNCERTAINTIES",
        "documentation": "Going Concern And Liquidity [TextBlock]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails",
      "http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails",
      "http://nanovibronix.com/role/StatementOfStockholdersEquity",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r106",
      "r122",
      "r123",
      "r124",
      "r134",
      "r135",
      "r136",
      "r138",
      "r144",
      "r146",
      "r162",
      "r195",
      "r196",
      "r230",
      "r259",
      "r260",
      "r261",
      "r265",
      "r266",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r306",
      "r341",
      "r342",
      "r343",
      "r357",
      "r427"
     ]
    },
    "NAOV_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "DisclosureLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "verboseLabel": "Schedule Of Liabilities Arising From Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r12",
      "r33",
      "r274",
      "r277",
      "r306",
      "r341",
      "r342",
      "r528",
      "r529",
      "r530",
      "r533",
      "r534",
      "r535"
     ]
    },
    "NAOV_ValueOfListedSecurites": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "ValueOfListedSecurites",
     "presentation": [
      "http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of listed securities",
        "documentation": "Value of listed securites."
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_ScheduleOfWarrantsAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "ScheduleOfWarrantsAssumptionsTableTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF WARRANTS ASSUMPTIONS",
        "documentation": "Schedule Of Warrants Assumptions [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Remaining Life (Years), Outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Life (Years), Outstanding - ending balance"
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Life (Years), Granted",
        "documentation": "Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_StockIssuedDuringPeriodSharesStockOptionsExpired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExpired",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Under Options, Expired",
        "documentation": "Stock issued during period shares stock options expired."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity address, address line one",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Life (Years), Expired"
       }
      }
     },
     "auth_ref": []
    },
    "NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://nanovibronix.com/20230930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Life (Years), Exercised",
        "documentation": "Weighted average remaining contractual term for option awards exercised, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r411"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r190",
      "r370",
      "r371",
      "r372",
      "r435",
      "r437",
      "r440",
      "r446",
      "r453",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r469",
      "r479",
      "r490",
      "r549",
      "r569"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-dilutiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilityMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r284",
      "r315",
      "r316",
      "r317",
      "r476",
      "r477",
      "r481",
      "r482",
      "r483"
     ]
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r194",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r269",
      "r271",
      "r287",
      "r545",
      "r546",
      "r560"
     ]
    },
    "us-gaap_WarrantExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantExercisePriceIncrease",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercise price",
        "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://nanovibronix.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets",
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://nanovibronix.com/role/LeasesDetailsNarrative",
      "http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails",
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r162",
      "r320",
      "r348",
      "r369",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r384",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r404",
      "r407",
      "r408",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r427",
      "r491"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://nanovibronix.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r67",
      "r115",
      "r330",
      "r345",
      "r346"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://nanovibronix.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r485"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrants, Outstanding, Balance",
        "periodEndLabel": "Warrants, Outstanding, Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerData"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r175",
      "r179",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r191"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants, Granted",
        "verboseLabel": "Warrants, granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncurrent assets:"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r191",
      "r480",
      "r549",
      "r569",
      "r570"
     ]
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyDamagesSoughtValue",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss contingency damages sought value",
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r543",
      "r544"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Major Customer [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r177",
      "r182",
      "r185",
      "r474"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants, Canceled",
        "verboseLabel": "Warrants, exercised",
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ASSETS AND LIABILITY MEASURED AT FAIR VALUE",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284"
     ]
    },
    "us-gaap_DeferredIncomeNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred licensing income",
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "srt_PlatformOperatorCryptoAssetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "PlatformOperatorCryptoAssetLineItems",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilityMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto-Asset [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "srt_PlatformOperatorCryptoAssetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "PlatformOperatorCryptoAssetTable",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilityMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto-Asset [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r133",
      "r169",
      "r177",
      "r182",
      "r185",
      "r194",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r287",
      "r474",
      "r545"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r486",
      "r572"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed assets, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r324",
      "r333",
      "r486"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling and marketing",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration risk, percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r39",
      "r53",
      "r54",
      "r191"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in foreign currency translation adjustments",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r5",
      "r290",
      "r296"
     ]
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less: Imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued, price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingAndMarketingExpenseMember",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedServicesFromEmployeesAndNon-employeesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling and Marketing Expense [Member]",
        "documentation": "Primary financial statement caption encompassing selling and marketing expense."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Present value of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gains and losses from foreign currency translation",
        "documentation": "Amount of tax expense (benefit), before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r5",
      "r289",
      "r290",
      "r296"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://nanovibronix.com/role/StatementOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rounding up of fractional shares due to stock split",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r58",
      "r59",
      "r85",
      "r357",
      "r427",
      "r448",
      "r497"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://nanovibronix.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://nanovibronix.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/GoingConcernLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance sale of equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r349"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE",
        "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r24"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance beginning",
        "periodEndLabel": "Balance ending",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs",
        "documentation": "Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r52"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://nanovibronix.com/role/OtherAssetsDetailsNarrative",
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative",
      "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of warrant or right exercise price",
        "verboseLabel": "Exercise price of warrants per share",
        "terseLabel": "Warrant price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r42",
      "r98",
      "r99",
      "r100",
      "r101"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF OPTIONS ACTIVITY",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r46"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of private placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(1)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(2)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "a",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-11"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-4"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//280/tableOfContent"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-9"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-5"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-21"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481174/470-10-25-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4"
  },
  "r539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>64
<FILENAME>0001493152-23-040577-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-040577-xbrl.zip
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MM3M*%CI*H",<YWVL@P6JB<9J_-:<[&MO>H/S/Q"3#Q'VQ70GW7E-LL7,@&N
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M.FNQ_?EEH)W3">[4NA_2P&;M3O-JI=NG=N'=+\=JY&CL:MW.:;?SI=N_&\M
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MR77/=$G>^TIZ5PXHRTV&S+!>N84A^-@'X(7^2*009 H)@B<BH\PC$VQBBB1
MALH,Q>P]#1X%8OBJ:2 F7.6>.0DC(HXAR>4$JVLW2.NY0-NB$A27F]6V1ST:
M@L5MH>D#G;N_CF";6L7GUH(V+/'C&U 65%LAG\CE3"">-CE_!^ZC#/JZ_%U@
M8AU;=)A2:FK_9". G\#:I%!T&.:&$+0D!S9X3;1UN$_GR_!EL3+L:W&N5YS5
M;6@2(Q7 IRO69>#8Y@I_#D1'1&D^CVNWB&K,[5P[$1/[U!&1+U%^/LKR,6-*
MW@I5'@JMV->_>8H>2)?W_<?+;RJ.O\,=O#\ GV=P?<'$5!B6LVA!RI0'3U!I
M:[N&>6@<.P>GC9T+(W\#+I-$.B?$ V4OT)!>]#R2B,\[V4&NH<I8JF+XI/U+
M11#B:RX1OB>#/ W]Z=7N^T;]?:/^:.\*HAS.)5*&#GGHN"B4 A@O==5\PSP5
M_):$4B'2O53RVPO_2T%U9/JDS"GWML41VX;ZP2,TM&)>/OXRR\I-"9H@50"1
M>J'6+,9M\P20Q8#]8,JRO?%P^5V)?0<[:1)<L0&+U@$>X8D?\/,_#Y4XK1=Z
M1:83K2:"1$O*1^6O7*:L%2+)E)X)/)V.=5$@^+TL &J?1='MO20#;_PQOKPI
ML>$GAW[2?ARB/M[_^3G1U -F6NP"JY<$6,"#HSH[W#\\>A#@RY&\0*)^D\O*
MJIS]ZK6A0/'PEAWL'6,1_>GE<\YA9]!MVN;]5T\ZS4'WP4G,>$3'2O,(?6QO
MYX>JE<%L&,B;"?5L+$7,/LVIY[+0OF\[Z)VKXM .\2XBI_I\LCC7*P>RN=IL
M'LD+TNH:B?ZST4#L0D4M=H7ZTH:;KSED$XVQS2XSK\!;[)QC?]%H5)'W!K]5
MD:V\VO?OS,U9L[IWNB%O%^2]3-:K9'Z?!]99>(6MUY/Z05#<GR$E8M]BE2')
M]7I*5XO4:6(NJFE9FLPFS2;-V#=N3CJG9=?LWHM]37K%LWCGDUX-_1-02P,$
M%     @ BH5M5X"\GP$N!   *@\   H   !E>#,R+3$N:'1MU5=M;^)&$/Z.
MQ'^86FH$DL$0+E$/?$@&3&.) PZ;4_-QL=>P/;-VUNL$^NL[:^,$\M(VNJ12
M^ #L>';FF6=>UFM>>5\G_6K%O+*M$?Z"^IB>XTWLOFD4O_C4.#PV![/1-;C>
M]<3^HH4QEUUHMQ()'MO2%*;T#A;QEG"]$.C@4L%"#3?BUOEK]_5@2\2:\2ZT
MM/X97Z5)SS3F/V^L!Y+N9(-$;(U+P=8;J?7-0=]<]NW=AJV8A,YYLVT:2Z0
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M?7!I0,)ME6;!LDAT1>[C$5VY4'DX7:(,2EEHQO.0B\.CR7ARD^$1W=57 &>
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M7/(* ,,"8)A-6(EQ,4E68$*.DX$<YU00,NP7JD'(#%E(@ )&4! *<4BTM\X
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M*HW'IQ*,-I@!P3QM;#X^E?8P/@7$L(.86=J@/CY=>FP:@( AVF!LUU/_XB]
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M2:A4!3']M_J/4+D4ZE]*PH2>)\Q<*-;)UV)>2@%0]P943&:F]?Z=TT;"GQ$
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MF%)5O$J)]W]0>?N(9\(C\\\DTTEB7,JD4FD( *+&D-9I";:ED-M8'3SZ_M/
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ML=#AQ4N$'5VI&>[V99@J'N/)48PP"@Q(TOA#V.B!!/&^ZCE&N;CT7V'J_(;
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MKMOW>2^CGI/&/7<XYPN-][QX_V[%?K^<-N[O0H<<3VN_?Z<9@M,V>[9LJ+:
MWA1$(@IR-*!;[]%%UO =;KS\#X^M77=&SZK :'14I)0X;XBBV.@:DB$U!M5B
M-I_+?[\T=!P[]3JX.7WWNM/)/BC8P2S;-6460%L<!!0L3ELX"$C5[*XN8PT:
MIH$61T!>X#@UTIDY$V[VK?]H:*2M5#XY=;QKY4NU;?Q\4@I/S?E(<T4TZX>)
MY?)L*%Z:B)<4DY+8&+P.7G^44-U$WUKTQ/,9JH:O_IV$9]Z,,6G-[KDVQT4"
M#RWP.99N:S@??'=/;Y#/:6<G@W3V-N2P?/"\BH=6 LGO5G_WIDYOV0VGT[>W
MM%;;"4R88]Y.E!JH9\=;LMR-QPNVC;UGX9&<!:TX#>T\MEIY?MD]J_7X=S*1
M.DE*N9-D.OW/DA1R_!41@<F=]"7V5*C52O7:Z6JM^&C"RX;,*B*PQH+>D"5I
M_#LVN="QQ9YE8=U.^C<A;M/#/Y;,#"P*.7R@(+N/AY[<LB<S4SU)-E+%'9>\
M'L;-';E0'/35\\:@W*HZF>*S4<RGZ)CM, [.D'3E,,"/DR:,Z)F(-M_<X6^2
MLZ<A+[NU^)=?7O._2VXJ9N8N'RK>_^SXH09/B91+3HA/Y.-2(N )\7$)*QEK
M%M]9FCHJ_KYV$3N33K*YK,\9\?ZM\&VS/W@XTF8R+B;CDAB"-I,G6;)K6EC:
M]#>QRVFR5!1W'%_%L9+V0L:T9>0,J<S?]))79E/M?'TT$*+(I_Y65[=D%0G6
M6%8</QG(H4UNJU&Q2H.T;2^Y%BI1.820=1:>A>5W5)F_2:6G3.K.0EU94TMO
M79*[*1BJ6UDV$Y7X6]9WZ^KA(7M>OC7:=)Q:,",;RB\@KP'>NBW3K8[S8IMH
ML1- O93-3LPF.+6[;747GOEEQ5TYR]\ +Z8,\-IXP0TQK3XF%7]+JXM//?'K
MM^^IYO/>?=A8NN"^:[,4S2K$;':G0)B:UC;U6%/,[LK?!ZWJ, -1,9NF8JGB
MLJ$Z,=7ZV%:=H:UBHQUH<J$QN/I5+F8>LK];+[EHO&/2"T%-1]8%96:P'W$P
MM4?7EST1,SE.G=\^W5SZ)),(,]+<V4<QG =B2QI_TCI?(*VR:2CAI!BWH"9R
MQH:A0,(QC*[-S0S=S"[NM_Z=+N-^-52RAT67S,8O1I+E0?/BH3%H91/E?N&K
M\^MA[X'DI?:&U&'O,Y '6:4[VEZ)4X^TL<I"'(=1B>U24[8T-;2<D)6_$1DH
M=7=U(5;%+V*4B8\*,SD.7]U1-B)><XG!=16>]:Q/T6]C/:4&4GHV1GD\7D,8
M_Z3(:[IA2^WG^?&/\=Q_D_^\;#,;MLP+^9G(6"YL0'VAB>\23>>7"Y6'TV5*
MHIW^R^PZ,&9?6^&9RNX9&W]CR4^[&N]L)*-U@V0;58DJ*LU[VVNIO\DT;\U>
M2];OFU]:D;J<D>3X&BRZUXUQLQGOX3>;AG9,YZY6]A%MBSWFI.'FB@_/^',B
M]3#3+\*<SB)Z]C[.(MX5C>N!]=!\-)M['+!-IPZQ,N);I ^9QMB>0U4QOVL
M=O#*#G$F8.?93G\CSBX8,4F@39NN9[&I^T$SV7V]4KYL8[$AY_UW-=BDV_.J
MV7O44:""I0WOL@& J,\42)E=V?\0-1SF'$,NU-@:YABB3407IPCQ1I,?-=W=
M/+1@J#7'5)[;IHYQ:GO;*K-2MGYS73B_OKFN7Y=J0J%\(=3JE>*W+Y6;BU*U
M-CSX5BA]O[^N_X+Y"3!&)J59GUZ8,L:05A5L->4W6F"@3\0!H]JR>S,^)=!W
M<I]4HOJ6:-X4!X5KNS&PRD:VC]0'5=0C*G[N>E)N.T&Q$/YL7;L[JR[*T61F
M[[,3>U54>$%A)D,_V^I.N,PV#@<I^!.KA]0ILO0WH?[#S4TG<_-%JF2CS+P.
MQ?6K<M[1Q$*=UPJ@9MKS@B>22'D@QZ@.0ZVF3.U:-N=OF-*485Z@)L(<HU;1
M"S)ZR-_\G$KF]>[RYO=C0=Z[!QL)*%B>A-3!,;T:.VXC):Z]Q=N:JB)\#=9?
M4GM[M/1$(I^.G<5G=I)C'=AS74T;OG32^.FE4W@CR^RO#,;$M/%-ZE]<UUZV
M68E&;0YO*C[G/]F\NE]@WHXIS3,_<7>^<E0]-W4W-'-L[X/?5R^-0?XY5:QT
MQ-XSINMHINZ4Q1$X_SA;[ ?Z 66>\G#N$!0>9O0IB6$."\-TM0QGCMB29OV^
M)U.X"F]Q0O#]3\I3=0V0H@QW.F@TCIT;M2ZKJQXZS+O2K9,XOTA6-)6%3(L]
M73O*1EY@J3YIN\#$KGS,E^9"]&5).K7729\\RK6AF!VTQLC.[[_>WKYV7Y];
M2G3Y%%U3D&&3(:CFRLQ_D+2L#VA7K1QS8=E&.@^Q0CQ!9S&2Z!\;S569>6:,
MS;E0*PWDGYG&X*UKE9.WZ9K>EZ(O. MEJ+FN)FH#A.U8&+7/:8M,EL7Z,W9T
M'>8 ,Y.*=( )Q2_4BE^*9J>C.611*JE$*V(88:)"AC)DTJEX:$R@F=_-\V\7
M=[]>Y3WM8Q4[FY+2G<A5IN7<ZS33W";IN^T!'&S^2B2'\T[FK]B:QHI<-]D=
M=0/$Q XQ38_25A7%[K$J;UJ,4<4K<L6!S%<(\\)WUG!0XNK9/>)L>AC>GH+#
M\.",HB[;.,!QKR^\:7:C,;D&<PFRB[/WO'7WB&\,\F;SYNO/;JTC)?<^D/<$
M$XK"6#3\>RR;8#:%R4$Y1#OY1&&I=NYDJV*Y>E!=1=TAJT:.7FEH6%V:VE#&
M9VHTPE/;]?63=*>B[W4S%1,<S2&-GFO%"6ZS);P0D4A=W5Q[4CNUQSN$(\3V
MJ/>9N_/J[Y^=3*#FK-UO,4![5HV$1E(W5@@=,(*_+E_.!NYW[M-MBHT8#C'V
MTHC$AT3";\"W\,%T*##I2B$N%'I.V[1PC*&>+EA==BE*O>=/?DO5VJK/7Q]R
M;Q>YTHV^')[N>4LX#AZ+%#N;;\[Y5LT)W=@NG^L_.BA]]^V/M%ES-@#L?(,B
ML;9M+"V0X+0M;"2X=))(),C_-[:P4?<YPNSQ.T3K[EAM^I@6\FGR1, _Z))C
M35^0WO\D7-LVF3]R"W1[CNW@%]B!+MIH<0VHO?M0M<_?QM<7L?*GGBJMQ;/F
M2K-HFN*:5E0F*J#:%'3QVDE^&RAO5RL\X; M4]VRV*"+C;LE=)XQ*R_]?+;X
MIM\FM^Z7=1Y@2;^$WI;,DWHE-JO9FK-IOVS,/5[/<$:84_W F>0KU+TOF@]?
MW?N2/)!CVLQU+75D>!C8#NS-&"ER%Y-)!HO<@\HN;2L[U*TQF>+)T4WQ7/B[
M3@=I>KW85*3$-C.[H:1X+OQ2/ LY$2FB',\2O3W7JNBJ^[,D.=E@21%&4CQ+
MFE-Y2]Z*XA7*&D\LYGA\I>8MQT.G$71S/.L&*F'G>); LY5(UJ74@_3]A[A3
MCF>[E%7HUF;8WWYV;B^*]_<:BSF>\("ZYQQ/^(*G?:M26<GN)/>8W5D"Y:IT
MG3!4Y_=K1=EW&B'TME1^.I7>U>OS;TO>+;USN<?TSI*VM*5Z]NO@"_K27S$'
MQ5IZ9TE;;IXS]X.KER]7@_6IJGVG=UC@RNW2.RQ(OG%ZAP6AMTOOA"\YI'?6
MI$A2(K_IG=36J2E([S"9WEE>HQ)*>J?D[SK?+JI*3RJA)_4IJO1.*5!Z9WF!
M$]WTSA*]W765IZ^U0>])7%%4L"*]DX@HO;.D.9=?;IK=2U0]KS*9WO&5FK?T
M#IU&'%9Z9PD\G6=30W?YM[2]6PE/:<_IG27-Z;=>OU;%>J;]:_TX,H+T3GA
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M RFXJ\Q.L!+!*GI!EBWKE>8/V;)D?&EC\*TL)=3:VW?'TOG9L)INJ=](39Z
M9E-X'6H+Z/ PZ1!29X ]YB-'*/,#N$8/5Z!*P![S5 EE?@#7Z.$*5 G88YXJ
MH<P/X!H]7($J 7NL4V4>ROP KM'#%:@2L,<\54*9'\ U>K@NV2.J7*@\!)KC
M7IPNC;QF;\FN4J*4YFN&>]=]I,#F&+6YP"X"ZO8 KAS!%>KV *[1PS6JB 9B
ME0TVZUNV7^^E:2$L8+%G6<A0^G6L?]MK?\%0W7>Z[+X;=^0YPFI'=?GMSK3<
M;QS'TAY[CORHH[IY)^/[.(V!TM:>OZG2UV_:(^S9-]-S(U5[(CL3%0OR6,=
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M@;V*3O9USJ94AX2$0L?L&0[[.F=3JD-" G "( $X 9  G !( $X )  G !*
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M<(T>KD"5@#WFJ1)*_ "NT<,5J!*PQSI59J'$#^ :/5R!*@%[S%,EE/@!7!F
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M:O&SN?6^R_R("LE"9T]DLTG*_#HFN3?6+_#A8?(AI,X >\R'CE#F!W"-'JY
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MT!YU[=:5EO-ZUF]]I+TL5Y[PAFDT'K>Y3(=#X7#XZ&-+C#=\/5'&4C$97 ,
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M'""N*2J2TB%?41$VJ#"#OB2Y8K2S 'V,ACD8KW,Z/D2D<T/P27!=A,\/$LN
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M);4N?N#M$1L663MD!NIA=!AJD%&Y:XJQ=2Q5XOK'TABD^HPL-=,+-8>U WI
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MVP3UT8GE8]4F8!X9EG8(<L>1F>V&-42SHP>F@5F680?C[7'EI(L, K,7&/Z
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M;N_>(BLT&D=BYU8'MIZD\"'-=$.&/T:J(O!:=TZ?@;Y1_[NX=%%L+O?'[GT
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M*KX<5MZA*L1A#@X!%'& 61KSC^]IV=<0R<3"1\,@L@35^9DMJ=R=MA-!ENW
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MO_S5;%L5NC0L[NF(FXE43'LC%='=4[&J?<8'K4E#N:V+SN>$9-6J"9LM!F.
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M:$I<E<ZN@=\E0F]$CP 1TA_@QT2+E^)ZZ5SN8?WHXK^PN<))/(->Z^F>W9G
MW?Q':/Y[^$/^N=W=VA;'?K)]?%R;APT^EL!ZAJ1CFB0$=^XPC#;+W=%6_&-&
M.^"Q).%E_?2T?GC61"O]_.#XK'%T.)$/?)6)P.G!#K-W\?08%6TB0^7P)L^9
MD1F"5>#G_]\?Z=3@^\-;$P_/4D2;C&LX@4S"^W^MT'K_MS4M?77W8E_95VV#
MO.6/*JN/0@C+([_)#(Z]8 YQ#4F*-".*?=0>A'=X%?G#,0MH]8$.U8&P,;R
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MH93SIN0/K\F()J<KW8N?M#J$VPB]C5+MXVKM-5L=]]G/TS?EQ0R.\NIZ<>;
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MT6NG@L*@QZ N1V?@)41\>@^ KM4-B?&(I_QS6[[J-SX/7/_3Y=KBX-;*I9G
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M<O%.H4JN)19D*:[KR)/SY,FEPK"@N%%B)%A@628:DT2E3 -V$FP"8 D*K!=
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MP/6G(#35SB9HMQ/5Q7EY*>*N>MSAU9TPKRIR'ITR\&7^V(2I&7[%PW%JV?(
M1 $^O#[ FE8>\+#SG*P.,.X#BR*O#G@%;K4^6YQYV/$2[#6,+:!I!*/M.#1N
MCS)<!(ZD?M\"8]*JK8,)1.=6%O)2*L'F(>"#)&SWB-1D&8N&WG-?4VP]I14Z
MTC46L>A[9.]3U4.#+Y-$C:9F@<J&<5P6\ RUX9]"NF#!*&;#+^6*8W!Z?-FG
M288.L-/EPAWD4V"=&SFL\WEAG6LYK//?)D!U>=5#].$S5U>M6-7-3'T2V,_;
M\-=:;59%U9I1H/2 !3^\H&I\P<M+LU:\,;.B:JTT:]F5QRW;L"/Y;+!+A1S?
MDK$K'UI7)7/VU,B#NQPJ(U.;B0M'N O*;W=76#W2R;BOP&JC9,"15M>FP9'N
MJ;!:+S,NNLKHZN<HL+K/Z#=JK'*J7(32*EE(BE+[<<[57955IN^6(?/QQ4V)
MC.ENLYU9I59 CP^GPBDU6=*KG5Z4E:WHRFGX]5:F/)Y,GU*84JZ8*8KUM<>"
M0G68IS9;!C\6%/IKBU,FZR%R]%5>"I"7 OQRFEA04GZI.JNR0CV7'V?:Y)CG
M7V\+/*HVY)&&P%-*0]:J90-.NC:MV\7=I2'KT@HH5V;WNIAB!DBG#$<DBQ G
M:4JM34,!J;WS>/T'KK"5N)Y#$YY%*W)C(2^CEJI>CBG-,?PYAC^GS!>K-JK)
M N>-S5SO+M2RGU31\=B@YU,+.BJ%]0VS/+.P49V"%[Q;"ZOZS%IMM@Y>N%-;
M4&++(?4YI/XU+_OE"H$J->F85JN5!VO(O [H-2P;-*0QHD"200&!OD4+U>(3
ME6(ZRR(500@>GI(47&6@H8%K ]VX^NA6!1)W/T4!3NEHS&,0T&WLV&Z8CK?C
M],Q01#06D=HF-6T_N;9S^/(KJOQY)"U.%OX $?Y9+E7F6?C3<4.XSUSY[U7^
M<P\T;C.'QCTO-&X]A\;]>SL>3BECB[)U;(\4D5/*V,K&*()IS0;R.K;?7@T_
MM8YM=;.LZ]C*T^O8*H6-S8U,)=O#O(5IA6S50G5C<TZE;. \Y;5L\ZUEVW=_
M)" 7XA$[KFHX^:F(0'JT\[&'\USV)2@=FBZG83K(0H2R8(G=QR#3M+GIFM]E
MY<G#(=Y<-J/&N6:GD4;PH331'EZ*#"TGGF'C&5X7<7(Z!XT&M=:3+NR,I4="
MX\!P0BOC$V#5;2$<GFN^6JAP"7<J$3!9I7#/W'".2M#D-'0:FFQ[44 #K7W1
MY>A*VXYZ5@=GNIOKR22(>(YZH5PN/T8JL@>!+X7W88R-WM2R/5M.648:L$!@
M(62VL+[!Q<,\+GZ&07#-P2"><&ON.AVYVE<J*)KX/-[OY:5I'UBTM@W_.U##
M>?E=XM[-HB%VOB,G9R*RAN R8<M5XX9D)AG\/9H^;(= JXD?)6V0$5$G\=2L
M19[ &Q5,#\YR O@H+& BZC9&5H=*S.#2.PFLP%@0GA)VQ!<\@AY'9=[ ?UP+
M;ZA/C7>$1N&A':,&9_,<[:)5CV@.HQK*ZT9D!V'B&[_/"9)6K,A-N93FN5"X
MCELMP=_:(O1SU31'64ASDM5\5)-90MN-J-;/57,1I=I"*J+8F* S?0 [C7,
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MP/@[ R4>C(Q[%.WJ5BQJ)%NDD!(8?+$5#ILZLD6JOYH5P0]1Q]:]-%1/-CG
M2*8:^R3<J7E<IF'<=EK_Z&/#;1"(<2^2P&4]P'MY*3O!>WQSR'I(9+S1T"Y8
MS_9GM5 NES$KP,J"+V[9'@W=PGXSU<+ZQOK,F>%%2^)Y&):E.-0)!-=R<C(H
MZ?#<IIA*PUF#8!0]F03R**"V#U1DQ=?"&^K/UG@ 1V;#"0[(0VX*F3##,_#Z
M5'$B\QKWD!5+. R[2A&'-5^&F*,@L<K!,!R..J3+19""]G BFLJH:+JRN%M?
MI!*3DY>9],4SMB?EJ0*9FB*U)1XH4A=.7OP&8H[]-!SW.-6*DNE9XB@Y+0\-
M3'2LI*6FW9'4D6!N&DL+HRMCSAC 2?9B@.(&N2KPI[T5ER,GXA+H!26%F;B6
M^IY[=:7Q:MFL2A(]L58Z@5+/B3>:;LB]0-B$1$@K<IVY(9BU$6$_XAYYZG(W
M!I]XBD$!GB R2"?Q&':=1M8)I!U'Z3>17:X^7+ZM@)GT[$$)N%ID)P0R<H 3
M+>269I"H"T:C"\I:;.(V.@1!Q4XK,I."SHN)L)>0)9S&QJ4=V1F'AW;DV#\*
M$W6^*A#C"+PS[;7*E2#3*H,Y$#+F+-E$C;P62<^P35=H7+05!QA(2 XI"">W
M1^?==R )$1=OG'\F;"!I@,P:B?R!"YEVJ)U<'Y8DS<21_'MJN=U)A$924CK+
M(*,9/]_#NO<" ?I\MY_TS6)UG7>10X&##OZA5/[KSTJQIM!I&@_(MV,]'H%;
M7"<EXS_+Q5*)&FQ%/13< 4]875YBRJ=EL=5\=W93R.AA-A!2M.J6?M TKF$-
MQCLV6<K%PI=-=".6-N4Q*5**\\?4C8PBB'+>(J^6'JA@+'>R,W5A2D<!Z8]
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M ^%<5523O.V;-<3Z+2;FN"Z'6==542\BQS0#&0T0E'%P<@HUCZ,:AZU6JMT
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M!S$A]D:G4OZL$O/LN_/B;[_1G89&COO$R78-5\)")NO)\>6Z EK;A^(LV!L
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M^V.V!&=]RCFU21):JX9R!$4--%&RJD(#)5!:JCU'<DQ3 WGEQ8Z=C=<,REY
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M1AIGC1'+Y6(>/31.@[DE_J^+)X\4X+S(,SJ"$F#J57"MDN7M!0,#.IL,&@U
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MK<TK>!Z;8)'675-*.^65VE%3B,+ED]9%DW()B'\VX"4B,Q6GC.IQRT"_030
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MZ: $P%!W']1=0E=I$"*S1&K>"@=-SQ!+!RJ7RY9I>M!Y<"H ^-QGH@&C54E
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M],FDDWX@T\?V#PW):>Q'!;W0?15FFR3SH@]I4FR(!OG;YR\^XV#WX+.B#B
MLWJB&X"]8@MVCPK,Z 6F*(202PP8?]53%FN5_(?U172'F_T#[Q X[W\.*C\>
M7T7<(BM+M5E3O) 456L;A-5G:YP4<.LE'*L(8'D23FR7>2-AF0KZ)BC3^9:N
ME='^X'7W <?Q-KY>O\*U!_'5^@J&#_( <!#80J*7HP?\&,;T-7'J*G#XCJ)8
M_4.1$F#L+2?VJVB)Z;4+$T+:>0TD??3B,NC!F,!/HC#PRB *MZ1"2 FP/^>K
M<CG B^I04GU[-T=*V^K;'<<LCM:3',=(&,SD\)C6" >6&VF?H5;J;$[73)\V
MI#H'M,L"5%@S+R]2/%_U.F4R0:N+GTJ@K45.00H,*Y70A"/(D\7X;GJ[G,YG
M:'Z-+N\7T]EDL3C1260Z3D1)1J!]2.AM:5H3:7P3DB$F"/-M=7GOGOZ<>V&L
MV14_0GK63BP?P^SZ%/,AB3GGY[$LZ-*8)83*E%"=%")I(7[MHY7:B>C=-(?D
M7,-8XI?\,A)WQ$V5K!'5V(":C;T:,"AG"E/@U7PZ^X#&\]EX<C<[0S?3O]Q/
MKZ;+G]%H=H7FRY\F=^B>?EN.IK/E=')POWEX@$5^NXF&H":^@F\0)E&C8#78
M82_P5LA"I;1SOAE#E-S8*!50I0')>5N$CW&X"GUZA%0P3=7##56V&J9MD$&M
ML&U&FF"8. BN$,_M_N/'T=W/U#E<3#_,IM?3\6BV1*/Q>'Y/NCS2.][.;Z9C
M"'T?#Q_5T]]UA>S'[M+U:VT), R2PA)V(WG(+4A=EA#;?Y;D>.=^]O9:YOK6
MG]488I;^50:%,ACR#44L]&#+^?C//\UOKB9WBW_^IW^_>/=O?T 3XL<M?W9.
MT(F7TE5YNM_'@FSV]5U*<:N]6 _H5G^FD 5#KAZ 0A]7BB,BCY@"I/ZN:TQ?
M_Z:1=TDH;?^E% 9+J;[^Z6:^6*!;,I-<_#2ZFZ#1[2WQIT:7-Q.TG).IY\>/
M\QEJ]&'.6;; CW1E^0YO:)#H^+'O 12EN-4QLP=T:XA4R()A6 ] 80#DXJB6
MA]1G=6T9X)V9:+KDF*E'UJ\&EGGF7MB'R?S#W>CVI^D836?7\[N/([;G0-?1
M/H[^S_P.C>]))_>1=(-7H^7HY/L/-_0@E.'>0E?6P;Z!'*YD3Z MZ)PW)NB$
M\9 ).>^8;G"685Q'L>"H^OJD/B6;W9&9 <V>2*_AG$R#8 JLFHP6 -:HJI!/
MXR3+LS):=/AW')0A2=OA2W<-I\?'.CA5NZ^Q'*4(V@^U')0D&&8?QPYEF#&6
M[!EJ)'R&RJ3/V($2OE7*DT>[]"'YB]("Z.N6^Y2LGJLR,J!U8$JK 8:\1C"%
M(TYL#W6T6$R6[CMG>BLZY ]XD:8V9B<:'W%,MTF,N^*!:5@]$+Z/>:W#LT,2
M ,/+?5 +)U9W:;".LI4*T)[2R.Z^GG-H(N#XK.U9AZ7PNAC=U_/2E<7I\N-D
MMERP6?AXSK9S)S,0>[EW.*)AKFZ]--\NZ95&_BAZWVF6?C6;!#4UHDG)/ATP
M)#0$*KQVS]40TT--14A]I\HX\XYS4 H02&G890Y0!T]5\\[R;G(S6DZNT.WH
M;ODS6MZ-9HO1F"Y@.F?JHGC(\&\%&0LFSP874=3B5E?*>T"WEL<5LF#8U0-0
MV(VIQ1&7A]3O=6WIW8-1R[ODDWZ_124,EE']9_0N%Y._W!-7#DT^48?..8\N
MO2S,YJO.<<,M_^\^4IDJVV38,(.:=#/3!,.]07"[1&3*[$IG\V8:G3!OTI#,
M3S81CRGK-Z^R.2?K?8;GJTF6AVOB):BNI'6%;))/#K!)LK8$&#))875)<\\C
MNN%*S#D?KI,4AX_QN RITYK<Q,%R%V G,^O/#DC/)LL.-KM)R+T3 \/=0RWH
MTKQ,3QJIR3GERW=J:'Q&NIQ$G='/8?XT+K(\6>/4C.=#$[$[Z]W'P/;$=T@*
M8&B\%VQQT88E0A_%3![C$ 1E9_A+PTE)DYC\T^=WWH<XF\.3L1N%<S\CV[$X
MAZ4!AKI[ A?)ZQ.5:(N\(-G0I4=O=]$NRXESZJ6!>Z=CX3_AH(B(O\0.#1-/
MFAX#6-/GZ-@0T0R;6T8AW2[9 X]]4_0C)&QU+G^T@FA-^@].%4RS.)HIPC+"
M^*?)U?W-A-[UF[.0$ M$5SD_0;@JL[-ZLMY$R1;C!4Z?0Q_+"V$4,1@L\,H=
M'[7H.1H6:8@=@S%O-D?/STUK.E&QR1O9D3,#V/9.8Z&N2;([(.ARM)A<H<E_
MW4YFB\D"W4W&\P^SZ7^3WQ:3NT_3,?GM^F[^$4T^WM[,?YY,^.;N;#X[KW\!
MU);E=_L^>RF9&^79/+T+'Y^&M-7!Z3D:V?8S6S&@#4L,8%O:SP)=6_D\NKL;
ML9,-\,:O$7$]@S JR,A,>@^_2%D\^,D+C:V' SY16V^**FS8T$M]I\C(32LY
M=D')F\^Q<@'8KHYLFB8T1'5-D=U@I)>K/XUNV,FBR\ED1D:K\<W]%1FBV,AT
M-;VY)XUR@KH7'^E0M9R>5]^=-]G&TLGD)<=I[$75LDEVN?V D\?4VSR%_HA&
M53::BQV4HJ/ELGU-5ZR=#4T.3+,ZW 9-^[FC^[;W$_1YNOQI.D.-RW*D98S<
M>VRR*S<WH?<01F2P_DB##9HN1^R5DNMK4X:F]MVEZDD&#-7WQZ[SR6ZFH\OI
MS92&22.LGBYH[" V(,S)&#!BH82.<TE+<?ES-RY6GN4HRXHU7RC1<G>XNK4K
MHGL85=\:':#KG)I[ C:;(RQ(3\S7NYQWM-=>F'[RH@+/<'Z%T_#9H\X;NU6S
M:X&D/18I#N;Q'77J4M)$V<&+^SAYR'#Z3 MB&A._CBXYQ#[180Z>4?=L,7^K
M>]NVB[6U%VXK<^>MU)7%NF8^_FDT^T"&'.)6W1 OZP:]9RMBU6CT,_I(!IW[
M.S([&2W1]6AZA\C<Y=[][&/7V=6ER2_7L?BEO!#);$Y5C /WAHZ2AYME@B,6
MCWR%X @9@&F9I[!*U_KXS<[7T>*D3^6F"X\M][-E246AFB@Z?])8:DCOF\8M
M+3 L-H9J^*IQ1C39&42FZ^AI''$57-HM"5*__!Y,O6C "9W$3O1WF4'!'S#Q
M8[W<?'439CD.RG50X9RO5M+:=$X/M9ZYR<6<TZ ?6Y<%3)BVO(B)HZQ>I7;4
M"(G#.HW]9(UODDSULO%.X)?W5LO\&:</289OM&>F9/ 4[P(2,=X1EH\WL0?"
MZA=#'-7 -*9W7I)T2T#**J#YW?(+6P;E+T77+?Y:Z P1,>=^#PO<07>"4OR$
MXXS,U#B%9">@^7GE#UX84X*-TC"C4> *ZB#R8PU+[T51-,?/QGK8EA,4DA#H
MY8AY.!\03FR8$&.0*/'X'!%1Q:67MX)\\'[D^\6Z8->3585$BX'-NQ2%.RP)
MRV]Z##:N\\J'L3X8KN\!6O(22)5$&9*KE0CBJ:!O:#K?HK^RI-S?'38T_":,
M\33':]5%N^') *2T8.0>M*[3>&W4[@(_D-XT.<32<\]QQ3%/NAGUR&XF7&YW
M(K?>EOXT^N*E07D>>U[D[,H!&<QFQ?H!IXJ2/D$^5A=G3U5,K9608V<"\1'I
M4QDI+,?01#)T'P>D.9:ZJ*%\ABZ]B*Z5?4U-\#.F!TMQ,"(3.^\13UYPZH<9
MODU#7^5L6<O]E397DR(]42/69?V5-VT#T[L-OE)!I0ZJE!#3HH]R\P=.SIK=
M *Q>X*&_\!X&%]X=7I-I)'\NDEV7+;QHB=/UA:X:;2.QWCNX*6JAI[ + XSC
M[<[VWFZC3@#=A"OBM/^,O33[MM5IP.@L#NAI/["S9M.8KS]]2!M; T?NTZ4Y
MO2970%-4QQSV)=G :JPGL<W$:3]#3!\'\%M=-J@@3N&L'Q,!J%9Z_*(=U'J/
ME_WK:=5'M_D C_U(78#J(/V!W@A#9^B'2(^!6\W?WE%^!\6ZNPM@,7/G;=J5
MQ7L[TP;M^=0'T^@Q.QPT]V&Y]]&,-E)U2('RX-J@5."=[CC !C/?K=9[_=Y;
M98I3!VX@B%?EP^U5P$=UXP8A<-[K.S7[ &?N:'W"B=RYX8M+IQB.]T'Q:ER[
M_8OX: [>< A0!F^WYI]Z 17P6J"C77R[7B/?[)O$@=U=_"%NY>!]_-?!*:A;
MS5\W_XQ,A[79K/)[S"=SFS#=36I;P\K@-.SY''N:M_,8!B;@W,$_!+7I])SI
M? V3<V((O^;C=GH^$,8KFZ#O5<A'GJ(/PN"\#3LV_*!I^E'ZAA--TDMT#B?H
M0Q&\FLGY?D5[M(GYL.R=-W!W-N\]$X?>LLOE0:=M>RB&5]2Z]RO>([;O80"^
MEA:^E]4'M'$H&V]ES'@<R%T@TAF1?RKO@AHJ6[TR-\B@UD4Y(TWGA-\+KC0>
M"F+- ?D-+82YFG->[KV&-$MBWJAY1)AIG.5IP5SXD]^&&Y0UJ+GE$0OS*&N@
M _+]JN[:#+=;&(+*4*5G7]EU.G7)E*>5[%5%G>$K;\*=@CMQPRUS S-\GMQ$
M=<M\-4?FAQ>!<";O]*7>R/*5-TC]@<83YO<U-\JND>IF"6=2=H)BN$[2%0[S
M@M38* X:R]7V:D(#X94WW-["/7%#5N;_-3?L/J/5#7U,7>'(W0'WKWDV]C4=
M1]G'[M<V'Q-"Z-*'A](,LP^+313FJE(UT;3:KYN;HH]P+*C!Z46-L<J>5"=R
M*&/K?AF5A,$]U=D9P3"EHS(T%>N<'&ZB\44F,0E87!V,N\O;:[KI0GI@+T(9
MTX1X*6V&O[!/P^NOUGQEE\]$W$+,9S8LTEC;,?["ZXX%P <PNQI'7I;5CSJ5
M[[URO//5[N'*L1<1'_%RVWT85E%>!Z=JLU\Z4A$T>7Y@DF#ZK>/8H6X.NYCS
MR&=IH(<M^E*F@I(4I2P=F*VD=8AM]RY:9?R[(67:GY;S%F%J;F\[Z$L(-OL-
MT7<YS]*BE"_979,;X>I8XX:FZ)SJI4$M,Z>Q3U]659U\T*O8)*X)^"8_=?)@
M:&@ 4C'1AL8M68/*\BLO9T_[?GX*_:=N>RJMUL1@/S11UQWK\ +HZV'-4P3#
M\:.8,:3/I<=*44#2=]XH^"2"3RY8VZ[>@->MX,GEK>\<Z& +JZTR83 $[$.H
MN*3$9W%GO']E5Q+8[,XYJ:2OM*UNV7.@^#;R?+;6JR@+4V7G[^HI#>I]6T_0
M!$/$07 -W]@C7>"&)X V50K.*<I:4.\5-U>7S_37P@!>V-)=I6("_3Z@JR7#
M4\:QLOM*7$X7<O=>2-1;H%Y%P>M-E&PQ:>=ET '<?VL&XI:N^SBV\!:>3VCD
M $(]OO9#>NJ;J2<J>&E.K^)D3W]1';,52K*!-:Z>Q+97TY>?_ (1N!YW(&[I
M7:)SP'>))B7!%CA])OZ@W,I9$C]C^BHPHW.V3'(O:GX?)UD^2_*?<7Z'_>0Q
M#O].RJOAO2C*UE+>-KM9J\79;%]6,@;3%=NT5NB<D_B<IUN>&.IX16>HB-,Z
M040DPS5[8*_5_GV2^=?;^/GH=IVDY4]43K4!:AO$5]$=: O82K\@1?#U=Q Z
MLX?W%%^J2_%>>2F>']I];3-U:/?HP'F1%FQ5'ZXVF*V_+E+!O5+RCT"\?NO5
M5,1PKI'Y3S@H(CQ?C>(\#,*HR,-GO#O#-GGQHR+  =UWH457Y,S(^6KBI31H
M259M".K>@S]V)E87C$Y20*V6>=0<P+@>)S%+6%<H,Z%K1,ULT"X?5&7$=_\:
M65&E*C-T6\7-@_-Z_6'%=M/WJOW1DK<:NN?(A=):FSM2VF":X)$-ZC:^HS4X
MFA%B.;WZ5C=:)X7R!,F1TGY%[:U='$=L;#SAKZ6EM:SI-K.KJHE%298!.DRU
M&^#I5:VXP.QPSN0EQVGL1>."S/77.*7.\4T2/]X0"X)1EN$\,W,5]TO4C6MX
M2 '(7<%]4@33&HYBAL[5JY+E(TR5,*I31EX<()KV.4L<\=3!>'8#2Z7/D]L_
M.9NMY5"CF^UDW[3 M) ##9!=W=ZG/1@Z7J=G!1\A>?S4SV'^5"'G(R@9*BEB
M\I]@Z;UH"#$D&7B+5(<8H63$(TX>4V_S%/K(HW=CG'=^N\%A0IRF?/LY#'")
M]G+[T?M;DM:TO=S>X4V2YL3F!7YDJVYFOL,!*;MQ( XN"KD7L7>R8#K*X]EB
MX$_0:[8LS5W/>49_J]-%5<)@7 FA5%IETN<Y&&M;W2P>9E)KE]=,%0R[A^%5
M]/%G'<["6D\9TPJG@QF=^=Z%V:]DSDM_\!ZQ\BJX5L7JQ40#\*UKAQIY,*0S
M "E<&6RJH)3HG-&%B%++LNO(HOE?A9D?)5F1XAMZX3<;/63,86K6BE80COMG
M!E,Y?,U7Z";T'L*(+[Z.2.W0D8IZD6A.*LEC Q=/U7EO<$,=5US#8J@J]-MR
MWS6[*O ,O^3++SAZQA^))_RD&K_V3\YF+W*HT<T>9M^TP/0^!QK0;0:48:^&
MU?1IC^67Y,"2J5.!R.&.B?M0MTSBU3&VC5M"U-^_&J(>6!(PJ7D()^U>EZ0'
M,'4+10-1=ZG(#GBB(@Z(ST'WG7" DMI1B&AB:%,F INQ]PT3)B\^$=5NO^Z9
M%A@N]YEK3&Q50J^CR^U!WV4[3>M'-*6[KX3H(=$B:-W?.5 8IR@0I;1-<O9
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M]4H-6>@!CZA\84$5/EWD9;0]+RF+-^!QM5XX2)RG01A9WO^Z&]%.LKZ\+.:
M!U>>H*<V,*:\4Z,%RY6H5$067Y"S:JTXIX:4,HR1Q5;?PQ*R@((<0.N$.3&>
MHX#>?:P"GVN/K9:2Q17D),D2ZM03+W4F#IE#O_!G:0\VD&FU+,:)8?R$W8CT
M@#K>QWYFHV'<BC&*RL(+<OSCBG=BJ.=)!#&-:+@G.T3L[C-K'>)<5TX69)##
M'ENP$R,\Q8@RC<BV._'CHM$&>+)<LF9>7GE9Q$'.>F)!89$?AF&,L"K^-;5D
M60 Y]LD*?>IY!MDQF?:V[ZX?%S1BAC'+5$K)8@URY&,)=6)LQ\$"6S2#ZGR[
M?@P\=GA(;4%9A$$.>!S13@SR03_JX2T5D046Y&17*P[0G&"^V$GH+MM[H;ZD
M+, @)SV><&!S[Y/4W/ND./>"G/A80@%AF_J&DQ$U>?3<)XL=2<:M(!UG XDX
M1]13Q^\E(3^%O!BWY(=ZV!E%90&'"9'DB7=JJ&/'C9"3=NG6]2W?)D>J?3)>
M!NK"6K($P,102@H-8M[_A#SO'W[PQ9\C*PQ\Y*1;?9Z%GUE%E@7 .T2!N" 4
M? R\F*"$$T=0S!@#C**RD />'3+$@_&]3)V:=VM/^H@"#W%6#5G@ 2\1^<("
M^:=%B/:99@.S(BOK(0]_5@U9_ $O%/G"@OG/XSY9>)X"_IUYJ: LVH"NL+6B
M@8 \7UN>5\[;7P=RJ: LR( ^K[6B@8!LKA%^(I/:'0Z^1*LLMI,'-J."+.B
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M&BKLN-@"@X^A*0XV"$?;J4<?5?<=^DCRAN[FN1,9OY8D,^U[@LJ"7EYGQ!"
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MCED#Z%ZLU!^) <>I CW !'24[X]$LFLRM.Y0\(2MS<JUA_XRP.O\5'IO_2O
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MBG)W>;XX/I<10\KBHZ+ _)!!CH;D1XZG6EU98)X8N/+!+W2_^#A#BP2$."J
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M;FC46M'#"B(5/J$F&/R5C61_*_N3QI2.=+ON::+0S4@?=7Y5U.2N+E5KVN7
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MIEO;1(_%FSQ.%>A+R3;C%'B@@-,VQ8&-D)-DXZ;]M'RZF)0MX#SKOUQ]Z 2
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MXS4/SE(12.-^#?7%ZZDZ68 N$%^$J!X6 3N;B5&MDP5\$UUW!)@A:CG/_[5
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M;61ATYWLLFE:\ <_> P1?J9S0G)&DG&R:/%;P(=6X9+,<H9H'>[&0<P;THW
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M 0  B@D   H              ( !     &5X,3 M,2YH=&U02P$"% ,4
M" "*A6U7Q)N_QVD'  !V*0  "@              @ 'Z 0  97@S,2TQ+FAT
M;5!+ 0(4 Q0    ( (J%;5?-XEBA@P<  "$J   *              "  8L)
M  !E>#,Q+3(N:'1M4$L! A0#%     @ BH5M5X"\GP$N!   *@\   H
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M   1              "  7QU 0!N86]V+3(P,C,P.3,P+GAS9%!+ 0(4 Q0
M   ( (J%;5>]#E#;OA   #.S   5              "  7>" 0!N86]V+3(P
M,C,P.3,P7V-A;"YX;6Q02P$"% ,4    " "*A6U7R7/+Q\<E  #[8 ( %0
M            @ %HDP$ ;F%O=BTR,#(S,#DS,%]D968N>&UL4$L! A0#%
M  @ BH5M5_E-64(V2   JP($ !4              ( !8KD! &YA;W8M,C R
M,S Y,S!?;&%B+GAM;%!+ 0(4 Q0    ( (J%;5?B/);"AC4  )A< P 5
M          "  <L! @!N86]V+3(P,C,P.3,P7W!R92YX;6Q02P4&      P
,# #; @  A#<"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
